<SEC-DOCUMENT>0001615219-20-000061.txt : 20200515
<SEC-HEADER>0001615219-20-000061.hdr.sgml : 20200515
<ACCEPTANCE-DATETIME>20200515162934
ACCESSION NUMBER:		0001615219-20-000061
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200515
DATE AS OF CHANGE:		20200515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Salarius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001615219
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465087339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36812
		FILM NUMBER:		20885831

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		346-772-0346

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Flex Pharma, Inc.
		DATE OF NAME CHANGE:	20140730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q/A
<SEQUENCE>1
<FILENAME>flks-20200331.htm
<DESCRIPTION>10-Q/A
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:b43fc1ac-9dfd-47d4-86a3-312a4f6202a7,g:fa4ae59e-aa52-4ad5-bb99-0a07ac3a7546,d:330ef634d79a46098535b93eedb2fa54--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:flks="http://www.flex-pharma.com/20200331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>flks-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV8xLTEtMS0xLTA_4a55b40b-29a5-4df7-9889-2ecda9c8999c">March 31, 2020</ix:nonNumeric><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV80LTEtMS0xLTA_8b8c3902-5dec-4620-98f5-fd2257496a9f">0001615219</ix:nonNumeric><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV81LTEtMS0xLTA_6739434a-496f-4ec2-9ceb-73e6d677f8d7">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt:datemonthdayyear" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV84LTEtMS0xLTA_4a55b40b-29a5-4df7-9889-2ecda9c8999c">3/31/2020</ix:nonNumeric><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV85LTEtMS0xLTA_00a36555-a315-47c0-90f5-a883ec60d2f9">2020</ix:nonNumeric><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV8xMC0xLTEtMS0w_880d4ed7-fc45-4b6a-8d8d-5deeab090c59">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV8xMS0xLTEtMS0w_4df50ec7-ccdb-45b7-b28a-c8dd296673d6">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i7dca2651f502440e853228b2558f473e_D20190501-20190531" name="flks:RevenueFromGrantsExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgwMA_62016ce1-9c77-440a-be57-b02c9bb2a0fd">P6M</ix:nonNumeric><ix:nonNumeric contextRef="i7dca2651f502440e853228b2558f473e_D20190501-20190531" name="flks:RevenueFromGrantsExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgxNQ_f84e63ce-cd9b-41a2-9e9b-5f34bd9cd7fe">P6M</ix:nonNumeric><ix:nonNumeric contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUxNA_5df20bb8-eba1-4ed3-bcaa-a88042c57c15">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ3MA_5232e6f4-81eb-413b-ad84-cc43a3411329">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i79fb058518ba480a82055d2644b14f06_D20200101-20200331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTk0Mg_3e677467-eb4d-4c5e-916f-d6b12ec0b478">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="flks-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4571822fa95e433cb31fe3b268a0157b_I20200505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="idff75338ab954067833daa55353126e4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316105bb8a4240588ac05a8d48949e71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70af0eeb6ae64595b3496e4f573820f7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6632a88f72bd4dce912e8beda5728be8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85b3036ab6d64f5c890474b22de3cea0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48e6839aa78b49d7a1b426193e822187_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9544fb2f862e407388524ab0bccddac0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16fda578275a497fa39ffdae434647bb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i296a0cb619044259822d223d39af65b2_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0351d160e9c47e49e8caea479d3bbb7_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i029a4238195344ce9ca54a046028a734_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cafa03bbcbf41e9af4d14448d9db3c5_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9edcc8fcaab54e3aacded026cb8d9b22_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9c5329d026f46fa9a0a9ab94fd1106c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7146557875c64c948bcec77e00b091b1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd590e1573a4c41a8193d12224c9c3c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f3e1bbf23f94c92b05cbed3fcbff616_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df749b27e2e4ab594097b6f0dfcbbfb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i139ce469438446e1aa69f17a3d9c7865_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9080f05ec45443fad3554f83e2eace9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48fe193ad62a4945adfc9947d631230b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2f7e69dbdb94177a53d56e0f77d4cf3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7aaa5165cb45d2809ccf6274968968_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i88b3e077cd5846b99d7bad5be157bb53_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i291b51edb08c4a50ba7e783e980e810b_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flks:FlexPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e9ef7d321148bfa7e0fc99f44856d7_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9335e01552494ea4aeab4ed31281b503_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flks:FlexPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c3c4f1bd73a41ab8a2603386c7cd387_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93571fc75180447ba55229d7f09f1868_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">flks:UniversityOfUtahResearchFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1d35ab3929b4fbe91e95df48a459f8e_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dca2651f502440e853228b2558f473e_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72557c4fa44d4ba5b0d57686b7176435_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib355700b35e94a5ba6f3b2d4a9975b06_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i401548a97a504666ac77f37acd7d7032_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib502bdc134494b80b87687b9029ffcca_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">flks:FlexPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08675e640c04365826f8bb18dab3ceb_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">flks:FlexPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide7180e8b2684c66b43dcb58cf485a4e_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8481df852a634528bdf8f167d58d97c5_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed98830a5f34cfda77f4a37fb71e8c4_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ec9f9e3c871475686ca302cf142454a_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibea4f4bd11db4c879d27ce92ac6637d8_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4d806ab35a84b6ba717db59bba7315a_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82641346e1074588aae8bc99288365f9_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac9b8222fe3849c3a6894033394a49ec_I20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1026e50b8014604b81db07f3826adb3_D20200211-20200211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-11</xbrli:startDate><xbrli:endDate>2020-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f20b1ecfb964b37a76c0654fff02596_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b8ac8f09be5476299897cdf23a7a0c4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">flks:ProfitInterestUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf829e8bf7e456b9116404177f196c9_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d5f52e15574141abe8b47621abead0_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">flks:CommonUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eeda48ea55c43c3921c1333146fc953_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id75dc2c494874c2590b7a7652f91ebca_I20190120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="trading_days"><xbrli:measure>flks:trading_Days</xbrli:measure></xbrli:unit><xbrli:context id="i923938e66ee44ac4a3049da0fb812f9f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d35d901c984cd9a8b3c067ed4795b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d0ed03a53041689adae6878926fead_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c08f3842d84b48b2fd04af17a3bc44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bbed367577c464aa83ed65a64104166_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e818517cf6e4951b3588a8d6e0e57a8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71357db1c2cb48d4a167d650fea320cc_I20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flks:WedbushSecuritiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flks:SatisfySuccessFeeDueToRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2defc6da5b484ddc838a55ab137797ca_D20190719-20190719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flks:WedbushSecuritiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flks:SatisfySuccessFeeDueToRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-19</xbrli:startDate><xbrli:endDate>2019-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ee10a83c58c467499b54edfb3d4578c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0229b2e923e041fe8797ef1f87ddd7eb_D20190910-20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-10</xbrli:startDate><xbrli:endDate>2019-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79fb058518ba480a82055d2644b14f06_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63ca0eae144c4e4a86b4c93b3bcd23ed_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc382e1599924272a66a5f62e9b3fb2e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0e99be21eb64f78a76597b9daad23be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82289f6d72fc4019908f2649c6567ffd_I20200413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-13</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i330ef634d79a46098535b93eedb2fa54_1"></div><div style="height:31.5pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMDk5NTExNjMwMTg3_81d5f2e5-d307-4cc0-9cc9-bf9e5d91c655">10-Q/A</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amendment No. 1</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:0.1%;"></td><td style="width:2.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:95.219%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Mark&#160;One)</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6YjM5MDU0M2RkOTNjNGJhYjhkMmEzOGIxNWM3ZmFlODEvdGFibGVyYW5nZTpiMzkwNTQzZGQ5M2M0YmFiOGQyYTM4YjE1YzdmYWU4MV8xLTAtMS0xLTA_aa95063c-c812-4e82-9d27-67d346af5493">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR&#160;15(d)&#160;OF&#160;THE SECURITIES&#160;EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the quarterly period ended March 31, 2020</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">OR</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6YjM5MDU0M2RkOTNjNGJhYjhkMmEzOGIxNWM3ZmFlODEvdGFibGVyYW5nZTpiMzkwNTQzZGQ5M2M0YmFiOGQyYTM4YjE1YzdmYWU4MV80LTAtMS0xLTA_1935c07b-e8af-41ff-8fa5-7c1f32b8b21f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR&#160;15(d)&#160;OF&#160;THE SECURITIES&#160;EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">For the Transition Period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMTY_fe96e7ad-1598-492c-ab84-c37ba01a656b">001-36812</ix:nonNumeric></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMjA_d5e06345-b980-45a9-abe5-be648cb20108">SALARIUS PHARMACEUTICALS,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.035%;"><tr><td style="width:1.0%;"></td><td style="width:14.420%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.779%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.599%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.779%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.423%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MDM5YzVkZTcyMjNlNGUwYTgzZTMwZWVjNGQ0NTQyNTQvdGFibGVyYW5nZTowMzljNWRlNzIyM2U0ZTBhODNlMzBlZWM0ZDQ1NDI1NF8wLTEtMS0xLTA_579188d1-1d18-4522-84c6-6e8fe0bb8977">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MDM5YzVkZTcyMjNlNGUwYTgzZTMwZWVjNGQ0NTQyNTQvdGFibGVyYW5nZTowMzljNWRlNzIyM2U0ZTBhODNlMzBlZWM0ZDQ1NDI1NF8wLTMtMS0xLTA_c2642d99-987f-49dc-bc29-b4c18fce3047">46-5087339</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">(State or other jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">incorporation or organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Identification Number)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xODE_f9989b98-1170-4af4-a27c-eea4da4b0e92">2450 Holcombe Blvd</ix:nonNumeric>., <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xODY_1bc3c851-bb5a-4460-99ba-11081476601e">Suite J 608</ix:nonNumeric>, <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xOTA_b2c715fc-eee8-41bd-ba3a-cfe085f88eb1">Houston</ix:nonNumeric>, <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xOTQ_a2184764-77e7-4961-9736-3c1ec28b6442">TX</ix:nonNumeric> <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xOTc_b7526b1f-674e-4a5b-9797-20ae6de0ebf2">77021</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(Address of principal executive offices)(Zip Code)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8zMDU_28e755aa-6273-47ee-ac37-74659f09604f">346</ix:nonNumeric>) <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8zMDk_540d9578-6ab6-4237-8cab-39a63313c603">772-0346</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%;">Registrant's telephone number, including area code</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">(Former name, former address and former fiscal year, If changed since last report)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:58.479%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:13.5pt;margin-top:3pt;margin-bottom:3pt;"><span><br/></span></div><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section&#160;12(b) of the Act</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:30.650%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:28.014%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:33.872%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of  each class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MWUyYjA5OWQ3YTRkNDdkZWIxMjYyN2I4YWJkNWVkOWYvdGFibGVyYW5nZToxZTJiMDk5ZDdhNGQ0N2RlYjEyNjI3YjhhYmQ1ZWQ5Zl8xLTAtMS0xLTA_9088c492-8ad3-4c77-b9d6-67d8cdb64a57">Common Stock, $ 0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MWUyYjA5OWQ3YTRkNDdkZWIxMjYyN2I4YWJkNWVkOWYvdGFibGVyYW5nZToxZTJiMDk5ZDdhNGQ0N2RlYjEyNjI3YjhhYmQ1ZWQ5Zl8xLTItMS0xLTA_5979325f-115d-4208-89f3-35f6f14c3e6b">SLRX</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MWUyYjA5OWQ3YTRkNDdkZWIxMjYyN2I4YWJkNWVkOWYvdGFibGVyYW5nZToxZTJiMDk5ZDdhNGQ0N2RlYjEyNjI3YjhhYmQ1ZWQ5Zl8xLTQtMS0xLTA_1260ecfd-d5a1-4163-8aea-157d2be126e2">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to the filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV84MTk_50a14973-ec44-4505-92ed-6eddbc262de1">Yes</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">No</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMTM5_72ce63cd-dae8-4e99-8199-69253fc6010f">Yes</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">No</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">&#9744;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:15.256%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.864%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.831%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.012%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.436%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.159%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.321%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.602%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.321%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.398%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Large Accelerated Filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Accelerated Filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6ZGUzYjM4M2RhNmFhNGZiZThjMDEyYTdhYTM3OTQ4NGYvdGFibGVyYW5nZTpkZTNiMzgzZGE2YWE0ZmJlOGMwMTJhN2FhMzc5NDg0Zl8wLTQtMS0xLTA_e65e214b-246a-43a0-b3d4-7c60db522a50">Non-accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Smaller Reporting Company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6ZGUzYjM4M2RhNmFhNGZiZThjMDEyYTdhYTM3OTQ4NGYvdGFibGVyYW5nZTpkZTNiMzgzZGE2YWE0ZmJlOGMwMTJhN2FhMzc5NDg0Zl8wLTctMS0xLTA_399a7667-cbb4-4179-9bfd-d2c2efdc395c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;Emerging Growth Company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6ZGUzYjM4M2RhNmFhNGZiZThjMDEyYTdhYTM3OTQ4NGYvdGFibGVyYW5nZTpkZTNiMzgzZGE2YWE0ZmJlOGMwMTJhN2FhMzc5NDg0Zl8wLTktMS0xLTA_faee4d86-6d06-4a9c-8f0c-c303ebc3d48c">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xNzQ0_a1cc0e96-aae2-48b4-933d-964a59283e14">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act.)&#160;Yes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xODY1_d44166df-887b-40dd-96ee-f9849170a44f">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">No</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#9746;</span></div><div><span><br/></span></div><div style="margin-top:3pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">As of May&#160;5, 2020, there were</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="shares" contextRef="i4571822fa95e433cb31fe3b268a0157b_I20200505" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMDk5NTExNjMwMDYw_ef230efd-61aa-4da1-bf86-19c1aa835ee1">13,650,752</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">shares of common stock outstanding.</span></div><div style="margin-top:3pt;margin-bottom:3pt;"><span><br/></span></div><div style="position:relative;width:100%;height:22.5pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_1124"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXPLANATORY NOTE</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Salarius Pharmaceuticals, Inc. is filing this Amendment No. 1 on Form 10-Q/A to its Quarterly Report on Form 10-Q for quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on May 14, 2020, solely for the purpose of providing XBRL as Exhibit 101 in accordance with Rule 405 of Regulation S-T. Other than as described above, no changes are made to the Quarterly Report on Form 10-Q as filed on May 14, 2020</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_7"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.855%;"><tr><td style="width:1.0%;"></td><td style="width:11.933%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:77.680%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.387%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="9" style="height:17pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_13">PART I. </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_13">Financial Information</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_16">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_19">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_19">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_22">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_22">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_22">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_25">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_25">Consolidated Statements of Cash Flows </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_25">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_28">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_28">Consolidated Statement</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_28">s</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_28"> of Stockholders' Equity</a> (Deficit)</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_28">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_31">Notes to</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_31"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_31">Condensed </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_31">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_64">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_64">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_64">20</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_76">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_76">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_76">24</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_79">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_79">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_79">24</a></span></div></td></tr><tr><td colspan="9" style="height:17pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_82">PART II.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_82">Other Information</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_85">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_85">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_85">25</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_88">Item 1A.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_88">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_88">25</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_103">Item 5. </a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_103">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_103">28</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_106">Item 6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_106">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_106">30</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_109">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_109">31</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_10"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">The information in this Quarterly Report on Form 10-Q, including the information incorporated herein by reference, include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These are statements that include, but are not limited to, statements about future periods; the Company's strategy and ongoing development programs; the Company's clinical trials, including status, costs, goals, timing and other expectations related thereto; the Company&#8217;s belief as to the potential of its lead compound, SP-2577; the Company's strategic collaborations and license agreements, intellectual property, FDA approval process and government regulation; the potential for Seclidemstat to target the epigenetic dysregulation underlying Ewing sarcoma and advanced solid tumors including, but not limited to, prostate, breast, ovarian, melanoma, colorectal and other cancers; expected timing and results of clinical studies; the nature, strategy and focus of the Company; the development and commercial potential of any product candidates; the Company's ability to regain and maintain compliance with Nasdaq's continued listing standards; the Company&#8217;s expectations as to revenue, cash flow, and expenses; critical accounting policies; the potential impact of the COVID-19 pandemic on the Company&#8217;s business, operations, cash flow and ability to obtain additional financing; the sufficiency of the Company's cash on hand for future operating and capital requirements; the Company's liquidity position, future capital requirements, and need for, and ability to secure, additional financing; the ability of the Company to access additional financing under the Grant Contract with Cancer Prevention and Research Institute of Texas; and the Company's operating losses and ability to continue as a going concern. These forward-looking statements are based on current expectations and beliefs and involve numerous risks and uncertainties, including those discussed under &#8220;Part I &#8212; Item 1A &#8212; Risk Factors,&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2019, and under Part II &#8212;  Item 1A &#8212; Risk Factors in this Quarterly Report on Form 10-Q. These risks and uncertainties that could cause actual results to differ materially from expectations or those expressed in these forward-looking statements. These forward-looking statements should not be relied upon as predictions of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. When used in this report, the words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;indicate,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;aim,&#8221; &#8220;target&#8221; and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">If any of these risks or uncertainties materializes or any of these assumptions proves incorrect, our results could differ materially from the forward-looking statements in this report. All forward-looking statements in this report are current only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any statement is made or to reflect the occurrence of unanticipated events. </span></div><div><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_13"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center;"><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_16"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:7.809%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.191%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Statements</span></td></tr></table></div><div><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_19"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:64.520%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.992%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.645%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNC0xLTEtMS0w_5dd91097-5bfb-4711-8e0a-e72201516bc5">9,646,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNC0zLTEtMS0w_c27e0247-02ab-48f0-a091-68250a150d4f">3,738,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Grants receivable from CPRIT</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNS0xLTEtMS0w_c1d40bb7-1ed7-43e3-bde5-3f0dc4c5496e">591,129</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNS0zLTEtMS0w_9782c75c-0539-4c0f-b408-f5b1f630273e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNy0xLTEtMS0w_ce9731f4-3c32-4940-ae0c-0f39236882e7">646,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNy0zLTEtMS0w_0603751a-a2d9-481d-9e07-5e7f351fb3f1">955,899</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfOC0xLTEtMS0w_fb5098fa-a175-44ca-bb94-93630c899b28">10,884,429</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfOC0zLTEtMS0w_f57298e3-15c0-4e64-baa0-52cfd90f385b">4,694,799</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfOS0xLTEtMS0w_fee7b8a8-6c39-42a3-af71-46c43d1db6f2">21,889</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfOS0zLTEtMS0w_79a7a2fe-65cb-47f2-9629-f3ab17ceb029">25,016</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTItMS0xLTEtMA_a3f79247-7ad6-4729-a083-5614992d92f0">8,865,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTItMy0xLTEtMA_e476d52a-5cf3-42e7-965e-499c7b93b1a1">8,865,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTMtMS0xLTEtMA_30cfc71f-3041-44fc-b248-67827050d4d4">293,147</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTMtMy0xLTEtMA_3957cab6-2d8c-4aff-bbe1-78d9baf727af">308,674</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTQtMS0xLTEtMA_7284bf7d-e42a-48ec-bd59-ce06261fa58d">20,065,374</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTQtMy0xLTEtMA_3fa084cc-d14d-4347-af12-9d26b8240328">13,894,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and stockholders' equity (deficit)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTctMS0xLTEtMA_e28b2030-4903-485f-a46c-e66af7fd93d2">979,823</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTctMy0xLTEtMA_2e16ad9e-ebcf-4f69-81b8-d7ee1694d23e">1,790,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="flks:AccruedExpensesAndOtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTgtMS0xLTEtMA_27406edd-a930-4b1d-b56e-dc3c78febcf0">795,567</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="flks:AccruedExpensesAndOtherCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTgtMy0xLTEtMA_87563e2f-4569-4ac2-bd76-d46b5ec53675">160,783</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Note payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjMtMS0xLTEtMA_195788b1-dbb5-4e4c-9703-824a6b32577b">252,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjMtMy0xLTEtMA_ff356518-ad92-411c-abde-0531442a182c">502,332</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjQtMS0xLTEtMA_cbc45075-6025-42a5-a4c7-1fb0c6712f7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjQtMy0xLTEtMA_bd410fd5-8f1f-4ffb-84cc-227467eb0aef">541,701</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjUtMS0xLTEtMA_2c2aec3e-c1ab-41b8-8e19-ec86f6baa1ed">34,692</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjUtMy0xLTEtMA_0f772696-2eea-4020-af32-c14406bf0f4a">317,762</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjYtMS0xLTEtMA_2cb012ee-6459-4f4b-9e53-d0d503382eee">2,062,761</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjYtMy0xLTEtMA_8519f2c8-85d1-40f8-8efb-9828a88632c4">3,313,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzAtMS0xLTEtMA_ce8f742c-c45d-43f6-a79c-e219895b6981"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzAtMy0xLTEtMA_90f972b9-6fe7-4fd0-9b7c-ec00304255f2"></ix:nonFraction></td></tr><tr><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders' equity (deficit):</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzIx_753a1b0d-bf11-418e-b024-a7a173f5fe73"><ix:nonFraction unitRef="usdPerShare" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzIx_bf42d8ac-e9dd-470d-90d1-3168d5b01d8c">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzM1_32e9c7c1-ac44-49b9-a7b7-7bda47f4c36b"><ix:nonFraction unitRef="shares" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzM1_4cccda8b-5477-4dbb-a9ea-0c8fa34335f2">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzU3_320732e5-1f86-4d0e-a557-06d48aeb9efe"><ix:nonFraction unitRef="shares" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzU3_7223a335-dce2-4eb2-9dd9-3b950c815024"><ix:nonFraction unitRef="shares" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzU3_a1a325f0-378d-47a7-adca-e843b6e80d06"><ix:nonFraction unitRef="shares" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzU3_c9f160a0-c8f6-4a95-bd90-3b7aa21e487d">468,694</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMS0xLTEtMA_0e06e732-7b3a-4489-bfc2-96da8b92a0bd">47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMy0xLTEtMA_144d591f-b1bd-4396-8ca1-12cea8ee7f13">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzE4_0fc468fa-cbf4-4b40-8f5c-70ca97fbe38e"><ix:nonFraction unitRef="usdPerShare" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzE4_ac9d0309-5c29-483a-982c-2fc255db4d6b">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzMy_3aad688a-0221-4e70-90a3-c5446324db0a"><ix:nonFraction unitRef="shares" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzMy_b8088a6a-9b24-4df3-babf-e95094f75ca2">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzU0_6e91fa8d-4af0-4313-9952-1f411494e2f8">13,650,838</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzYx_6e5d5910-b2f9-4b44-b898-fd6779d59fba">4,519,533</ix:nonFraction> shares issued at March&#160;31, 2020 and December&#160;31, 2019, and <ix:nonFraction unitRef="shares" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4Xzk2_98fdc90c-4bf9-4faa-9b9e-fe17b707ef63">13,645,677</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzEwMw_0ac9dc1c-ce61-4cc8-a84b-3e668abd8e88">4,511,174</ix:nonFraction> shares outstanding at March&#160;31, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMS0xLTEtMA_52013082-48ec-45bb-ab1a-9c31668cafa0">1,364</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMy0xLTEtMA_da853bdf-4712-4275-bbc9-617ebafbff02">451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzUtMS0xLTEtMA_6d36717b-dcf9-4070-8b8c-c99c266bd14c">32,161,718</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzUtMy0xLTEtMA_c2a3f275-da1f-4244-ade1-58f86e5e2bf8">22,657,103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzctMS0xLTEtMA_df00db5f-599d-4e95-9b72-910153750d03">14,160,516</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzctMy0xLTEtMA_41e63c20-016a-436a-9430-600ae5e97ee0">12,076,700</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders' equity </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzgtMS0xLTEtMA_1979f5f3-c037-4300-8991-8d0d45d8f455">18,002,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzgtMy0xLTEtMA_a8779e8f-3bf0-41df-a73c-346e4a6cda81">10,580,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzktMS0xLTEtMA_55005a9d-86ee-4878-9dc3-68a00a6fbdef">20,065,374</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzktMy0xLTEtMA_7d46244f-f552-40d8-8f4f-b4a174ce03c6">13,894,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_22"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:67.736%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.473%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.115%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.476%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Grant revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMi0xLTEtMS0w_0c1cf9d8-c720-411f-8c10-911997ac9515">1,132,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMi0zLTEtMS0w_c672dcfc-8123-48a5-a9c7-fc91644f132d">655,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNC0xLTEtMS0w_b056b350-3261-4e1c-b413-ab15f5dc4114">1,643,371</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNC0zLTEtMS0w_7265851c-491a-426d-8320-b508b775ea33">699,929</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNS0xLTEtMS0w_3c3eca60-a562-4ed2-854d-fca03298e9bf">1,859,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNS0zLTEtMS0w_97963191-e855-4858-89e6-1062b0df8e21">1,488,490</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNi0xLTEtMS0w_1131130e-0264-4daf-9d62-4b9bbcb20ddd">3,502,388</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNi0zLTEtMS0w_acf130f2-2d0b-481d-a508-57b758fcf567">2,188,419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before other income (expense)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNy0xLTEtMS0w_fdf189de-366f-40fc-bd6c-49a4d7f22a6c">2,369,558</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNy0zLTEtMS0w_13cb9da4-4ce5-4694-8d6e-3e2d8ff215fc">1,532,784</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of warrant liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfOC0xLTEtMS0w_52dfb0b8-2878-4ff9-a7c1-163ed91ab554">283,070</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfOC0zLTEtMS0w_cea4d865-4138-4887-a093-a0451f1a195b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfOS0xLTEtMS0w_80312d9c-2aa1-4f2a-beef-d652ca87d8ae">2,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfOS0zLTEtMS0w_db6a8ac5-e2f9-474b-8153-6442afd236cf">10,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMTAtMS0xLTEtMA_a1429d2e-12b9-4afc-91c3-85322f0e4e10">2,083,816</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMTAtMy0xLTEtMA_42578e81-5f90-4e28-94f7-b8456f34f2f8">1,522,076</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss per common share&#160;&#8212; basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMjEtMS0xLTEtMA_a574d433-fc9b-43a8-ac2f-f13e3e56c4d1">0.22</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMjEtMy0xLTEtMA_4e138149-2c35-4cc9-9d00-9ced9ba8e9e2">0.64</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-4.5pt;padding-left:4.5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average number of common shares outstanding&#160;&#8212; basic and diluted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMjItMS0xLTEtMA_2f949f9c-ce9f-449b-8346-fa2374387d34">9,534,842</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMjItMy0xLTEtMA_f99bd2b3-7dbb-49c0-b76c-4800e09cfb28">2,372,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_25"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.321%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.473%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.476%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMi0xLTEtMS0w_cb9abbfe-3d02-4856-8260-4ea52db19226">2,083,816</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMi0zLTEtMS0w_f952b459-f8a8-4019-986c-b537f01fb672">1,522,076</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation, amortization and impairment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNC0xLTEtMS0w_790965ec-1189-4558-bf89-9167d5ca7043">4,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNC0zLTEtMS0w_103d13a3-3d75-4f81-bdb9-0750775fd4ac">114,707</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNS0xLTEtMS0w_c2b78535-5c70-4938-ad1b-87bc370e89de">38,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNS0zLTEtMS0w_8b6c2b53-9c01-4ccf-969a-030fef4f33e5">35,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of warrant liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNy0xLTEtMS0w_2094bd50-43c3-4e04-963b-7fba1eb87991">283,070</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNy0zLTEtMS0w_c3c35b0b-df83-492f-b00c-14bf8e54978f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Grants receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTAtMS0xLTEtMA_6adc4c95-fd4c-4f67-8aa8-8452df9ec3b5">591,129</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTAtMy0xLTEtMA_c41171fe-8276-4dd5-a357-21dc4427fc1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTEtMS0xLTEtMA_d5f1294d-6f34-4d21-9e31-5af19e473313">298,959</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTEtMy0xLTEtMA_20f2d194-3c12-47ca-bd8e-f5b7ba46c8f3">30,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTMtMS0xLTEtMA_b63b4fbc-15d8-4705-8eab-0008e14b7ed0">911,301</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTMtMy0xLTEtMA_06cd015f-d125-4738-9248-d00e9a0f17f7">589,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTQtMS0xLTEtMA_15a23f9a-b367-4efd-881f-a59a95b838ce">361,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTQtMy0xLTEtMA_0d0c7642-b2ee-4f67-87ba-90ed6acf2498">462,816</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Due to/from related party</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTUtMS0xLTEtMA_06695fc8-da86-423c-8512-419c95f535b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTUtMy0xLTEtMA_72dfc569-4eae-4a40-bd5b-df118e30f67e">1,256</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTYtMS0xLTEtMA_fac28c56-640f-4381-8914-073f9393440b">541,701</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTYtMy0xLTEtMA_223185c7-874f-4935-9aff-62bbc3294244">655,634</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTgtMS0xLTEtMA_f5aa85a7-bb49-43ea-9ba0-f7b612e051b2">3,708,034</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTgtMy0xLTEtMA_b10619ac-19a5-403f-91db-f374abd24e38">1,868,713</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of equity securities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMjgtMS0xLTEtMA_7f369767-5c93-4485-9f03-ef1d60652e62">9,865,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMjgtMy0xLTEtMA_707e690a-3e32-4f93-ae5a-693bd0b5aecb">1,508,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments on note payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzAtMS0xLTEtMA_15dadfbf-f64c-4484-9ff5-d9b25a91205d">249,653</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzAtMy0xLTEtMA_80308866-d57e-4321-bb25-c2ffc2c8378a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzItMS0xLTEtMA_ccef80cd-1754-4678-954f-fbc1831c7524">9,616,074</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzItMy0xLTEtMA_859dcedd-e19b-4f5c-9488-7da52c039c91">1,508,179</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net  increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzQtMS0xLTEtMA_828d8fb6-4569-4b07-895a-2840bb4d97ba">5,908,040</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzQtMy0xLTEtMA_c1f362e6-1f70-4c28-8b7a-a7aec8a58b95">360,534</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzUtMS0xLTEtMA_0da29106-3606-4216-a55d-d429753311de">3,738,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i70af0eeb6ae64595b3496e4f573820f7_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzUtMy0xLTEtMA_b9c3ab99-667e-4c9b-80d4-89a290a48ac5">6,131,781</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents and restricted cash at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzYtMS0xLTEtMA_c1fdfc38-5284-4e35-8eb4-828885000330">9,646,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6632a88f72bd4dce912e8beda5728be8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzYtMy0xLTEtMA_23e91c79-bc2d-4b10-ab9d-2ead814dea5c">5,771,247</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:5pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for interest</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzktMS0xLTEtMA_8aceab1d-db1d-49c7-8fe6-08a6869050bd">3,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzktMy0xLTEtMA_78dd5b42-afb4-4f29-9cb1-47f869f916b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued issuance costs for public offering </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="flks:StockIssuanceCostsAccruedAndAmortized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNDQtMS0xLTEtMA_cd0525ec-6903-4bcb-8bc0-dacc1ceea758">398,561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:zerodash" name="flks:StockIssuanceCostsAccruedAndAmortized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNDQtMy0xLTEtMA_9ae8dd8c-f235-4ce5-ae3d-345e6fc6bf33">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of shares for license</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzQtMS0xLTEtMjEyOQ_b0f5fbe9-63ef-4c2b-9db4-908a83c02451">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzUtMy0xLTEtMTk2Mg_40a97a14-af81-4daa-9691-3ae88116425b">110,474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of liabilities to equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzYtMS0xLTEtMTk1Ng_23fc7534-ab37-4980-a6d7-8790fde60801">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzYtMy0xLTEtMTk1Ng_5c32e6ba-5f6b-4075-a881-ec8438509cb3">2,869,412</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_28"></div><hr style="page-break-after:always"/><div style="height:36pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:90.060%;"><tr><td style="width:1.0%;"></td><td style="width:24.644%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.026%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.357%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.023%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.357%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.144%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.245%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.144%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.245%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.144%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.357%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.928%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.245%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.941%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Deficit</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders' Equity (Deficit)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i85b3036ab6d64f5c890474b22de3cea0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctMS0xLTEtMA_916d68d4-55fe-4f99-8592-24c7732cf90b">2,032,763</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i85b3036ab6d64f5c890474b22de3cea0_I20181231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctMy0xLTEtMA_a45232c8-b2a8-4cfb-bf63-7ca108f29139">203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i48e6839aa78b49d7a1b426193e822187_I20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMy01LTEtMS0xNjk3_5a9ff340-890f-463c-9b7c-44d336cbb198">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48e6839aa78b49d7a1b426193e822187_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMy03LTEtMS0xNjk3_29c6a058-58ca-4310-8d6f-59490a069c03">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9544fb2f862e407388524ab0bccddac0_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctNS0xLTEtMA_1a8160b7-4f5f-4b30-a733-5e4ccfa2dd4c">3,869,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i16fda578275a497fa39ffdae434647bb_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctNy0xLTEtMA_d4e7fbd6-e371-4510-a762-12bec70c3414">5,140,437</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i70af0eeb6ae64595b3496e4f573820f7_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctOS0xLTEtMA_934583e5-3d3b-47f5-a5da-56875a9dce7e">1,271,114</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of equity securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTgtMS0xLTEtMA_3f3c2197-7f42-45df-9cd2-72cb43aa66b1">960,489</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTgtMy0xLTEtMA_b2233200-6149-4d19-bbf3-b4630bc887a7">96</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i296a0cb619044259822d223d39af65b2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTgtNS0xLTEtMA_65c57d25-f9ab-4473-92d1-d6f74a5a00d2">4,377,495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTgtOS0xLTEtMA_e07946a1-f01b-4b94-98dd-3e1793dfbd05">4,377,591</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of equity securities for license</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTktMS0xLTEtMA_b8b267a3-88a6-4585-91ed-82716e8dc611">12,907</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTktMy0xLTEtMA_120a3fe8-eec8-40fd-be5a-69bf62703394">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i296a0cb619044259822d223d39af65b2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTktNS0xLTEtMA_acf6d933-3950-4315-aa28-822fbd3a2b05">110,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTktOS0xLTEtMA_e46cdc05-ab85-453f-afab-4a36fc30082c">110,474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjAtMS0xLTEtMA_392359ff-d8f8-4927-a58c-38bf0a7f9ad7">9,550</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjAtMy0xLTEtMA_1f7baa89-3503-4249-a125-4672070b15ab">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i296a0cb619044259822d223d39af65b2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjAtNS0xLTEtMA_4839433c-7c47-434d-88b4-1d4287b2f361">35,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjAtOS0xLTEtMA_427468bf-744e-4c36-83aa-a761d0c9d431">35,407</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic0351d160e9c47e49e8caea479d3bbb7_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjEtNy0xLTEtMA_60865ade-025a-46fb-b082-62dab2278c94">1,522,076</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjEtOS0xLTEtMA_f69a0d48-4aa7-45e2-9a3b-9eb657d3cc3e">1,522,076</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i029a4238195344ce9ca54a046028a734_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItMS0xLTEtMA_499aeba5-a46a-40bb-82bb-f5efafb5909e">3,015,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i029a4238195344ce9ca54a046028a734_I20190331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItMy0xLTEtMA_a3820351-ad2f-49bf-8a42-848d0afdbf93">301</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4cafa03bbcbf41e9af4d14448d9db3c5_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItNS0xLTEtMA_aad5830c-101a-4132-bc25-515996adbb6b">8,392,494</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9edcc8fcaab54e3aacded026cb8d9b22_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItNy0xLTEtMA_9c46f1b8-a4aa-4ad4-b7f0-e55174ba15ca">6,662,513</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6632a88f72bd4dce912e8beda5728be8_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItOS0xLTEtMA_c4837b57-c229-4414-8d7a-ab5f5383a180">1,730,282</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic9c5329d026f46fa9a0a9ab94fd1106c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtMS0xLTEtMA_ef976c3b-d428-4a90-9886-ef5c7ff3d5eb">4,511,174</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9c5329d026f46fa9a0a9ab94fd1106c_I20191231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtMy0xLTEtMA_8303a891-e99b-42e3-9902-9da01ee86ee0">451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7146557875c64c948bcec77e00b091b1_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTAtNS0xLTEtMTY5NQ_7ce9d0ac-8cd5-4693-b3b9-deeb13824f03">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7146557875c64c948bcec77e00b091b1_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTAtNy0xLTEtMTY5NQ_a2f2e8f9-90d1-4966-936e-fbbac569cff6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bd590e1573a4c41a8193d12224c9c3c_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtNS0xLTEtMA_11438646-d64a-4c6c-96f3-7f7b32cd916c">22,657,103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6f3e1bbf23f94c92b05cbed3fcbff616_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtNy0xLTEtMA_7fc26b52-6ccd-4929-aa8e-7b60312a279a">12,076,700</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtOS0xLTEtMA_32e66f49-e242-418e-880e-687307740cb4">10,580,854</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Issuance of equity securities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjctMS0xLTEtMA_b899acde-b2e9-4097-a0b0-446560ae309b">8,353,480</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjctMy0xLTEtMA_1b115917-1067-4776-b635-07ed65d56355">835</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTEtNS0xLTEtMTY5MQ_ce528552-93a2-452c-b5ca-7fbe3cb08ca7">1,246,519</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTEtNy0xLTEtMTY5MQ_0036f470-c71e-4f78-9a6e-1708ec405a56">125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5df749b27e2e4ab594097b6f0dfcbbfb_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjctNS0xLTEtMA_870aad8b-6a6b-4b27-b7bf-81e6f9bd42cd">9,466,206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjctOS0xLTEtMA_da1b3aee-d5ef-4400-86df-fbc1c57e4c1b">9,467,166</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred shares  converted to common shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjgtMS0xLTEtMA_e990fe60-50ab-4476-9c1a-854e55fc1edf">777,825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjgtMy0xLTEtMA_9e5ffdf6-0939-42f4-97d5-e061d837b7c8">78</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTItNS0xLTEtMTY4Ng_24c6f4ed-5003-4895-bdee-cd1a65d0534d">777,825</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTItNy0xLTEtMTY4OA_ea15a0d2-6151-4171-96c6-e5b343394c3f">78</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjgtOS0xLTEtMA_9aab2991-a45e-46c8-8a48-f097a3e26136">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjktMS0xLTEtMA_12b7f438-6f6e-4f65-8191-2436f9096c4b">3,198</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5df749b27e2e4ab594097b6f0dfcbbfb_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjktNS0xLTEtMA_6474963a-f65e-4d43-bec4-99f8b264c3df">38,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjktOS0xLTEtMA_cd43383a-8d54-4ab0-87c8-96868f575904">38,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:6pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i139ce469438446e1aa69f17a3d9c7865_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTQtMTEtMS0xLTE3MDE_5c859466-2a01-40b8-9f2e-e4b133b5f027">2,083,816</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTQtMTMtMS0xLTE3MDE_39b584e5-05e0-41fc-b5e2-ab6c5325ec76">2,083,816</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie9080f05ec45443fad3554f83e2eace9_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtMS0xLTEtMA_dd7d559c-347d-4c28-972d-19156acc8aa9">13,645,677</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie9080f05ec45443fad3554f83e2eace9_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtMy0xLTEtMA_80d6a1af-f839-4346-b7a1-5d8c1d3a9fa0">1,364</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:11pt;font-weight:700;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i48fe193ad62a4945adfc9947d631230b_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTUtNS0xLTEtMTY5Mw_e65415dc-dcdd-415d-afa5-fbeb62d27b7b">468,694</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:11pt;font-weight:700;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:11pt;font-weight:700;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i48fe193ad62a4945adfc9947d631230b_I20200331" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTUtNy0xLTEtMTY5Mw_212d780c-c0d1-4aff-9b80-64f376934118">47</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:11pt;font-weight:700;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic2f7e69dbdb94177a53d56e0f77d4cf3_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtNS0xLTEtMA_6907b9fc-8aa2-4aa8-ab94-4986455d7f9b">32,161,718</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifd7aaa5165cb45d2809ccf6274968968_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtNy0xLTEtMA_7ba0c387-837d-4764-b15d-fb2fc6d27d4d">14,160,516</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtOS0xLTEtMA_93f2c932-9395-4d7b-811b-462fe7812e05">18,002,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:6pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_31"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="i330ef634d79a46098535b93eedb2fa54_34"></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 1. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNC9mcmFnOjhiNDIwMmIzYjdjNDRhOTE5ZWJhODIwZWQ2ODZlYzA5L3RleHRyZWdpb246OGI0MjAyYjNiN2M0NGE5MTllYmE4MjBlZDY4NmVjMDlfMzI5Nw_eb97b43d-d158-48d6-8097-351e060e6875" continuedAt="i7eb0636df2cf4c95899b109cf70731ee" escape="true">ORGANIZATION AND OPERATIONS</ix:nonNumeric></span></div><div style="margin-bottom:1pt;"><span><br/></span></div><ix:continuation id="i7eb0636df2cf4c95899b109cf70731ee"><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Nature of Business</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Salarius Pharmaceuticals, Inc. (&#8220;Salarius&#8221; or the &#8220;Company&#8221;), together with its subsidiaries, Salarius Pharmaceuticals, LLC, Flex Innovation Group LLC, and TK Pharma, Inc., is a clinical-stage biotechnology company focused on developing effective treatments for cancers with high unmet medical need caused by dysregulated gene expression.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Epigenetics refers to the regulatory system that affects gene expression and the Company's lead epigenetic enzyme technology was licensed from the University of Utah Research Foundation in 2011. The Company is located in Houston, Texas.</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Merger with Flex Pharma, Inc.</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January&#160;3, 2019, Flex Pharma, Inc. ("Flex Pharma"), Salarius Pharmaceuticals LLC ("Private Salarius") and Falcon Acquisition Sub, LLC (&#8220;Merger Sub&#8221;), a wholly owned subsidiary of Flex Pharma, entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;). Pursuant to the Merger Agreement, Merger Sub merged with and into Private Salarius, with Private Salarius continuing as a wholly owned subsidiary of Flex Pharma. The merger was completed on July 19, 2019. After the merger, Flex Pharma was renamed Salarius Pharmaceuticals, Inc. The merger was accounted for as a reverse acquisition with Private Salarius being deemed the acquiring company for accounting purposes. See Note&#160;3.</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Covid-19 Pandemic</span></div><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outbreak of COVID-19 has spread worldwide. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company&#8217;s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&#8217;s ability to access capital, which could negatively impact the Company&#8217;s long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&#8217;s liquidity, capital resources, operations and business and those of the third parties on which we rely.</span></div></ix:continuation><div style="margin-bottom:8pt;"><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_37"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 2. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxMg_7dcd2435-e651-4d48-9572-6ba5e6557290" continuedAt="ia28fce769826451aa10349a69dc1cfe1" escape="true">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia28fce769826451aa10349a69dc1cfe1" continuedAt="i54380634748448d48f389f6b9e0e390a"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzI_f639e0ea-90d0-4446-9b36-9ac09821dd1f" continuedAt="ic1dec17feaca444485335121993ae791" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As described above, the merger with Flex Pharma closed on July 19, 2019. The merger was accounted for as a reverse acquisition with Private Salarius being deemed the acquiring company for accounting purposes. Private Salarius&#8217; historical financial statements have replaced Flex Pharma&#8217;s historical consolidated financial statements with respect to periods prior to the completion of the merger with retroactive adjustments to Private Salarius' legal capital to reflect the legal capital of Flex Pharma. Flex Pharma (renamed Salarius Pharmaceuticals, Inc.) remains the continuing registrant and reporting company. Accordingly, the historical financial and operating data of Salarius Pharmaceuticals, Inc., which covers periods prior to the closing date of the merger, reflects the assets, liabilities and results of operations of Private Salarius and does not reflect the assets, liabilities and results of operations of Flex Pharma for the periods prior to July 19, 2019. The Company has retrospectively adjusted its Statement of Changes in Stockholders&#8217; Equity (Deficit) and the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding common unit, profits interest common unit and Series A Preferred unit of </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><ix:continuation id="i54380634748448d48f389f6b9e0e390a" continuedAt="ic5e61e4ad0f741e18b4f69e340a55f9a"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="ic1dec17feaca444485335121993ae791">Private Salarius that converted into shares of the Company&#8217;s common stock upon the merger, and to reflect the effect of the <ix:nonFraction unitRef="number" contextRef="i88b3e077cd5846b99d7bad5be157bb53_D20190719-20190719" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTkwMw_e61f8b89-3a2d-467e-982a-ca45f7bdd7bc">25</ix:nonFraction> to 1 reverse stock split of the Company&#8217;s common stock which occurred upon the merger.</ix:continuation></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzc_a4384e37-c083-4f17-bbb6-1f83d9f2b824" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Unaudited Interim Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December&#160;31, 2019 included elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 23, 2020. In the opinion of management, the unaudited interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of March&#160;31, 2020 and the results of operations for the three months ended March&#160;31, 2020 and 2019. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December&#160;31, 2019 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzA_bb74579d-4995-4bae-a6da-400dbb54b15a" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzg_b57a4236-0053-4462-8a9d-3020df247e68" continuedAt="i9d4bb1b6332d40e297a2fcff7cfa086c" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i9d4bb1b6332d40e297a2fcff7cfa086c">Salarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At March&#160;31, 2020 and December&#160;31, 2019, Salarius also held approximately $<ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfNDY3Mg_e453c91d-b8ff-4070-ab83-1ee32f60cb25">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfNDY3OQ_f9595e16-e070-4d7a-b090-0ded0432d7c5">1.0</ix:nonFraction> million, respectively, which represents funds received from Cancer Prevention and Research Institution of Texas ("CPRIT").  These funds were used for costs for allowable expenses, primarily research and development expenses. The grant has a mandatory fund matching requirement. Subject to CPRIT review, the Company believes that all matching fund requirements have been met at March&#160;31, 2020.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMTc_2ec7ec45-b904-4478-a6c8-d72b1fd30c6c" continuedAt="i97f1645d123444abb228ecff7cbf1fca" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i97f1645d123444abb228ecff7cbf1fca">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.</ix:continuation>  During the three months ended March&#160;31, 2020 and March&#160;31, 2019 , impairment charges related to long-lived assets were $<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfNjM4NQ_7499deed-da94-440c-acbf-03fc6ce94dd8">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfNjM5Mg_c949065d-a9ac-41a5-bbfb-9bfecbe0007b">110,474</ix:nonFraction>, respectively. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxNA_820151c1-cd3c-4084-a8eb-82013ac33f09" continuedAt="i61a5104f7cbd4e9484440839d047b8f9" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Goodwill</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><ix:continuation id="ic5e61e4ad0f741e18b4f69e340a55f9a" continuedAt="i0ad0648d288c4f23af0211e1b475740d"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i61a5104f7cbd4e9484440839d047b8f9">value of goodwill has been impaired.</ix:continuation> There was no impairment of goodwill during the three months ended March&#160;31, 2020 or March&#160;31, 2019, respectively.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMjc_ffcc6eeb-4dbd-457a-987d-d17d60fe74aa" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxNQ_ff0670e4-a698-461a-84df-7b9ce0032b99" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the reverse merger transaction, the Company issued rights to receive warrants to purchase the Company&#8217;s common stock. Further, on February 11, 2020, the Company issued warrants to purchase the Company's common stock in a registered public offering. The Company determines whether the warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within Change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Clinical Trial Accruals</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s preclinical and clinical trials are performed by third party contract research organizations (CROs) and/or clinical investigators, and clinical supplies are manufactured by contract manufacturing organizations (CMOs). Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CMOs regarding the status and cost of the studies, and may not match the actual services performed by the organizations. This could result in adjustments to the Company&#8217;s research and development expenses in future periods. To date the Company has had no significant adjustments.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxNg_6b3c372c-d0f4-42d1-bc19-8ab8a14dbbf7" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Grants Receivable and Revenue Recognition </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Salarius&#8217; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grants receivable.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMTk_27d01ec5-4403-41e8-bbac-7485cbb81dfb" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMjA_caffe2f4-3ff0-4ed6-ad72-a73c64ba7869" continuedAt="ib5a91269647e4869b1af06ad1eb7681f" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Equity-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><ix:continuation id="i0ad0648d288c4f23af0211e1b475740d" continuedAt="i0a9a843038fb48e29c6e96fb6f37e344"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib5a91269647e4869b1af06ad1eb7681f">The Company uses the Black-Scholes option valuation model and the Backsolve method (which is similar to the Black-Scholes valuation model and produces similar results) to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMjE_310c10a7-cd03-4b06-8ab9-5b0bfb918d42" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</span></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of anti-dilutive shares, consisting of common shares underlying (i) common stock options, (ii) stock purchase warrants, (iii) unvested restricted stock, (iv) convertible preferred stock and (v) rights entitling holders to receive warrants to purchase the Company's common shares, which have been excluded from the computation of diluted loss per share, was <ix:nonFraction unitRef="shares" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTI3NDY_2f32a1d5-ef7d-40be-9538-39a6156ce595">10,597,729</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTI3NTM_a9523ed4-b55c-4d90-8485-118d682c131a">30,395</ix:nonFraction> shares as of March&#160;31, 2020 and 2019, respectively.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxNw_0f969298-4a5e-426a-87bd-fbb0688bd29f" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzY_173d2a66-a514-4304-aee2-4ec39d9bc132" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Subsequent Events</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxMw_7b5770e6-11be-4159-9051-813cdd06d747" continuedAt="if18e7fda32304e918f02ff07118d6a03" escape="true"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Application of New Accounting Standards</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Intangibles-Goodwill and Other,&#8221; which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">years, and interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact on its consolidated financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Pronouncements Not Yet Adopted</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><ix:continuation id="i0a9a843038fb48e29c6e96fb6f37e344"><ix:continuation id="if18e7fda32304e918f02ff07118d6a03"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_40"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 3. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfNDkwMQ_e0f8cacf-fd06-4334-b6ab-a9c058244aa1" continuedAt="i11a9b9f3fd1e49b6a64dfc330d67ff56" escape="true">REVERSE ACQUISITION AND DISPOSAL</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i11a9b9f3fd1e49b6a64dfc330d67ff56" continuedAt="i23d151a1fbc14c139a0bf040d943f197"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reverse Acquisition</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January&#160;3, 2019, Flex Pharma, Private Salarius and Merger Sub entered into the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into Private Salarius, with Private Salarius continuing as a wholly owned subsidiary of Flex Pharma, with Flex Pharma deemed the legal acquiror and Private Salarius deemed the accounting acquiror, as described below. The merger was completed on July&#160;19, 2019. After the merger, Flex Pharma was renamed Salarius Pharmaceuticals, Inc. The merger was accounted for as a reverse acquisition business acquisition with Private Salarius being deemed the acquiring company for accounting purposes. Private Salarius, as the accounting acquirer, recorded the assets acquired and liabilities assumed of Flex Pharma in the merger at their fair values as of the acquisition date. Private Salarius&#8217; historical financial statements have replaced Flex Pharma&#8217;s historical consolidated financial statements with respect to periods prior to the completion of the merger with retroactive adjustments to Private Salarius' legal capital to reflect the legal capital of Flex Pharma. Flex Pharma (which was renamed Salarius Pharmaceuticals, Inc. in connection with the merger) remains the continuing registrant and reporting company.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Private Salarius was determined to be the accounting acquirer based on the following facts and circumstances: (1)&#160;members of Private Salarius owned approximately <ix:nonFraction unitRef="number" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfMTQyNw_df526ce9-1b18-4c96-842a-5c7c9da63b33">80.7</ix:nonFraction>% of the voting interests of the combined company immediately following the closing of the transaction; (2)&#160;the majority of the board of directors of the combined company was composed of directors designated by Private Salarius under the terms of the Merger Agreement; and (3)&#160;existing members of Private Salarius management became the management of the combined company. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The business purposes of the merger included, among other purposes, obtaining the following potential advantages: (i) the combined organization&#8217;s resources would be immediately available to support Private Salarius&#8217; research on Seclidemstat; and (ii) the public company status would allow the Company greater potential access to additional capital.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the closing of the merger, each outstanding common unit, profits interest common unit and Series A Preferred unit of Private Salarius converted into shares of the Company&#8217;s common stock (subject to the payment of cash in lieu of fractional shares and after giving effect to a <ix:nonFraction unitRef="number" contextRef="i88b3e077cd5846b99d7bad5be157bb53_D20190719-20190719" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfMjQzMQ_200b873c-e26f-4440-bda0-00913de016b2">25</ix:nonFraction> to 1 reverse stock split of the Company&#8217;s common stock) at the conversion ratio formulae described in the Merger Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, at the closing of the merger, the Company distributed <ix:nonFraction unitRef="shares" contextRef="if8e9ef7d321148bfa7e0fc99f44856d7_I20190719" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfMjYyNg_1ea8ea08-4ac9-469a-ab76-bd98e4f05e65">one</ix:nonFraction> right per share of common stock to stockholders of record as of the close of business on July 18, 2019. Each right entitles such stockholders to receive </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><ix:continuation id="i23d151a1fbc14c139a0bf040d943f197"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a warrant to purchase shares of the Company&#8217;s common stock <ix:nonNumeric contextRef="i9335e01552494ea4aeab4ed31281b503_D20190719-20190719" format="ixt-sec:durwordsen" name="flks:ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfMjg0MQ_00e707e5-140d-4654-8ac1-e6ae9eb5df2a">six months</ix:nonNumeric> and one day following the closing date of the merger. See Note 8.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounted for the acquisition as a reverse merger using purchase accounting. Because the merger qualifies as a reverse acquisition and given that Private Salarius was a private company at the time of the merger and therefore its value was not readily determinable, the fair value of the merger consideration was deemed to be equal to the sum of the quoted market capitalization of the Company at the merger date, the fair value of the Flex Pharma options that fully vested upon the merger together, and the fair value of the rights to receive warrants that were granted to the pre-merger Flex Pharma stockholders. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfNDkwMg_7e376e58-6324-46f7-abdb-eab3cb32ca4c" continuedAt="ie5ae40712094425698f983acefa2d1b7" escape="true">Total purchase consideration is as follows:</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><ix:continuation id="ie5ae40712094425698f983acefa2d1b7"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"></td><td style="width:61.595%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:34.405%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Flex Pharma market capitalization at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmVlYjJhN2U3Y2MxNDRlZTlhYTgwYjY5Y2I4OGZkOGE4L3RhYmxlcmFuZ2U6ZWViMmE3ZTdjYzE0NGVlOWFhODBiNjljYjg4ZmQ4YThfMC0xLTEtMS0w_18f99bf6-eaa5-4751-ae2c-52fee10fd198">10,963,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of rights to warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719" decimals="0" format="ixt:numdotdecimal" name="flks:BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmVlYjJhN2U3Y2MxNDRlZTlhYTgwYjY5Y2I4OGZkOGE4L3RhYmxlcmFuZ2U6ZWViMmE3ZTdjYzE0NGVlOWFhODBiNjljYjg4ZmQ4YThfMS0xLTEtMS0w_607cb662-22c8-45f4-a55e-eeda2123d947">1,629,095</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of Flex Pharma outstanding options on the merger date</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719" decimals="0" format="ixt:numdotdecimal" name="flks:BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmVlYjJhN2U3Y2MxNDRlZTlhYTgwYjY5Y2I4OGZkOGE4L3RhYmxlcmFuZ2U6ZWViMmE3ZTdjYzE0NGVlOWFhODBiNjljYjg4ZmQ4YThfMi0xLTEtMS0w_93436273-8869-48c0-8264-9706980aa905">132,227</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total purchase consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmVlYjJhN2U3Y2MxNDRlZTlhYTgwYjY5Y2I4OGZkOGE4L3RhYmxlcmFuZ2U6ZWViMmE3ZTdjYzE0NGVlOWFhODBiNjljYjg4ZmQ4YThfMy0xLTEtMS0w_501728b9-3a9d-434c-abab-27385f5b2be4">12,724,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recorded all tangible and intangible assets acquired and liabilities assumed at their preliminary estimated fair values on the merger date. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfNDkwMw_095fd89f-08b6-4663-be54-264da26eaad0" continuedAt="i7df7890ec0064df8b5451731244b7e60" escape="true">The following represents the allocation of the estimated purchase consideration:</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><ix:continuation id="i7df7890ec0064df8b5451731244b7e60"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:60.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.059%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of assets acquired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMS0xLTEtMS0w_543dc472-dc96-4f42-bc7c-d5bff49d1397">5,405,826</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMi0xLTEtMS0w_bb00562c-6b51-49b4-b48c-129f95e958ae">15,168</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMy0xLTEtMS0w_f92cf9fb-bc74-4041-a6fe-7ff9273f13ae">122,235</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expense and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfNC0xLTEtMS0w_cfaffd20-7e11-4df1-aebb-11e78642b001">106,319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill and intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="0" format="ixt:numdotdecimal" name="flks:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfNS0xLTEtMS0w_5d1d3c63-af3f-4c90-bdd7-18f9120dc69b">8,937,899</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfNi0xLTEtMS0w_183d40b6-c84d-4dfb-91cb-58281766066a">14,587,447</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable, accrued liabilities and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfOS0xLTEtMS0w_2c8eaf5e-6b2f-4788-9f55-62b5ba64c1b2">1,862,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of liabilities assumed</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMTAtMS0xLTEtMA_fc4aa921-ce95-4b3a-939f-8fb92d9f2f8a">1,862,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMTItMS0xLTEtMA_14d17b41-db76-4954-8226-33f1b76e94d0">12,724,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Unaudited Pro Forma Disclosure</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfNDg5OQ_a9fb34b5-e7c8-477e-8b18-9e7f7bb2423d" escape="true"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following unaudited pro forma financial information summarizes the results of operations for the three months ended March&#160;31, 2020 and 2019 as if the merger described above had been completed as of January 1, 2019. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the merger had been completed as of January 1, 2019, the transaction costs would have been expensed in the prior period.</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:64.422%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.422%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.423%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMS0xLTEtMS0w_8494ee3c-0209-401e-99d2-63542f26477b">1,132,830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMS0zLTEtMS0w_6b5797d8-96ce-4c9d-b2d9-bcc4ad7df68d">655,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMi0xLTEtMS0w_c5cccc6c-9ec0-4de5-b48b-dcd90663b983">2,083,816</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMi0zLTEtMS0w_486cba67-24d7-4df3-9e92-ea86f7659bc4">9,415,074</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMy0xLTEtMS0w_bedcf97b-9721-42e9-ac3e-b8e2472c952a">0.22</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="2" sign="-" name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMy0zLTEtMS0w_7b9cde3a-23bd-4803-8a42-c4434a541dc7">3.97</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_1115"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 4. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMTE1L2ZyYWc6YTljZGFkYWJkZmNiNDJhMzg1ZmFmYjhiNmM2NWFmZDUvdGV4dHJlZ2lvbjphOWNkYWRhYmRmY2I0MmEzODVmYWZiOGI2YzY1YWZkNV8xMDk5NTExNjI4MTE0_e8d66aaa-1c88-41d7-a487-2783f3b39f0b" continuedAt="i19d621d650ff41d391de0dca82333d59" escape="true">GRANTS RECEIVABLE</ix:nonNumeric></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i19d621d650ff41d391de0dca82333d59">Grants receivable represents qualifying costs incurred and there is reasonable assurance that conditions of the grant have been met but the corresponding funds have not been received as of the reporting date. Grants receivable balances are $<ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMTE1L2ZyYWc6YTljZGFkYWJkZmNiNDJhMzg1ZmFmYjhiNmM2NWFmZDUvdGV4dHJlZ2lvbjphOWNkYWRhYmRmY2I0MmEzODVmYWZiOGI2YzY1YWZkNV8yMTk5MDIzMjU1ODIz_c1d40bb7-1ed7-43e3-bde5-3f0dc4c5496e">591,129</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" name="us-gaap:ReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMTE1L2ZyYWc6YTljZGFkYWJkZmNiNDJhMzg1ZmFmYjhiNmM2NWFmZDUvdGV4dHJlZ2lvbjphOWNkYWRhYmRmY2I0MmEzODVmYWZiOGI2YzY1YWZkNV8yMTk5MDIzMjU1ODMw_9782c75c-0539-4c0f-b408-f5b1f630273e">0</ix:nonFraction> as of March 31, 2020 and December 31, 2019, respectively.</ix:continuation></span></div><div id="i330ef634d79a46098535b93eedb2fa54_43"></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 5. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMTA5OTUxMTYyOTI0Mw_6a8ffbf4-3c6c-45f1-86a8-d89e1c3be19d" continuedAt="i2aafa4c0e9d1492f8dfc6c335454c06a" escape="true">PREPAID EXPENSES AND OTHER CURRENT ASSETS</ix:nonNumeric></span></div><ix:continuation id="i2aafa4c0e9d1492f8dfc6c335454c06a" continuedAt="id87cf993cf0d4ad58e0dd0fdac4df844"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMTQ2_3238adc9-4c30-4784-a3bb-1b6b36ee366b" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets at March&#160;31, 2020 and December&#160;31, 2019 consisted of the following: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:64.422%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.422%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.423%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid clinical trial expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="flks:PrepaidClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfMS0xLTEtMS0w_22e5ffd8-d75a-407a-8cc8-a327c219888c">140,964</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="flks:PrepaidClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfMS0zLTEtMS0w_db3a2777-5af6-4f3b-93d4-125917e07a45">202,743</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfMi0xLTEtMS0w_8d235a3d-ab0a-4010-bf31-e9856615806c">360,608</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfMi0zLTEtMS0w_afea2e52-94f8-4248-8742-3240cf1f2204">617,096</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid and current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfNC0xLTEtMS0w_47e10e1c-cb0d-488b-9d8b-19ae28bb2fa9">144,788</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfNC0zLTEtMS0w_30004eb2-3a54-458c-8765-63d6f090c0e2">136,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfNS0xLTEtMS0w_1b605ee9-e92b-4d63-be51-ecc123f05cd7">646,360</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfNS0zLTEtMS0w_3dd07658-3be0-4c44-9093-c21012846cc8">955,899</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="id87cf993cf0d4ad58e0dd0fdac4df844">Prepaid insurance is comprised of prepaid directors' and officers' insurance. In July 2019, the Company financed their directors' and officers' insurance premium with a short term note, the principal amount of which is approximately $<ix:nonFraction unitRef="usd" contextRef="i3c3c4f1bd73a41ab8a2603386c7cd387_I20190731" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMTA5OTUxMTYyOTI1OQ_b78ed048-eba7-4991-913f-ddd6fc2d45f0">0.9</ix:nonFraction> million bearing interest at a rate of <ix:nonFraction unitRef="number" contextRef="i3c3c4f1bd73a41ab8a2603386c7cd387_I20190731" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMTA5OTUxMTYyOTI2Nw_3a1538e0-8a3e-4669-bf60-f12d832c5952">4.61</ix:nonFraction>%. The note payable balances were $<ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMjc0ODc3OTA3MDYzOA_195788b1-dbb5-4e4c-9703-824a6b32577b">252,679</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMjc0ODc3OTA3MDY1OQ_ff356518-ad92-411c-abde-0531442a182c">502,332</ix:nonFraction>, which were included within Current Liabilities on the Condensed Consolidated Balance Sheets at March&#160;31, 2020 and December&#160;31, 2019, respectively.</ix:continuation> </span></div><div style="margin-bottom:12pt;"><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_46"></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 6. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjk5Mw_f0319540-d1a0-418d-9db5-5ca6a76bd06b" continuedAt="i80d542f4cc0240a6892c173e27f22b5a" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i80d542f4cc0240a6892c173e27f22b5a" continuedAt="i628ffb6991754e42a20fe1d28714b717"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">License Agreement with the University of Utah Research Foundation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2011, the Company entered into a license agreement with the University of Utah, under which, the Company acquired an exclusive license to and epigenetic enzyme lysine specific demethylase 1 ("LSD 1"). In exchange for the license, the Company issued <ix:nonFraction unitRef="number" contextRef="i93571fc75180447ba55229d7f09f1868_I20111231" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjk0_e6440e8d-b539-4fe6-993c-b957f2b24140">2</ix:nonFraction>% equity ownership in the Company based on a fully diluted basis at the effective date of the agreement and subject to certain adjustments specified in the agreement, granted revenue sharing rights on any resulting products or processes to commence on first commercial sale, and milestone payments based upon regulatory approval of any resulting product or process as well as on the second anniversary of first commercial sale.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cancer Prevention and Research Institute of Texas</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Company entered into a Cancer Research Grant Contract with CPRIT. Pursuant to the contract, CPRIT awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="ic1d35ab3929b4fbe91e95df48a459f8e_D20160601-20160630" decimals="-5" format="ixt:numdotdecimal" name="flks:RevenueFromGrantsMaximumAward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfOTI1_5c307293-a94f-4641-8255-82473a99e53b">18.7</ix:nonFraction> million to fund the development of LSD-1 inhibitor. This is a <ix:nonNumeric contextRef="ic1d35ab3929b4fbe91e95df48a459f8e_D20160601-20160630" format="ixt-sec:duryear" name="flks:RevenueFromGrantsAwardTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfOTc4_4c29b3d6-6a75-4585-bc91-d354b09ad612">3</ix:nonNumeric>-year grant award which originally expired on May 31, 2019. However, a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgwMA_62016ce1-9c77-440a-be57-b02c9bb2a0fd">six</span>-month extension was approved by CPRIT in May 2019 and an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgxNQ_f84e63ce-cd9b-41a2-9e9b-5f34bd9cd7fe">six</span>-month extension through May 2020. The Company has applied for an extension with a proposed contract end date of November 30, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract, up to a maximum repayment of certain percentage of the aggregate amount paid to the Company by CPRIT under the CPRIT contract. The payments are determined as a percentage of net sales, which may be reduced if the Company is required to obtain a license from a third party to sell any such product. In addition, upon meeting the foregoing limitation on revenue-sharing payments, the Company agreed to make continued revenue-sharing payments to CPRIT of less than <ix:nonFraction unitRef="number" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" name="flks:RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjM1OQ_1d1b9fbe-2de7-4b5f-bb8e-43b6882b8385">1</ix:nonFraction>% of net sales.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i628ffb6991754e42a20fe1d28714b717">The CPRIT grant is subject to funding conditions including a matching funds requirement where the Company will match <ix:nonFraction unitRef="number" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" name="flks:RevenueFromGrantsMatchingFundsRequirement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjQ5NA_21dc9e0f-f0fc-4a77-b47d-f9ffd48f88f8">50</ix:nonFraction>% of funding from the CPRIT grant. As of March&#160;31, 2020, the Company has received an aggregate of $<ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="-5" format="ixt:numdotdecimal" name="flks:RevenueFromGrantsAggregateAmountReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjU4MQ_02386baa-eb03-4052-bf8c-498c475084dd">9.6</ix:nonFraction> million from the CPRIT grant and there was $<ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="-5" format="ixt:numdotdecimal" name="flks:RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjYxOQ_78cb199b-ddfc-467c-af8c-abcf1993c852">9.1</ix:nonFraction> million of funds available for the Company to draw upon meeting certain requirements. There was <ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="flks:RevenueFromGrantsCurrentFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjcxMA_ed1d7d16-9e10-4b2b-aa9f-048a1e7f81b7">no</ix:nonFraction> funding received from CPRIT during the three months ended March&#160;31, 2020. At March&#160;31, 2020 and December&#160;31, 2019, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjgyMg_5779557e-8829-44cb-bc1c-64ca5aeab764">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjgyOQ_8d345c4e-7236-4b48-a05d-1317f44c8aa0">541,701</ix:nonFraction>, respectively, related to the CPRIT contract. At March&#160;31, 2020 and December&#160;31, 2019, the Company had grants receivable of $<ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjE5OTAyMzI2MDE0OQ_c1d40bb7-1ed7-43e3-bde5-3f0dc4c5496e">591,129</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" name="us-gaap:ReceivablesNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjE5OTAyMzI2MDE1Mw_9782c75c-0539-4c0f-b408-f5b1f630273e">0</ix:nonFraction>, respectively, related to the CPRIT contract.</ix:continuation></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_1090"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 7. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGV4dHJlZ2lvbjpmOWJmMWY3NzYxZTA0YjIwYjJiYmQxNTYyZGY1NGFlM18xMDk5NTExNjI5NDE1_261c161e-2abc-4cb7-876c-f3f3713c5d9b" continuedAt="ib51da2874ada4d7b93b06cc372550e52" escape="true">FAIR VALUE OF FINANCIAL INSTRUMENTS </ix:nonNumeric></span></div><ix:continuation id="ib51da2874ada4d7b93b06cc372550e52"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-40.5pt;padding-left:76.5pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 - Significant unobservable inputs including Salarius&#8217; own assumptions in determining fair value.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.</span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGV4dHJlZ2lvbjpmOWJmMWY3NzYxZTA0YjIwYjJiYmQxNTYyZGY1NGFlM18xMDk5NTExNjI5NDE2_02833243-d6d1-4272-970f-603c20eff849" escape="true"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrant associated with the Flex Pharma merger measured at fair value on a recurring basis for the three months ended March&#160;31, 2020: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.532%;"><tr><td style="width:1.0%;"></td><td style="width:23.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.000%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:22.080%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:22.450%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i72557c4fa44d4ba5b0d57686b7176435_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGFibGU6MTM5YWVkNWJjNWEwNDg0OWJjMzBjN2Q0ZjE2NGE2ZDkvdGFibGVyYW5nZToxMzlhZWQ1YmM1YTA0ODQ5YmMzMGM3ZDRmMTY0YTZkOV8xLTEtMS0xLTMxNTk_93347a45-8df1-47c8-82e0-e0c0155cb8cf">317,762</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib355700b35e94a5ba6f3b2d4a9975b06_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGFibGU6MTM5YWVkNWJjNWEwNDg0OWJjMzBjN2Q0ZjE2NGE2ZDkvdGFibGVyYW5nZToxMzlhZWQ1YmM1YTA0ODQ5YmMzMGM3ZDRmMTY0YTZkOV8xLTMtMS0xLTMxNTk_fd9a0294-5546-4bcf-9365-a7b52ccfab38">283,070</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i401548a97a504666ac77f37acd7d7032_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGFibGU6MTM5YWVkNWJjNWEwNDg0OWJjMzBjN2Q0ZjE2NGE2ZDkvdGFibGVyYW5nZToxMzlhZWQ1YmM1YTA0ODQ5YmMzMGM3ZDRmMTY0YTZkOV8xLTUtMS0xLTMxNTk_148a4a6a-a2b3-462a-96ef-297e332a9e34">34,692</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_49"></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 8. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzk1OQ_66ea41c0-c9b8-4f32-abb4-03bfa9328b02" continuedAt="icfdcdbe7670d4223b71902c5e44ae4d7" escape="true">STOCKHOLDERS' EQUITY</ix:nonNumeric></span></div><ix:continuation id="icfdcdbe7670d4223b71902c5e44ae4d7" continuedAt="ib3fa5f6622f64770aa76c6bc98f2280e"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated statements of stockholders' equity (deficit) and the footnotes to the interim financial statements have been retroactively adjusted to reflect the equity structure (that is, the number and type of equity interests issued) of Flex Pharma, the legal parent (accounting acquiree) of the merger closed on July 19, 2019, with the retained earnings and other equity balances of the Private Salarius before the merger. Private Salarius' equity was restated using the exchange ratio established in the merger agreement to reflect the number of shares of Flex Pharma issued in the merger. Concurrent with the merger, the Company's shareholders approved a 1-for-<ix:nonFraction unitRef="number" contextRef="ib502bdc134494b80b87687b9029ffcca_D20190719-20190719" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfNzA0_95f2c709-2577-4591-ad73-8b032ccab047">25</ix:nonFraction> reverse stock split, which became effective on July 19, 2019. Total shares owned by Flex Pharma pre-merger shareholders (net of fraction shares paid in cash) was <ix:nonFraction unitRef="shares" contextRef="id08675e640c04365826f8bb18dab3ceb_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfODY5_5ed9baa6-3149-4647-9b8b-14e9561921df">8,353,480</ix:nonFraction> shares after reverse stock-split. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock and Preferred Stock </span></div><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On February 11, 2020, the Company completed a public offering with total gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ide7180e8b2684c66b43dcb58cf485a4e_D20200211-20200211" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjM5NQ_e0682367-e4bf-47f5-978e-5e0017d30c97">11.0</ix:nonFraction> million, which includes the full exercise of the underwriter's over-allotment option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="ide7180e8b2684c66b43dcb58cf485a4e_D20200211-20200211" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ0MQ_5e358f69-a973-44a0-8b5b-d21f4b1d62d1">1,252,173</ix:nonFraction> shares and warrants prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius. The offering is comprised of <ix:nonFraction unitRef="shares" contextRef="i8481df852a634528bdf8f167d58d97c5_D20200211-20200211" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQxMA_a628f1f1-4c28-4049-904e-2399ae31f96b">7,101,307</ix:nonFraction> Class A units, priced at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaed98830a5f34cfda77f4a37fb71e8c4_I20200211" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUwMA_c44352c1-bd83-42f1-89f4-331b03bea3d0">1.15</ix:nonFraction> per unit, with each unit consisting of one share of common stock and a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUxNA_5df20bb8-eba1-4ed3-bcaa-a88042c57c15">five</span>-year warrant to purchase <ix:nonFraction unitRef="shares" contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUzNg_5d1cec89-58cd-4215-bc90-60e84e022298">one</ix:nonFraction> share of </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><ix:continuation id="ib3fa5f6622f64770aa76c6bc98f2280e"><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUyMQ_5a47bacc-6e41-4ddd-a523-849472e6a0a2">1.15</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="i8ec9f9e3c871475686ca302cf142454a_D20200211-20200211" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ1Mg_d5af0b55-8082-4bc9-a6cc-a66c35718145">1,246,519</ix:nonFraction> Class B units, priced at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibea4f4bd11db4c879d27ce92ac6637d8_I20200211" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ3OA_172be438-69e9-4d15-8a20-3dec8761daa2">1.15</ix:nonFraction> per unit, with each unit consisting of one share of Series A convertible preferred stock and a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ3MA_5232e6f4-81eb-413b-ad84-cc43a3411329">five</span>-year warrant to purchase <ix:nonFraction unitRef="shares" contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjU1MQ_eb6675cb-7c92-40c3-a25e-dd68266f237c">one</ix:nonFraction> share of common stock with and exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ5Mg_b5390ad3-7271-4f3c-8618-22d5940f5470">1.15</ix:nonFraction> per share. A total of <ix:nonFraction unitRef="shares" contextRef="ib4d806ab35a84b6ba717db59bba7315a_D20200211-20200211" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjgxMw_423a26ff-7d62-41a0-a1d9-59862d64171c">8,343,480</ix:nonFraction> shares of common stock, <ix:nonFraction unitRef="shares" contextRef="i82641346e1074588aae8bc99288365f9_D20200211-20200211" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjgyNA_2fddfb90-530c-4e12-8d8a-db2278cd3039">1,246,519</ix:nonFraction> shares of Series A convertible preferred stock, and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="iac9b8222fe3849c3a6894033394a49ec_I20200211" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjgzNQ_0924faa2-ff36-4287-a76e-02095f26f5d2">9,599,999</ix:nonFraction> shares of common stock were issued in the offering, including the full exercise of the over-allotment option. The convertible preferred stock issued in this transaction includes a beneficial ownership limitation on conversion, but has no dividend rights (except to the extent that dividends are also paid on the common stock). The conversion price of the Series A convertible preferred stock in the offering as well as the exercise price of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, <ix:nonFraction unitRef="shares" contextRef="ib1026e50b8014604b81db07f3826adb3_D20200211-20200211" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUzMQ_ef7fe020-d884-4e1f-ae70-bf0526088b53">777,825</ix:nonFraction> shares of Series A convertible preferred stock were converted to common stock. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2019 the Company issued <ix:nonFraction unitRef="shares" contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfOTcy_a53fcc85-dc4f-4879-9d81-d6f28d8afc35">960,489</ix:nonFraction> common shares (<ix:nonFraction unitRef="shares" contextRef="i7f20b1ecfb964b37a76c0654fff02596_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfOTkw_357b0543-4002-4538-acc7-bd9b66de28a3">4,035</ix:nonFraction> Series A preferred units and <ix:nonFraction unitRef="shares" contextRef="i3b8ac8f09be5476299897cdf23a7a0c4_D20190101-20190331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTAyMg_74381f9f-b063-4d3f-ba37-054f019e2a8d">350</ix:nonFraction> profit interest units of Private Salarius) for $<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA3Mg_f545bd69-f939-4031-a968-7ed63afe7abb">4,377,591</ix:nonFraction> (net of offering cost of $<ix:nonFraction unitRef="usd" contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTEwMA_19e4fe2a-5963-4724-a076-33b0413c7c4a">10,617</ix:nonFraction>).</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company agreed to issue an unrelated party <ix:nonFraction unitRef="shares" contextRef="ibaf829e8bf7e456b9116404177f196c9_D20181201-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTM1Mw_8ffb5637-725a-444d-919e-48a408ec2849">12,907</ix:nonFraction> common shares (<ix:nonFraction unitRef="shares" contextRef="if9d5f52e15574141abe8b47621abead0_D20181201-20181231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTM3MQ_cf0aad6f-e560-4e36-a802-d59156cd6902">91</ix:nonFraction> common units of Private Salarius) to acquire licenses for the DNMT1 inhibitor. The issuance was approved in January 2019 and the license was granted in 2018. . </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Right to Warrants</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the Merger Agreement (See Note 3), Flex Pharma distributed <ix:nonFraction unitRef="shares" contextRef="if8e9ef7d321148bfa7e0fc99f44856d7_I20190719" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTc1Nw_1ea8ea08-4ac9-469a-ab76-bd98e4f05e65">one</ix:nonFraction> right per share of common stock to stockholders of record as of the close of business on July 18, 2019. Each right entitles such stockholders to receive a warrant to purchase the Company's common shares on January 20, 2020. These warrants are exercisable, in the aggregate, into <ix:nonFraction unitRef="shares" contextRef="i3eeda48ea55c43c3921c1333146fc953_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMjAzOQ_e8a546c4-21bf-449b-b3ee-5690cd513ac4">142,711</ix:nonFraction> shares of the Company's common stock with a <ix:nonNumeric contextRef="id75dc2c494874c2590b7a7652f91ebca_I20190120" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMjA4Ng_250807c2-ea3d-4b98-827b-7900e004b5ce">5</ix:nonNumeric>-year term from January 20, 2020, and an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3eeda48ea55c43c3921c1333146fc953_I20190719" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMjE0Nw_650a5976-f7e6-49f1-84b5-94efcfc6b495">15.17</ix:nonFraction> per share. The warrants are subject to a cashless exercise, at the option of the Company, at the closing of an issuance and sale of the Company&#8217;s common stock in certain qualified financing, upon the closing of which the holders of warrants shall be entitled to receive a number of shares of common stock equal to the greater of two formulae defined by the Merger Agreement, which are based on the volume weighted average price of the Company's common stock during the <ix:nonFraction unitRef="trading_days" contextRef="i9335e01552494ea4aeab4ed31281b503_D20190719-20190719" decimals="INF" name="flks:ClassOfWarrantOrRightThresholdConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMjYxOQ_8d1c5470-a95f-4b03-8a21-fa5c192817a4">10</ix:nonFraction> consecutive trading days ending on the trading day immediately preceding the date of exercise. As a result, the warrants have been classified as a liability.</span></div><div style="padding-left:18pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounted for these warrants at fair value using Level 3 inputs. The Company determined the fair value of this warrant liability using a Black-Scholes valuation model as the Company believes the value will closely approximate the value from the binomial asset pricing model that consisted of a conditional probability weighted expected return method that values the Company&#8217;s equity securities assuming various possible future outcomes to estimate the allocation of value within one or more of the scenarios. Using this method, unobservable inputs included the Company&#8217;s equity value, expected timing of possible outcomes, risk free interest rates and stock</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">price volatility. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzk2NA_4a0ecf34-da9a-421b-9e0f-f487feaafab2" escape="true"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Variables used in the Black-Scholes model are as follows:</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:75.146%;"><tr><td style="width:1.0%;"></td><td style="width:42.163%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.161%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:24.459%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.356%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:24.461%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i923938e66ee44ac4a3049da0fb812f9f_I20200331" decimals="4" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMS0yLTEtMS0w_8b4a358f-bb0b-421e-90e2-ef51a8851439">0.37</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="if3d35d901c984cd9a8b3c067ed4795b3_I20191231" decimals="4" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMS00LTEtMS0w_9a8ad301-68cd-435e-92b5-16bd16fcd927">1.69</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="idff75338ab954067833daa55353126e4_I20200331" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMi0yLTEtMS0w_c733e389-d48d-4bc2-a012-88ff23412b70">4.81</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMi00LTEtMS0w_2ad205af-4523-4d8b-a33f-5cdc82a7a2d2">5.06</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i18d0ed03a53041689adae6878926fead_I20200331" decimals="4" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMy0yLTEtMS0w_da773777-87a1-40a5-acc9-3de611d6ed3b">113.17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="if5c08f3842d84b48b2fd04af17a3bc44_I20191231" decimals="4" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMy00LTEtMS0w_608137b0-f307-494b-b489-9c35b71c366d">103.07</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i6bbed367577c464aa83ed65a64104166_I20200331" decimals="INF" format="ixt:zerodash" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfNC0yLTEtMS0w_4cf0c7a4-fcf0-463f-8e0e-cf637db2fc3c">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="i2e818517cf6e4951b3588a8d6e0e57a8_I20191231" decimals="INF" format="ixt:zerodash" name="flks:WarrantsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfNC00LTEtMS0w_3386ca6f-1ebf-4b4f-99a2-7fc83991e79c">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Wedbush Warrant</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 19, 2019, upon the closing of the merger, the Company elected to issue warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzY1MA_5fc59672-c147-411e-9992-9d0a114d978b">42,928</ix:nonFraction> common shares to Wedbush Securities Inc. ("Wedbush") to satisfy $<ix:nonFraction unitRef="usd" contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzcxNw_c69aa001-086c-4f2f-b0cd-1ed1e2828cbf">500,000</ix:nonFraction> of the $<ix:nonFraction unitRef="usd" contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzcyNw_0983cee3-f07f-4655-ae01-adc943c12bd0">1,000,000</ix:nonFraction> success fee payable to Wedbush at the closing of the merger. The remaining $<ix:nonFraction unitRef="usd" contextRef="i2defc6da5b484ddc838a55ab137797ca_D20190719-20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzgwNQ_1d409471-89f7-48ce-b74a-d2c883a423e3">500,000</ix:nonFraction> success fee was paid in cash. These warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzg3OQ_4982e9f9-a262-4477-89a8-881fc51bfc23">18.90</ix:nonFraction> and a <ix:nonNumeric contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzg4OA_6c3f0d04-f749-4769-8cc3-c0a4b966cec7">5</ix:nonNumeric>-year term. As of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">March&#160;31, 2020, all warrants issued to Wedbush were outstanding.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_52"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="margin-top:8pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 9. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMjg2MA_a381cb55-97ce-4216-907e-04b69fef14a6" continuedAt="i9c40066837ed4ca3a3e283ea0b592ac9" escape="true">EQUITY-BASED COMPENSATION </ix:nonNumeric></span></div><ix:continuation id="i9c40066837ed4ca3a3e283ea0b592ac9"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Equity Incentive Plans</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has granted options to employees, directors, and consultants under the 2015 Equity Incentive Plan (the "2015 Plan"). On July 19, 2019, the Company completed a merger with Flex Pharma and Flex Pharma had fully vested options to purchase <ix:nonFraction unitRef="shares" contextRef="i3eeda48ea55c43c3921c1333146fc953_I20190719" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTA5OTUxMTYzNTY0Mg_752f2a49-5f37-4479-ac5f-1440bf825ed9">90,279</ix:nonFraction> common shares outstanding as of the date of the merger that continue to be exercisable.  The 2015 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of March&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i8ee10a83c58c467499b54edfb3d4578c_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTcwNg_6dcc9188-0d23-409d-a50b-255a30013382">34,087</ix:nonFraction> shares remaining available for the grant of stock awards under the 2015 Plan.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 23, 2020, the Company awarded <ix:nonFraction unitRef="shares" contextRef="i0229b2e923e041fe8797ef1f87ddd7eb_D20190910-20190910" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMzg0ODI5MDcwMDk4Mg_478b60a7-0c14-4d25-8e80-8500c7d5a3cc">182,000</ix:nonFraction> stock options to its employees and directors, pursuant to the plan described above. Stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTk0Mg_3e677467-eb4d-4c5e-916f-d6b12ec0b478">one</span> to <ix:nonNumeric contextRef="i63ca0eae144c4e4a86b4c93b3bcd23ed_D20200101-20200331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTk0OA_9ddc7c05-294c-4c6e-9038-dc07ba2d4918">four years</ix:nonNumeric> and have a contractual term of <ix:nonNumeric contextRef="ifc382e1599924272a66a5f62e9b3fb2e_D20200101-20200331" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTk4Mg_1f0cd44f-d24b-425b-8326-9ec6c7352302">ten years</ix:nonNumeric>. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTA5OTUxMTYzNTYyNQ_9d9157f3-d652-435c-b360-a58204948f57" continuedAt="i6a412797118a4613931b85f9a2e4f560" escape="true">The fair value of the option grants of $<ix:nonFraction unitRef="usd" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTA5OTUxMTYzNTYyNw_3d8dae91-1078-4ba8-bf85-8da2907773de">92,007</ix:nonFraction> has been estimated with the following assumptions for the three months ended March&#160;31, 2020:</ix:nonNumeric></span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><ix:continuation id="i6a412797118a4613931b85f9a2e4f560"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.701%;"><tr><td style="width:1.0%;"></td><td style="width:30.427%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:64.847%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOjAyMTlmZWU0OWU0NTQ0NjBiNzYzZTM0N2JkYzdkNTFmL3RhYmxlcmFuZ2U6MDIxOWZlZTQ5ZTQ1NDQ2MGI3NjNlMzQ3YmRjN2Q1MWZfMC0xLTEtMS0xODc3_9cd6180f-13df-4498-8ce9-f608a15377ad">0.48</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOjAyMTlmZWU0OWU0NTQ0NjBiNzYzZTM0N2JkYzdkNTFmL3RhYmxlcmFuZ2U6MDIxOWZlZTQ5ZTQ1NDQ2MGI3NjNlMzQ3YmRjN2Q1MWZfMS0xLTEtMS0xODc3_76a74d95-bc93-4ad7-a779-7f322c8ad3e5">113.17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOjAyMTlmZWU0OWU0NTQ0NjBiNzYzZTM0N2JkYzdkNTFmL3RhYmxlcmFuZ2U6MDIxOWZlZTQ5ZTQ1NDQ2MGI3NjNlMzQ3YmRjN2Q1MWZfMi0xLTEtMS0xODc3_ca52400c-db8c-4cae-b67b-5f978c13618d">5.80</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOjAyMTlmZWU0OWU0NTQ0NjBiNzYzZTM0N2JkYzdkNTFmL3RhYmxlcmFuZ2U6MDIxOWZlZTQ5ZTQ1NDQ2MGI3NjNlMzQ3YmRjN2Q1MWZfMy0xLTEtMS0xODc3_e049acef-d462-4c27-875c-91829ada8f28">0</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr></table></ix:continuation></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMjg3MQ_ef1a4bc8-5584-4124-b4ca-d6fe3c735e4f" escape="true"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2020: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"><tr><td style="width:1.0%;"></td><td style="width:43.901%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.965%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.965%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.965%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.545%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.969%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMS0xLTEtMS0w_5040eb58-5e7d-4ec2-abdc-f0affdc729f6">166,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMS0zLTEtMS0w_401c1c18-5f2a-45d8-9c97-e70c3166e382">34.42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib0e99be21eb64f78a76597b9daad23be_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMS01LTEtMS0w_9709e140-0a8a-4d7e-976c-f0a1fd6c4055">6.53</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMS03LTEtMS0w_05ae42c7-e2fc-42cf-9210-417687914af6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMi0xLTEtMS0w_4ee46765-54ca-4a8a-b430-8b2241d90091">182,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMi0zLTEtMS0w_8f9d329d-3cbe-4072-a1e3-5ddaa75a0c17">0.61</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNS0xLTEtMS0w_91793b0a-201f-47c3-86dd-76f0cadd657b">10,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNS0zLTEtMS0w_8108323b-e752-4fcd-9185-a43d7d586f01">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNy0xLTEtMS0w_1f1c1324-3f51-4aab-b35f-281a37fda22e">338,233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNy0zLTEtMS0w_e752b765-05fa-4154-884b-f01d1bda0803">17.01</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNy01LTEtMS0w_f9b00f5d-dd2a-4717-b759-af699f5b1e2c">8.18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNy03LTEtMS0w_4529dcfb-61a2-40c9-b6ca-0a4075109c8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfOC0xLTEtMS0w_1ec20289-c3d5-446b-8c7a-dcade979ea3a">84,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfOC0zLTEtMS0w_f0c4d2ef-a5a4-4b55-8ea0-6f77a9609047">59.85</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfOC01LTEtMS0w_5cd3cb6f-e7b5-4a4f-9e3a-4f7708a5630a">3.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfOC03LTEtMS0w_d10a0b65-c3af-4e5b-b4b7-24439dd6463b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="idff75338ab954067833daa55353126e4_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMjI5OA_c469ba51-9455-463d-bf44-d1ca181b4c90">489,641</ix:nonFraction> of total unrecognized compensation cost related to unvested stock options. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMjU4Ng_4c9d9f8f-6e23-4231-bf15-14cfc6c1f38d">3.27</ix:nonNumeric> years.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:8pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_61"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTE 10. <ix:nonNumeric contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF82MS9mcmFnOjU3OTAxNjcyY2UxMzRlZGQ5NjVmZWQyNjU4ODcwNDhlL3RleHRyZWdpb246NTc5MDE2NzJjZTEzNGVkZDk2NWZlZDI2NTg4NzA0OGVfMTA5OTUxMTYzOTQ2OA_14a40bfa-746d-4402-a627-863bcec00a06" continuedAt="ia23af87e782445cfb5ce6a17e65e9ab1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia23af87e782445cfb5ce6a17e65e9ab1" continuedAt="i9598f0f716ad417eb42743f3f965534a"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 9, 2020, the Company was notified (the &#8220;Notice&#8221;) by Nasdaq Stock Market, LLC (&#8220;Nasdaq&#8221;) that on April 8, 2020 the average closing price of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the &#8220;Minimum Bid Requirement&#8221;). The Notice has no immediate effect on the listing or trading of the Company&#8217;s common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, to regain compliance with the Minimum Bid Requirement. To regain compliance, the closing bid price of the Company&#8217;s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during this 180-day period.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2020, the Company was notified by Nasdaq that it has determined to toll the compliance periods for bid price and market value of publicly held shares (&#8220;MVPHS&#8221;) requirements (collectively, the &#8220;Price-based Requirements&#8221;) through June 30, 2020. In that regard, on April 16, 2020, Nasdaq filed an immediately effective rule change with the Securities and Exchange Commission. As a result, companies presently in compliance periods for any Price-based Requirements will remain at that same stage of the process and will not be subject to being delisted for these concerns. Starting on July 1, 2020, companies will receive the balance of any pending compliance period in effect at the start of the tolling period to regain compliance.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accordingly, since the Company had 173 calendar days remaining in its bid price compliance period as of April 16, 2020, it will, upon reinstatement of the Price-based Requirements, still has 173 calendar days from July 1, 2020, or until December 21, 2020, subject to any extensions granted by Nasdaq, to regain compliance. The Company can regain compliance, either during the suspension or during the compliance period resuming after the suspension by evidencing compliance with the Price-based Requirements for a minimum of 10 consecutive trading days.</span></div></ix:continuation><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"><ix:continuation id="i9598f0f716ad417eb42743f3f965534a">On April 13, 2020, the Company was granted a loan of approximately $<ix:nonFraction unitRef="usd" contextRef="i82289f6d72fc4019908f2649c6567ffd_I20200413" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF82MS9mcmFnOjU3OTAxNjcyY2UxMzRlZGQ5NjVmZWQyNjU4ODcwNDhlL3RleHRyZWdpb246NTc5MDE2NzJjZTEzNGVkZDk2NWZlZDI2NTg4NzA0OGVfMTA5OTUxMTYzOTQ3MA_ad3ddb40-066b-4309-af7b-8f08b06a84f0">180,000</ix:nonFraction> from Paycheck Protection Program established under the CARES Act. The loan matures on April 13, 2022 and bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="i82289f6d72fc4019908f2649c6567ffd_I20200413" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF82MS9mcmFnOjU3OTAxNjcyY2UxMzRlZGQ5NjVmZWQyNjU4ODcwNDhlL3RleHRyZWdpb246NTc5MDE2NzJjZTEzNGVkZDk2NWZlZDI2NTg4NzA0OGVfMTA5OTUxMTYzOTQ4MA_b4414a56-42ae-4753-b38a-c75407069af9">0.5</ix:nonFraction>% per annum. The loan will be forgiven if the Company use it to pay payroll costs including benefit, mortgage interest, rent, and utilities payment over the 8 weeks after getting the loan</ix:continuation>, by submitting a request to the lender that is servicing the loan.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_64"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:7.558%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.442%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">The following discussion and analysis should be read in conjunction with the unaudited financial information and the notes thereto included herein, as well as our audited financial statements and notes thereto contained in our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> Annual Report</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"> on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 23, 2020. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under "Part I - Item 1A - Risk Factors" discussed in our </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Annual Report</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"> on Form 10-K for the year ended December 31, 2019, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">for the year ended December 31, 2019,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;"> filed with the SEC on March 23, 2020, in other subsequent filings with the SEC, and elsewhere in this Quarterly Report on Form 10-Q. These statements, like all statements in this report, speak only as of the date of this Quarterly Report on Form 10-Q (unless another date is indicated), and we undertake no obligation to update or revise these statements in light of future developments.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are a clinical-stage biotechnology company focused on developing effective treatments for cancer with high, unmet medical need caused by dysregulated gene expression. Epigenetics refers to the regulatory system that affects gene expression and our lead epigenetic enzyme technology was licensed from the University of Utah Research Foundation in 2011.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are focused on strategies addressing dysregulated gene expression, epigenetic strategies for cancer treatment. Epigenetics refers to the system that regulates gene expression through conformational changes to the chromatin rather than changes to the DNA sequence itself. Our compound, Seclidemstat (&#8220;SP-2577&#8221;), is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (&#8220;LSD1&#8221;). LSD1 is an enzyme that removes mono- and di-methyl marks on histones (core protein of chromatin) to alter gene expression.  LSD1&#8217;s enzymatic activity can cause genes to turn on or off and thereby affect the cell&#8217;s gene expression and overall activity. In addition, LSD1 can act via its scaffolding properties, independently of its enzymatic function, to alter gene expression and modulate cell fate. In healthy cells, LSD1 is necessary for stem cell maintenance and cell development processes. However, in several cancers LSD1 is highly expressed and acts aberrantly to incorrectly silence or activate genes leading to disease progression. High levels of LSD1 expression are often associated with aggressive cancer phenotypes and poor patient prognosis. Hence, development of targeted LSD1 inhibitors is of interest for the treatment of various cancers. SP-2577 uses a novel, reversible mechanism to effectively inhibit LSD1&#8217;s enzymatic and scaffolding properties and thereby treat and prevent cancer progression. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our first indication of interest for SP-2577 is a devastating bone and soft-tissue cancer called Ewing sarcoma. Ewing sarcoma mostly afflicts adolescents and young adults, with the median age of diagnosis being 15. The most commonly expressed fusion oncoprotein in Ewing sarcoma is the EWS-FLI fusion protein, which is present in approximately 85% of Ewing sarcoma cases. The LSD1 enzyme associates with EWS-FLI (and other E26 Transformation-Specific (&#8220;ETS&#8221;) fusion proteins) and is thought to promote tumorigenesis. We believe the SP-2577 molecule helps inhibit EWS-FLI activity by disrupting EWS-FLI from associating with coregulators (including LSD1) that are necessary for its cancer promoting activity. Therefore, we believe that SP-2577 can potentially reverse the aberrant gene expression and thereby possibly prevent Ewing sarcoma cell proliferation and even promote cell death. Preclinical studies of SP-2577 in certain Ewing sarcoma animal models show a significant tumor reduction as well as a significant survival benefit compared to untreated animals. Our ongoing Phase 1/2 clinical trial is designed as a single agent dose escalation followed by a dose expansion study. The trial can enroll up to 50 relapsed or refractory Ewing sarcoma patients. The primary objectives of the study are to assess the safety and tolerability of SP-2577. Secondary objectives include assessing preliminary efficacy of SP-2577.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As LSD1 can associate with over 60 regulatory proteins other than EWS-FLI, we believe that LSD1 may also play a critical role in progression of various other cancer types. These include both solid tumors and hematologic malignancies. In the second quarter of 2019, we initiated a second company-sponsored Phase 1 trial to study SP-2577 in Advanced Solid Tumors. The Advanced Solid Tumor (&#8220;AST&#8221;) trial is a single agent dose escalation, dose expansion study enrolling patients with advanced malignancies, excluding Ewing sarcoma or central nervous system tumors.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, recent data from &#8220;LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade&#8221; by W. Sheng, et al. and &#8220;Inhibition of Histone Lysine-specific Demethylase 1 Elicits Breast Tumor Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade&#8221; by Y. Qin, et al. suggests that LSD1 plays a role in tumor immune activity and can sensitize tumors to checkpoint inhibitors. These recent works have sparked  interest </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">in combining LSD1 inhibitors with checkpoint inhibitors. We are conducting preclinical work with SP-2577 in this area.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since inception. We had an accumulated deficit of $14,160,516 as of March&#160;31, 2020. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lack of revenue from product sales to date and recurring losses from operations since our inception raise substantial doubt about our ability to continue as a going concern. Our financial statements are prepared using Generally Accepted Accounting Principles in the United States of America (&#8220;GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities should we be unable to continue as a going concern.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years as we initiate and continue the clinical development of, and seek regulatory approval for, our product candidates, add personnel necessary to continue to operate as a public company upon closing of the merger, and work to develop an advanced clinical pipeline of product candidates. We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs and efforts to achieve regulatory approval.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had cash and cash equivalents of $9,646,940, which includes $0 for funds received from Cancer Prevention and Research Institution of Texas ("CPRIT").  As of March&#160;31, 2020, CPRIT fund matching requirements had been fully met. As of March&#160;31, 2020, we have received an aggregate of $9.6 million from the CPRIT grant and there was $9.1 million of funds available for us to draw upon meeting certain requirements. The Company has applied for an extension with a proposed contract end date of November 30, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our $9.6 million in cash and cash equivalents currently on hand are sufficient to fund our anticipated operating and capital requirements through at least 12 months from the date this quarterly report on Form 10-Q is filed, however we will continue to require substantial additional capital to continue our clinical development activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations as a whole. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development, regulatory and commercialization efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop and commercialize our product candidates and to fund our operations.</span></div><div style="text-align:justify;margin-top:6.6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend, when required, to obtain additional capital through the sale of equity securities in one or more offerings or through issuances of debt instruments. We may also consider new collaborations or selectively partnering our technology. However, we cannot provide any assurance that we will be successful in accomplishing any of our plans to obtain additional capital or be able to do so on favorable terms or on terms acceptable to us.</span></div><div style="text-align:justify;margin-top:6.6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6.6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Special Note About Coronavirus (COVID-19)</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The COVID-19 pandemic is significantly affecting the United States, global economies, and businesses worldwide.  While the potential magnitude and duration of the economic and social impact of the COVID-19 pandemic is difficult to assess or predict, the impact on the global financial markets may, in the future, reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. The COVID-19 pandemic could also have a material and negative impact on our liquidity, capital resources (including our ability to secure additional financing if and when needed), our business and operations, and our workforce, as well as those of the third parties with which we do business or upon which we rely. While, the situation is fluid and we do not yet know the full extent of potential delays or impacts on us or on healthcare systems or the global economy in general, Salarius has worked to adapt to the unexpected and challenging circumstances resulting from the COVID-19 pandemic and at this time we are experiencing minimal COVID-19 disruptions to our clinical programs, our manufacturing capabilities, or our financing capabilities. However, we may experience disruptions in the future that have and could further adversely impact our business operations as well as our preclinical studies and clinical trials. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:6.6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although at this time we are experiencing minimal disruption to our clinical trials, our ongoing Phase 1/2 clinical trial can enroll up to 50 relapsed or refractory Ewing sarcoma patients and in the future we may encounter delays in enrolling</span></div><div style="text-align:justify;margin-top:6.6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although at this time we are experiencing minimal disruption to our clinical trials, our ongoing Phase 1/2 clinical trial can enroll up to 50 relapsed or refractory Ewing sarcoma patients and in the future we may encounter delays in enrolling new patients due to concerns or healthcare resource constraints as a result of the COVID-19 pandemic. In addition, although at this time we have experienced no disruptions to manufacturing capabilities, certain aspects of our supply chain may be disrupted as certain of our third party suppliers and manufacturers have paused their operations in response to the COVID-19 pandemic or have otherwise encountered delays in providing supplies and services. We continue to evaluate the extent to which these delays will impact our ability to manufacture our product candidates for our clinical trials and conduct other research and development operations and maintain applicable timelines. The ultimate impact of the COVID-19 pandemic on our business operations as well as our preclinical studies and clinical trials remains uncertain and subject to change and will depend on future developments, which cannot be accurately predicted. We will continue to monitor the situation closely.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_67"></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Results of Operations</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Three Months Ended March&#160;31, 2020 Compared to the Three Months Ended March&#160;31, 2019 </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the condensed consolidated results of our operations for the three months ended March&#160;31, 2020 compared to the three months ended March&#160;31, 2019. </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:33.818%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.115%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.115%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.011%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.115%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.940%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Grant revenue</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,132,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">655,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">477,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,643,371)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(699,929)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(943,442)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">135&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,859,017)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,488,490)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(370,527)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of warrant liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">283,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">283,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,672&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,036)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(75)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,083,816)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,522,076)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(561,740)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Grant Revenue</span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Grant revenue, which was derived solely from the CPRIT grant, was $1,132,830 during the three months ended March&#160;31, 2020 compared to $655,635 during the three months ended March&#160;31, 2019. The increase in revenue from the CPRIT grant was due to an increase in overall expenses which resulted in an increase in the amount of expenses reimbursable under the grant. Given the nature of the development process, grant revenue will fluctuate depending on the stage of development and the timing of expenses.</span></div><div style="margin-top:8pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Research and development expenses were $1,643,371 during the three months ended March&#160;31, 2020 compared to $699,929 during the three months ended March&#160;31, 2019. The increase of $943,442 was principally due to the production of tablets for use in clinical trials, increased consulting fee related to clinic trials and a pre-clinical study for our next generation Seclidemstat program, and increased clinical trial costs resulting from the increased number of patients enrolled and additional clinical trial sites. </span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">General and administrative expenses were $1,859,017 for the three months ended March&#160;31, 2020 compared to $1,488,490 for the three months ended March&#160;31, 2019. The net increase of $370,527 resulted from the costs related to the Company' transformation into a public company during July 2019 more than offsetting reduced spending for professional fees and legal costs compared to the same period in the prior year. During the current period the transformation accounted for higher director and officer insurance expense, and fees related to its NASDAQ listing and investor relations costs. Additionally, compensation expense increased compared to the three months ended March&#160;31, 2019 resulting from the payment of bonuses and increased personnel, These higher costs </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">were partially offset by decreased legal and professional services expenses resulting from 2019 costs incurred for the announced reverse merger with Flex Pharma that did not  recur in the current period.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Change in Fair Value of Warrant Liability</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The change in fair value of warrant liability of $283,070 was primarily due to the fluctuation of the price of our common stock ($3.78 per share on December&#160;31, 2019 compared to $0.68 per share on March&#160;31, 2020). The Company recognized a gain of $283,070 due the change in fair value of warrant liability. </span></div><div id="i330ef634d79a46098535b93eedb2fa54_70"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Overview</span></div><div style="text-align:justify;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, we have incurred operating losses and we anticipate that we will continue to incur losses for the foreseeable future. To date, we have generated revenue solely from CPRIT grant, and have not generated any revenue from product sales.</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercializes any of our product candidates. At the same time, we expect our expenses to increase in connection with our ongoing development and manufacturing activities, particularly as we continue the research, development, manufacture and clinical trials of, and seek regulatory approval for our product candidates.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had $8,821,668 of working capital and our cash and cash equivalents totaled $9,646,940, which were held in bank deposit accounts and money market funds. Our cash and cash equivalents balance increased during the three months ended March&#160;31, 2020, primarily due to our public offering closed on February 11, 2020.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:55.540%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.912%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.410%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.938%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,708,034)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,868,713)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,616,074&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,508,179&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,908,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(360,534)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Operating Activities</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities was $3,708,034 and $1,868,713 for the three months ended March&#160;31, 2020, and March&#160;31, 2019, respectively, an increase of $1,839,321. This cash spending increase was primarily due to increased clinical trial and related research costs plus the Company's increased spending for the transformation into a public company during 2020. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Financing Activities</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Net cash provided by financing activities was $9,616,074 for the first quarter of the year 2020, compared to $1,508,179 for the same period of the year 2019. The increase of cash provided by financing activities resulted from the Company completing a public offering on February 11, 2020 with net proceeds of approximately $9.8 million, partially offset by the payment of $249,653 towards the principal on an insurance financing note by the Company. There were no such payments during the three months ended March&#160;31, 2019. </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_73"></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management's discussion and analysis of our financial condition and results of operations is based on our  condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the date of the condensed consolidated balance sheet and the reported amounts of expenses during the reporting period. In </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our condensed consolidated financial statements prospectively from the date of the change in estimate.</span></div><div style="text-align:justify;margin-top:6.6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material changes to our critical accounting policies from those described in "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our Annual Report on Form 10-K filed with SEC on March 23, 2020.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Readers should refer to our&#160;Annual Report on&#160;Form10-K&#160;filed with SEC on March 23, 2020,  Note 2, Basis of Presentation and Significant Accounting Policies to the accompanying financial statements for descriptions of these policies and estimates.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Application of New Accounting Standards</span></div><div style="text-align:justify;margin-top:6.6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Intangibles-Goodwill and Other,&#8221; which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We do not expect adoption of this ASU to have a material impact on our condensed consolidated financial statements.</span></div><div id="i330ef634d79a46098535b93eedb2fa54_76"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:7.558%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.442%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Quantitative and Qualitative Disclosures about Market Risk</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i330ef634d79a46098535b93eedb2fa54_79"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:7.558%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.442%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Controls and Procedures</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rules 13a-15(e) </span><span style="background-color:#ffffff;color:#333333;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;">and 15d-15(e) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">under the Exchange Act, that are designed to ensure that information required to be disclosed in our periodic and current reports that we file under the Exchange Act with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer and principal accounting officer), as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Based on management&#8217;s evaluation </span><span style="background-color:#ffffff;color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">(</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">with the participation of our principal executive officer and principal financial officer</span><span style="background-color:#ffffff;color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">), </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial and accounting officer) have concluded that, as of such date, our disclosure controls and procedures (</span><span style="background-color:#ffffff;color:#333333;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;">as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">were effective at the reasonable assurance level.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2020, there was no significant change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="i330ef634d79a46098535b93eedb2fa54_82"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II - OTHER INFORMATION</span></div><div id="i330ef634d79a46098535b93eedb2fa54_85"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:7.558%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.442%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1. </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal Proceedings</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are not a party to any material legal proceedings on the date of this report. We may from time to time become involved in legal proceedings arising in the ordinary course of business, and the resolution of any such claims could be material.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">.</span></div><div id="i330ef634d79a46098535b93eedb2fa54_88"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:7.558%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.442%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1A.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk Factors</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For a discussion of certain factors that could materially affect our business, financial condition, and operating results, you should carefully review and consider the information under &#8220;Part I, Item 1A- Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 23, 2020, as well as the risk factors set forth below.  The risk factors below are in addition to and supplement (and with respect to certain matters, update) the risk factors discussed in our Annual Report on Form 10-K.  Other than as set forth below, there have been no material changes to the risk factors included in our Annual Report on Form 10-K filed with the SEC on March 23, 2020.</span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Business and Our Industry</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">The COVID-19 pandemic could adversely affect our business, results of operations, and financial condition.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">To date, the COVID-19 pandemic has negatively impacted the global economy and the magnitude, severity, and duration of this impact is unclear and difficult to assess. Salarius has worked to adapt to the unexpected and challenging circumstances resulting from the COVID-19 pandemic and we have experienced minimal COVID-19 disruptions to our clinical programs, our manufacturing capabilities and our financing capabilities during the three months ended March 31, 2020.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">Both our Ewing Sarcoma clinical study and our Advanced Solid Tumor clinical study are active and continue to enroll patients. Salarius plans to release clinical data from both studies, as previously disclosed, during 2020 and 2021.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">However, the impact of COVID-19 changes daily and is difficult to predict. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">To combat the spread of COVID-19, the United States and other locations in which we operate have imposed measures such as quarantines and &#8220;shelter-in-place&#8221; orders that are restricting business operations and travel and requiring individuals to work from home (&#8220;WFH&#8221;), which has impacted all aspects of our business as well as those of the third-parties we rely upon for certain supplies and services.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:103%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:103%;">The continuation of WFH and other restrictions for an extended period of time may negatively impact our productivity, research and development, operations, preclinical studies and clinical trials, business and financial results. Among other things, the COVID-19 pandemic may result in: </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">a global economic recession or depression that could significantly and negatively impact our business or those of third parties upon which we rely for services and supplies;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">constraints on our ability to conduct our operations and our preclinical studies and clinical trials;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">delays in our ability to extend the term of the CPRIT grant;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">reduced productivity in our business operations, research and development, marketing, and other activities; </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">disruptions to our third-party manufacturers and suppliers;</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">increased costs resulting from WFH or from our efforts to mitigate the impact of COVID-19; and</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">reduced access to financing to fund our operations due to a deterioration of credit and financial markets.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:99%;">We will continue to monitor the situation but the continued disruption of the COVID-19 pandemic and its effects on the worldwide economy could negatively and materially impact our operating and financial operating results. The resumption of normal business operations may be delayed and a resurgence of COVID-19 could occur resulting in continued disruption to us or third parties with whom we do business. As a result, the effects of the COVID-19 pandemic could have a material adverse impact on our business, results of operations and financial condition for the remainder of 2020 and beyond.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:99%;">  </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Salarius&#8217; Financial Condition and Capital Requirements</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We will continue to require substantial additional capital to fund our clinical activities and operations and the impact of the COVID-19 pandemic on the financial markets will likely negatively impact our ability to raise additional financing. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are a clinical development-stage biopharmaceutical company with a limited operating history. We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since inception. Our net losses were $6,936,263 and $2,083,816 for the year ended December 31, 2019 and the three months ended March 31, 2020, respectively. We have prepared our financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should we be unable to continue in existence.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We will continue to require substantial additional capital to continue our clinical development and potential commercialization activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. To date, we have financed our operations primarily through the sale of equity securities. Our stock price has been negatively impacted in part by the downturn in the financial markets due to the COVID-19 pandemic.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">This in turn will likely negatively impact our ability to raise funds through equity-related financings.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Further, the global economic downturn may impair our ability to obtain additional financing through other means, such as debt financing.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There can be no assurance we will be able to secure additional financing on favorable terms to us, or at all.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Further any debt financing may contain restrictive covenants which limit our operating flexibility and any equity financing will likely result in additional and possibly significant dilution to existing stockholders. Failure to raise sufficient capital, as and when needed, would have a significant and negative impact on our financial condition and our ability to develop our product candidates.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Salarius&#8217; Reliance on Third Parties</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:99%;">We rely on third parties to conduct our clinical trials, manufacture our product candidates, and perform other services. If these parties are not able to successfully perform due to the impact of the COVID-19 pandemic or otherwise, there may be delays in our ability to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have relied upon and plan to continue to rely upon third-parties such as CROs, hospitals, etc. to conduct, monitor and manage our ongoing clinical programs. We rely on these parties for execution of clinical trials and manage and control only some aspects of their activities. In addition, third parties may not prioritize Salarius&#8217; clinical trials relative to those of other customers due to resource or other constraints as a result of COVID-19. Due to the continued impact of COVID-19 pandemic or otherwise, we may experience enrollment at a slower pace at certain of our clinical trial sites than initially anticipated.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Further, our clinical trial sites may be required to suspend enrollment due to travel restrictions, workplace safety concerns, quarantine, facility closures, and other governmental restrictions.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As a result, results from our clinical trials may be delayed, which in turn would have a material adverse impact on our clinical trial plans and timelines and impair our ability to successfully complete clinical development, obtain regulatory approval, or commercialize our product candidates. This in turn would substantially harm our business and operations.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Salarius expects to rely on third parties to manufacture its clinical product supplies and to produce and process its product candidates, if approved.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Salarius&#8217; commercialization of any of its product candidates could be stopped, delayed or made less profitable if those third parties are unable to provide Salarius with sufficient quantities of drug product, or to do so at acceptable quality levels or prices due to the COVID-19 pandemic or otherwise.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Salarius currently relies on outside vendors to manufacture its clinical supplies of its product candidates and plans to continue relying on third parties to manufacture its product candidates on a commercial scale, if approved.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The COVID-19 pandemic has placed a significant strain on the pharmaceutical industry, manufacturers of clinical supplies, healthcare-related supplies and resources, and the healthcare-related manufacturing sector in general.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The impact of the COVID-19 pandemic has exacerbated the risks to which Salarius is subject due to its reliance on third-party manufacturers.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">For example, Salarius may be unable to identify manufacturers on acceptable terms or at all or third-party manufacturers may not be able to execute Salarius&#8217; manufacturing procedures appropriately or may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply its clinical trials or to successfully produce, store and distribute its products. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, Salarius&#8217; manufacturers may experience manufacturing difficulties due to resource constraints, the impact of the COVID-19 pandemic, or as a result of labor disputes or unstable political environments. If Salarius&#8217; manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, Salarius&#8217; ability to provide its product candidates to patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require Salarius to commence new clinical trials at additional expense or terminate clinical trials completely.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Salarius&#8217; Business Operations</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Due to its limited number of employees, Salarius&#8217; operations could be significantly and disproportionately impacted if any of its personnel were to test positive for COVID-19.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Salarius is a small company with a limited number of employees performing multiple tasks each. Salarius is also highly dependent on David J. Arthur, its president and chief executive officer, the loss of whose services may adversely impact the achievement of its objectives. There is currently a shortage of highly qualified personnel in Salarius&#8217; industry, which is likely to continue. Additionally, this shortage of highly qualified personnel is particularly acute in the area where Salarius is located. If any of Salarius&#8217; personnel were to test positive for COVID-19, it would likely significantly impair Salarius&#8217; operations.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The loss of services of any of Salarius&#8217; personnel, including Mr. Arthur, particularly for an extended period due to COVID-19 or otherwise, would likely impede the progress of Salarius&#8217; research, development, and commercialization objectives and would negatively impact Salarius&#8217; ability to succeed in its product development strategy.</span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">We may face business disruption and related risks resulting from President Trump's recent invocation of the Defense Production Act, either of which could have a material adverse effect on our business.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In response to the COVID-19 pandemic, President Trump invoked the Defense Production Act, codified at 50 U.S.C. &#167;&#167; 4501 et seq. (the &#8220;Defense Production Act&#8221;). Pursuant to the, Defense Production Act the federal government may, among other things, require domestic industries to provide essential goods and services needed for the national defense. While we have not experienced any significant impact on our business as a result of such actions, we continue to assess the potential impact COVID-19 and the invocation of the Defense Production Act may have on our ability to effectively conduct our commercialization efforts and development programs and otherwise conduct our business operations as planned.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There can be no assurance that we will not be further impacted by the COVID-19 pandemic or by any action taken by the federal government under the Defense Production Act, including downturns in business sentiment generally or in our industry and business in particular.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks Related to Our Common Stock</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">If we are unable to maintain listing of our securities on the Nasdaq Capital Market or another reputable stock exchange, it may be more difficult for our stockholders to sell their securities.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Nasdaq Stock Market has experienced significant volatility and declines due to the COVID-19 pandemic.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, we have a limited public float and our stock price has experienced a significant decline since the reverse merger.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Between January 1, 2020 and April 30, 2020, our closing stock price has fluctuated from a high of $3.82 at January 3, 2020 to a low of $0.57 at March 24, 2020.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, Nasdaq requires listing issuers to comply with certain standards in order to remain listed on its exchange. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On April 9, 2020, we were notified by Nasdaq that on April 8, 2020 the average closing price of our common stock over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the &#8220;Minimum Bid Requirement&#8221;).</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days, to regain compliance with the Minimum Bid Requirement. To regain compliance, the closing bid price of our common stock must be at least $1.00 per share for a minimum of ten consecutive business days during this 180-day period. During this 180-day period, we would anticipate reviewing our options to regain compliance with the minimum bid requirements, including conducting a reverse stock split.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If we do not achieve compliance with the Minimum Bid Requirement during the initial 180 calendar day period, we may be eligible for an additional 180 calendar days compliance period. To qualify, we would be required to meet the continued listing requirement for market value of publicly held shares and all other Nasdaq initial listing standards, with the exception of the bid price requirement, and would need to provide written notice of our intention to cure the deficiency during the second compliance period. However, if it appears to Nasdaq staff that we will not be able to cure the deficiency, or if we do not meet the other listing standards, Nasdaq could provide notice that our common stock will become subject to delisting. In the event we receive notice that our common stock is being delisted, Nasdaq rules permit the us to appeal any delisting determination by the Nasdaq staff.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">There can be no assurance that we will be able to regain compliance with the Minimum Bid Requirement or maintain compliance with the other listing requirements. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On April 20, 2020, we were notified by Nasdaq that it has determined to toll the compliance periods for bid price and market value of publicly held shares requirements (collectively, the &#8220;Price-based Requirements&#8221;) through June 30, 2020. In that regard, on April 16, 2020, Nasdaq filed an immediately effective rule change with the SEC. As a result, companies presently in compliance periods for any Price-based Requirements will remain at that same stage of the process and will not be subject to being delisted for these concerns. Starting on July 1, 2020, companies will receive the balance of any pending compliance period in effect at the start of the tolling period to regain compliance.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Accordingly, since we had 173 calendar days remaining in our bid price compliance period as of April 16, 2020, we will, upon reinstatement of the Price-based Requirements, still have 173 calendar days from July 1, 2020, or until December 21, 2020, to regain compliance.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">If, for any reason, Nasdaq should delist our securities from trading on its exchange and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or all of the following may occur, each of which could materially adversely affect our stockholders:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the liquidity of our common stock;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the market price of our common stock;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">our ability to obtain financing for the continuation of our operations;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the number of institutional and general investors that will consider investing in our common stock;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the number of market makers in our common stock;</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the availability of information concerning the trading prices and volume of our common stock; and</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt;">the number of broker-dealers willing to execute trades in shares of our common stock. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">To the extent that we are unable to resolve any listing deficiency, there is a risk that our common stock may be delisted from Nasdaq, which would adversely impact liquidity of our common stock and potentially result in even lower bid prices for our common stock. </span></div><div id="i330ef634d79a46098535b93eedb2fa54_103"></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:7.558%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.442%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 5.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other Information</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As previously disclosed in the Current Report on Form 8-K that the Company filed with the SEC on April 24, 2020, the Company entered into an employment agreement with Mark J. Rosenblum, its Chief Financial Officer and Executive Vice President of Finance (the "Employment Agreement"), with the following terms: </span></div><div style="text-indent:27pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration: underline;">Cash Compensation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Mr. Rosenblum&#8217;s annual base salary will equal $265,000 (&#8220;Base Salary&#8221;) and he will be eligible to receive a target annual bonus of at least 35% of his base salary, to be earned based upon the </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">achievement of performance objectives to be determined by the Compensation Committee of the Board of Directors of the Company.</span></div><div style="text-indent:27pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Benefits</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Mr. Rosenblum will be eligible to participate in any company-sponsored benefit plans and programs, including medical, dental, life and disability insurance, holidays and other perquisites, at a level appropriate for his position and duties and to the extent that the Company makes such benefits generally available to executives of the Company. The Company may from time to time, in its sole discretion, amend, adjust or discontinue the benefits available to the Company&#8217;s executives and employees. </span></div><div style="text-indent:27pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Termination for Cause or as a Result of Death, Disability or Resignation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. If Mr. Rosenblum is terminated by the Company for &#8220;cause&#8221; or if his employment is terminated as a result of his death or &#8220;disability&#8221; or Mr. Rosenblum&#8217;s resignation without &#8220;good reason&#8221;, the Company shall pay Mr. Rosenblum (i) any unpaid Base Salary accrued up to the date of termination, (ii) accrued but unused vacation, (iii) benefits payable to Mr. Rosenblum pursuant to the terms and conditions of any benefit plan or program in which he participated during the term of his employment and (iv) unreimbursed business expenses.</span></div><div style="text-indent:27pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;">Termination without Cause or Resignation for Good Reason</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. If the Company terminates Mr. Rosenblum&#8217;s employment other than for &#8220;cause,&#8221; or in the event Mr. Rosenblum terminates with &#8220;good reason,&#8221; then Mr. Rosenblum will receive (i) severance pay in an amount equal to nine months of his then current Base Salary which shall be paid in equal installments over such period and (ii) a monthly payment as a reimbursement that in the aggregate is equal to nine months of COBRA benefits at active employee rates. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The information under this Item 5 is being provided to clarify that Mr. Rosenblum's title under the Employment Agreement is Chief Financial Officer and Executive Vice President of Finance.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_106"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:center;margin-top:8pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.701%;"><tr><td style="width:1.0%;"></td><td style="width:7.558%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:88.442%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6.</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibits</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.425%;"><tr><td style="width:1.0%;"></td><td style="width:7.248%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.479%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:84.273%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit<br/>number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description of Document</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000110465915007801/a15-4061_1ex3d1.htm">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on February 9, 2015).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:95%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000119312519199074/d754556dex31.htm">Certificate of Amendment of Certificate of Incorporation, filed with Secretary of State of Delaware on July 18, 2019 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on July 22, 2019).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000119312520033412/d863520dex31.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, dated February 10, 2020</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000119312520033412/d863520dex31.htm"> (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on February 12, 2020).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000119312519199074/d754556dex32.htm">Amended and Restated Bylaws, effective July 19, 2019 (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on July 22, 2019).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000119312520033412/d863520dex41.htm">Common Stock Purchase Warrant dated February 11, 2020 (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed on February 12, 2020).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000119312520025727/d857822dex48.htm">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.8 to the Registrant&#8217;s Registration Statement on Form S-1/A filed on February 6, 2020).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000119312520025727/d857822dex49.htm">Form of Preferred Stock Certificate of Registrant (incorporated by reference to Exhibit 4.9 to the Registrant&#8217;s Registration Statement on Form S-1/A filed on February 6, 2020).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000161521920000014/slrx20191231seperation.htm">Separation and Release Agreement between Scott Jordan and the Registrant, dated March 18, 2020 (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 23, 2020).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000161521920000014/slrx20191231-brucemccr.htm">Consulting Agreement between Bruce McCreedy and the Registrant, dated March 6, 2020(incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 23, 2020).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3+&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1615219/000161521920000050/mrosenblum-executiveem.htm">Employment Agreement between Mark J. Rosenblum and Salarius Pharmaceutical, Inc., dated April 24, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on April 29, 2020).</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="slrx20200331ex-311.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="slrx20200331ex-312.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1*&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="slrx20200331ex-321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The following materials from Salarius Pharmaceuticals, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in XBRL (eXtensible Business Reporting Language):(i) Unaudited Condensed Consolidated Balance Sheets, (ii) Unaudited Condensed Consolidated Statements of Operations (iii) Unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit), (iv) Unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Unaudited Consolidated Financial Statements.</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:38.362%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">+  Management contract or compensatory plans or arrangements.</span></div><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;">*   The material contained in Exhibit 32.1 is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language contained in such filing, except to the extent that the registrant specifically incorporates it by reference.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><div id="i330ef634d79a46098535b93eedb2fa54_109"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i330ef634d79a46098535b93eedb2fa54_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:36pt;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:3.908%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:39.211%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.283%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:45.122%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">SALARIUS PHARMACEUTICALS,&#160;INC.</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ David J. Arthur</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">David J. Arthur</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">President and Chief Executive Officer (Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Mark J. Rosenblum</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Mark J. Rosenblum</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Chief Financial Officer and Executive Vice President of Finance (Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>slrx20200331ex-311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i5bb8dfc41eee4ad3af1dc8f40c99c7bd_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:8pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.1</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Certification Pursuant to Securities Exchange Act Rules 13a-14 and 15d-14 as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, David J. Arthur, President and Chief Executive Officer, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. I have reviewed this Quarterly Report on Form 10-Q&#47;A of Salarius Pharmaceuticals, Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:47.25pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:18.527%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.299%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:49.174%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David J. Arthur</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David J. Arthur</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief&#160;Executive&#160;Officer (Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>slrx20200331ex-312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i87c306bc046644c193474cf91d2bb3f8_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:8pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.2</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Certification Pursuant to Securities Exchange Act Rules 13a-14 and 15d-14 as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Mark J. Rosenblum, Executive Vice President and Interim Chief Financial Officer, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. I have reviewed this Quarterly Report on Form 10-Q&#47;A of Salarius Pharmaceuticals, Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="padding-left:47.25pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;"><font><br></font></div><div style="padding-left:72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:18.527%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:26.299%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:49.174%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President and Interim Chief Financial Officer<br>(Principal&#160;Financial and Accounting&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>slrx20200331ex-321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i0e6070f90a3d4bcd92656d2a53dbeb3b_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;margin-top:8pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;32.1</font></div><div><font><br></font></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q&#47;A of Salarius Pharmaceuticals, Inc. (the &#34;Company&#34;) for the fiscal period ended March&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:47.25pt;"><font><br></font></div><div style="padding-left:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:17.501%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.325%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:49.174%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; David J. Arthur</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">David J. Arthur</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">President and Chief&#160;Executive&#160;Officer (Principal&#160;Executive&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:17.501%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.325%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:49.174%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mark J. Rosenblum</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 15, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President and Interim Chief Financial Officer<br>(Principal&#160;Financial Officer and Principal Accounting&#160;Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>flks-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b43fc1ac-9dfd-47d4-86a3-312a4f6202a7,g:fa4ae59e-aa52-4ad5-bb99-0a07ac3a7546-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:flks="http://www.flex-pharma.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.flex-pharma.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVERPAGE" roleURI="http://www.flex-pharma.com/role/COVERPAGE">
        <link:definition>0001001 - Document - COVER PAGE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited" roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDOPERATIONS" roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS">
        <link:definition>2101101 - Disclosure - ORGANIZATION AND OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2102102 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2203201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2404401 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVERSEACQUISITIONANDDISPOSAL" roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL">
        <link:definition>2105103 - Disclosure - REVERSE ACQUISITION AND DISPOSAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVERSEACQUISITIONANDDISPOSALTables" roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables">
        <link:definition>2306301 - Disclosure - REVERSE ACQUISITION AND DISPOSAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVERSEACQUISITIONANDDISPOSALNarrativeDetails" roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails">
        <link:definition>2407402 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails" roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails">
        <link:definition>2408403 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Summary of Purchase Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2409404 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails" roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails">
        <link:definition>2410405 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Schedule of Unaudited Pro Forma Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GRANTSRECEIVABLE" roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLE">
        <link:definition>2111104 - Disclosure - GRANTS RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GRANTSRECEIVABLEDetails" roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails">
        <link:definition>2412406 - Disclosure - GRANTS RECEIVABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETS" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS">
        <link:definition>2113105 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables">
        <link:definition>2314302 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2415407 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails">
        <link:definition>2416408 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2117106 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2418409 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEOFFINANCIALINSTRUMENTS" roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS">
        <link:definition>2119107 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEOFFINANCIALINSTRUMENTSTables" roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables">
        <link:definition>2320303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEOFFINANCIALINSTRUMENTSDetails" roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails">
        <link:definition>2421410 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2122108 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2323304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>2424411 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails">
        <link:definition>2425412 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATION" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION">
        <link:definition>2126109 - Disclosure - EQUITY-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONTables" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables">
        <link:definition>2327305 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2428413 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails">
        <link:definition>2429414 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails" roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails">
        <link:definition>2430415 - Disclosure - EQUITY-BASED COMPENSATION - Summary of stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS">
        <link:definition>2131110 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2432416 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="flks_UniversityOfUtahResearchFoundationMember" abstract="true" name="UniversityOfUtahResearchFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="flks_EquityIncentivePlan2015Member" abstract="true" name="EquityIncentivePlan2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" abstract="false" name="ClassOfWarrantOrRightThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" abstract="false" name="RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="flks_RevenueFromGrantsAggregateAmountReceived" abstract="false" name="RevenueFromGrantsAggregateAmountReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_StockIssuanceCostsAccruedAndAmortized" abstract="false" name="StockIssuanceCostsAccruedAndAmortized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_ProfitInterestUnitsMember" abstract="true" name="ProfitInterestUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="flks_RevenueFromGrantsMatchingFundsRequirement" abstract="false" name="RevenueFromGrantsMatchingFundsRequirement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="flks_SatisfySuccessFeeDueToRelatedPartyMember" abstract="true" name="SatisfySuccessFeeDueToRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions" abstract="false" name="BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_FlexPharmaMember" abstract="true" name="FlexPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable" abstract="false" name="RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable" abstract="false" name="ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="flks_WarrantsOutstandingMeasurementInput" abstract="false" name="WarrantsOutstandingMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="flks_RevenueFromGrantsMaximumAward" abstract="false" name="RevenueFromGrantsMaximumAward" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants" abstract="false" name="BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_RevenueFromGrantsCurrentFundingReceived" abstract="false" name="RevenueFromGrantsCurrentFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_RevenueFromGrantsAwardTerm" abstract="false" name="RevenueFromGrantsAwardTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="flks_CommonUnitsMember" abstract="true" name="CommonUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="flks_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_WedbushSecuritiesIncMember" abstract="true" name="WedbushSecuritiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="flks_PrepaidClinicalTrialExpense" abstract="false" name="PrepaidClinicalTrialExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="flks_RevenueFromGrantsExtensionTerm" abstract="false" name="RevenueFromGrantsExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>flks-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b43fc1ac-9dfd-47d4-86a3-312a4f6202a7,g:fa4ae59e-aa52-4ad5-bb99-0a07ac3a7546-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="simple" xlink:href="flks-20200331.xsd#COVERPAGE"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8d437b3f-5d2e-4b52-94cd-384942087a74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76b0eb8d-fd74-425c-8c5e-6b726dc5e1d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8d437b3f-5d2e-4b52-94cd-384942087a74" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76b0eb8d-fd74-425c-8c5e-6b726dc5e1d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bd206c91-ef37-4f2b-8ed4-b625530e2a32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8d437b3f-5d2e-4b52-94cd-384942087a74" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bd206c91-ef37-4f2b-8ed4-b625530e2a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_3fae31be-db12-4099-b748-ce5234937309" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8d437b3f-5d2e-4b52-94cd-384942087a74" xlink:to="loc_us-gaap_ReceivablesNetCurrent_3fae31be-db12-4099-b748-ce5234937309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_96e1096c-cbed-4cc2-8a68-6714cec43a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d1b45396-0a9b-4a7c-bba4-96a5f770a199" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_96e1096c-cbed-4cc2-8a68-6714cec43a1c" xlink:to="loc_us-gaap_StockholdersEquity_d1b45396-0a9b-4a7c-bba4-96a5f770a199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ae246ace-bccb-46be-8914-2f34be5e28e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_96e1096c-cbed-4cc2-8a68-6714cec43a1c" xlink:to="loc_us-gaap_Liabilities_ae246ace-bccb-46be-8914-2f34be5e28e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d66fdb4c-d5bc-4049-a97d-0272ab85de92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_0fdd8807-8704-4f9f-a6e0-d6db36206c68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d66fdb4c-d5bc-4049-a97d-0272ab85de92" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_0fdd8807-8704-4f9f-a6e0-d6db36206c68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7e4cd80e-54b0-4ba4-b01f-b23ee06e997a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d66fdb4c-d5bc-4049-a97d-0272ab85de92" xlink:to="loc_us-gaap_AccountsPayableCurrent_7e4cd80e-54b0-4ba4-b01f-b23ee06e997a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_d6ccdb5b-0dc7-4057-8feb-70ee43cafa13" xlink:href="flks-20200331.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d66fdb4c-d5bc-4049-a97d-0272ab85de92" xlink:to="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_d6ccdb5b-0dc7-4057-8feb-70ee43cafa13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_b5e12d7c-1c2c-4501-8898-363941671bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d66fdb4c-d5bc-4049-a97d-0272ab85de92" xlink:to="loc_us-gaap_NotesPayableCurrent_b5e12d7c-1c2c-4501-8898-363941671bc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f8066caa-a4b5-49e1-9819-6d132d83383b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d66fdb4c-d5bc-4049-a97d-0272ab85de92" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f8066caa-a4b5-49e1-9819-6d132d83383b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3c4dc349-d6c5-4421-b16e-bb2dc446f75f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2e96fe62-d96c-4a47-9257-593365ac14e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3c4dc349-d6c5-4421-b16e-bb2dc446f75f" xlink:to="loc_us-gaap_PreferredStockValue_2e96fe62-d96c-4a47-9257-593365ac14e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4bb74179-1bfe-469d-aabe-e7fc0294bb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3c4dc349-d6c5-4421-b16e-bb2dc446f75f" xlink:to="loc_us-gaap_CommonStockValue_4bb74179-1bfe-469d-aabe-e7fc0294bb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5520b0f0-dcbc-4e85-a54c-ff36e8a21798" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3c4dc349-d6c5-4421-b16e-bb2dc446f75f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5520b0f0-dcbc-4e85-a54c-ff36e8a21798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_97a39587-0ed9-4489-9483-caf57fbe2194" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3c4dc349-d6c5-4421-b16e-bb2dc446f75f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_97a39587-0ed9-4489-9483-caf57fbe2194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cd54536b-ccaf-4419-8a0e-0dc0dc687e69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_58d50f60-5420-401d-a60c-1266f7e94f93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cd54536b-ccaf-4419-8a0e-0dc0dc687e69" xlink:to="loc_us-gaap_AssetsCurrent_58d50f60-5420-401d-a60c-1266f7e94f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0d6d0a7c-36c8-49cf-8dae-55bcbe68a0e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cd54536b-ccaf-4419-8a0e-0dc0dc687e69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0d6d0a7c-36c8-49cf-8dae-55bcbe68a0e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_28dd5a1b-5437-40ce-9256-09de98079891" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cd54536b-ccaf-4419-8a0e-0dc0dc687e69" xlink:to="loc_us-gaap_Goodwill_28dd5a1b-5437-40ce-9256-09de98079891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_56c20d50-c940-4846-b241-250f01c7f530" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cd54536b-ccaf-4419-8a0e-0dc0dc687e69" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_56c20d50-c940-4846-b241-250f01c7f530" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5d2945bd-4dc9-4020-85f7-eaee029ff25f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_64361453-8943-42c9-b15e-6ebe6f29d11e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5d2945bd-4dc9-4020-85f7-eaee029ff25f" xlink:to="loc_us-gaap_OperatingExpenses_64361453-8943-42c9-b15e-6ebe6f29d11e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d728e639-fcc4-47f3-a20b-a2b715124850" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5d2945bd-4dc9-4020-85f7-eaee029ff25f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d728e639-fcc4-47f3-a20b-a2b715124850" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8c56f895-094e-4a0e-8bc5-72749a4a38a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2f70dbe7-18b8-4999-a434-34d94aae7e54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8c56f895-094e-4a0e-8bc5-72749a4a38a5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2f70dbe7-18b8-4999-a434-34d94aae7e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d090d7a8-9fb5-456a-9c2c-71ce7dc682c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8c56f895-094e-4a0e-8bc5-72749a4a38a5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d090d7a8-9fb5-456a-9c2c-71ce7dc682c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_663a9b9b-7382-492f-a837-306c810d4e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_44df3611-c8f9-43ca-b1f1-418c7868971f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_663a9b9b-7382-492f-a837-306c810d4e1a" xlink:to="loc_us-gaap_OperatingIncomeLoss_44df3611-c8f9-43ca-b1f1-418c7868971f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_28643b0b-e3cb-40c0-8884-7aa3d0ce06d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_663a9b9b-7382-492f-a837-306c810d4e1a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_28643b0b-e3cb-40c0-8884-7aa3d0ce06d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_32522189-b29e-4a0c-b0dc-1c82c3892348" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_663a9b9b-7382-492f-a837-306c810d4e1a" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_32522189-b29e-4a0c-b0dc-1c82c3892348" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_09bc0a4a-0392-49b7-a36c-8b6b32307bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_7ed9fc7b-3733-48a1-81ef-3b0244c882bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_09bc0a4a-0392-49b7-a36c-8b6b32307bbf" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_7ed9fc7b-3733-48a1-81ef-3b0244c882bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e6baa514-50d2-4a65-b114-ed1631d2104c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_09bc0a4a-0392-49b7-a36c-8b6b32307bbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_e6baa514-50d2-4a65-b114-ed1631d2104c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c59d6f1-d0a4-40f9-924a-6d9709ac3122" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb2d8d63-407e-40d2-b989-425d4f832bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c59d6f1-d0a4-40f9-924a-6d9709ac3122" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb2d8d63-407e-40d2-b989-425d4f832bb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbebbb76-f5a9-469d-97bc-1492553ed902" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c59d6f1-d0a4-40f9-924a-6d9709ac3122" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bbebbb76-f5a9-469d-97bc-1492553ed902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f87c04f1-1499-4a53-9a4c-42ce20dc2563" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_ShareBasedCompensation_f87c04f1-1499-4a53-9a4c-42ce20dc2563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_af182fd9-1b48-45de-8d7c-ed3a5ce5117e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_af182fd9-1b48-45de-8d7c-ed3a5ce5117e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f8429e22-193a-45d9-b732-81db529a1588" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f8429e22-193a-45d9-b732-81db529a1588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae233bb9-5e69-4ef8-a339-7eb4bd51e53e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae233bb9-5e69-4ef8-a339-7eb4bd51e53e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3203597c-d099-4c58-9d0a-72389e616e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3203597c-d099-4c58-9d0a-72389e616e5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_000896b2-e4a7-4261-a26e-4ee5bc079134" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_000896b2-e4a7-4261-a26e-4ee5bc079134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d584a2c-6a91-40ca-b1d0-ff5e8f5974c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_NetIncomeLoss_9d584a2c-6a91-40ca-b1d0-ff5e8f5974c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_be71bd7b-fa63-4c33-96b3-abc4aaa8f9ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_be71bd7b-fa63-4c33-96b3-abc4aaa8f9ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9ce04aa2-9cf2-4759-8671-b8e235e0a612" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9ce04aa2-9cf2-4759-8671-b8e235e0a612" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_e805d856-3503-4122-84f5-58ba3c85b314" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8e97f7-4726-4957-ad66-cb8224273ed0" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_e805d856-3503-4122-84f5-58ba3c85b314" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="simple" xlink:href="flks-20200331.xsd#ORGANIZATIONANDOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="flks-20200331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="flks-20200331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSAL"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALTables"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9feda236-f4c9-4e46-8813-0f7be7071cce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a83f4651-91e6-4cbb-bb9a-7e7cb8cdfaf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9feda236-f4c9-4e46-8813-0f7be7071cce" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a83f4651-91e6-4cbb-bb9a-7e7cb8cdfaf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants_04e30d2c-6f0b-473c-bf9d-9eaaaa3c3e4a" xlink:href="flks-20200331.xsd#flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9feda236-f4c9-4e46-8813-0f7be7071cce" xlink:to="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants_04e30d2c-6f0b-473c-bf9d-9eaaaa3c3e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions_39f8b9a9-dcda-40e5-b641-5f558e0a8a58" xlink:href="flks-20200331.xsd#flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_9feda236-f4c9-4e46-8813-0f7be7071cce" xlink:to="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions_39f8b9a9-dcda-40e5-b641-5f558e0a8a58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da0a7a7b-d19a-42e8-af1f-b75ea1338f17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e7f5f19c-cca5-43d1-9aee-76b46b8a1594" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da0a7a7b-d19a-42e8-af1f-b75ea1338f17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_e7f5f19c-cca5-43d1-9aee-76b46b8a1594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_bbbbd1c2-6476-41e1-b600-b235680faa3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da0a7a7b-d19a-42e8-af1f-b75ea1338f17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_bbbbd1c2-6476-41e1-b600-b235680faa3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e16e0756-4740-4e28-82be-318b46a235c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da0a7a7b-d19a-42e8-af1f-b75ea1338f17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e16e0756-4740-4e28-82be-318b46a235c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets_cd9d69f0-80ff-4d46-a8d1-8d03fef4637a" xlink:href="flks-20200331.xsd#flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da0a7a7b-d19a-42e8-af1f-b75ea1338f17" xlink:to="loc_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets_cd9d69f0-80ff-4d46-a8d1-8d03fef4637a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_f658ff44-f97b-45c9-9f38-9a2df66b2b98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_da0a7a7b-d19a-42e8-af1f-b75ea1338f17" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_f658ff44-f97b-45c9-9f38-9a2df66b2b98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4de98549-6663-4ad8-9fcd-7221719a4977" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_60185ad1-5adb-45a6-9bb3-72a1538a3fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4de98549-6663-4ad8-9fcd-7221719a4977" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_60185ad1-5adb-45a6-9bb3-72a1538a3fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_807b0fd9-37ec-42ac-b727-6ca33e8fa1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2a9cdcc6-ad06-4f8e-a3b1-d67dc30ece74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_807b0fd9-37ec-42ac-b727-6ca33e8fa1f1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2a9cdcc6-ad06-4f8e-a3b1-d67dc30ece74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_fbe05f8a-426b-444f-85fd-df95edbb05ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_807b0fd9-37ec-42ac-b727-6ca33e8fa1f1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_fbe05f8a-426b-444f-85fd-df95edbb05ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLE" xlink:type="simple" xlink:href="flks-20200331.xsd#GRANTSRECEIVABLE"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/GRANTSRECEIVABLE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#GRANTSRECEIVABLEDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_100ae25f-30bc-4192-80b5-4e5dc4a6ccee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_4ea30e18-d7cb-4e10-8bac-3d84e23c2fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_100ae25f-30bc-4192-80b5-4e5dc4a6ccee" xlink:to="loc_us-gaap_OtherAssetsCurrent_4ea30e18-d7cb-4e10-8bac-3d84e23c2fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense_f8e9442d-4b89-459c-90b1-daf969625359" xlink:href="flks-20200331.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_100ae25f-30bc-4192-80b5-4e5dc4a6ccee" xlink:to="loc_flks_PrepaidClinicalTrialExpense_f8e9442d-4b89-459c-90b1-daf969625359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_3743084b-c23a-439a-934f-2f35e115074c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_100ae25f-30bc-4192-80b5-4e5dc4a6ccee" xlink:to="loc_us-gaap_PrepaidInsurance_3743084b-c23a-439a-934f-2f35e115074c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="flks-20200331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="flks-20200331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="flks-20200331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTSTables"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTSDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATION"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONTables"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="flks-20200331.xsd#SUBSEQUENTEVENTS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>flks-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b43fc1ac-9dfd-47d4-86a3-312a4f6202a7,g:fa4ae59e-aa52-4ad5-bb99-0a07ac3a7546-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="simple" xlink:href="flks-20200331.xsd#COVERPAGE"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="extended" id="i2f181220935f466888eb9e8cb8dedf8f_COVERPAGE"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended" id="ifc01fb146aed492494e70ca5e3d23467_CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended" id="i0c94bc108fce4ac785563f6e9b93687c_CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="extended" id="i06f1fbd5cdd14b26b005234b0413b272_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended" id="i1d6bf06311664546b9f528f26a8731b3_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited" xlink:type="extended" id="ib0b799225f84492c9e227e66c7f65511_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d5b57787-7eec-48d0-ac6c-b25d895a739c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5b57787-7eec-48d0-ac6c-b25d895a739c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f5c960b6-97e5-4655-a528-4bc4b9d06419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_SharesOutstanding_f5c960b6-97e5-4655-a528-4bc4b9d06419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c458737-201e-4cdf-8deb-8d2ea7465178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockholdersEquity_9c458737-201e-4cdf-8deb-8d2ea7465178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fbe91e19-ca4d-4795-9aa7-39eeedb150a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fbe91e19-ca4d-4795-9aa7-39eeedb150a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7b2c9bd5-615f-420a-af21-73e36bf97d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7b2c9bd5-615f-420a-af21-73e36bf97d5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_241ff711-637b-4f2b-bd18-60f32251bf2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_241ff711-637b-4f2b-bd18-60f32251bf2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_752f8047-c88b-4d59-802f-fc48ba2d292d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_752f8047-c88b-4d59-802f-fc48ba2d292d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e95b2fb3-ce8b-44f3-b3b1-b9c5f685ce14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e95b2fb3-ce8b-44f3-b3b1-b9c5f685ce14" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e931d99d-fbf9-4f72-9d09-e51e819201af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e931d99d-fbf9-4f72-9d09-e51e819201af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3e2f3bb1-3c11-4edc-b543-198a5b124acb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3e2f3bb1-3c11-4edc-b543-198a5b124acb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_fdc2cf18-e97d-4781-bde1-696d85d813d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_fdc2cf18-e97d-4781-bde1-696d85d813d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8275e799-c29a-4ecc-bd7c-bf80d62a6473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_NetIncomeLoss_8275e799-c29a-4ecc-bd7c-bf80d62a6473" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f5efe667-3750-479f-bca2-c86068c5bb70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_94f9bdf5-2d5e-42ee-a486-8c6f6514017d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e9ce42f6-92fe-4f84-affc-38bbe77bc08e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d5b57787-7eec-48d0-ac6c-b25d895a739c" xlink:to="loc_us-gaap_StatementTable_e9ce42f6-92fe-4f84-affc-38bbe77bc08e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9ec6102f-26d7-4198-b71b-66c9e7607b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e9ce42f6-92fe-4f84-affc-38bbe77bc08e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9ec6102f-26d7-4198-b71b-66c9e7607b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9ec6102f-26d7-4198-b71b-66c9e7607b9f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9ec6102f-26d7-4198-b71b-66c9e7607b9f" xlink:to="loc_us-gaap_EquityComponentDomain_9ec6102f-26d7-4198-b71b-66c9e7607b9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9ec6102f-26d7-4198-b71b-66c9e7607b9f" xlink:to="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5a7c3363-9e95-4c29-84e7-065288985b36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:to="loc_us-gaap_CommonStockMember_5a7c3363-9e95-4c29-84e7-065288985b36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d10ef3c0-6231-4615-ad60-5eb162b2e82d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:to="loc_us-gaap_PreferredStockMember_d10ef3c0-6231-4615-ad60-5eb162b2e82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f9ce772d-2e26-43a5-ab85-ea1d100f89c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f9ce772d-2e26-43a5-ab85-ea1d100f89c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b6e5106f-e2e0-4d9f-992e-88cea6042bda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:to="loc_us-gaap_RetainedEarningsMember_b6e5106f-e2e0-4d9f-992e-88cea6042bda" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="simple" xlink:href="flks-20200331.xsd#ORGANIZATIONANDOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="extended" id="i29877479fc814989bb2ab380aaf5222a_ORGANIZATIONANDOPERATIONS"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="flks-20200331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="icdcb110c835a4af6b9e02c6e226e585f_BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="flks-20200331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="ifcb88d6a4f544d6895743606ff27a32f_BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended" id="ic9c7c2b05533414cab9f69286e8b49fe_BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8cd239a5-3e99-4380-9987-551573840aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8cd239a5-3e99-4380-9987-551573840aa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9dc63644-5f5e-4b65-8baf-36aa524fd820" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9dc63644-5f5e-4b65-8baf-36aa524fd820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9e2a059d-2be5-4b9a-8c9b-fe2e047cfb03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9e2a059d-2be5-4b9a-8c9b-fe2e047cfb03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_052eaac6-8fa8-43fa-a485-03ee4598bfbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_052eaac6-8fa8-43fa-a485-03ee4598bfbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dad4f2e6-4b49-4a0e-a985-e6263f6fd912" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dad4f2e6-4b49-4a0e-a985-e6263f6fd912" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e3bebcc9-41eb-4a6c-aa6a-e7a8ef6dbea7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dad4f2e6-4b49-4a0e-a985-e6263f6fd912" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e3bebcc9-41eb-4a6c-aa6a-e7a8ef6dbea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e3bebcc9-41eb-4a6c-aa6a-e7a8ef6dbea7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e3bebcc9-41eb-4a6c-aa6a-e7a8ef6dbea7" xlink:to="loc_us-gaap_EquityComponentDomain_e3bebcc9-41eb-4a6c-aa6a-e7a8ef6dbea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bcc3926a-7b0b-47c6-b614-af69bd893b37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e3bebcc9-41eb-4a6c-aa6a-e7a8ef6dbea7" xlink:to="loc_us-gaap_EquityComponentDomain_bcc3926a-7b0b-47c6-b614-af69bd893b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_944a9946-442e-448a-8f03-8d44838c0bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bcc3926a-7b0b-47c6-b614-af69bd893b37" xlink:to="loc_us-gaap_CommonStockMember_944a9946-442e-448a-8f03-8d44838c0bcb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSAL"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL" xlink:type="extended" id="i385cca418a0b4546acc4e04953ec34c6_REVERSEACQUISITIONANDDISPOSAL"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALTables"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables" xlink:type="extended" id="id1f0d0824d264ac697e2c1fcb8f28a08_REVERSEACQUISITIONANDDISPOSALTables"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails" xlink:type="extended" id="i994ce89320454ddaaeea1f315a455460_REVERSEACQUISITIONANDDISPOSALNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_ecf840fb-4fb0-4f46-b327-9f7dc0a5c7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_ecf840fb-4fb0-4f46-b327-9f7dc0a5c7ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24e68edc-162d-4a2b-9478-3c4402bcc7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24e68edc-162d-4a2b-9478-3c4402bcc7bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3ae1537f-b5af-46a1-90e3-39373c102853" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3ae1537f-b5af-46a1-90e3-39373c102853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable_6b14bdd9-5f7a-44a4-be6a-bffcb54d2e64" xlink:href="flks-20200331.xsd#flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:to="loc_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable_6b14bdd9-5f7a-44a4-be6a-bffcb54d2e64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_544e3ab2-0896-456a-9773-1d60f29aa37f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_544e3ab2-0896-456a-9773-1d60f29aa37f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5a458a3f-d4e4-4196-9f62-4eb3d72dc2da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_544e3ab2-0896-456a-9773-1d60f29aa37f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5a458a3f-d4e4-4196-9f62-4eb3d72dc2da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a458a3f-d4e4-4196-9f62-4eb3d72dc2da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5a458a3f-d4e4-4196-9f62-4eb3d72dc2da" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a458a3f-d4e4-4196-9f62-4eb3d72dc2da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c6330a7-1898-4c55-8e7d-a19cd2e6d722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5a458a3f-d4e4-4196-9f62-4eb3d72dc2da" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c6330a7-1898-4c55-8e7d-a19cd2e6d722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_FlexPharmaMember_8259d70a-cb24-4bb5-8876-9e40e75bfbc5" xlink:href="flks-20200331.xsd#flks_FlexPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c6330a7-1898-4c55-8e7d-a19cd2e6d722" xlink:to="loc_flks_FlexPharmaMember_8259d70a-cb24-4bb5-8876-9e40e75bfbc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4cf95a77-0f78-4e89-9b4a-0a4e5e4a0626" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_544e3ab2-0896-456a-9773-1d60f29aa37f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4cf95a77-0f78-4e89-9b4a-0a4e5e4a0626" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4cf95a77-0f78-4e89-9b4a-0a4e5e4a0626_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4cf95a77-0f78-4e89-9b4a-0a4e5e4a0626" xlink:to="loc_us-gaap_EquityComponentDomain_4cf95a77-0f78-4e89-9b4a-0a4e5e4a0626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d5a73ab7-573d-4a10-a8ef-18083720dcf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4cf95a77-0f78-4e89-9b4a-0a4e5e4a0626" xlink:to="loc_us-gaap_EquityComponentDomain_d5a73ab7-573d-4a10-a8ef-18083720dcf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3404ef04-9062-47fa-b9ef-b3c450f0a5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d5a73ab7-573d-4a10-a8ef-18083720dcf0" xlink:to="loc_us-gaap_CommonStockMember_3404ef04-9062-47fa-b9ef-b3c450f0a5ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails" xlink:type="extended" id="i0621f5bb9a0d413eb96d93926331c4d5_REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4c8ec3ed-29d6-4bd7-88cb-60c760dd1d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4c8ec3ed-29d6-4bd7-88cb-60c760dd1d1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants_c0115479-38f3-4e74-81d3-f25c4edf9e7b" xlink:href="flks-20200331.xsd#flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:to="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants_c0115479-38f3-4e74-81d3-f25c4edf9e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions_d763768d-2f4e-4448-bc24-848bf680d911" xlink:href="flks-20200331.xsd#flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:to="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions_d763768d-2f4e-4448-bc24-848bf680d911" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0b0804f4-dde0-4634-8959-fcd9e42674f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0b0804f4-dde0-4634-8959-fcd9e42674f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dd37511-9e86-4384-807f-2b079b9f224f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dd37511-9e86-4384-807f-2b079b9f224f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c9ace9a8-057a-47d0-be01-3308c2b02445" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dd37511-9e86-4384-807f-2b079b9f224f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c9ace9a8-057a-47d0-be01-3308c2b02445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9ace9a8-057a-47d0-be01-3308c2b02445_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c9ace9a8-057a-47d0-be01-3308c2b02445" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9ace9a8-057a-47d0-be01-3308c2b02445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c764c0-8df3-43d5-bc8c-cb833abd7d91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c9ace9a8-057a-47d0-be01-3308c2b02445" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c764c0-8df3-43d5-bc8c-cb833abd7d91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_FlexPharmaMember_ab8bf299-3a4c-4d73-9881-190bbde6f2e2" xlink:href="flks-20200331.xsd#flks_FlexPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c764c0-8df3-43d5-bc8c-cb833abd7d91" xlink:to="loc_flks_FlexPharmaMember_ab8bf299-3a4c-4d73-9881-190bbde6f2e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i2427fbba8fb84b2b8a1cb81f6ffea616_REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ebd26b1b-03db-4782-a88b-e5e52968b010" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ebd26b1b-03db-4782-a88b-e5e52968b010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1dabc85c-d506-4a0d-8cb3-bca3e1638318" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1dabc85c-d506-4a0d-8cb3-bca3e1638318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_bee711c5-009d-4a63-8ef3-458ad0590024" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_bee711c5-009d-4a63-8ef3-458ad0590024" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ad321106-75ee-4620-b328-af6e5906b809" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ad321106-75ee-4620-b328-af6e5906b809" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets_9557d06a-da5d-48a4-89a0-ada814cff5b2" xlink:href="flks-20200331.xsd#flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets_9557d06a-da5d-48a4-89a0-ada814cff5b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7c107a81-eeba-4dd8-89f1-dea4600c96d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7c107a81-eeba-4dd8-89f1-dea4600c96d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_575cb45f-e35a-4c69-b75c-636b1e5b5b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_575cb45f-e35a-4c69-b75c-636b1e5b5b9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_49e8bc2b-512b-491a-a6c3-958ada9cf4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_49e8bc2b-512b-491a-a6c3-958ada9cf4d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_cd4a9027-64ed-43c7-8327-7f4c318f66f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_cd4a9027-64ed-43c7-8327-7f4c318f66f2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3a9d23e5-5050-4f83-9d8a-41bbcbddec1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3a9d23e5-5050-4f83-9d8a-41bbcbddec1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93e40d04-2129-4967-9c2c-a3fd8ee30712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3a9d23e5-5050-4f83-9d8a-41bbcbddec1d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93e40d04-2129-4967-9c2c-a3fd8ee30712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93e40d04-2129-4967-9c2c-a3fd8ee30712_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93e40d04-2129-4967-9c2c-a3fd8ee30712" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93e40d04-2129-4967-9c2c-a3fd8ee30712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_202564b6-6808-4d56-adde-ddfc0dec902d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93e40d04-2129-4967-9c2c-a3fd8ee30712" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_202564b6-6808-4d56-adde-ddfc0dec902d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_FlexPharmaMember_e4a3278b-8a1e-4ea7-b479-98249f97dfc3" xlink:href="flks-20200331.xsd#flks_FlexPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_202564b6-6808-4d56-adde-ddfc0dec902d" xlink:to="loc_flks_FlexPharmaMember_e4a3278b-8a1e-4ea7-b479-98249f97dfc3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails" xlink:type="extended" id="i2836ce2f0184401eb065a34666bad055_REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLE" xlink:type="simple" xlink:href="flks-20200331.xsd#GRANTSRECEIVABLE"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/GRANTSRECEIVABLE" xlink:type="extended" id="iee58030b16314826a64f6d0b260a1c72_GRANTSRECEIVABLE"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#GRANTSRECEIVABLEDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails" xlink:type="extended" id="i5bf56343451e480d87f74b5060530014_GRANTSRECEIVABLEDetails"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETS"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="extended" id="ic4e02c10a1ac4fc8b673f6e3267e9b7a_PREPAIDEXPENSESANDOTHERCURRENTASSETS"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="extended" id="if7b59557b41f476e8c1ac54631b9260f_PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended" id="i5f88ce2f23c542a3b3a2d3f874662850_PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="extended" id="i4adf218c7cab4f9c94b90034f4429109_PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ee0346e5-c1ef-40f8-abf9-11da4b5fc3df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ee0346e5-c1ef-40f8-abf9-11da4b5fc3df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a4ddcb5a-58db-4080-bd79-fb876bbab222" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a4ddcb5a-58db-4080-bd79-fb876bbab222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_6e7c4966-e63d-47a6-b42a-084cacf0d711" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:to="loc_us-gaap_NotesPayableCurrent_6e7c4966-e63d-47a6-b42a-084cacf0d711" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_f6b14e19-2f6a-4c19-a847-17b65037bcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_f6b14e19-2f6a-4c19-a847-17b65037bcfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_bb741790-2af4-420d-9bce-3f0839c46f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f6b14e19-2f6a-4c19-a847-17b65037bcfc" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_bb741790-2af4-420d-9bce-3f0839c46f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_bb741790-2af4-420d-9bce-3f0839c46f2b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_bb741790-2af4-420d-9bce-3f0839c46f2b" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_bb741790-2af4-420d-9bce-3f0839c46f2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_cd4343ce-3113-4b94-aee1-cefe5d55ac0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_bb741790-2af4-420d-9bce-3f0839c46f2b" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_cd4343ce-3113-4b94-aee1-cefe5d55ac0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_9265d23c-8777-4cd1-a5fe-12cc3dd6a91c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_cd4343ce-3113-4b94-aee1-cefe5d55ac0f" xlink:to="loc_us-gaap_NotesPayableToBanksMember_9265d23c-8777-4cd1-a5fe-12cc3dd6a91c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="flks-20200331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="ic1b3dfdb04d7495e8ec556f2a3f62c8f_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended" id="i980637ed7aae4eaabe335d988d635c96_COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5c96b251-fc81-41e2-8708-a3d135d37ced" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5c96b251-fc81-41e2-8708-a3d135d37ced" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMaximumAward_d8a0781c-d94e-42a3-8381-24292960c2ce" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsMaximumAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsMaximumAward_d8a0781c-d94e-42a3-8381-24292960c2ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAwardTerm_e46d3ad6-c856-4940-883d-cf7f083b4184" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsAwardTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsAwardTerm_e46d3ad6-c856-4940-883d-cf7f083b4184" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsExtensionTerm_32e8f6bc-c1b7-4d57-9224-e3d59453314a" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsExtensionTerm_32e8f6bc-c1b7-4d57-9224-e3d59453314a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_2448b780-a629-4ad2-9afe-733a52dc7aa6" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_2448b780-a629-4ad2-9afe-733a52dc7aa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMatchingFundsRequirement_e713894e-7787-447e-b108-12cd838fc383" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsMatchingFundsRequirement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsMatchingFundsRequirement_e713894e-7787-447e-b108-12cd838fc383" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAggregateAmountReceived_33dc2a61-e7d0-4396-aa8a-b9492f7857da" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsAggregateAmountReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsAggregateAmountReceived_33dc2a61-e7d0-4396-aa8a-b9492f7857da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable_df152373-d9cc-413e-872b-dfa1cced255d" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable_df152373-d9cc-413e-872b-dfa1cced255d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsCurrentFundingReceived_9a06f245-1622-433b-bd1b-30676a70becc" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsCurrentFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsCurrentFundingReceived_9a06f245-1622-433b-bd1b-30676a70becc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2cf1e260-19b2-4709-846d-0032e5bdc087" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2cf1e260-19b2-4709-846d-0032e5bdc087" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_64cd65d1-b727-413f-afa5-0675111b50a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_us-gaap_ReceivablesNetCurrent_64cd65d1-b727-413f-afa5-0675111b50a4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_171b6886-3bbb-4dfb-be56-b76a94e1a7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_171b6886-3bbb-4dfb-be56-b76a94e1a7a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bba93833-d633-458f-b9ba-ca518abd0762" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_171b6886-3bbb-4dfb-be56-b76a94e1a7a8" xlink:to="loc_srt_OwnershipAxis_bba93833-d633-458f-b9ba-ca518abd0762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bba93833-d633-458f-b9ba-ca518abd0762_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_bba93833-d633-458f-b9ba-ca518abd0762" xlink:to="loc_srt_OwnershipDomain_bba93833-d633-458f-b9ba-ca518abd0762_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6e24e514-8b1f-4254-a255-c996a9ca3fc7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_bba93833-d633-458f-b9ba-ca518abd0762" xlink:to="loc_srt_OwnershipDomain_6e24e514-8b1f-4254-a255-c996a9ca3fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_UniversityOfUtahResearchFoundationMember_2aba7ca9-c306-4a46-9739-d783ff2f4b1b" xlink:href="flks-20200331.xsd#flks_UniversityOfUtahResearchFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_6e24e514-8b1f-4254-a255-c996a9ca3fc7" xlink:to="loc_flks_UniversityOfUtahResearchFoundationMember_2aba7ca9-c306-4a46-9739-d783ff2f4b1b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="flks-20200331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTS"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="extended" id="i52a050aa753f4de09d5c611f636689ae_FAIRVALUEOFFINANCIALINSTRUMENTS"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="flks-20200331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTSTables"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="extended" id="i5be4cc42c5ba49218b3bef1941120abb_FAIRVALUEOFFINANCIALINSTRUMENTSTables"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="extended" id="i42e95a5be4314f5dbb1dbd74c1499ca7_FAIRVALUEOFFINANCIALINSTRUMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5f957e12-f26f-4a74-9fda-0a1ff3faa704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77f7bfdd-cb75-43c0-b6f4-14a43812000f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5f957e12-f26f-4a74-9fda-0a1ff3faa704" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77f7bfdd-cb75-43c0-b6f4-14a43812000f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_165825ff-1100-4e7a-86ea-46832a5a60e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77f7bfdd-cb75-43c0-b6f4-14a43812000f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_165825ff-1100-4e7a-86ea-46832a5a60e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_bc27555e-7ae4-4aad-a8db-1e483b05c761" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77f7bfdd-cb75-43c0-b6f4-14a43812000f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_bc27555e-7ae4-4aad-a8db-1e483b05c761" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_43d6f046-e914-4250-a8b7-0fb08bada5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceec8c68-0a0a-492a-8feb-ad93904fdf13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5f957e12-f26f-4a74-9fda-0a1ff3faa704" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceec8c68-0a0a-492a-8feb-ad93904fdf13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f310b97c-e9cf-4766-8b62-cdd3f79cbbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceec8c68-0a0a-492a-8feb-ad93904fdf13" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f310b97c-e9cf-4766-8b62-cdd3f79cbbe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f310b97c-e9cf-4766-8b62-cdd3f79cbbe6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f310b97c-e9cf-4766-8b62-cdd3f79cbbe6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f310b97c-e9cf-4766-8b62-cdd3f79cbbe6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64a03944-2cce-4732-81a4-e27e85c81831" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f310b97c-e9cf-4766-8b62-cdd3f79cbbe6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64a03944-2cce-4732-81a4-e27e85c81831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fca5ee63-e185-487b-9e49-05c3a3089e85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64a03944-2cce-4732-81a4-e27e85c81831" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fca5ee63-e185-487b-9e49-05c3a3089e85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7d1b2d07-913f-42bb-b0c9-e076b7b8bb08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceec8c68-0a0a-492a-8feb-ad93904fdf13" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7d1b2d07-913f-42bb-b0c9-e076b7b8bb08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7d1b2d07-913f-42bb-b0c9-e076b7b8bb08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7d1b2d07-913f-42bb-b0c9-e076b7b8bb08" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7d1b2d07-913f-42bb-b0c9-e076b7b8bb08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bba53f43-e835-4143-b498-36189c340705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7d1b2d07-913f-42bb-b0c9-e076b7b8bb08" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bba53f43-e835-4143-b498-36189c340705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c3fb3fd6-11f0-4476-8fe9-45d5e1403235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bba53f43-e835-4143-b498-36189c340705" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c3fb3fd6-11f0-4476-8fe9-45d5e1403235" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended" id="i6b7cf91074e545eba16a08b51753dd5e_STOCKHOLDERSEQUITY"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended" id="i7471bf5b4cfb4d0b9e337c709ee2fec1_STOCKHOLDERSEQUITYTables"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended" id="iefbc1a5a0034415bb00f3486e770b11c_STOCKHOLDERSEQUITYNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a2ef3b2b-0961-4057-885a-4d606ee71882" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a2ef3b2b-0961-4057-885a-4d606ee71882" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56f4b90f-ea7a-4955-ab1e-9fea91b5dbb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_56f4b90f-ea7a-4955-ab1e-9fea91b5dbb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_89d0375e-4d2f-41d9-8849-cc5b7bc9959f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_89d0375e-4d2f-41d9-8849-cc5b7bc9959f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_274f3682-e42e-484e-8fc3-26ddf67d9ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_274f3682-e42e-484e-8fc3-26ddf67d9ae8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_94bd4168-950f-4182-9815-e90f5c8566e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_94bd4168-950f-4182-9815-e90f5c8566e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e2e4992f-6113-4ba7-b48f-a55108b0d621" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e2e4992f-6113-4ba7-b48f-a55108b0d621" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e9c5ff11-53a6-48c7-8a5a-07b04691943b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e9c5ff11-53a6-48c7-8a5a-07b04691943b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6d655170-b57d-4552-8cc8-95f65acadac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6d655170-b57d-4552-8cc8-95f65acadac0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_00f1652f-9849-43d9-b6f8-879bc2cad188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_00f1652f-9849-43d9-b6f8-879bc2cad188" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9d767ef8-6a4e-4146-8561-bf38d779d505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9d767ef8-6a4e-4146-8561-bf38d779d505" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f30d0fa0-e337-4e43-88ca-a4eca908db9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f30d0fa0-e337-4e43-88ca-a4eca908db9c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e28eebe2-a755-476f-8211-5c6cad276b54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e28eebe2-a755-476f-8211-5c6cad276b54" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_5abc1ff7-c572-44ac-a4c9-2dd5aa8161ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_5abc1ff7-c572-44ac-a4c9-2dd5aa8161ab" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_ffe8b29a-9018-40cf-86be-b37ae44d5a97" xlink:href="flks-20200331.xsd#flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_ffe8b29a-9018-40cf-86be-b37ae44d5a97" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_88b88015-2070-442a-b480-2989319614ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_88b88015-2070-442a-b480-2989319614ed" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_ec732baa-59e7-4668-94e2-59e565a46a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_ec732baa-59e7-4668-94e2-59e565a46a6d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_9e8bba43-b9e0-4b3e-aa5b-b627743bd493" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_9e8bba43-b9e0-4b3e-aa5b-b627743bd493" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66e57a2e-2ded-4ec2-a89e-6137f7a814d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66e57a2e-2ded-4ec2-a89e-6137f7a814d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_66e57a2e-2ded-4ec2-a89e-6137f7a814d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66e57a2e-2ded-4ec2-a89e-6137f7a814d0" xlink:to="loc_us-gaap_RelatedPartyDomain_66e57a2e-2ded-4ec2-a89e-6137f7a814d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4a42d6fe-16e1-4ba0-a195-2e6f6f70a13f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66e57a2e-2ded-4ec2-a89e-6137f7a814d0" xlink:to="loc_us-gaap_RelatedPartyDomain_4a42d6fe-16e1-4ba0-a195-2e6f6f70a13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WedbushSecuritiesIncMember_9dbcecd6-40ea-4e56-809d-f5fc63aac527" xlink:href="flks-20200331.xsd#flks_WedbushSecuritiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4a42d6fe-16e1-4ba0-a195-2e6f6f70a13f" xlink:to="loc_flks_WedbushSecuritiesIncMember_9dbcecd6-40ea-4e56-809d-f5fc63aac527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_142a78ee-fadd-432c-86cf-2cca5debf4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_142a78ee-fadd-432c-86cf-2cca5debf4b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_142a78ee-fadd-432c-86cf-2cca5debf4b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_142a78ee-fadd-432c-86cf-2cca5debf4b4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_142a78ee-fadd-432c-86cf-2cca5debf4b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0b71563c-e00a-4f3e-97c6-0e95f06dc72c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_142a78ee-fadd-432c-86cf-2cca5debf4b4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0b71563c-e00a-4f3e-97c6-0e95f06dc72c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember_ca1537b0-8be8-476f-ba55-dfa9d36e40e2" xlink:href="flks-20200331.xsd#flks_SatisfySuccessFeeDueToRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0b71563c-e00a-4f3e-97c6-0e95f06dc72c" xlink:to="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember_ca1537b0-8be8-476f-ba55-dfa9d36e40e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d4889827-1acb-46ef-84de-52f5098eaa4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d4889827-1acb-46ef-84de-52f5098eaa4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d4889827-1acb-46ef-84de-52f5098eaa4e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d4889827-1acb-46ef-84de-52f5098eaa4e" xlink:to="loc_us-gaap_ClassOfStockDomain_d4889827-1acb-46ef-84de-52f5098eaa4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d4889827-1acb-46ef-84de-52f5098eaa4e" xlink:to="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_793c2e86-5f37-4995-83bc-7de2e749c340" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_us-gaap_CommonClassAMember_793c2e86-5f37-4995-83bc-7de2e749c340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_4f79a407-d7e8-43e3-85c9-00c218b453ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_us-gaap_CommonClassBMember_4f79a407-d7e8-43e3-85c9-00c218b453ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_db0f030f-60ee-4b58-aef2-e84ae002a274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_db0f030f-60ee-4b58-aef2-e84ae002a274" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ProfitInterestUnitsMember_9e6da217-ca27-4f46-be68-ae65c6f7a527" xlink:href="flks-20200331.xsd#flks_ProfitInterestUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_flks_ProfitInterestUnitsMember_9e6da217-ca27-4f46-be68-ae65c6f7a527" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_CommonUnitsMember_056e66b3-ba37-4920-94f4-14b4b997ae69" xlink:href="flks-20200331.xsd#flks_CommonUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_flks_CommonUnitsMember_056e66b3-ba37-4920-94f4-14b4b997ae69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_acc69678-ff21-4bd5-9d53-292d964fcd07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_acc69678-ff21-4bd5-9d53-292d964fcd07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_acc69678-ff21-4bd5-9d53-292d964fcd07_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_acc69678-ff21-4bd5-9d53-292d964fcd07" xlink:to="loc_us-gaap_EquityComponentDomain_acc69678-ff21-4bd5-9d53-292d964fcd07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c4dc505a-8ec6-4b4f-8c04-15b90a0e2a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_acc69678-ff21-4bd5-9d53-292d964fcd07" xlink:to="loc_us-gaap_EquityComponentDomain_c4dc505a-8ec6-4b4f-8c04-15b90a0e2a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_baf05ee9-d90a-4961-af16-9c56feb1122f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4dc505a-8ec6-4b4f-8c04-15b90a0e2a0a" xlink:to="loc_us-gaap_CommonStockMember_baf05ee9-d90a-4961-af16-9c56feb1122f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ba987e50-26ab-408a-bce4-8b55769bff59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4dc505a-8ec6-4b4f-8c04-15b90a0e2a0a" xlink:to="loc_us-gaap_PreferredStockMember_ba987e50-26ab-408a-bce4-8b55769bff59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9f661906-84fc-4454-b34c-cf6f2b613ef6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_dei_LegalEntityAxis_9f661906-84fc-4454-b34c-cf6f2b613ef6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9f661906-84fc-4454-b34c-cf6f2b613ef6_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9f661906-84fc-4454-b34c-cf6f2b613ef6" xlink:to="loc_dei_EntityDomain_9f661906-84fc-4454-b34c-cf6f2b613ef6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cdc57442-0b74-4a86-b19a-7613ee22264a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9f661906-84fc-4454-b34c-cf6f2b613ef6" xlink:to="loc_dei_EntityDomain_cdc57442-0b74-4a86-b19a-7613ee22264a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_FlexPharmaMember_09bf0826-11ab-44eb-b785-3b268e36c9a8" xlink:href="flks-20200331.xsd#flks_FlexPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_cdc57442-0b74-4a86-b19a-7613ee22264a" xlink:to="loc_flks_FlexPharmaMember_09bf0826-11ab-44eb-b785-3b268e36c9a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d88e6ecf-4087-4f64-a402-c3fba1962f95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d88e6ecf-4087-4f64-a402-c3fba1962f95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d88e6ecf-4087-4f64-a402-c3fba1962f95_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d88e6ecf-4087-4f64-a402-c3fba1962f95" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d88e6ecf-4087-4f64-a402-c3fba1962f95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49877bec-0650-484d-84d9-3b7316475ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d88e6ecf-4087-4f64-a402-c3fba1962f95" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49877bec-0650-484d-84d9-3b7316475ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_0a280828-e5be-44db-9a77-c5f70fab7c19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49877bec-0650-484d-84d9-3b7316475ec2" xlink:to="loc_us-gaap_OverAllotmentOptionMember_0a280828-e5be-44db-9a77-c5f70fab7c19" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="extended" id="i2b97c78927e3479e9bfbafe81dae35f5_STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_57968601-8f49-4209-b8a8-befda27c5101" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WarrantsOutstandingMeasurementInput_2fcddf41-66f3-46f4-8619-14d17f0308f1" xlink:href="flks-20200331.xsd#flks_WarrantsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_57968601-8f49-4209-b8a8-befda27c5101" xlink:to="loc_flks_WarrantsOutstandingMeasurementInput_2fcddf41-66f3-46f4-8619-14d17f0308f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e3189142-389b-434c-94f0-7a587afd86fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_57968601-8f49-4209-b8a8-befda27c5101" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e3189142-389b-434c-94f0-7a587afd86fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_508f2b7f-c497-48f6-b920-1846085d91ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_57968601-8f49-4209-b8a8-befda27c5101" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_508f2b7f-c497-48f6-b920-1846085d91ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_04e0ec82-5be6-4601-bb21-36a43500c1ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_508f2b7f-c497-48f6-b920-1846085d91ac" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_04e0ec82-5be6-4601-bb21-36a43500c1ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_04e0ec82-5be6-4601-bb21-36a43500c1ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_04e0ec82-5be6-4601-bb21-36a43500c1ec" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_04e0ec82-5be6-4601-bb21-36a43500c1ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_04e0ec82-5be6-4601-bb21-36a43500c1ec" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_6bc9832a-85d0-4739-a564-880f9d517dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_6bc9832a-85d0-4739-a564-880f9d517dd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_a0687153-659b-409b-b6a7-0ca133acccec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_a0687153-659b-409b-b6a7-0ca133acccec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_c3a5a596-e403-4f55-b2bc-e5dce9c9f679" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_c3a5a596-e403-4f55-b2bc-e5dce9c9f679" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATION"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="extended" id="idd17e56577074fdc8a8e8f4bc64e12f1_EQUITYBASEDCOMPENSATION"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONTables"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="extended" id="ib3e8fe005a194f0fbee2bf81e30711ca_EQUITYBASEDCOMPENSATIONTables"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="ib5d5aae3937b47a885c2cf56b70ef526_EQUITYBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8a56859-0fa2-4759-a92f-eafd825810e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8a56859-0fa2-4759-a92f-eafd825810e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_32cd9ab1-3011-498d-94c1-3550d9d3e6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_32cd9ab1-3011-498d-94c1-3550d9d3e6a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e646587f-f475-4875-8c7e-20995729c5a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e646587f-f475-4875-8c7e-20995729c5a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_09daba07-5e68-44cc-96a2-79be31d4f782" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_09daba07-5e68-44cc-96a2-79be31d4f782" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dd662b7a-b217-4068-afb7-e4793bfba963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dd662b7a-b217-4068-afb7-e4793bfba963" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d95e51b9-1b94-4d59-b108-82205fd92d65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d95e51b9-1b94-4d59-b108-82205fd92d65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_13a40422-b673-4051-a07e-3bb03da32111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_13a40422-b673-4051-a07e-3bb03da32111" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b399de83-7873-40bd-80de-57ae89e97144" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b399de83-7873-40bd-80de-57ae89e97144" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6f41dd18-4fad-452e-b03a-4be95a415e62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:to="loc_us-gaap_PlanNameAxis_6f41dd18-4fad-452e-b03a-4be95a415e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6f41dd18-4fad-452e-b03a-4be95a415e62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6f41dd18-4fad-452e-b03a-4be95a415e62" xlink:to="loc_us-gaap_PlanNameDomain_6f41dd18-4fad-452e-b03a-4be95a415e62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c265d4fb-46ea-4af9-8b5f-4bc5f7778b89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6f41dd18-4fad-452e-b03a-4be95a415e62" xlink:to="loc_us-gaap_PlanNameDomain_c265d4fb-46ea-4af9-8b5f-4bc5f7778b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EquityIncentivePlan2015Member_dfdfc867-40f4-4fd5-b283-b7216dbd8783" xlink:href="flks-20200331.xsd#flks_EquityIncentivePlan2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c265d4fb-46ea-4af9-8b5f-4bc5f7778b89" xlink:to="loc_flks_EquityIncentivePlan2015Member_dfdfc867-40f4-4fd5-b283-b7216dbd8783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9201c210-15b8-4951-914c-0fa4952e206e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:to="loc_srt_RangeAxis_9201c210-15b8-4951-914c-0fa4952e206e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9201c210-15b8-4951-914c-0fa4952e206e_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9201c210-15b8-4951-914c-0fa4952e206e" xlink:to="loc_srt_RangeMember_9201c210-15b8-4951-914c-0fa4952e206e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4b3d7a7-f652-483a-ab88-af6bcd39b2bc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9201c210-15b8-4951-914c-0fa4952e206e" xlink:to="loc_srt_RangeMember_a4b3d7a7-f652-483a-ab88-af6bcd39b2bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1c71a08c-db13-4f27-98e1-546c9d8b4430" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a4b3d7a7-f652-483a-ab88-af6bcd39b2bc" xlink:to="loc_srt_MinimumMember_1c71a08c-db13-4f27-98e1-546c9d8b4430" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a626c745-5077-4c16-958d-508f793506fe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a4b3d7a7-f652-483a-ab88-af6bcd39b2bc" xlink:to="loc_srt_MaximumMember_a626c745-5077-4c16-958d-508f793506fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_229a94f4-70ea-4060-a23b-e6b403d329f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:to="loc_us-gaap_AwardTypeAxis_229a94f4-70ea-4060-a23b-e6b403d329f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_229a94f4-70ea-4060-a23b-e6b403d329f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_229a94f4-70ea-4060-a23b-e6b403d329f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_229a94f4-70ea-4060-a23b-e6b403d329f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5004cc4-c9a4-4a22-a24d-27c0559e2736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_229a94f4-70ea-4060-a23b-e6b403d329f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5004cc4-c9a4-4a22-a24d-27c0559e2736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f57dcf89-ba60-4eec-a6a3-54fb1ce0d361" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5004cc4-c9a4-4a22-a24d-27c0559e2736" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f57dcf89-ba60-4eec-a6a3-54fb1ce0d361" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="extended" id="i81883bd2e58541988a2e25c5db8cb048_EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails" xlink:type="extended" id="i4b8b35eef4de4222bcbdce303d686ae2_EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="flks-20200331.xsd#SUBSEQUENTEVENTS"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="extended" id="i14c13ca02eb74163b52e33137e61fac7_SUBSEQUENTEVENTS"/>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="i63eb0cc93ad04b69ae15d2056f590722_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1178af40-1d19-489c-862f-6e6fa13094c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a4fc71f7-5803-4729-817d-a58afc03f09f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1178af40-1d19-489c-862f-6e6fa13094c1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a4fc71f7-5803-4729-817d-a58afc03f09f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12ab0bf5-e3cc-4dc9-ada5-06e235a6ca53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1178af40-1d19-489c-862f-6e6fa13094c1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12ab0bf5-e3cc-4dc9-ada5-06e235a6ca53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1a0fc76c-455f-4ef4-be63-762454b5aeca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1178af40-1d19-489c-862f-6e6fa13094c1" xlink:to="loc_us-gaap_SubsequentEventTable_1a0fc76c-455f-4ef4-be63-762454b5aeca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e34da8d5-da39-4e41-aadb-02abd0648daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1a0fc76c-455f-4ef4-be63-762454b5aeca" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e34da8d5-da39-4e41-aadb-02abd0648daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e34da8d5-da39-4e41-aadb-02abd0648daf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e34da8d5-da39-4e41-aadb-02abd0648daf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e34da8d5-da39-4e41-aadb-02abd0648daf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5c720dc4-075c-4714-bc2d-0a12962254d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e34da8d5-da39-4e41-aadb-02abd0648daf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5c720dc4-075c-4714-bc2d-0a12962254d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5321bc93-93a2-4ad2-bb1a-51ae4cd77668" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5c720dc4-075c-4714-bc2d-0a12962254d6" xlink:to="loc_us-gaap_SubsequentEventMember_5321bc93-93a2-4ad2-bb1a-51ae4cd77668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5afe8c3e-eac9-4e50-a04d-bb773f798696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1a0fc76c-455f-4ef4-be63-762454b5aeca" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5afe8c3e-eac9-4e50-a04d-bb773f798696" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5afe8c3e-eac9-4e50-a04d-bb773f798696_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5afe8c3e-eac9-4e50-a04d-bb773f798696" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5afe8c3e-eac9-4e50-a04d-bb773f798696_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1061163c-d62e-4eda-8ca3-0d7b2cb5299e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5afe8c3e-eac9-4e50-a04d-bb773f798696" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1061163c-d62e-4eda-8ca3-0d7b2cb5299e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_3ab41317-0b60-4dfa-9d2a-5db8d5b80b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1061163c-d62e-4eda-8ca3-0d7b2cb5299e" xlink:to="loc_us-gaap_LoansPayableMember_3ab41317-0b60-4dfa-9d2a-5db8d5b80b1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>flks-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b43fc1ac-9dfd-47d4-86a3-312a4f6202a7,g:fa4ae59e-aa52-4ad5-bb99-0a07ac3a7546-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_9e82e879-7fe1-4c14-8bed-13babcb71617_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsMaximumAward_81cdbfd2-1846-4003-b6db-a0d9eaeb0b48_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award amount</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMaximumAward_label_en-US" xlink:label="lab_flks_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMaximumAward_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMaximumAward" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsMaximumAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsMaximumAward" xlink:to="lab_flks_RevenueFromGrantsMaximumAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_ef740b54-360c-4c7f-ab3a-a0182bc6b1e4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of equity securities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8cc4fca0-80a7-4b32-bef7-9d0601411377_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0bc09843-5f3e-4468-8b4d-ccc019d4cc22_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_80be8896-5803-4e82-b6a8-71233427f82d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_d3faaa39-0ff3-471e-ac2b-4eec61d14e71_terseLabel_en-US" xlink:label="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days</link:label>
    <link:label id="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:href="flks-20200331.xsd#flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:to="lab_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_5709c44e-4945-4c1c-b4a7-efed91c9dda5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0cb75087-0b9c-4a10-a7cb-fb4e719b20e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2498dbc2-e44c-4188-8f3e-3ad92cbf49db_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c9475d60-76c8-415d-a811-d0ce39d74590_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3a7e729c-5ed3-4ac2-b5cd-7f20c1f81268_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bd3a0a11-a837-4c60-bfc1-34bb11c5606f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_StockIssuanceCostsAccruedAndAmortized_921dd605-c60f-4e46-be5d-cfc0cb4046ae_terseLabel_en-US" xlink:label="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued issuance costs for public offering</link:label>
    <link:label id="lab_flks_StockIssuanceCostsAccruedAndAmortized_label_en-US" xlink:label="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Accrued and Amortized</link:label>
    <link:label id="lab_flks_StockIssuanceCostsAccruedAndAmortized_documentation_en-US" xlink:label="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Accrued and Amortized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuanceCostsAccruedAndAmortized" xlink:href="flks-20200331.xsd#flks_StockIssuanceCostsAccruedAndAmortized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_StockIssuanceCostsAccruedAndAmortized" xlink:to="lab_flks_StockIssuanceCostsAccruedAndAmortized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_fece3dfa-5774-4192-9ff9-f6f81cec1445_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variables used in Black-Scholes Model</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_82ae9efa-0b6b-41fe-9009-c564b3825157_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_0ad55917-2975-4b26-ad74-199eac4aaee6_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_95917c9f-0b5c-41c4-a3f2-7c1c6253d35b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e3dbf5b0-0f3a-42ad-81ba-6f642f65a9bf_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Application of New Accounting Standards and Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_a188adb4-a011-405f-ae71-9e8523a45c53_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_194f5ed3-f31b-414c-ba3a-9ef644c79461_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_af8ad235-71b9-4014-baf8-4c53d03e5289_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c0df8ed2-4610-4bdd-a7a1-b123f8406627_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_5967fb0f-c4e8-4eb1-8449-5bdfb11251bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_2bce2eb2-d07b-44db-b4b0-4f1fe647b5d4_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_efd16520-fdd8-45c7-ae7d-6b6b36aa2643_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_e5d3099f-5bbb-451d-a95c-e343327b90c7_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_430bfa10-fdf8-46a3-ace4-02e600886f67_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_16a0df37-a8c1-4355-b64e-5f1349e5d6ca_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_8355bdb7-d532-4ed4-a450-7232a807555f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_c739d3ff-4667-42c3-a612-f317c4094c90_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions_208be865-d882-4978-ada8-7bbc94a7a25c_terseLabel_en-US" xlink:label="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Flex Pharma outstanding options on the merger date</link:label>
    <link:label id="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions_label_en-US" xlink:label="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Fair Value of Outstanding Options</link:label>
    <link:label id="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions_documentation_en-US" xlink:label="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Fair Value of Outstanding Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions" xlink:href="flks-20200331.xsd#flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions" xlink:to="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b5ee232d-6bb7-488a-8855-ea5098926eac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f21f3d21-45ad-48df-a345-d410f7398592_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d9147b9b-a1c5-41a5-9fb1-e27416977134_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_2fa1a304-8df7-416a-98f5-d70fcfddccb8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_d54587ad-cf53-42ae-87a5-bd7d3967a418_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of equity securities</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c344751a-82a8-4837-9b23-35af097804d6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b73b48ed-0e4d-433c-a546-30887df98341_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f05779a0-c693-44f8-a34e-b37695c45aac_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bd594455-1951-4d9a-aa30-77eaad3b5cd3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7bc9ecbf-435e-49ec-b7af-1b9fc0a3ca40_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related party</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_2f50968b-7b15-4951-a7ab-b74917d1153d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3545560d-5fa5-4db9-be44-f1207ddc37b0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1a3ab1f1-5b03-4397-8c28-6a50223623c9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0bf6f5a3-8e06-4b12-9b9a-49038a88d399_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3c7e1b12-9184-4bcb-88e2-71f871bf0365_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f94fb424-eb3a-4f32-86bc-74ff790787dd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_7b21e081-e270-4f19-96e8-2862cde33fd0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ee1a0c47-85ab-42c3-8fa9-7bf02be3c0fd_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_9e74f461-656e-444a-8124-cdf0e4291cdb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_f5fc12a8-a9b7-4c34-b0f0-cdca0598614b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of equity securities for license (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_435846b8-a5d8-4af2-9da0-fadb76e9c379_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_279c86ee-50cb-4610-94bc-e2dcd57c8905_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable_d0e86f52-bcac-4abb-9511-92f45948ec0d_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current funding available</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable_label_en-US" xlink:label="lab_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Aggregate Amount Received, Current Funding Available</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Aggregate Amount Received, Current Funding Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable" xlink:to="lab_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsAwardTerm_8456b688-6be2-40af-984e-e15a739c20ec_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsAwardTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award term</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAwardTerm_label_en-US" xlink:label="lab_flks_RevenueFromGrantsAwardTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Award Term</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAwardTerm_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsAwardTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Award Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAwardTerm" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsAwardTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsAwardTerm" xlink:to="lab_flks_RevenueFromGrantsAwardTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_91205a51-8633-4042-b033-eef9e82c8c4a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92b5d080-3178-4159-8741-6c4bfd300d19_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6c9030aa-5fc2-489f-a520-051deaad49c9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_020564e6-df8c-4457-9ced-63dae5c4262e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_022b01d4-5f49-44cb-a97b-9ae658a699c4_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment to related party</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_6bf807e3-fc61-4f5f-8d27-fb5e051543c7_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3f7aa6b4-b98c-4046-a9ce-39872f577cd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_e7171faf-b6c2-49a4-962b-87b8f97c751d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b4b483e3-2e1a-4a2f-894f-3d199c6d32dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_800aa0e2-4de5-439e-a063-9144b63baa74_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9ec33fd9-43ef-481b-acba-32dc25b36787_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_32466217-bdd6-4e50-bec0-3a509b255c4a_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_WedbushSecuritiesIncMember_ec171942-c43e-4c5c-942b-fe0305fd7fb6_terseLabel_en-US" xlink:label="lab_flks_WedbushSecuritiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wedbush</link:label>
    <link:label id="lab_flks_WedbushSecuritiesIncMember_label_en-US" xlink:label="lab_flks_WedbushSecuritiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wedbush Securities Inc. [Member]</link:label>
    <link:label id="lab_flks_WedbushSecuritiesIncMember_documentation_en-US" xlink:label="lab_flks_WedbushSecuritiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wedbush Securities Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WedbushSecuritiesIncMember" xlink:href="flks-20200331.xsd#flks_WedbushSecuritiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_WedbushSecuritiesIncMember" xlink:to="lab_flks_WedbushSecuritiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ec65e5fe-474a-4163-a9a9-6ae427aa62d4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_6ee0e09c-f5c9-4b08-8c15-54950e0ece86_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unaudited Pro Forma Results</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_f94004d6-7568-4f2a-9780-dd988913bcc7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a8251958-23c4-4116-a9cd-88fcc7075ae6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1e613409-3cfe-4bfc-8a90-6128a6734c62_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fb5907ce-55aa-455f-a01d-62a02ef38af9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4b2ba5d5-b7c3-4cf0-93d4-d77a714e10e1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_b2bcee51-ab8f-4107-bc23-299eab2ea64a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_800b1e89-767d-47e2-92d9-8df95309a852_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec6dce35-0dc0-4902-ba19-5a98f0d8ecd0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_780a6929-79d8-49ca-aac0-1e978d8a1af1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9a5f5fa0-e34c-4f73-a39f-8db142cefd3d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding&#160;&#8212; basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_121f6269-c64c-46fb-a431-b5897478ab9f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_51ba0b8a-c14e-402f-9be4-700d17210ee3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4ddde159-34c2-41df-91f5-5cb33f5fd1a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_475a5a17-a96d-4e59-afeb-a99338ff5026_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_689f706a-8848-418d-b5ca-3772f85ba441_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a7225cbb-6768-4d0c-a150-c358aacec15f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9d70d1ee-b693-4c6a-8bef-05776217677d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_9ec24c3d-b875-45a5-9117-af0a4f736954_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f0e5f5da-d58b-4911-a1bb-264564f22f2d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4bb70a65-498d-4fb2-8e26-a2fa0b847c09_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ede8c254-7dbb-4811-9dd5-d2f30f623494_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_69c4223e-adc5-47cd-8964-f5f62534047c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_529f90a0-70ec-4777-a3a3-2ac4ad90e37b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_94e860c6-3918-4ab4-a804-f186ed309b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60817eec-17a5-418f-bdee-24b49e0c0ecd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_99755317-3262-4372-91d7-9b7887babd7a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_e66a48c3-dc03-43e3-8510-a595a6fd74a8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_b46c8ae3-2b42-48b8-ad15-22826016c306_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e47990f4-4dcf-4c24-a2f1-e70980d7db32_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9ddc210b-c55e-4d54-af6b-115c0073e0ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c3b02d53-1558-4acc-9811-842e226c180b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at March 31, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_87e39ae2-94b5-4cbf-824e-889e9bdc710e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_350d35b0-26fc-4805-8d1e-2c6ed2451032_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets_2aa06c4e-ea2d-4751-94f4-baed28e50cb4_terseLabel_en-US" xlink:label="lab_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangibles</link:label>
    <link:label id="lab_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets</link:label>
    <link:label id="lab_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets_documentation_en-US" xlink:label="lab_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets" xlink:href="flks-20200331.xsd#flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets" xlink:to="lab_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad2cdc73-5454-4413-a3cb-e5f336fee2e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_17286939-c6f5-4dcc-a8cd-442de4693a3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_03b466db-7c05-4e0e-9514-f63a7db4f910_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e4128f78-b48c-4d9f-8636-317fb6b288ec_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before other income (expense)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e5626870-4207-4582-aa51-5b2a715126db_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_fdfb33da-9fa2-41bc-af03-2f6cfaffb5ac_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5eb23577-37c9-4a34-8222-e9429b349b15_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_47f1f9c5-067e-4f64-ad91-b2deb1358394_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_df8bf0e5-0926-40a3-b3c7-3e0aa46ef349_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_979e4d49-db17-4c65-97c7-992686508fe2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_df641106-5d49-4c45-97c6-6feedeef59cb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2a044363-47fd-445a-8d5a-9c9cccd24f9d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_88a631aa-c84f-494e-80d5-c77dd898f20b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_da076af8-b369-4147-a662-153f99d53771_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9b2d5a73-f57a-4d61-8415-63a3d37bf026_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b0f06ae3-8c34-4346-833c-01c6d1f58bc0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_819d00d1-0833-4ffe-8e2e-8132bcd55013_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_92200fa5-9c32-4330-b826-5d94d4f21a53_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c344780f-9165-4da6-99c0-841ec5cd16f7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f56c08b0-23e7-49c1-847f-290d57ee6ed1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7563df1f-9cd4-40e8-859a-b39ec31f43da_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_15513f48-3e96-4b0d-9f34-54043fb74292_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_86c9e26a-e781-44de-bde7-2626a173cd87_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_73db74c5-856f-46db-95b2-13df7b387764_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_13024978-faf4-472c-90dd-fe555c3040b1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99f8ece0-f317-4e8f-b5eb-37e2cfb03cb7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2ec6efb4-b36e-4011-9415-c4542f4ae578_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fb0f9c6d-9b7e-4434-bcfc-c5846ede5355_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6ed3adf4-bbfb-4245-b17b-912a78c62fb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsCurrentFundingReceived_c8ffc69c-9782-4815-ba71-5cc31cd9645a_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsCurrentFundingReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current funding received</link:label>
    <link:label id="lab_flks_RevenueFromGrantsCurrentFundingReceived_label_en-US" xlink:label="lab_flks_RevenueFromGrantsCurrentFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Current Funding Received</link:label>
    <link:label id="lab_flks_RevenueFromGrantsCurrentFundingReceived_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsCurrentFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Funding Received During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsCurrentFundingReceived" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsCurrentFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsCurrentFundingReceived" xlink:to="lab_flks_RevenueFromGrantsCurrentFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e1a65b1d-e850-4ee2-b7c7-4328ed049b5e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d9743b20-b3c8-4e5d-a503-99a2e5ca3599_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_602690fe-d598-4a4b-a6fa-214ec45d8d3b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flex Pharma market capitalization at closing</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ad505423-a06f-491a-a79c-7c633ff53043_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2cc7ddce-6663-4e96-9e16-6402f79cd35b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_441dbae6-ebf8-4229-81b6-573790cfb2df_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e429ecac-561a-438b-9d6b-a682d98febff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_07a78542-eeb1-4448-bee8-b3d83cf9eded_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_61f031c7-3b0c-4031-bb7d-af7aff3c2b86_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants_460521dd-0b92-498e-9060-c72fcf8f4b64_terseLabel_en-US" xlink:label="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of rights to warrants</link:label>
    <link:label id="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants_label_en-US" xlink:label="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Fair Value of Rights to Warrants</link:label>
    <link:label id="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants_documentation_en-US" xlink:label="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Fair Value of Rights to Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants" xlink:href="flks-20200331.xsd#flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants" xlink:to="lab_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_760d779b-0a35-49f2-b551-f796fe6794ae_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of rights per share</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_263a294a-1ad0-4b8b-9e42-35de53718a19_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_64509f3a-05ab-42ab-b4ca-c37f7a9ce500_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a0281363-509d-42e2-872f-1d562108dc3d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e3407ce4-48b6-4338-baf1-4853aa783b39_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3342556a-a157-4dc0-932d-3f8e9f3247f7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_24ba855a-284f-4db6-869b-747fd4f6e901_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_61dcb596-6084-4d33-8d30-36288f8b4546_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_e66c56a9-f5c8-42d1-84e3-d81901ca647f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of equity securities for license</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_16cb6c04-192a-479e-9688-954b74853ff9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_EquityIncentivePlan2015Member_816f9546-c32d-454e-b306-f8e00f51ffea_terseLabel_en-US" xlink:label="lab_flks_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_flks_EquityIncentivePlan2015Member_label_en-US" xlink:label="lab_flks_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:label id="lab_flks_EquityIncentivePlan2015Member_documentation_en-US" xlink:label="lab_flks_EquityIncentivePlan2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EquityIncentivePlan2015Member" xlink:href="flks-20200331.xsd#flks_EquityIncentivePlan2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_EquityIncentivePlan2015Member" xlink:to="lab_flks_EquityIncentivePlan2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_96b795ff-aef3-4ab4-a48b-cff2c17a569a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_293f11df-a9b7-49aa-bf79-5e101e3c1446_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_4d91cf6d-cd37-465e-af22-232c192dbb44_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_aa94788a-0b46-4a40-959a-6068d1600ddd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_fb27333c-9640-4946-af59-f3f30eb9487d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ccbcabff-8e62-49ec-b89c-1d3192f64a5c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_335b410e-130a-457a-a908-d691df8e0642_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_78f34dc9-15c6-440f-af68-c9eb2b13c605_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_6568735e-780e-4394-8844-89ddb273e4db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c07e4f52-a7d2-4771-97f1-a0f0985fcc50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_3839e470-4644-497d-b336-81fd3a481b60_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0b90a712-9444-47a5-ab49-5a45b8666a05_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_f7135eea-3f66-4f4d-90aa-90dd705cd259_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9324b9ca-d359-4e39-9e2f-ad02b2dfa305_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7b8a0a5d-1a4e-4010-a0f6-fe9efbd8819f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f88cff83-4492-4505-952f-dfe210ee1034_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_599fe02a-8e7a-4eb5-b537-f24ebb5838cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_62e48199-cb4d-4aff-986b-3407d1c62c35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_e99ca40a-5c58-4f4a-b7e3-01feb0c3968a_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on note payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ce5f5de0-135b-4768-a13c-2d9ce12d9b70_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_84589d62-150f-4eec-8ffa-0b17b8f7bf4d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember_17bfc769-cbc5-4b1f-8ee3-f1be7188651f_verboseLabel_en-US" xlink:label="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfy success fee</link:label>
    <link:label id="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember_label_en-US" xlink:label="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfy Success Fee Due to Related Party [Member]</link:label>
    <link:label id="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember_documentation_en-US" xlink:label="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Satisfy Success Fee Due to Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:href="flks-20200331.xsd#flks_SatisfySuccessFeeDueToRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:to="lab_flks_SatisfySuccessFeeDueToRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_a68c481c-818f-4d81-b989-f814db5d6d0e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_723a0baf-0b12-47f6-b853-6e61d98561c8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1d4c9ecd-c090-4c83-942e-1efaabfbc200_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_94f9dcf5-1f56-4ce7-b093-fba4c83be326_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_91c3b3b7-efb1-43d3-af94-c2983b329137_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_cc6a78da-f8e3-40bc-98c4-85bc13b20cb1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_bef8e839-331d-4d25-831d-8f3a1e12a666_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8b5a4eaf-5e17-4e6c-806d-b93d593c18f4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_e2bbec26-b8de-43e1-bb07-7b20292cc483_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_252687b8-6ab7-4d11-9c90-480934923fc2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b8d4981f-8812-41f2-8df4-34e7c62f4b6c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_ce634c61-8475-4eda-821c-761648b4f9f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1b879926-168c-4c78-97ec-a7016d365b74_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_2f9dd18e-0574-4034-bb61-88f11b02d2ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7e98e505-7253-47f4-ba82-c899720e41bb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_4fbec1cc-7a15-4fa2-81f4-369ff47e6b73_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f05d150c-a342-4292-8627-c09430c2baa0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6ae9583a-0976-45c8-a262-f728facfe122_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_e83c061f-91a3-4d11-aa74-122c0d0beb18_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable from CPRIT</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c8fb7ad-e06c-4df1-9631-f5761b4dbbcd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_cc96886d-4d9f-4ef5-b785-396306f80969_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_dfd40572-4d8a-4562-a215-aa277e0d934b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsExtensionTerm_2b34cc37-48d2-493c-8b03-8bb8c5721a46_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension term</link:label>
    <link:label id="lab_flks_RevenueFromGrantsExtensionTerm_label_en-US" xlink:label="lab_flks_RevenueFromGrantsExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Extension Term</link:label>
    <link:label id="lab_flks_RevenueFromGrantsExtensionTerm_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsExtensionTerm" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsExtensionTerm" xlink:to="lab_flks_RevenueFromGrantsExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_09a0cd14-fd90-43ca-95b4-ee6d3f141584_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9422ad7a-6932-4fbc-92fe-6e58418af48c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8068ed0d-abea-4ccd-843e-bf6e5e5ff963_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_67244d2d-6948-4345-9976-bdc5eebabddc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f3389a84-329e-4f4e-8547-c694994922a6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties_1065f513-d135-4a56-9e0e-4a0b2944628d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to/from related party</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_10b9b99c-b182-4416-b001-8dd05c4c54f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable_8bf83207-a7a3-41ce-b176-ca1e03217dcb_terseLabel_en-US" xlink:label="lab_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period the right is unexercisable</link:label>
    <link:label id="lab_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable_label_en-US" xlink:label="lab_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Period Warrants or Rights Unexercisable</link:label>
    <link:label id="lab_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable_documentation_en-US" xlink:label="lab_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Period Warrants or Rights Unexercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable" xlink:href="flks-20200331.xsd#flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable" xlink:to="lab_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e165eee3-a1d0-462a-8d70-748e9b0f0558_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_ProfitInterestUnitsMember_ea65a2f2-dc9b-49ad-a346-da3336674be7_terseLabel_en-US" xlink:label="lab_flks_ProfitInterestUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Interest Units</link:label>
    <link:label id="lab_flks_ProfitInterestUnitsMember_label_en-US" xlink:label="lab_flks_ProfitInterestUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Interest Units [Member]</link:label>
    <link:label id="lab_flks_ProfitInterestUnitsMember_documentation_en-US" xlink:label="lab_flks_ProfitInterestUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Interest Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ProfitInterestUnitsMember" xlink:href="flks-20200331.xsd#flks_ProfitInterestUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_ProfitInterestUnitsMember" xlink:to="lab_flks_ProfitInterestUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_d7fdd2d8-60a4-4b57-971d-bd529314d70d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0aa77c02-74f8-488e-9f78-d03f39eb948c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3e7651b0-b1de-488b-883a-6bf4bcca24a7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_45d0763c-95dc-4ce7-ae85-d9e5842ef053_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_26af9777-a24f-4f0e-b8ce-0a88b5a2e1e8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares converted to common shares (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b130ca8c-8d47-4c99-b241-583f70900879_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c4fb6aee-e3c0-4367-a384-75b11d20d0c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Fair Value of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8410396b-fc2e-4f14-9d15-7e7b2bd2fd04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_WarrantsOutstandingMeasurementInput_4e4da552-0bc8-4a28-8d0c-bc5b22b61257_terseLabel_en-US" xlink:label="lab_flks_WarrantsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants measurement input</link:label>
    <link:label id="lab_flks_WarrantsOutstandingMeasurementInput_label_en-US" xlink:label="lab_flks_WarrantsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Measurement Input</link:label>
    <link:label id="lab_flks_WarrantsOutstandingMeasurementInput_documentation_en-US" xlink:label="lab_flks_WarrantsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WarrantsOutstandingMeasurementInput" xlink:href="flks-20200331.xsd#flks_WarrantsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_WarrantsOutstandingMeasurementInput" xlink:to="lab_flks_WarrantsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_FlexPharmaMember_ea164cfb-0d2d-49c2-9208-1046f635ffcc_terseLabel_en-US" xlink:label="lab_flks_FlexPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flex Pharma</link:label>
    <link:label id="lab_flks_FlexPharmaMember_label_en-US" xlink:label="lab_flks_FlexPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flex Pharma [Member]</link:label>
    <link:label id="lab_flks_FlexPharmaMember_documentation_en-US" xlink:label="lab_flks_FlexPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flex Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_FlexPharmaMember" xlink:href="flks-20200331.xsd#flks_FlexPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_FlexPharmaMember" xlink:to="lab_flks_FlexPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b4d97d77-3fcb-4afa-9ac9-ef10963317f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining available for grant of stock awards (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ec0d576-797a-4156-bf88-5cef39dd777c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6083aee6-1091-4831-a202-54181e81a47d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_038c2342-ab37-4fcb-8ba6-593fdd1d5f11_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d4a09c0d-f7e0-43d5-bd9e-a4d38b6d6953_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d1623f1a-0700-4ae6-8359-1256a32ca020_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86fe5817-3a75-4ae7-884c-b4985468504e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of equity securities (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_001f57fd-7763-4ae6-a7c9-1cac3a1e6489_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_46194bb0-6442-4bf7-92d2-e532998fbc27_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ccc7bc25-f2ce-4eac-8b26-39264f146720_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_85eb39b9-30c4-4d11-9c65-5227b06969d9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e9349ae8-6dee-4e55-9128-bf49efb5b35c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_d2aae9f5-3460-448a-aff4-a86fe6da5949_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2e6a3c22-1943-46cd-8ad1-5a5f7a82c4c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_588f1ce8-e938-49ae-a483-83c6177e75c4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments and Credit Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0a0ef435-76d9-484b-9d80-ca0852bef91b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_01953b61-d16d-4060-aea0-75fafa284333_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f1735a1f-be45-4533-9c5d-bd992bef65f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_edd041ff-a841-415b-ae41-8140ffdda272_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_ccbf0cfc-0135-4d77-8f74-ed7c6018433a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVERSE ACQUISITION AND DISPOSAL</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_95fcf02e-14cf-4b88-bc0a-09590349f8a6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_ec541446-5708-4ffa-838c-3da2ed1d8ccd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f0f7725c-4725-418d-8522-27016b547bbb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 100,000,000 shares authorized; 13,650,838 and 4,519,533 shares issued at March&#160;31, 2020 and December&#160;31, 2019, and 13,645,677 and 4,511,174 shares outstanding at March&#160;31, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_8e9f0d12-7080-4fb2-b9ac-2102e3c20ac5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1b3503a9-bacd-411e-8d7f-cdf621a07277_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4d84b283-a763-45bf-a6e7-b40a352573fe_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_ea3bffc1-22c1-4e81-be54-1a8de545eb20_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_451b3743-7ce1-41b5-91c0-801a0f4870ad_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9840e274-3b13-405f-a3ab-a9aa98cc3a9d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0ef36553-ac37-4388-9424-cdb8a2478c0d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsMatchingFundsRequirement_23cb7de2-ca7a-4edc-853e-38599b75b594_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching funds requirement</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMatchingFundsRequirement_label_en-US" xlink:label="lab_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Matching Funds Requirement</link:label>
    <link:label id="lab_flks_RevenueFromGrantsMatchingFundsRequirement_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Matching Funds Requirement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsMatchingFundsRequirement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:to="lab_flks_RevenueFromGrantsMatchingFundsRequirement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_ca9c1f29-33dd-45a1-ada4-0f27c6fca934_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_PrepaidClinicalTrialExpense_89b27468-29f7-4bfb-9640-df6ad183c249_terseLabel_en-US" xlink:label="lab_flks_PrepaidClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical trial expenses</link:label>
    <link:label id="lab_flks_PrepaidClinicalTrialExpense_label_en-US" xlink:label="lab_flks_PrepaidClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Trial Expense</link:label>
    <link:label id="lab_flks_PrepaidClinicalTrialExpense_documentation_en-US" xlink:label="lab_flks_PrepaidClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense" xlink:href="flks-20200331.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_PrepaidClinicalTrialExpense" xlink:to="lab_flks_PrepaidClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d89b4d64-e4b4-4027-9a47-d63fb7471ed7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_64ef9138-1cde-448e-b48e-29bd4a4621c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8a3296a2-84aa-4ec4-bda0-def5c6da0e14_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f62423cb-cb0f-482f-afc0-6ef7f490ca87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ba9f757b-b677-480c-bb15-8e423f7cb826_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f830c978-f983-4933-a556-16eb773f557d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f47d0581-2797-425c-b265-d74f3e33c68a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9a0d3b81-0e1a-4a6f-9773-152c729971f3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6351fdfe-4e26-4fa4-ba01-1c2d0d9cc736_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9727b64c-c4da-436a-a6c1-fedcd34cedce_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9a98ffbb-a911-491a-8bae-c30369e9fc8f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant contract amount</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3b3b213e-f945-4cbd-bcbc-c4c1a7a7d8b1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_38d2076e-fa0e-47fa-957d-9c5b9cecba61_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_fa3a1ede-0b44-40c3-b741-33b6a13e28fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of liabilities to equity</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_30ebc95c-f0af-4f3e-b994-966d1c8781e7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_AccruedExpensesAndOtherCurrentLiabilities_590577ac-eb18-4124-8664-cae23c38939a_terseLabel_en-US" xlink:label="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_flks_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_flks_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="flks-20200331.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_flks_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_615599dc-3b49-4d17-9e83-b15bf2956181_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GRANTS RECEIVABLE</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5446e2a7-95b8-423e-8c2e-9006eab4dc7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_a9792810-51d2-4d15-bd0e-6c2657784108_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_afe0df46-2be6-4bda-967c-38555f0983de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_7321240a-2bc9-4081-847d-71a3736e7ad8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_66632ee1-3268-4302-8b84-cd4d3997231d_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cc7a68a5-e664-4576-a110-60f0476ed6a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_10f665f1-87a5-41bb-aaf3-2f0754c475fa_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant value</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_6a1bf4ab-1f4e-47e7-886a-0a2a00cf38bc_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_02caf781-14e5-49f3-8229-56371108c287_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, amortization and impairment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_64444982-056e-4ab6-89c0-e5a2e9476d14_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares converted to common shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_90025a8c-f0b3-47bd-b2b4-2295bef1d8a1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_799c2229-123e-4c4e-833f-004d7c93b8c8_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling Owner</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_4e0cc7e3-2c94-4267-822b-471bdfcc90bb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares for license</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_96535903-8fd9-4e17-a287-0859bcd43dd2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_9aa3d006-ad51-4a2c-82af-c6e8cb1511f6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_f6276a02-7602-4ef7-bce0-a834819abfbd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 468,694 issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_CommonUnitsMember_52162d3f-5812-4d4b-8441-888be32f480f_terseLabel_en-US" xlink:label="lab_flks_CommonUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Units</link:label>
    <link:label id="lab_flks_CommonUnitsMember_label_en-US" xlink:label="lab_flks_CommonUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Units [Member]</link:label>
    <link:label id="lab_flks_CommonUnitsMember_documentation_en-US" xlink:label="lab_flks_CommonUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_CommonUnitsMember" xlink:href="flks-20200331.xsd#flks_CommonUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_CommonUnitsMember" xlink:to="lab_flks_CommonUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3ad60f6b-206a-4b25-96b9-46a3880eeb00_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_669d4a35-0fc7-44cb-8e85-5c4fdc3fc6e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Purchase Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_748af04b-015a-4934-b2b3-86dcd9fc0e75_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a4bac3fa-419a-46b6-ac46-8dd204f12027_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_e59d1b8b-bf07-4771-8392-4bd79f0658ab_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable and Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a1808c36-bb20-439c-8e9d-f430d280ecb3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_d6e31567-b997-440c-8939-b02d3849d96a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_9caee2e1-895e-4def-a330-0cce101491c4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4b359d22-fe5c-4c30-9cb2-62a1b70593f8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_dc336943-c95b-4a0b-ac76-bf122d8e9e43_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ad9397af-e4f1-4567-ad57-a9317cb86e52_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ea21af1f-b69f-458b-9f14-1de1603009aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f6083312-4ee4-4d48-b802-ff7fe66f844d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7ae473c7-e695-4c0a-9a7f-a0a588a827d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_19737f45-85f3-4018-9087-8247697ab779_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_UniversityOfUtahResearchFoundationMember_cc9fd8d1-e554-4117-b2b4-eae130dbb030_terseLabel_en-US" xlink:label="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utah Research Foundation</link:label>
    <link:label id="lab_flks_UniversityOfUtahResearchFoundationMember_label_en-US" xlink:label="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utah Research Foundation [Member]</link:label>
    <link:label id="lab_flks_UniversityOfUtahResearchFoundationMember_documentation_en-US" xlink:label="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Utah Research Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_UniversityOfUtahResearchFoundationMember" xlink:href="flks-20200331.xsd#flks_UniversityOfUtahResearchFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_UniversityOfUtahResearchFoundationMember" xlink:to="lab_flks_UniversityOfUtahResearchFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ea68c17d-2b0f-4f3f-99fb-fffa0e7ba83f_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_67f48234-29fd-403a-bdc0-9147e069835d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_08bfc18f-90d2-4b64-af6a-1b97fe9d158a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_e158bdac-e2db-45e2-b848-9464d2202f7b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsAggregateAmountReceived_30f67f4e-ac37-4720-b6f0-61f20ef2698f_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsAggregateAmountReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount received</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAggregateAmountReceived_label_en-US" xlink:label="lab_flks_RevenueFromGrantsAggregateAmountReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Aggregate Amount Received</link:label>
    <link:label id="lab_flks_RevenueFromGrantsAggregateAmountReceived_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsAggregateAmountReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Aggregate Amount Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAggregateAmountReceived" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsAggregateAmountReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsAggregateAmountReceived" xlink:to="lab_flks_RevenueFromGrantsAggregateAmountReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_be97ce03-dc30-43a9-9df4-d4aad13e86b4_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e9cd698d-76ec-4ed9-a657-c7b9ee031a6b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8bc4895d-31b8-4c12-8128-85ef8afa67f5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_345956d0-f859-44a3-b07b-4b3109ac622b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d04dd443-d2d2-404e-9868-67f2334135e6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_fa1e6050-2a8d-4402-9748-eae25800511e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ed589212-da4e-41a1-8426-c74e8798598e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_019a572c-a47c-4be2-939d-4a9868709aad_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4bf2c3a8-5307-45ac-8044-3ef916af9b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_1c09f4a3-884c-4e1a-94ad-3e759e79ac56_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f6b63e99-76a1-466b-b031-7a10debc205c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_66088652-4619-44bf-ab05-c881ac51f81b_terseLabel_en-US" xlink:label="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continued payments, percent of net sales</link:label>
    <link:label id="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_label_en-US" xlink:label="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales</link:label>
    <link:label id="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_documentation_en-US" xlink:label="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:to="lab_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>flks-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b43fc1ac-9dfd-47d4-86a3-312a4f6202a7,g:fa4ae59e-aa52-4ad5-bb99-0a07ac3a7546-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="simple" xlink:href="flks-20200331.xsd#COVERPAGE"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/COVERPAGE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e81e33c8-205f-4a5d-a4d4-a51824aec192" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityRegistrantName_e81e33c8-205f-4a5d-a4d4-a51824aec192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_285708fa-23c8-48e6-857b-01b521c8f729" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityCentralIndexKey_285708fa-23c8-48e6-857b-01b521c8f729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2f7a415c-89bf-43be-98c1-0a8243907656" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_CurrentFiscalYearEndDate_2f7a415c-89bf-43be-98c1-0a8243907656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_72c76778-5e6f-442e-87da-226953dcda1d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityFilerCategory_72c76778-5e6f-442e-87da-226953dcda1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_801b8e58-495e-4170-be35-f45fb9d0b0f5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_DocumentType_801b8e58-495e-4170-be35-f45fb9d0b0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_edaf5cec-83a5-42e3-8cdf-38b0a2fea8f9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_DocumentPeriodEndDate_edaf5cec-83a5-42e3-8cdf-38b0a2fea8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8bfc4fe3-e50e-4cdf-9852-e27a91b9a28a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_DocumentFiscalYearFocus_8bfc4fe3-e50e-4cdf-9852-e27a91b9a28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e30397f8-f5de-493a-9fbd-d66f6ca46444" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e30397f8-f5de-493a-9fbd-d66f6ca46444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5535e24e-24b4-4bf3-bc23-66b45522cc02" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_AmendmentFlag_5535e24e-24b4-4bf3-bc23-66b45522cc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e69de52e-0838-4841-b604-a01985f021f6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntitySmallBusiness_e69de52e-0838-4841-b604-a01985f021f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ae681d4e-f387-445e-bce5-91662ae64e77" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityEmergingGrowthCompany_ae681d4e-f387-445e-bce5-91662ae64e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f31574ab-399f-4d56-8f8d-d791729e3a50" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityExTransitionPeriod_f31574ab-399f-4d56-8f8d-d791729e3a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b0647591-9d27-4cdc-b5ef-8e1584d2b2b1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b0647591-9d27-4cdc-b5ef-8e1584d2b2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4737af24-4514-4e0b-99a9-7083136a3a42" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityCurrentReportingStatus_4737af24-4514-4e0b-99a9-7083136a3a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d28ba8d1-24bc-4aee-aeb3-a10aa1a0c5a3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityShellCompany_d28ba8d1-24bc-4aee-aeb3-a10aa1a0c5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8fc8a1c3-75af-4490-b86d-f76b8405d0b1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_Security12bTitle_8fc8a1c3-75af-4490-b86d-f76b8405d0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d9e07a76-4db2-4574-a814-7b834f91af14" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_TradingSymbol_d9e07a76-4db2-4574-a814-7b834f91af14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f0637675-ed0b-4edd-b3f9-e8cf183e0960" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_SecurityExchangeName_f0637675-ed0b-4edd-b3f9-e8cf183e0960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ef359df3-8b4b-47ef-8a2d-617c0406e3f9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_DocumentQuarterlyReport_ef359df3-8b4b-47ef-8a2d-617c0406e3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_151a23fa-fd36-41f7-be51-c9cb9d5372b4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_DocumentTransitionReport_151a23fa-fd36-41f7-be51-c9cb9d5372b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_51960bd4-2ea3-4c1e-ba5f-9d46093da339" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityFileNumber_51960bd4-2ea3-4c1e-ba5f-9d46093da339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a12ff65e-7fbc-46d2-bf48-89ca7c7fbee7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a12ff65e-7fbc-46d2-bf48-89ca7c7fbee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_48314215-d2aa-4979-8eab-754e73ce8ec9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityAddressAddressLine1_48314215-d2aa-4979-8eab-754e73ce8ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_a333feda-af92-499d-a7c4-80d1ed3d81de" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityAddressAddressLine2_a333feda-af92-499d-a7c4-80d1ed3d81de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_59f3eddb-23de-46ae-a104-9b72be869943" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityAddressCityOrTown_59f3eddb-23de-46ae-a104-9b72be869943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_53768851-51b2-4444-9662-a16b20baaf5e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityAddressStateOrProvince_53768851-51b2-4444-9662-a16b20baaf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bc5b802b-f1b8-4b18-b61c-29c492dab594" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityAddressPostalZipCode_bc5b802b-f1b8-4b18-b61c-29c492dab594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d32fd1fa-3dc6-4466-9e68-d7816560b08c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityTaxIdentificationNumber_d32fd1fa-3dc6-4466-9e68-d7816560b08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d05bf119-f705-4ade-aeff-1589fd028c94" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_CityAreaCode_d05bf119-f705-4ade-aeff-1589fd028c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_dbb8425b-047c-42d6-bc7b-794504e1b3b6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_LocalPhoneNumber_dbb8425b-047c-42d6-bc7b-794504e1b3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_da5834fc-96ab-43a0-b39e-47ecc1dd2ba7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46320e7e-5f40-4d67-821a-46b27cab251f" xlink:to="loc_dei_EntityInteractiveDataCurrent_da5834fc-96ab-43a0-b39e-47ecc1dd2ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a6167657-0d34-4849-86f4-83004016e511" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b225d486-9f58-4c7b-9174-4ee4245fd8c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6167657-0d34-4849-86f4-83004016e511" xlink:to="loc_us-gaap_AssetsAbstract_b225d486-9f58-4c7b-9174-4ee4245fd8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0ab99f21-6807-48eb-8bbf-5a6dd55eaf56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b225d486-9f58-4c7b-9174-4ee4245fd8c5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0ab99f21-6807-48eb-8bbf-5a6dd55eaf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0df642c-525a-4fe4-8ec4-503bf36e557a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0ab99f21-6807-48eb-8bbf-5a6dd55eaf56" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0df642c-525a-4fe4-8ec4-503bf36e557a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_56d6596a-04cb-44f2-960a-39538f4772c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0ab99f21-6807-48eb-8bbf-5a6dd55eaf56" xlink:to="loc_us-gaap_ReceivablesNetCurrent_56d6596a-04cb-44f2-960a-39538f4772c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a5ff135b-3980-42e2-9ca0-8e31828425ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0ab99f21-6807-48eb-8bbf-5a6dd55eaf56" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a5ff135b-3980-42e2-9ca0-8e31828425ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7d8de30d-aff7-4cb3-b12b-4734dc384495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0ab99f21-6807-48eb-8bbf-5a6dd55eaf56" xlink:to="loc_us-gaap_AssetsCurrent_7d8de30d-aff7-4cb3-b12b-4734dc384495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a82c9e09-bccb-47f3-a147-53f58e0adb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b225d486-9f58-4c7b-9174-4ee4245fd8c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a82c9e09-bccb-47f3-a147-53f58e0adb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9c365df8-322b-4b31-b341-8a911a39edec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b225d486-9f58-4c7b-9174-4ee4245fd8c5" xlink:to="loc_us-gaap_Goodwill_9c365df8-322b-4b31-b341-8a911a39edec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a02fffab-af03-4101-bebd-64c2762fc5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b225d486-9f58-4c7b-9174-4ee4245fd8c5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a02fffab-af03-4101-bebd-64c2762fc5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d7ed77d4-a480-4cd7-9b76-439ae61bd91c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b225d486-9f58-4c7b-9174-4ee4245fd8c5" xlink:to="loc_us-gaap_Assets_d7ed77d4-a480-4cd7-9b76-439ae61bd91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6619853a-5318-4aa6-8639-2c6f598c9b9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a6167657-0d34-4849-86f4-83004016e511" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6619853a-5318-4aa6-8639-2c6f598c9b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_51f51406-f17b-4186-bfa6-45ad5d8498ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6619853a-5318-4aa6-8639-2c6f598c9b9a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_51f51406-f17b-4186-bfa6-45ad5d8498ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5e0412f6-a5f5-4bbe-bfb2-ef9a10ca1f84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51f51406-f17b-4186-bfa6-45ad5d8498ea" xlink:to="loc_us-gaap_AccountsPayableCurrent_5e0412f6-a5f5-4bbe-bfb2-ef9a10ca1f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_4d9afaef-3bfa-4e7a-92f8-6edb590724a0" xlink:href="flks-20200331.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51f51406-f17b-4186-bfa6-45ad5d8498ea" xlink:to="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_4d9afaef-3bfa-4e7a-92f8-6edb590724a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_d9c36181-caa9-4578-a9da-4316ea4b5abb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51f51406-f17b-4186-bfa6-45ad5d8498ea" xlink:to="loc_us-gaap_NotesPayableCurrent_d9c36181-caa9-4578-a9da-4316ea4b5abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7d960618-0b5a-4e3e-b6be-39735a0e26a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51f51406-f17b-4186-bfa6-45ad5d8498ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7d960618-0b5a-4e3e-b6be-39735a0e26a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_bcfd127c-5222-44fa-b30e-45c7af758a34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_51f51406-f17b-4186-bfa6-45ad5d8498ea" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_bcfd127c-5222-44fa-b30e-45c7af758a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f4fe4f6f-f852-497a-994d-12ea829da5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6619853a-5318-4aa6-8639-2c6f598c9b9a" xlink:to="loc_us-gaap_Liabilities_f4fe4f6f-f852-497a-994d-12ea829da5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_dd425224-be1d-448b-8302-e5a35240c3db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6619853a-5318-4aa6-8639-2c6f598c9b9a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_dd425224-be1d-448b-8302-e5a35240c3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0a9809b6-f624-4916-9882-5b7ac1ca77ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6619853a-5318-4aa6-8639-2c6f598c9b9a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0a9809b6-f624-4916-9882-5b7ac1ca77ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1f2a3290-2a1c-47f5-91c5-f84b6fd73b75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a9809b6-f624-4916-9882-5b7ac1ca77ca" xlink:to="loc_us-gaap_PreferredStockValue_1f2a3290-2a1c-47f5-91c5-f84b6fd73b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_73036754-6778-49d5-80f2-e8b3d74ea372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a9809b6-f624-4916-9882-5b7ac1ca77ca" xlink:to="loc_us-gaap_CommonStockValue_73036754-6778-49d5-80f2-e8b3d74ea372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_10621ce4-a39c-4a86-88be-67dd329d38fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a9809b6-f624-4916-9882-5b7ac1ca77ca" xlink:to="loc_us-gaap_AdditionalPaidInCapital_10621ce4-a39c-4a86-88be-67dd329d38fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a806a8e3-5e18-4d21-bc0e-c7360185df44" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a9809b6-f624-4916-9882-5b7ac1ca77ca" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a806a8e3-5e18-4d21-bc0e-c7360185df44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a3d38ea0-a0d3-4c72-adc5-f758cfbe3197" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0a9809b6-f624-4916-9882-5b7ac1ca77ca" xlink:to="loc_us-gaap_StockholdersEquity_a3d38ea0-a0d3-4c72-adc5-f758cfbe3197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4af40a37-fc1b-4301-9bd5-c17e82f33f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6619853a-5318-4aa6-8639-2c6f598c9b9a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4af40a37-fc1b-4301-9bd5-c17e82f33f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_aa454102-e4dd-4afd-9d58-0248cf87b057" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6a74464f-b5b8-4f9e-bb90-6c9ec324da3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa454102-e4dd-4afd-9d58-0248cf87b057" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6a74464f-b5b8-4f9e-bb90-6c9ec324da3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ac6c30ce-8994-4d30-945c-d6b8959610da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa454102-e4dd-4afd-9d58-0248cf87b057" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ac6c30ce-8994-4d30-945c-d6b8959610da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d9646eca-91c3-49ee-873e-eba7745d81de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa454102-e4dd-4afd-9d58-0248cf87b057" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d9646eca-91c3-49ee-873e-eba7745d81de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_869f7be4-da29-4076-9aaf-5128e8e2abaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa454102-e4dd-4afd-9d58-0248cf87b057" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_869f7be4-da29-4076-9aaf-5128e8e2abaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ddc489cf-702c-40c8-b16d-f36669a8369d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa454102-e4dd-4afd-9d58-0248cf87b057" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ddc489cf-702c-40c8-b16d-f36669a8369d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_63fa75cf-fada-4f2d-b536-3c329cfed4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa454102-e4dd-4afd-9d58-0248cf87b057" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_63fa75cf-fada-4f2d-b536-3c329cfed4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_56290b84-cd1b-4255-b6b7-1612029ba6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa454102-e4dd-4afd-9d58-0248cf87b057" xlink:to="loc_us-gaap_CommonStockSharesIssued_56290b84-cd1b-4255-b6b7-1612029ba6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7d29e0fa-d248-42fb-a0bf-41cae0ca6448" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aa454102-e4dd-4afd-9d58-0248cf87b057" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7d29e0fa-d248-42fb-a0bf-41cae0ca6448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5dafb669-cbca-4d9f-9c6e-8aa809ff01ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1cd4a65b-6095-424a-8cb1-64df9010af19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5dafb669-cbca-4d9f-9c6e-8aa809ff01ba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1cd4a65b-6095-424a-8cb1-64df9010af19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9859035e-bdee-4cc1-b1d2-8458f5c5eebc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5dafb669-cbca-4d9f-9c6e-8aa809ff01ba" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9859035e-bdee-4cc1-b1d2-8458f5c5eebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6befd2fd-0552-410d-aec4-97df7546c83d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9859035e-bdee-4cc1-b1d2-8458f5c5eebc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6befd2fd-0552-410d-aec4-97df7546c83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_36feda5f-4f11-49e8-be25-35b9c9795181" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9859035e-bdee-4cc1-b1d2-8458f5c5eebc" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_36feda5f-4f11-49e8-be25-35b9c9795181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_784413cb-9e44-4c0c-83a3-b93ff88920ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9859035e-bdee-4cc1-b1d2-8458f5c5eebc" xlink:to="loc_us-gaap_OperatingExpenses_784413cb-9e44-4c0c-83a3-b93ff88920ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c4b162c-9778-4ae8-ac60-39aee19891a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5dafb669-cbca-4d9f-9c6e-8aa809ff01ba" xlink:to="loc_us-gaap_OperatingIncomeLoss_6c4b162c-9778-4ae8-ac60-39aee19891a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_36f91eb9-f701-4344-b0b4-3bd43a9fbed3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5dafb669-cbca-4d9f-9c6e-8aa809ff01ba" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_36f91eb9-f701-4344-b0b4-3bd43a9fbed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_312b7494-59af-4fa8-a331-7cfdfb170f86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5dafb669-cbca-4d9f-9c6e-8aa809ff01ba" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_312b7494-59af-4fa8-a331-7cfdfb170f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9edbcb25-fcd1-4ce8-a126-d916474727c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5dafb669-cbca-4d9f-9c6e-8aa809ff01ba" xlink:to="loc_us-gaap_NetIncomeLoss_9edbcb25-fcd1-4ce8-a126-d916474727c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_ff8a166e-0f23-4b6c-82ec-bc098b070ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5dafb669-cbca-4d9f-9c6e-8aa809ff01ba" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_ff8a166e-0f23-4b6c-82ec-bc098b070ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c320bc85-90e9-4073-9ad7-cc94f421ad9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5dafb669-cbca-4d9f-9c6e-8aa809ff01ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_c320bc85-90e9-4073-9ad7-cc94f421ad9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e2adba4c-568f-4dc4-a428-86e42b5df457" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d6125e-3e30-49a6-a5e3-64c1f2f7549a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e2adba4c-568f-4dc4-a428-86e42b5df457" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d6125e-3e30-49a6-a5e3-64c1f2f7549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b845032a-f07f-4cc6-921b-e662ea9686dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d6125e-3e30-49a6-a5e3-64c1f2f7549a" xlink:to="loc_us-gaap_NetIncomeLoss_b845032a-f07f-4cc6-921b-e662ea9686dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9eda1e2e-6449-43de-aa38-5d49e7273b66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d6125e-3e30-49a6-a5e3-64c1f2f7549a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9eda1e2e-6449-43de-aa38-5d49e7273b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_865fae29-8514-4bf2-bbd6-44b99727106e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9eda1e2e-6449-43de-aa38-5d49e7273b66" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_865fae29-8514-4bf2-bbd6-44b99727106e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5fd8ebcf-1add-4a1c-82b6-7eb1e8db6a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9eda1e2e-6449-43de-aa38-5d49e7273b66" xlink:to="loc_us-gaap_ShareBasedCompensation_5fd8ebcf-1add-4a1c-82b6-7eb1e8db6a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_6c7a1d34-e915-4961-bbbd-4a69623b7770" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9eda1e2e-6449-43de-aa38-5d49e7273b66" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_6c7a1d34-e915-4961-bbbd-4a69623b7770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b99960f3-4406-4276-b06b-57068f4c32ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9eda1e2e-6449-43de-aa38-5d49e7273b66" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b99960f3-4406-4276-b06b-57068f4c32ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_93129980-1c9d-41bd-9979-7d7cfdaa38c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b99960f3-4406-4276-b06b-57068f4c32ac" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_93129980-1c9d-41bd-9979-7d7cfdaa38c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85d598db-a064-4218-9e1b-a1cfc909eb8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b99960f3-4406-4276-b06b-57068f4c32ac" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85d598db-a064-4218-9e1b-a1cfc909eb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e31bdf6d-bfd5-4cf0-ac15-e40a86650ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b99960f3-4406-4276-b06b-57068f4c32ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e31bdf6d-bfd5-4cf0-ac15-e40a86650ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9770725c-0286-4e73-b38a-d421e26d0a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b99960f3-4406-4276-b06b-57068f4c32ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9770725c-0286-4e73-b38a-d421e26d0a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_47f54de7-8981-4111-8bdd-0ff06ef582ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b99960f3-4406-4276-b06b-57068f4c32ac" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedParties_47f54de7-8981-4111-8bdd-0ff06ef582ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c74366c3-52af-4c97-823b-a19fc9e89db5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b99960f3-4406-4276-b06b-57068f4c32ac" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c74366c3-52af-4c97-823b-a19fc9e89db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef5e3386-7687-4923-b848-bb2a12ee6115" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7d6125e-3e30-49a6-a5e3-64c1f2f7549a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef5e3386-7687-4923-b848-bb2a12ee6115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_145b1338-d56c-493a-99b1-3a57cac129d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e2adba4c-568f-4dc4-a428-86e42b5df457" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_145b1338-d56c-493a-99b1-3a57cac129d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5a03f121-5d75-4e71-8052-8e37c5670def" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_145b1338-d56c-493a-99b1-3a57cac129d7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_5a03f121-5d75-4e71-8052-8e37c5670def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_3c4ddfd9-79c2-4223-9218-216cea5fce48" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_145b1338-d56c-493a-99b1-3a57cac129d7" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_3c4ddfd9-79c2-4223-9218-216cea5fce48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f008ddb7-53a4-49b6-a689-10ba54de9dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_145b1338-d56c-493a-99b1-3a57cac129d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f008ddb7-53a4-49b6-a689-10ba54de9dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b55f4c2-6126-4a76-b8a0-4cdebd69b07a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e2adba4c-568f-4dc4-a428-86e42b5df457" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6b55f4c2-6126-4a76-b8a0-4cdebd69b07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a481ba2-cce5-4b3d-adbe-b3ef912ba3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e2adba4c-568f-4dc4-a428-86e42b5df457" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0a481ba2-cce5-4b3d-adbe-b3ef912ba3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c0402c0-4a94-4102-a81a-87bbe26b5edb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e2adba4c-568f-4dc4-a428-86e42b5df457" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c0402c0-4a94-4102-a81a-87bbe26b5edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_57115392-23c0-4495-a689-684b5b95687e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e2adba4c-568f-4dc4-a428-86e42b5df457" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_57115392-23c0-4495-a689-684b5b95687e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_16363f0a-2bf9-4252-9a2d-6d1720718c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_57115392-23c0-4495-a689-684b5b95687e" xlink:to="loc_us-gaap_InterestPaidNet_16363f0a-2bf9-4252-9a2d-6d1720718c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_16a7322f-22ee-419f-81ee-540a5b1911a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e2adba4c-568f-4dc4-a428-86e42b5df457" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_16a7322f-22ee-419f-81ee-540a5b1911a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_StockIssuanceCostsAccruedAndAmortized_029b94e9-12e6-44db-b474-0959bbd513cb" xlink:href="flks-20200331.xsd#flks_StockIssuanceCostsAccruedAndAmortized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_16a7322f-22ee-419f-81ee-540a5b1911a1" xlink:to="loc_flks_StockIssuanceCostsAccruedAndAmortized_029b94e9-12e6-44db-b474-0959bbd513cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_c3eb3414-d630-4e66-9986-4db54533d36b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_16a7322f-22ee-419f-81ee-540a5b1911a1" xlink:to="loc_us-gaap_StockIssued1_c3eb3414-d630-4e66-9986-4db54533d36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_bb6fdfb2-4cb6-464d-a98a-d1fe991936f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_16a7322f-22ee-419f-81ee-540a5b1911a1" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_bb6fdfb2-4cb6-464d-a98a-d1fe991936f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited" xlink:type="simple" xlink:href="flks-20200331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_061295e5-d7a0-4726-89c9-c9c017a9fd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e9ce42f6-92fe-4f84-affc-38bbe77bc08e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_061295e5-d7a0-4726-89c9-c9c017a9fd1a" xlink:to="loc_us-gaap_StatementTable_e9ce42f6-92fe-4f84-affc-38bbe77bc08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9ec6102f-26d7-4198-b71b-66c9e7607b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e9ce42f6-92fe-4f84-affc-38bbe77bc08e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9ec6102f-26d7-4198-b71b-66c9e7607b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9ec6102f-26d7-4198-b71b-66c9e7607b9f" xlink:to="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5a7c3363-9e95-4c29-84e7-065288985b36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:to="loc_us-gaap_CommonStockMember_5a7c3363-9e95-4c29-84e7-065288985b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d10ef3c0-6231-4615-ad60-5eb162b2e82d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:to="loc_us-gaap_PreferredStockMember_d10ef3c0-6231-4615-ad60-5eb162b2e82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f9ce772d-2e26-43a5-ab85-ea1d100f89c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f9ce772d-2e26-43a5-ab85-ea1d100f89c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b6e5106f-e2e0-4d9f-992e-88cea6042bda" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_afb4af48-59d4-42d4-b5a6-2a8ebe180f1a" xlink:to="loc_us-gaap_RetainedEarningsMember_b6e5106f-e2e0-4d9f-992e-88cea6042bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d5b57787-7eec-48d0-ac6c-b25d895a739c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e9ce42f6-92fe-4f84-affc-38bbe77bc08e" xlink:to="loc_us-gaap_StatementLineItems_d5b57787-7eec-48d0-ac6c-b25d895a739c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5b57787-7eec-48d0-ac6c-b25d895a739c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f5c960b6-97e5-4655-a528-4bc4b9d06419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_SharesOutstanding_f5c960b6-97e5-4655-a528-4bc4b9d06419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c458737-201e-4cdf-8deb-8d2ea7465178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockholdersEquity_9c458737-201e-4cdf-8deb-8d2ea7465178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fbe91e19-ca4d-4795-9aa7-39eeedb150a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fbe91e19-ca4d-4795-9aa7-39eeedb150a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7b2c9bd5-615f-420a-af21-73e36bf97d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7b2c9bd5-615f-420a-af21-73e36bf97d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_241ff711-637b-4f2b-bd18-60f32251bf2d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_241ff711-637b-4f2b-bd18-60f32251bf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_752f8047-c88b-4d59-802f-fc48ba2d292d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_752f8047-c88b-4d59-802f-fc48ba2d292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e95b2fb3-ce8b-44f3-b3b1-b9c5f685ce14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_e95b2fb3-ce8b-44f3-b3b1-b9c5f685ce14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e931d99d-fbf9-4f72-9d09-e51e819201af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_e931d99d-fbf9-4f72-9d09-e51e819201af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3e2f3bb1-3c11-4edc-b543-198a5b124acb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3e2f3bb1-3c11-4edc-b543-198a5b124acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_fdc2cf18-e97d-4781-bde1-696d85d813d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_fdc2cf18-e97d-4781-bde1-696d85d813d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8275e799-c29a-4ecc-bd7c-bf80d62a6473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_NetIncomeLoss_8275e799-c29a-4ecc-bd7c-bf80d62a6473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f5efe667-3750-479f-bca2-c86068c5bb70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_SharesOutstanding_f5efe667-3750-479f-bca2-c86068c5bb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_94f9bdf5-2d5e-42ee-a486-8c6f6514017d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_543bee82-e0ef-4827-acff-4182869d0291" xlink:to="loc_us-gaap_StockholdersEquity_94f9bdf5-2d5e-42ee-a486-8c6f6514017d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="simple" xlink:href="flks-20200331.xsd#ORGANIZATIONANDOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07bd5296-7354-4410-bfcc-9d74ac69edbb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_57919ea5-70d9-49a5-8950-248354926fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_07bd5296-7354-4410-bfcc-9d74ac69edbb" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_57919ea5-70d9-49a5-8950-248354926fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="flks-20200331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_703615de-a8f2-4483-93ca-cdd2799aa0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_43d693af-a4de-419b-af07-66259ae77f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_703615de-a8f2-4483-93ca-cdd2799aa0b2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_43d693af-a4de-419b-af07-66259ae77f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="flks-20200331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9792167d-3e6f-46fe-a789-6186cf4ca8d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9792167d-3e6f-46fe-a789-6186cf4ca8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3b970f71-38f4-424e-ba20-3df8083f273b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3b970f71-38f4-424e-ba20-3df8083f273b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c07eb02c-ad63-4fa5-a72f-1017d7c5663e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_UseOfEstimates_c07eb02c-ad63-4fa5-a72f-1017d7c5663e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e8c28da2-bf80-453e-bfb7-0d85f6e8058d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e8c28da2-bf80-453e-bfb7-0d85f6e8058d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f5a9057b-1c22-47fd-98e1-b541c3532fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f5a9057b-1c22-47fd-98e1-b541c3532fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ba0e0291-2f2b-4f5f-9dc3-1e2d651cf0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ba0e0291-2f2b-4f5f-9dc3-1e2d651cf0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_0379f380-3a43-4aa0-a012-f3608f3ac7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_0379f380-3a43-4aa0-a012-f3608f3ac7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_36994d80-4865-4d5d-8b59-2b10d53af4f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_36994d80-4865-4d5d-8b59-2b10d53af4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_a405d424-6ff2-493b-a407-2d69b82d1054" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_a405d424-6ff2-493b-a407-2d69b82d1054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3870ae8d-1156-4f83-a69a-894ebeb50fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3870ae8d-1156-4f83-a69a-894ebeb50fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_84d3a4eb-150e-46c2-a17a-025fa41e427a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_84d3a4eb-150e-46c2-a17a-025fa41e427a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_11877f0d-5b7c-4813-a0d7-2dac98718828" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_11877f0d-5b7c-4813-a0d7-2dac98718828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_20646175-6aae-47a4-ab79-e1a47ecde104" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_20646175-6aae-47a4-ab79-e1a47ecde104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_4c9c9a72-4106-4e05-bb55-f4ba4fcd3feb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_4c9c9a72-4106-4e05-bb55-f4ba4fcd3feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0c6bde2a-015c-44cb-a28e-8c869aace6f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_647aeddf-9a5d-4a59-8020-f061191704f4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0c6bde2a-015c-44cb-a28e-8c869aace6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bbacfb29-1c0c-4fcd-8e2d-18808a4f8178" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dad4f2e6-4b49-4a0e-a985-e6263f6fd912" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bbacfb29-1c0c-4fcd-8e2d-18808a4f8178" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dad4f2e6-4b49-4a0e-a985-e6263f6fd912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e3bebcc9-41eb-4a6c-aa6a-e7a8ef6dbea7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dad4f2e6-4b49-4a0e-a985-e6263f6fd912" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e3bebcc9-41eb-4a6c-aa6a-e7a8ef6dbea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bcc3926a-7b0b-47c6-b614-af69bd893b37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e3bebcc9-41eb-4a6c-aa6a-e7a8ef6dbea7" xlink:to="loc_us-gaap_EquityComponentDomain_bcc3926a-7b0b-47c6-b614-af69bd893b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_944a9946-442e-448a-8f03-8d44838c0bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bcc3926a-7b0b-47c6-b614-af69bd893b37" xlink:to="loc_us-gaap_CommonStockMember_944a9946-442e-448a-8f03-8d44838c0bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dad4f2e6-4b49-4a0e-a985-e6263f6fd912" xlink:to="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8cd239a5-3e99-4380-9987-551573840aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_8cd239a5-3e99-4380-9987-551573840aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9dc63644-5f5e-4b65-8baf-36aa524fd820" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9dc63644-5f5e-4b65-8baf-36aa524fd820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9e2a059d-2be5-4b9a-8c9b-fe2e047cfb03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9e2a059d-2be5-4b9a-8c9b-fe2e047cfb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_052eaac6-8fa8-43fa-a485-03ee4598bfbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_89040b4b-ea26-4104-b708-68d9a339b108" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_052eaac6-8fa8-43fa-a485-03ee4598bfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSAL"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_aad281c7-79fa-44f4-b86c-ae393bc2b0ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_cb9f5942-45f2-4606-b8cc-d0a14709a2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_aad281c7-79fa-44f4-b86c-ae393bc2b0ab" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_cb9f5942-45f2-4606-b8cc-d0a14709a2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_68805f30-e763-4bcf-b735-897c680e89b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_29423a67-01d1-4920-b242-25143a408116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_68805f30-e763-4bcf-b735-897c680e89b5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_29423a67-01d1-4920-b242-25143a408116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_bf9da2b2-5fa3-4313-867b-6c1224cfaf65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_68805f30-e763-4bcf-b735-897c680e89b5" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_bf9da2b2-5fa3-4313-867b-6c1224cfaf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_9ef8e00f-c5bb-4527-b846-11d5c42b2bee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_68805f30-e763-4bcf-b735-897c680e89b5" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_9ef8e00f-c5bb-4527-b846-11d5c42b2bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_83cb183c-313c-488e-ad30-9122b36cd37b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_544e3ab2-0896-456a-9773-1d60f29aa37f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_83cb183c-313c-488e-ad30-9122b36cd37b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_544e3ab2-0896-456a-9773-1d60f29aa37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5a458a3f-d4e4-4196-9f62-4eb3d72dc2da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_544e3ab2-0896-456a-9773-1d60f29aa37f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5a458a3f-d4e4-4196-9f62-4eb3d72dc2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c6330a7-1898-4c55-8e7d-a19cd2e6d722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5a458a3f-d4e4-4196-9f62-4eb3d72dc2da" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c6330a7-1898-4c55-8e7d-a19cd2e6d722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_FlexPharmaMember_8259d70a-cb24-4bb5-8876-9e40e75bfbc5" xlink:href="flks-20200331.xsd#flks_FlexPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c6330a7-1898-4c55-8e7d-a19cd2e6d722" xlink:to="loc_flks_FlexPharmaMember_8259d70a-cb24-4bb5-8876-9e40e75bfbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4cf95a77-0f78-4e89-9b4a-0a4e5e4a0626" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_544e3ab2-0896-456a-9773-1d60f29aa37f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4cf95a77-0f78-4e89-9b4a-0a4e5e4a0626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d5a73ab7-573d-4a10-a8ef-18083720dcf0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4cf95a77-0f78-4e89-9b4a-0a4e5e4a0626" xlink:to="loc_us-gaap_EquityComponentDomain_d5a73ab7-573d-4a10-a8ef-18083720dcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3404ef04-9062-47fa-b9ef-b3c450f0a5ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d5a73ab7-573d-4a10-a8ef-18083720dcf0" xlink:to="loc_us-gaap_CommonStockMember_3404ef04-9062-47fa-b9ef-b3c450f0a5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_544e3ab2-0896-456a-9773-1d60f29aa37f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_ecf840fb-4fb0-4f46-b327-9f7dc0a5c7ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_ecf840fb-4fb0-4f46-b327-9f7dc0a5c7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24e68edc-162d-4a2b-9478-3c4402bcc7bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_24e68edc-162d-4a2b-9478-3c4402bcc7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3ae1537f-b5af-46a1-90e3-39373c102853" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3ae1537f-b5af-46a1-90e3-39373c102853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable_6b14bdd9-5f7a-44a4-be6a-bffcb54d2e64" xlink:href="flks-20200331.xsd#flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2ed8c0d7-d410-4790-adf3-7c39ea1b51be" xlink:to="loc_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable_6b14bdd9-5f7a-44a4-be6a-bffcb54d2e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8c845072-042b-4897-b5c9-fbf17cd12b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dd37511-9e86-4384-807f-2b079b9f224f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8c845072-042b-4897-b5c9-fbf17cd12b1b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dd37511-9e86-4384-807f-2b079b9f224f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c9ace9a8-057a-47d0-be01-3308c2b02445" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dd37511-9e86-4384-807f-2b079b9f224f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c9ace9a8-057a-47d0-be01-3308c2b02445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c764c0-8df3-43d5-bc8c-cb833abd7d91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c9ace9a8-057a-47d0-be01-3308c2b02445" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c764c0-8df3-43d5-bc8c-cb833abd7d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_FlexPharmaMember_ab8bf299-3a4c-4d73-9881-190bbde6f2e2" xlink:href="flks-20200331.xsd#flks_FlexPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a7c764c0-8df3-43d5-bc8c-cb833abd7d91" xlink:to="loc_flks_FlexPharmaMember_ab8bf299-3a4c-4d73-9881-190bbde6f2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0dd37511-9e86-4384-807f-2b079b9f224f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4c8ec3ed-29d6-4bd7-88cb-60c760dd1d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_4c8ec3ed-29d6-4bd7-88cb-60c760dd1d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants_c0115479-38f3-4e74-81d3-f25c4edf9e7b" xlink:href="flks-20200331.xsd#flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:to="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants_c0115479-38f3-4e74-81d3-f25c4edf9e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions_d763768d-2f4e-4448-bc24-848bf680d911" xlink:href="flks-20200331.xsd#flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:to="loc_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions_d763768d-2f4e-4448-bc24-848bf680d911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0b0804f4-dde0-4634-8959-fcd9e42674f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e4bfbb-f693-48d4-9bc2-bbdc72bfe717" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_0b0804f4-dde0-4634-8959-fcd9e42674f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6787f648-5c59-4f60-9aa2-d4f5c716262d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3a9d23e5-5050-4f83-9d8a-41bbcbddec1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6787f648-5c59-4f60-9aa2-d4f5c716262d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3a9d23e5-5050-4f83-9d8a-41bbcbddec1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93e40d04-2129-4967-9c2c-a3fd8ee30712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3a9d23e5-5050-4f83-9d8a-41bbcbddec1d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93e40d04-2129-4967-9c2c-a3fd8ee30712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_202564b6-6808-4d56-adde-ddfc0dec902d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93e40d04-2129-4967-9c2c-a3fd8ee30712" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_202564b6-6808-4d56-adde-ddfc0dec902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_FlexPharmaMember_e4a3278b-8a1e-4ea7-b479-98249f97dfc3" xlink:href="flks-20200331.xsd#flks_FlexPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_202564b6-6808-4d56-adde-ddfc0dec902d" xlink:to="loc_flks_FlexPharmaMember_e4a3278b-8a1e-4ea7-b479-98249f97dfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3a9d23e5-5050-4f83-9d8a-41bbcbddec1d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ebd26b1b-03db-4782-a88b-e5e52968b010" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ebd26b1b-03db-4782-a88b-e5e52968b010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1dabc85c-d506-4a0d-8cb3-bca3e1638318" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1dabc85c-d506-4a0d-8cb3-bca3e1638318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_bee711c5-009d-4a63-8ef3-458ad0590024" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_bee711c5-009d-4a63-8ef3-458ad0590024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ad321106-75ee-4620-b328-af6e5906b809" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ad321106-75ee-4620-b328-af6e5906b809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets_9557d06a-da5d-48a4-89a0-ada814cff5b2" xlink:href="flks-20200331.xsd#flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets_9557d06a-da5d-48a4-89a0-ada814cff5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7c107a81-eeba-4dd8-89f1-dea4600c96d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_7c107a81-eeba-4dd8-89f1-dea4600c96d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_575cb45f-e35a-4c69-b75c-636b1e5b5b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_575cb45f-e35a-4c69-b75c-636b1e5b5b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_49e8bc2b-512b-491a-a6c3-958ada9cf4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_49e8bc2b-512b-491a-a6c3-958ada9cf4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_cd4a9027-64ed-43c7-8327-7f4c318f66f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_86fc5d2b-17cb-40fd-8991-a06ee64fba1f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_cd4a9027-64ed-43c7-8327-7f4c318f66f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e5664ddc-86e2-4547-911f-204afc78b8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_bafd6636-7fc8-4fae-abef-81123239f067" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e5664ddc-86e2-4547-911f-204afc78b8e0" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_bafd6636-7fc8-4fae-abef-81123239f067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_060a991a-e90e-4b69-9eb5-2023674e73fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e5664ddc-86e2-4547-911f-204afc78b8e0" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_060a991a-e90e-4b69-9eb5-2023674e73fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_3ff5656c-95af-41c3-875c-a2bbcaf57bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e5664ddc-86e2-4547-911f-204afc78b8e0" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_3ff5656c-95af-41c3-875c-a2bbcaf57bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLE" xlink:type="simple" xlink:href="flks-20200331.xsd#GRANTSRECEIVABLE"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/GRANTSRECEIVABLE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_264ccfae-16ec-4bfd-92d1-6bc40d23cb5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_c742e651-f211-4b3d-93f4-2ca6706c724e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_264ccfae-16ec-4bfd-92d1-6bc40d23cb5c" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_c742e651-f211-4b3d-93f4-2ca6706c724e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#GRANTSRECEIVABLEDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_535ff247-859b-49e0-9031-248ee62e52ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_54b0b070-c0ab-48e6-af92-e2ca47a8d1ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_535ff247-859b-49e0-9031-248ee62e52ba" xlink:to="loc_us-gaap_ReceivablesNetCurrent_54b0b070-c0ab-48e6-af92-e2ca47a8d1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b4a2fbc0-5f0d-448e-b9e2-2e0907c511d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_e46b3359-30b2-4474-a0c0-93cd392e8aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_b4a2fbc0-5f0d-448e-b9e2-2e0907c511d2" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_e46b3359-30b2-4474-a0c0-93cd392e8aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_bd4a6b07-82da-4df9-a4e0-38a2bb19bd43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_c466af04-8dd6-43bc-b7fc-56abdbf09e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_bd4a6b07-82da-4df9-a4e0-38a2bb19bd43" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_c466af04-8dd6-43bc-b7fc-56abdbf09e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_239e4e02-8cd2-4801-a364-6859996290d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense_8775117e-485c-4130-a70c-26772813addb" xlink:href="flks-20200331.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_239e4e02-8cd2-4801-a364-6859996290d2" xlink:to="loc_flks_PrepaidClinicalTrialExpense_8775117e-485c-4130-a70c-26772813addb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_7664cbbd-e921-4cb2-bbef-d01e05626986" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_239e4e02-8cd2-4801-a364-6859996290d2" xlink:to="loc_us-gaap_PrepaidInsurance_7664cbbd-e921-4cb2-bbef-d01e05626986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b7b09b25-1d12-4fe7-b6b2-304b6a1fd6f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_239e4e02-8cd2-4801-a364-6859996290d2" xlink:to="loc_us-gaap_OtherAssetsCurrent_b7b09b25-1d12-4fe7-b6b2-304b6a1fd6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_700105ac-7ae9-4075-a072-6b56df7005c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_239e4e02-8cd2-4801-a364-6859996290d2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_700105ac-7ae9-4075-a072-6b56df7005c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_572de051-32bd-46ca-8c50-a99bfad45488" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_f6b14e19-2f6a-4c19-a847-17b65037bcfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_572de051-32bd-46ca-8c50-a99bfad45488" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_f6b14e19-2f6a-4c19-a847-17b65037bcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_bb741790-2af4-420d-9bce-3f0839c46f2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f6b14e19-2f6a-4c19-a847-17b65037bcfc" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_bb741790-2af4-420d-9bce-3f0839c46f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_cd4343ce-3113-4b94-aee1-cefe5d55ac0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_bb741790-2af4-420d-9bce-3f0839c46f2b" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_cd4343ce-3113-4b94-aee1-cefe5d55ac0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_9265d23c-8777-4cd1-a5fe-12cc3dd6a91c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_cd4343ce-3113-4b94-aee1-cefe5d55ac0f" xlink:to="loc_us-gaap_NotesPayableToBanksMember_9265d23c-8777-4cd1-a5fe-12cc3dd6a91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_f6b14e19-2f6a-4c19-a847-17b65037bcfc" xlink:to="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ee0346e5-c1ef-40f8-abf9-11da4b5fc3df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ee0346e5-c1ef-40f8-abf9-11da4b5fc3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a4ddcb5a-58db-4080-bd79-fb876bbab222" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a4ddcb5a-58db-4080-bd79-fb876bbab222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_6e7c4966-e63d-47a6-b42a-084cacf0d711" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2eb8f4d8-bb61-436a-a200-6396583a55e9" xlink:to="loc_us-gaap_NotesPayableCurrent_6e7c4966-e63d-47a6-b42a-084cacf0d711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="flks-20200331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_53357f1c-ee0d-4348-a116-3885ec7118e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a05bfd46-f4c0-4ea4-bea7-b2c3ab290e15" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_53357f1c-ee0d-4348-a116-3885ec7118e2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a05bfd46-f4c0-4ea4-bea7-b2c3ab290e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_071eb4fa-3339-4101-a061-9152df22a5ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_171b6886-3bbb-4dfb-be56-b76a94e1a7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_071eb4fa-3339-4101-a061-9152df22a5ba" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_171b6886-3bbb-4dfb-be56-b76a94e1a7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bba93833-d633-458f-b9ba-ca518abd0762" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_171b6886-3bbb-4dfb-be56-b76a94e1a7a8" xlink:to="loc_srt_OwnershipAxis_bba93833-d633-458f-b9ba-ca518abd0762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6e24e514-8b1f-4254-a255-c996a9ca3fc7" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_bba93833-d633-458f-b9ba-ca518abd0762" xlink:to="loc_srt_OwnershipDomain_6e24e514-8b1f-4254-a255-c996a9ca3fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_UniversityOfUtahResearchFoundationMember_2aba7ca9-c306-4a46-9739-d783ff2f4b1b" xlink:href="flks-20200331.xsd#flks_UniversityOfUtahResearchFoundationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_6e24e514-8b1f-4254-a255-c996a9ca3fc7" xlink:to="loc_flks_UniversityOfUtahResearchFoundationMember_2aba7ca9-c306-4a46-9739-d783ff2f4b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_171b6886-3bbb-4dfb-be56-b76a94e1a7a8" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5c96b251-fc81-41e2-8708-a3d135d37ced" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5c96b251-fc81-41e2-8708-a3d135d37ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMaximumAward_d8a0781c-d94e-42a3-8381-24292960c2ce" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsMaximumAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsMaximumAward_d8a0781c-d94e-42a3-8381-24292960c2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAwardTerm_e46d3ad6-c856-4940-883d-cf7f083b4184" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsAwardTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsAwardTerm_e46d3ad6-c856-4940-883d-cf7f083b4184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsExtensionTerm_32e8f6bc-c1b7-4d57-9224-e3d59453314a" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsExtensionTerm_32e8f6bc-c1b7-4d57-9224-e3d59453314a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_2448b780-a629-4ad2-9afe-733a52dc7aa6" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales_2448b780-a629-4ad2-9afe-733a52dc7aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsMatchingFundsRequirement_e713894e-7787-447e-b108-12cd838fc383" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsMatchingFundsRequirement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsMatchingFundsRequirement_e713894e-7787-447e-b108-12cd838fc383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAggregateAmountReceived_33dc2a61-e7d0-4396-aa8a-b9492f7857da" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsAggregateAmountReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsAggregateAmountReceived_33dc2a61-e7d0-4396-aa8a-b9492f7857da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable_df152373-d9cc-413e-872b-dfa1cced255d" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable_df152373-d9cc-413e-872b-dfa1cced255d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_RevenueFromGrantsCurrentFundingReceived_9a06f245-1622-433b-bd1b-30676a70becc" xlink:href="flks-20200331.xsd#flks_RevenueFromGrantsCurrentFundingReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_flks_RevenueFromGrantsCurrentFundingReceived_9a06f245-1622-433b-bd1b-30676a70becc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2cf1e260-19b2-4709-846d-0032e5bdc087" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2cf1e260-19b2-4709-846d-0032e5bdc087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_64cd65d1-b727-413f-afa5-0675111b50a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d8001922-f78f-4259-ad1d-8f389b9dd666" xlink:to="loc_us-gaap_ReceivablesNetCurrent_64cd65d1-b727-413f-afa5-0675111b50a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="flks-20200331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fb1d2a9c-4751-4860-845a-7ebc2c7cbc85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6af880fc-6eb2-47b9-a803-2e5910cda843" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fb1d2a9c-4751-4860-845a-7ebc2c7cbc85" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6af880fc-6eb2-47b9-a803-2e5910cda843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="flks-20200331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6836a933-02cb-4dc9-85cb-5598629371e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e2387227-e0bc-4a92-b43e-cfebc9fcd444" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6836a933-02cb-4dc9-85cb-5598629371e0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e2387227-e0bc-4a92-b43e-cfebc9fcd444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#FAIRVALUEOFFINANCIALINSTRUMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b7017c87-a245-4b10-9fdb-426608cd3e37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceec8c68-0a0a-492a-8feb-ad93904fdf13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b7017c87-a245-4b10-9fdb-426608cd3e37" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceec8c68-0a0a-492a-8feb-ad93904fdf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f310b97c-e9cf-4766-8b62-cdd3f79cbbe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceec8c68-0a0a-492a-8feb-ad93904fdf13" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f310b97c-e9cf-4766-8b62-cdd3f79cbbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64a03944-2cce-4732-81a4-e27e85c81831" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f310b97c-e9cf-4766-8b62-cdd3f79cbbe6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64a03944-2cce-4732-81a4-e27e85c81831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fca5ee63-e185-487b-9e49-05c3a3089e85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64a03944-2cce-4732-81a4-e27e85c81831" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fca5ee63-e185-487b-9e49-05c3a3089e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7d1b2d07-913f-42bb-b0c9-e076b7b8bb08" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceec8c68-0a0a-492a-8feb-ad93904fdf13" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7d1b2d07-913f-42bb-b0c9-e076b7b8bb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bba53f43-e835-4143-b498-36189c340705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7d1b2d07-913f-42bb-b0c9-e076b7b8bb08" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bba53f43-e835-4143-b498-36189c340705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c3fb3fd6-11f0-4476-8fe9-45d5e1403235" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bba53f43-e835-4143-b498-36189c340705" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c3fb3fd6-11f0-4476-8fe9-45d5e1403235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5f957e12-f26f-4a74-9fda-0a1ff3faa704" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceec8c68-0a0a-492a-8feb-ad93904fdf13" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5f957e12-f26f-4a74-9fda-0a1ff3faa704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77f7bfdd-cb75-43c0-b6f4-14a43812000f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5f957e12-f26f-4a74-9fda-0a1ff3faa704" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77f7bfdd-cb75-43c0-b6f4-14a43812000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_165825ff-1100-4e7a-86ea-46832a5a60e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77f7bfdd-cb75-43c0-b6f4-14a43812000f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_165825ff-1100-4e7a-86ea-46832a5a60e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_bc27555e-7ae4-4aad-a8db-1e483b05c761" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77f7bfdd-cb75-43c0-b6f4-14a43812000f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_bc27555e-7ae4-4aad-a8db-1e483b05c761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_43d6f046-e914-4250-a8b7-0fb08bada5a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_77f7bfdd-cb75-43c0-b6f4-14a43812000f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_43d6f046-e914-4250-a8b7-0fb08bada5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cb9ede2a-3866-4760-a8ca-7c2b085efb81" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fbff2b49-1ab7-401e-af6c-3eea5ef9db6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cb9ede2a-3866-4760-a8ca-7c2b085efb81" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fbff2b49-1ab7-401e-af6c-3eea5ef9db6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8aa0c9af-0738-4c65-8d49-4985fa0ae33c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9d152013-07e0-4714-a63c-a7b0456096a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8aa0c9af-0738-4c65-8d49-4985fa0ae33c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9d152013-07e0-4714-a63c-a7b0456096a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a75df5ea-0a5f-4a97-bc9c-30fb17139fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a75df5ea-0a5f-4a97-bc9c-30fb17139fc0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66e57a2e-2ded-4ec2-a89e-6137f7a814d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66e57a2e-2ded-4ec2-a89e-6137f7a814d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4a42d6fe-16e1-4ba0-a195-2e6f6f70a13f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66e57a2e-2ded-4ec2-a89e-6137f7a814d0" xlink:to="loc_us-gaap_RelatedPartyDomain_4a42d6fe-16e1-4ba0-a195-2e6f6f70a13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WedbushSecuritiesIncMember_9dbcecd6-40ea-4e56-809d-f5fc63aac527" xlink:href="flks-20200331.xsd#flks_WedbushSecuritiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4a42d6fe-16e1-4ba0-a195-2e6f6f70a13f" xlink:to="loc_flks_WedbushSecuritiesIncMember_9dbcecd6-40ea-4e56-809d-f5fc63aac527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_142a78ee-fadd-432c-86cf-2cca5debf4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_142a78ee-fadd-432c-86cf-2cca5debf4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0b71563c-e00a-4f3e-97c6-0e95f06dc72c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_142a78ee-fadd-432c-86cf-2cca5debf4b4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0b71563c-e00a-4f3e-97c6-0e95f06dc72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember_ca1537b0-8be8-476f-ba55-dfa9d36e40e2" xlink:href="flks-20200331.xsd#flks_SatisfySuccessFeeDueToRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0b71563c-e00a-4f3e-97c6-0e95f06dc72c" xlink:to="loc_flks_SatisfySuccessFeeDueToRelatedPartyMember_ca1537b0-8be8-476f-ba55-dfa9d36e40e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d4889827-1acb-46ef-84de-52f5098eaa4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d4889827-1acb-46ef-84de-52f5098eaa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d4889827-1acb-46ef-84de-52f5098eaa4e" xlink:to="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_793c2e86-5f37-4995-83bc-7de2e749c340" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_us-gaap_CommonClassAMember_793c2e86-5f37-4995-83bc-7de2e749c340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_4f79a407-d7e8-43e3-85c9-00c218b453ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_us-gaap_CommonClassBMember_4f79a407-d7e8-43e3-85c9-00c218b453ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_db0f030f-60ee-4b58-aef2-e84ae002a274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_db0f030f-60ee-4b58-aef2-e84ae002a274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ProfitInterestUnitsMember_9e6da217-ca27-4f46-be68-ae65c6f7a527" xlink:href="flks-20200331.xsd#flks_ProfitInterestUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_flks_ProfitInterestUnitsMember_9e6da217-ca27-4f46-be68-ae65c6f7a527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_CommonUnitsMember_056e66b3-ba37-4920-94f4-14b4b997ae69" xlink:href="flks-20200331.xsd#flks_CommonUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cd3c96da-1f63-4a53-a44c-9f0a8d36fac9" xlink:to="loc_flks_CommonUnitsMember_056e66b3-ba37-4920-94f4-14b4b997ae69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_acc69678-ff21-4bd5-9d53-292d964fcd07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_acc69678-ff21-4bd5-9d53-292d964fcd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c4dc505a-8ec6-4b4f-8c04-15b90a0e2a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_acc69678-ff21-4bd5-9d53-292d964fcd07" xlink:to="loc_us-gaap_EquityComponentDomain_c4dc505a-8ec6-4b4f-8c04-15b90a0e2a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_baf05ee9-d90a-4961-af16-9c56feb1122f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4dc505a-8ec6-4b4f-8c04-15b90a0e2a0a" xlink:to="loc_us-gaap_CommonStockMember_baf05ee9-d90a-4961-af16-9c56feb1122f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ba987e50-26ab-408a-bce4-8b55769bff59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4dc505a-8ec6-4b4f-8c04-15b90a0e2a0a" xlink:to="loc_us-gaap_PreferredStockMember_ba987e50-26ab-408a-bce4-8b55769bff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9f661906-84fc-4454-b34c-cf6f2b613ef6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_dei_LegalEntityAxis_9f661906-84fc-4454-b34c-cf6f2b613ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cdc57442-0b74-4a86-b19a-7613ee22264a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9f661906-84fc-4454-b34c-cf6f2b613ef6" xlink:to="loc_dei_EntityDomain_cdc57442-0b74-4a86-b19a-7613ee22264a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_FlexPharmaMember_09bf0826-11ab-44eb-b785-3b268e36c9a8" xlink:href="flks-20200331.xsd#flks_FlexPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_cdc57442-0b74-4a86-b19a-7613ee22264a" xlink:to="loc_flks_FlexPharmaMember_09bf0826-11ab-44eb-b785-3b268e36c9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d88e6ecf-4087-4f64-a402-c3fba1962f95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d88e6ecf-4087-4f64-a402-c3fba1962f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49877bec-0650-484d-84d9-3b7316475ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d88e6ecf-4087-4f64-a402-c3fba1962f95" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49877bec-0650-484d-84d9-3b7316475ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_0a280828-e5be-44db-9a77-c5f70fab7c19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49877bec-0650-484d-84d9-3b7316475ec2" xlink:to="loc_us-gaap_OverAllotmentOptionMember_0a280828-e5be-44db-9a77-c5f70fab7c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c5ee82b5-9ad0-4a10-811b-9f48a164a7aa" xlink:to="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a2ef3b2b-0961-4057-885a-4d606ee71882" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_a2ef3b2b-0961-4057-885a-4d606ee71882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_56f4b90f-ea7a-4955-ab1e-9fea91b5dbb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_56f4b90f-ea7a-4955-ab1e-9fea91b5dbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_89d0375e-4d2f-41d9-8849-cc5b7bc9959f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_89d0375e-4d2f-41d9-8849-cc5b7bc9959f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_274f3682-e42e-484e-8fc3-26ddf67d9ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_274f3682-e42e-484e-8fc3-26ddf67d9ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_94bd4168-950f-4182-9815-e90f5c8566e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_94bd4168-950f-4182-9815-e90f5c8566e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e2e4992f-6113-4ba7-b48f-a55108b0d621" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e2e4992f-6113-4ba7-b48f-a55108b0d621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e9c5ff11-53a6-48c7-8a5a-07b04691943b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e9c5ff11-53a6-48c7-8a5a-07b04691943b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6d655170-b57d-4552-8cc8-95f65acadac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_6d655170-b57d-4552-8cc8-95f65acadac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_00f1652f-9849-43d9-b6f8-879bc2cad188" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_00f1652f-9849-43d9-b6f8-879bc2cad188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9d767ef8-6a4e-4146-8561-bf38d779d505" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9d767ef8-6a4e-4146-8561-bf38d779d505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f30d0fa0-e337-4e43-88ca-a4eca908db9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_f30d0fa0-e337-4e43-88ca-a4eca908db9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e28eebe2-a755-476f-8211-5c6cad276b54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e28eebe2-a755-476f-8211-5c6cad276b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_5abc1ff7-c572-44ac-a4c9-2dd5aa8161ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_5abc1ff7-c572-44ac-a4c9-2dd5aa8161ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_ffe8b29a-9018-40cf-86be-b37ae44d5a97" xlink:href="flks-20200331.xsd#flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_ffe8b29a-9018-40cf-86be-b37ae44d5a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_88b88015-2070-442a-b480-2989319614ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_88b88015-2070-442a-b480-2989319614ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_ec732baa-59e7-4668-94e2-59e565a46a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_ec732baa-59e7-4668-94e2-59e565a46a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_9e8bba43-b9e0-4b3e-aa5b-b627743bd493" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cf768418-505e-42d5-bfbe-52279c9f613b" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_9e8bba43-b9e0-4b3e-aa5b-b627743bd493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_46be95d8-f6d5-418e-ac6d-ef4c1cb213ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_508f2b7f-c497-48f6-b920-1846085d91ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_46be95d8-f6d5-418e-ac6d-ef4c1cb213ff" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_508f2b7f-c497-48f6-b920-1846085d91ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_04e0ec82-5be6-4601-bb21-36a43500c1ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_508f2b7f-c497-48f6-b920-1846085d91ac" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_04e0ec82-5be6-4601-bb21-36a43500c1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_04e0ec82-5be6-4601-bb21-36a43500c1ec" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_6bc9832a-85d0-4739-a564-880f9d517dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_6bc9832a-85d0-4739-a564-880f9d517dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_a0687153-659b-409b-b6a7-0ca133acccec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_a0687153-659b-409b-b6a7-0ca133acccec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_c3a5a596-e403-4f55-b2bc-e5dce9c9f679" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_84708254-2dcf-4b6f-847a-6f8879b84f67" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_c3a5a596-e403-4f55-b2bc-e5dce9c9f679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_57968601-8f49-4209-b8a8-befda27c5101" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_508f2b7f-c497-48f6-b920-1846085d91ac" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_57968601-8f49-4209-b8a8-befda27c5101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_WarrantsOutstandingMeasurementInput_2fcddf41-66f3-46f4-8619-14d17f0308f1" xlink:href="flks-20200331.xsd#flks_WarrantsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_57968601-8f49-4209-b8a8-befda27c5101" xlink:to="loc_flks_WarrantsOutstandingMeasurementInput_2fcddf41-66f3-46f4-8619-14d17f0308f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e3189142-389b-434c-94f0-7a587afd86fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_57968601-8f49-4209-b8a8-befda27c5101" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_e3189142-389b-434c-94f0-7a587afd86fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7556a5f3-0c7d-4f1e-8ac1-f7e56d36fbcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d3a6e068-18ff-4866-9bc8-165b98a056bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7556a5f3-0c7d-4f1e-8ac1-f7e56d36fbcd" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d3a6e068-18ff-4866-9bc8-165b98a056bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68e7890e-2209-47b7-932d-d6ae586a360a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0b596706-1364-448c-99f7-c52001f766b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68e7890e-2209-47b7-932d-d6ae586a360a" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0b596706-1364-448c-99f7-c52001f766b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_243573fa-ff50-48d4-a559-87345df66b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68e7890e-2209-47b7-932d-d6ae586a360a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_243573fa-ff50-48d4-a559-87345df66b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eba16cce-d819-4a1a-94b5-d9b735914f72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eba16cce-d819-4a1a-94b5-d9b735914f72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6f41dd18-4fad-452e-b03a-4be95a415e62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:to="loc_us-gaap_PlanNameAxis_6f41dd18-4fad-452e-b03a-4be95a415e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c265d4fb-46ea-4af9-8b5f-4bc5f7778b89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6f41dd18-4fad-452e-b03a-4be95a415e62" xlink:to="loc_us-gaap_PlanNameDomain_c265d4fb-46ea-4af9-8b5f-4bc5f7778b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_EquityIncentivePlan2015Member_dfdfc867-40f4-4fd5-b283-b7216dbd8783" xlink:href="flks-20200331.xsd#flks_EquityIncentivePlan2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c265d4fb-46ea-4af9-8b5f-4bc5f7778b89" xlink:to="loc_flks_EquityIncentivePlan2015Member_dfdfc867-40f4-4fd5-b283-b7216dbd8783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9201c210-15b8-4951-914c-0fa4952e206e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:to="loc_srt_RangeAxis_9201c210-15b8-4951-914c-0fa4952e206e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4b3d7a7-f652-483a-ab88-af6bcd39b2bc" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9201c210-15b8-4951-914c-0fa4952e206e" xlink:to="loc_srt_RangeMember_a4b3d7a7-f652-483a-ab88-af6bcd39b2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1c71a08c-db13-4f27-98e1-546c9d8b4430" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a4b3d7a7-f652-483a-ab88-af6bcd39b2bc" xlink:to="loc_srt_MinimumMember_1c71a08c-db13-4f27-98e1-546c9d8b4430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a626c745-5077-4c16-958d-508f793506fe" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a4b3d7a7-f652-483a-ab88-af6bcd39b2bc" xlink:to="loc_srt_MaximumMember_a626c745-5077-4c16-958d-508f793506fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_229a94f4-70ea-4060-a23b-e6b403d329f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:to="loc_us-gaap_AwardTypeAxis_229a94f4-70ea-4060-a23b-e6b403d329f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5004cc4-c9a4-4a22-a24d-27c0559e2736" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_229a94f4-70ea-4060-a23b-e6b403d329f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5004cc4-c9a4-4a22-a24d-27c0559e2736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f57dcf89-ba60-4eec-a6a3-54fb1ce0d361" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5004cc4-c9a4-4a22-a24d-27c0559e2736" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f57dcf89-ba60-4eec-a6a3-54fb1ce0d361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96d05d99-1253-4556-872c-945601381d17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8a56859-0fa2-4759-a92f-eafd825810e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8a56859-0fa2-4759-a92f-eafd825810e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_32cd9ab1-3011-498d-94c1-3550d9d3e6a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_32cd9ab1-3011-498d-94c1-3550d9d3e6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e646587f-f475-4875-8c7e-20995729c5a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e646587f-f475-4875-8c7e-20995729c5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_09daba07-5e68-44cc-96a2-79be31d4f782" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_09daba07-5e68-44cc-96a2-79be31d4f782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dd662b7a-b217-4068-afb7-e4793bfba963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dd662b7a-b217-4068-afb7-e4793bfba963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d95e51b9-1b94-4d59-b108-82205fd92d65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d95e51b9-1b94-4d59-b108-82205fd92d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_13a40422-b673-4051-a07e-3bb03da32111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_13a40422-b673-4051-a07e-3bb03da32111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b399de83-7873-40bd-80de-57ae89e97144" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ce072fd5-d885-4fb0-93b2-30acc2e39a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b399de83-7873-40bd-80de-57ae89e97144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b47f805-47a9-4929-8732-524df391092c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44068e8a-6a54-4b4f-82d8-e1a52617324e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b47f805-47a9-4929-8732-524df391092c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_44068e8a-6a54-4b4f-82d8-e1a52617324e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_357706c6-6294-42ad-ab50-3a71be8605ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b47f805-47a9-4929-8732-524df391092c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_357706c6-6294-42ad-ab50-3a71be8605ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29217178-1bb4-449d-b198-7abda2011744" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b47f805-47a9-4929-8732-524df391092c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29217178-1bb4-449d-b198-7abda2011744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_82ac129c-1cc3-4080-b08d-74eb9213bd21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b47f805-47a9-4929-8732-524df391092c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_82ac129c-1cc3-4080-b08d-74eb9213bd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc0131f1-61c3-4c73-a210-0ee73c106ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_268a121c-30df-4287-9e64-ae332a6146a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc0131f1-61c3-4c73-a210-0ee73c106ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_268a121c-30df-4287-9e64-ae332a6146a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_63f75a22-a9cf-4b4b-b67e-c67ed5adc579" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_268a121c-30df-4287-9e64-ae332a6146a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_63f75a22-a9cf-4b4b-b67e-c67ed5adc579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7b8bf3fb-a1c1-4096-90e3-d2f41e4692e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_268a121c-30df-4287-9e64-ae332a6146a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7b8bf3fb-a1c1-4096-90e3-d2f41e4692e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5c9c3fd2-e5a2-4e9d-9f6c-728280cc18fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_268a121c-30df-4287-9e64-ae332a6146a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5c9c3fd2-e5a2-4e9d-9f6c-728280cc18fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d43b62a4-60d7-4fcc-a235-2cecb444212c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_268a121c-30df-4287-9e64-ae332a6146a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d43b62a4-60d7-4fcc-a235-2cecb444212c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_953188f8-5fcb-4181-96ae-4a9ffc01d517" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc0131f1-61c3-4c73-a210-0ee73c106ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_953188f8-5fcb-4181-96ae-4a9ffc01d517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cea9e173-1a27-4f3e-be58-6e8292aacba6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc0131f1-61c3-4c73-a210-0ee73c106ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cea9e173-1a27-4f3e-be58-6e8292aacba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_434ca695-69c2-465c-b436-04479619a192" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cea9e173-1a27-4f3e-be58-6e8292aacba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_434ca695-69c2-465c-b436-04479619a192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26e10b58-28ed-4c3c-a2a7-c621d2f3739a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cea9e173-1a27-4f3e-be58-6e8292aacba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_26e10b58-28ed-4c3c-a2a7-c621d2f3739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a4587d6d-ed79-4fe1-ab38-3615496f8c37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cea9e173-1a27-4f3e-be58-6e8292aacba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a4587d6d-ed79-4fe1-ab38-3615496f8c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40decfe6-d028-42c1-9059-8bc07894cca4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cea9e173-1a27-4f3e-be58-6e8292aacba6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40decfe6-d028-42c1-9059-8bc07894cca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cd579d6b-21d8-423d-899f-4a34b4693b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc0131f1-61c3-4c73-a210-0ee73c106ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cd579d6b-21d8-423d-899f-4a34b4693b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_79e6147d-cc35-4767-9085-43d5210046fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc0131f1-61c3-4c73-a210-0ee73c106ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_79e6147d-cc35-4767-9085-43d5210046fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_aaa26e5a-81d5-41df-aaa3-bce9a807f0d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_79e6147d-cc35-4767-9085-43d5210046fa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_aaa26e5a-81d5-41df-aaa3-bce9a807f0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4cf3694e-6c8a-4b0f-9a30-d7f1a59fbc6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_79e6147d-cc35-4767-9085-43d5210046fa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4cf3694e-6c8a-4b0f-9a30-d7f1a59fbc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_db3817e4-a12d-4ccc-9c56-d6019a844a9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_79e6147d-cc35-4767-9085-43d5210046fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_db3817e4-a12d-4ccc-9c56-d6019a844a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1f910c58-54ee-4916-8c53-90d3cb3e75cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_79e6147d-cc35-4767-9085-43d5210046fa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1f910c58-54ee-4916-8c53-90d3cb3e75cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="flks-20200331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1773a99e-2d49-41f9-8955-8d2253f2faf8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_77b1132c-fbdf-4636-9940-be67911217f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1773a99e-2d49-41f9-8955-8d2253f2faf8" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_77b1132c-fbdf-4636-9940-be67911217f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="flks-20200331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b9538c0a-8ad7-4eaf-9ee3-9aa83cf7638f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1a0fc76c-455f-4ef4-be63-762454b5aeca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b9538c0a-8ad7-4eaf-9ee3-9aa83cf7638f" xlink:to="loc_us-gaap_SubsequentEventTable_1a0fc76c-455f-4ef4-be63-762454b5aeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e34da8d5-da39-4e41-aadb-02abd0648daf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1a0fc76c-455f-4ef4-be63-762454b5aeca" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e34da8d5-da39-4e41-aadb-02abd0648daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5c720dc4-075c-4714-bc2d-0a12962254d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e34da8d5-da39-4e41-aadb-02abd0648daf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5c720dc4-075c-4714-bc2d-0a12962254d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5321bc93-93a2-4ad2-bb1a-51ae4cd77668" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5c720dc4-075c-4714-bc2d-0a12962254d6" xlink:to="loc_us-gaap_SubsequentEventMember_5321bc93-93a2-4ad2-bb1a-51ae4cd77668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5afe8c3e-eac9-4e50-a04d-bb773f798696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1a0fc76c-455f-4ef4-be63-762454b5aeca" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5afe8c3e-eac9-4e50-a04d-bb773f798696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1061163c-d62e-4eda-8ca3-0d7b2cb5299e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5afe8c3e-eac9-4e50-a04d-bb773f798696" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1061163c-d62e-4eda-8ca3-0d7b2cb5299e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_3ab41317-0b60-4dfa-9d2a-5db8d5b80b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1061163c-d62e-4eda-8ca3-0d7b2cb5299e" xlink:to="loc_us-gaap_LoansPayableMember_3ab41317-0b60-4dfa-9d2a-5db8d5b80b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1178af40-1d19-489c-862f-6e6fa13094c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1a0fc76c-455f-4ef4-be63-762454b5aeca" xlink:to="loc_us-gaap_SubsequentEventLineItems_1178af40-1d19-489c-862f-6e6fa13094c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a4fc71f7-5803-4729-817d-a58afc03f09f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1178af40-1d19-489c-862f-6e6fa13094c1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a4fc71f7-5803-4729-817d-a58afc03f09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12ab0bf5-e3cc-4dc9-ada5-06e235a6ca53" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1178af40-1d19-489c-862f-6e6fa13094c1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12ab0bf5-e3cc-4dc9-ada5-06e235a6ca53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6847512944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text">PREPAID EXPENSES AND OTHER CURRENT ASSETS<div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets at March&#160;31, 2020 and December&#160;31, 2019 consisted of the following: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:64.422%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.422%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.423%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid clinical trial expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360,608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">617,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid and current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">646,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">955,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>Prepaid insurance is comprised of prepaid directors' and officers' insurance. In July 2019, the Company financed their directors' and officers' insurance premium with a short term note, the principal amount of which is approximately $0.9 million bearing interest at a rate of 4.61%. The note payable balances were $252,679 and $502,332, which were included within Current Liabilities on the Condensed Consolidated Balance Sheets at March&#160;31, 2020 and December&#160;31, 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6642206976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY-BASED COMPENSATION</a></td>
<td class="text">EQUITY-BASED COMPENSATION <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Equity Incentive Plans</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has granted options to employees, directors, and consultants under the 2015 Equity Incentive Plan (the "2015 Plan"). On July 19, 2019, the Company completed a merger with Flex Pharma and Flex Pharma had fully vested options to purchase 90,279 common shares outstanding as of the date of the merger that continue to be exercisable.  The 2015 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of March&#160;31, 2020, there were 34,087 shares remaining available for the grant of stock awards under the 2015 Plan.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 23, 2020, the Company awarded 182,000 stock options to its employees and directors, pursuant to the plan described above. Stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTk0Mg_3e677467-eb4d-4c5e-916f-d6b12ec0b478">one</span> to four years and have a contractual term of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. The fair value of the option grants of $92,007 has been estimated with the following assumptions for the three months ended March&#160;31, 2020:</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.701%;"><tr><td style="width:1.0%;"/><td style="width:30.427%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:64.847%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113.17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.80</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr></table></div><div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"><span><br/></span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2020: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"><tr><td style="width:1.0%;"/><td style="width:43.901%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.965%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.965%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.965%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.969%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.53</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.18</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.23</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, there was approximately $489,641 of total unrecognized compensation cost related to unvested stock options. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of 3.27 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6609961632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Prepaid expenses and other current assets at March&#160;31, 2020 and December&#160;31, 2019 consisted of the following: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:64.422%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.422%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.423%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid clinical trial expenses</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140,964&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">202,743&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid insurance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">360,608&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">617,096&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other prepaid and current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">144,788&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">136,060&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total prepaid expenses and other current assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">646,360&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">955,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6610002000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">113.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762677792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair Value</a></td>
<td class="nump">$ 283,070<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2019</a></td>
<td class="nump">317,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair Value</a></td>
<td class="nump">283,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at March 31, 2020</a></td>
<td class="nump">$ 34,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6857094912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Grant revenue</a></td>
<td class="nump">$ 1,132,830<span></span>
</td>
<td class="nump">$ 655,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,643,371<span></span>
</td>
<td class="nump">699,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,859,017<span></span>
</td>
<td class="nump">1,488,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,502,388<span></span>
</td>
<td class="nump">2,188,419<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss before other income (expense)</a></td>
<td class="num">(2,369,558)<span></span>
</td>
<td class="num">(1,532,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">283,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income net</a></td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">10,708<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,083,816)<span></span>
</td>
<td class="num">$ (1,522,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share (usd per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares outstanding&#160;&#8212; basic and diluted</a></td>
<td class="nump">9,534,842<span></span>
</td>
<td class="nump">2,372,940<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6609915600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As described above, the merger with Flex Pharma closed on July 19, 2019. The merger was accounted for as a reverse acquisition with Private Salarius being deemed the acquiring company for accounting purposes. Private Salarius&#8217; historical financial statements have replaced Flex Pharma&#8217;s historical consolidated financial statements with respect to periods prior to the completion of the merger with retroactive adjustments to Private Salarius' legal capital to reflect the legal capital of Flex Pharma. Flex Pharma (renamed Salarius Pharmaceuticals, Inc.) remains the continuing registrant and reporting company. Accordingly, the historical financial and operating data of Salarius Pharmaceuticals, Inc., which covers periods prior to the closing date of the merger, reflects the assets, liabilities and results of operations of Private Salarius and does not reflect the assets, liabilities and results of operations of Flex Pharma for the periods prior to July 19, 2019. The Company has retrospectively adjusted its Statement of Changes in Stockholders&#8217; Equity (Deficit) and the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding common unit, profits interest common unit and Series A Preferred unit of </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Private Salarius that converted into shares of the Company&#8217;s common stock upon the merger, and to reflect the effect of the 25 to 1 reverse stock split of the Company&#8217;s common stock which occurred upon the merger.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Unaudited Interim Financial Information</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December&#160;31, 2019 included elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 23, 2020. In the opinion of management, the unaudited interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#8217;s financial position as of March&#160;31, 2020 and the results of operations for the three months ended March&#160;31, 2020 and 2019. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December&#160;31, 2019 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Salarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. </span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At March&#160;31, 2020 and December&#160;31, 2019, Salarius also held approximately $0 and $1.0 million, respectively, which represents funds received from Cancer Prevention and Research Institution of Texas ("CPRIT").  These funds were used for costs for allowable expenses, primarily research and development expenses. The grant has a mandatory fund matching requirement. Subject to CPRIT review, the Company believes that all matching fund requirements have been met at March&#160;31, 2020.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impairment of Long-Lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.  During the three months ended March&#160;31, 2020 and March&#160;31, 2019 , impairment charges related to long-lived assets were $0 and $110,474, respectively. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Goodwill</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">value of goodwill has been impaired. There was no impairment of goodwill during the three months ended March&#160;31, 2020 or March&#160;31, 2019, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the reverse merger transaction, the Company issued rights to receive warrants to purchase the Company&#8217;s common stock. Further, on February 11, 2020, the Company issued warrants to purchase the Company's common stock in a registered public offering. The Company determines whether the warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within Change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Clinical Trial Accruals</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s preclinical and clinical trials are performed by third party contract research organizations (CROs) and/or clinical investigators, and clinical supplies are manufactured by contract manufacturing organizations (CMOs). Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CMOs. The Company&#8217;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CMOs regarding the status and cost of the studies, and may not match the actual services performed by the organizations. This could result in adjustments to the Company&#8217;s research and development expenses in future periods. To date the Company has had no significant adjustments.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Grants Receivable and Revenue Recognition </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Salarius&#8217; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grants receivable.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Equity-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company uses the Black-Scholes option valuation model and the Backsolve method (which is similar to the Black-Scholes valuation model and produces similar results) to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of anti-dilutive shares, consisting of common shares underlying (i) common stock options, (ii) stock purchase warrants, (iii) unvested restricted stock, (iv) convertible preferred stock and (v) rights entitling holders to receive warrants to purchase the Company's common shares, which have been excluded from the computation of diluted loss per share, was 10,597,729 and 30,395 shares as of March&#160;31, 2020 and 2019, respectively.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Subsequent Events</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Application of New Accounting Standards</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Intangibles-Goodwill and Other,&#8221; which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">years, and interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact on its consolidated financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Pronouncements Not Yet Adopted</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>flks-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:flks="http://www.flex-pharma.com/20200331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="flks-20200331.xsd" xlink:type="simple"/>
    <context id="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4571822fa95e433cb31fe3b268a0157b_I20200505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2020-05-05</instant>
        </period>
    </context>
    <context id="idff75338ab954067833daa55353126e4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i316105bb8a4240588ac05a8d48949e71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i70af0eeb6ae64595b3496e4f573820f7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6632a88f72bd4dce912e8beda5728be8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i85b3036ab6d64f5c890474b22de3cea0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i48e6839aa78b49d7a1b426193e822187_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9544fb2f862e407388524ab0bccddac0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i16fda578275a497fa39ffdae434647bb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i296a0cb619044259822d223d39af65b2_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic0351d160e9c47e49e8caea479d3bbb7_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i029a4238195344ce9ca54a046028a734_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4cafa03bbcbf41e9af4d14448d9db3c5_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9edcc8fcaab54e3aacded026cb8d9b22_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic9c5329d026f46fa9a0a9ab94fd1106c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7146557875c64c948bcec77e00b091b1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7bd590e1573a4c41a8193d12224c9c3c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6f3e1bbf23f94c92b05cbed3fcbff616_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5df749b27e2e4ab594097b6f0dfcbbfb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i139ce469438446e1aa69f17a3d9c7865_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie9080f05ec45443fad3554f83e2eace9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i48fe193ad62a4945adfc9947d631230b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic2f7e69dbdb94177a53d56e0f77d4cf3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifd7aaa5165cb45d2809ccf6274968968_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i88b3e077cd5846b99d7bad5be157bb53_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="i291b51edb08c4a50ba7e783e980e810b_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flks:FlexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="if8e9ef7d321148bfa7e0fc99f44856d7_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="i9335e01552494ea4aeab4ed31281b503_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">flks:FlexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="i3c3c4f1bd73a41ab8a2603386c7cd387_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i93571fc75180447ba55229d7f09f1868_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">flks:UniversityOfUtahResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="ic1d35ab3929b4fbe91e95df48a459f8e_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i7dca2651f502440e853228b2558f473e_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i72557c4fa44d4ba5b0d57686b7176435_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib355700b35e94a5ba6f3b2d4a9975b06_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i401548a97a504666ac77f37acd7d7032_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib502bdc134494b80b87687b9029ffcca_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flks:FlexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="id08675e640c04365826f8bb18dab3ceb_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">flks:FlexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="ide7180e8b2684c66b43dcb58cf485a4e_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i8481df852a634528bdf8f167d58d97c5_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="iaed98830a5f34cfda77f4a37fb71e8c4_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="i8ec9f9e3c871475686ca302cf142454a_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="ibea4f4bd11db4c879d27ce92ac6637d8_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="ib4d806ab35a84b6ba717db59bba7315a_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i82641346e1074588aae8bc99288365f9_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="iac9b8222fe3849c3a6894033394a49ec_I20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-11</instant>
        </period>
    </context>
    <context id="ib1026e50b8014604b81db07f3826adb3_D20200211-20200211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-11</startDate>
            <endDate>2020-02-11</endDate>
        </period>
    </context>
    <context id="i7f20b1ecfb964b37a76c0654fff02596_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3b8ac8f09be5476299897cdf23a7a0c4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">flks:ProfitInterestUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ibaf829e8bf7e456b9116404177f196c9_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if9d5f52e15574141abe8b47621abead0_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">flks:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3eeda48ea55c43c3921c1333146fc953_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="id75dc2c494874c2590b7a7652f91ebca_I20190120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <instant>2019-01-20</instant>
        </period>
    </context>
    <context id="i923938e66ee44ac4a3049da0fb812f9f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if3d35d901c984cd9a8b3c067ed4795b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18d0ed03a53041689adae6878926fead_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if5c08f3842d84b48b2fd04af17a3bc44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6bbed367577c464aa83ed65a64104166_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2e818517cf6e4951b3588a8d6e0e57a8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71357db1c2cb48d4a167d650fea320cc_I20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flks:SatisfySuccessFeeDueToRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flks:WedbushSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-19</instant>
        </period>
    </context>
    <context id="i2defc6da5b484ddc838a55ab137797ca_D20190719-20190719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">flks:SatisfySuccessFeeDueToRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">flks:WedbushSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-19</startDate>
            <endDate>2019-07-19</endDate>
        </period>
    </context>
    <context id="i8ee10a83c58c467499b54edfb3d4578c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">flks:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0229b2e923e041fe8797ef1f87ddd7eb_D20190910-20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2019-09-10</startDate>
            <endDate>2019-09-10</endDate>
        </period>
    </context>
    <context id="i79fb058518ba480a82055d2644b14f06_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i63ca0eae144c4e4a86b4c93b3bcd23ed_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifc382e1599924272a66a5f62e9b3fb2e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib0e99be21eb64f78a76597b9daad23be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82289f6d72fc4019908f2649c6567ffd_I20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-13</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="trading_days">
        <measure>flks:trading_Days</measure>
    </unit>
    <dei:DocumentPeriodEndDate
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV8xLTEtMS0xLTA_4a55b40b-29a5-4df7-9889-2ecda9c8999c">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV80LTEtMS0xLTA_8b8c3902-5dec-4620-98f5-fd2257496a9f">0001615219</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV81LTEtMS0xLTA_6739434a-496f-4ec2-9ceb-73e6d677f8d7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV84LTEtMS0xLTA_4a55b40b-29a5-4df7-9889-2ecda9c8999c">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV85LTEtMS0xLTA_00a36555-a315-47c0-90f5-a883ec60d2f9">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV8xMC0xLTEtMS0w_880d4ed7-fc45-4b6a-8d8d-5deeab090c59">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80L2ZyYWc6MjYxNDMxYzY0NTYyNDdmMmFkMzg1ZDg4MDQzZTc3NGEvdGFibGU6MjRmNDg3OWEzNzMzNDBjMmJiYTVlNTQ5ZDM1NzgwOTUvdGFibGVyYW5nZToyNGY0ODc5YTM3MzM0MGMyYmJhNWU1NDlkMzU3ODA5NV8xMS0xLTEtMS0w_4df50ec7-ccdb-45b7-b28a-c8dd296673d6">false</dei:AmendmentFlag>
    <flks:RevenueFromGrantsExtensionTerm
      contextRef="i7dca2651f502440e853228b2558f473e_D20190501-20190531"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgwMA_62016ce1-9c77-440a-be57-b02c9bb2a0fd">P6M</flks:RevenueFromGrantsExtensionTerm>
    <flks:RevenueFromGrantsExtensionTerm
      contextRef="i7dca2651f502440e853228b2558f473e_D20190501-20190531"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgxNQ_f84e63ce-cd9b-41a2-9e9b-5f34bd9cd7fe">P6M</flks:RevenueFromGrantsExtensionTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUxNA_5df20bb8-eba1-4ed3-bcaa-a88042c57c15">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ3MA_5232e6f4-81eb-413b-ad84-cc43a3411329">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i79fb058518ba480a82055d2644b14f06_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTk0Mg_3e677467-eb4d-4c5e-916f-d6b12ec0b478">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMDk5NTExNjMwMTg3_81d5f2e5-d307-4cc0-9cc9-bf9e5d91c655">10-Q/A</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6YjM5MDU0M2RkOTNjNGJhYjhkMmEzOGIxNWM3ZmFlODEvdGFibGVyYW5nZTpiMzkwNTQzZGQ5M2M0YmFiOGQyYTM4YjE1YzdmYWU4MV8xLTAtMS0xLTA_aa95063c-c812-4e82-9d27-67d346af5493">true</dei:DocumentQuarterlyReport>
    <dei:DocumentTransitionReport
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6YjM5MDU0M2RkOTNjNGJhYjhkMmEzOGIxNWM3ZmFlODEvdGFibGVyYW5nZTpiMzkwNTQzZGQ5M2M0YmFiOGQyYTM4YjE1YzdmYWU4MV80LTAtMS0xLTA_1935c07b-e8af-41ff-8fa5-7c1f32b8b21f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMTY_fe96e7ad-1598-492c-ab84-c37ba01a656b">001-36812</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMjA_d5e06345-b980-45a9-abe5-be648cb20108">SALARIUS PHARMACEUTICALS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MDM5YzVkZTcyMjNlNGUwYTgzZTMwZWVjNGQ0NTQyNTQvdGFibGVyYW5nZTowMzljNWRlNzIyM2U0ZTBhODNlMzBlZWM0ZDQ1NDI1NF8wLTEtMS0xLTA_579188d1-1d18-4522-84c6-6e8fe0bb8977">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MDM5YzVkZTcyMjNlNGUwYTgzZTMwZWVjNGQ0NTQyNTQvdGFibGVyYW5nZTowMzljNWRlNzIyM2U0ZTBhODNlMzBlZWM0ZDQ1NDI1NF8wLTMtMS0xLTA_c2642d99-987f-49dc-bc29-b4c18fce3047">46-5087339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xODE_f9989b98-1170-4af4-a27c-eea4da4b0e92">2450 Holcombe Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xODY_1bc3c851-bb5a-4460-99ba-11081476601e">Suite J 608</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xOTA_b2c715fc-eee8-41bd-ba3a-cfe085f88eb1">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xOTQ_a2184764-77e7-4961-9736-3c1ec28b6442">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xOTc_b7526b1f-674e-4a5b-9797-20ae6de0ebf2">77021</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8zMDU_28e755aa-6273-47ee-ac37-74659f09604f">346</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8zMDk_540d9578-6ab6-4237-8cab-39a63313c603">772-0346</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MWUyYjA5OWQ3YTRkNDdkZWIxMjYyN2I4YWJkNWVkOWYvdGFibGVyYW5nZToxZTJiMDk5ZDdhNGQ0N2RlYjEyNjI3YjhhYmQ1ZWQ5Zl8xLTAtMS0xLTA_9088c492-8ad3-4c77-b9d6-67d8cdb64a57">Common Stock, $ 0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MWUyYjA5OWQ3YTRkNDdkZWIxMjYyN2I4YWJkNWVkOWYvdGFibGVyYW5nZToxZTJiMDk5ZDdhNGQ0N2RlYjEyNjI3YjhhYmQ1ZWQ5Zl8xLTItMS0xLTA_5979325f-115d-4208-89f3-35f6f14c3e6b">SLRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6MWUyYjA5OWQ3YTRkNDdkZWIxMjYyN2I4YWJkNWVkOWYvdGFibGVyYW5nZToxZTJiMDk5ZDdhNGQ0N2RlYjEyNjI3YjhhYmQ1ZWQ5Zl8xLTQtMS0xLTA_1260ecfd-d5a1-4163-8aea-157d2be126e2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV84MTk_50a14973-ec44-4505-92ed-6eddbc262de1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMTM5_72ce63cd-dae8-4e99-8199-69253fc6010f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6ZGUzYjM4M2RhNmFhNGZiZThjMDEyYTdhYTM3OTQ4NGYvdGFibGVyYW5nZTpkZTNiMzgzZGE2YWE0ZmJlOGMwMTJhN2FhMzc5NDg0Zl8wLTQtMS0xLTA_e65e214b-246a-43a0-b3d4-7c60db522a50">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6ZGUzYjM4M2RhNmFhNGZiZThjMDEyYTdhYTM3OTQ4NGYvdGFibGVyYW5nZTpkZTNiMzgzZGE2YWE0ZmJlOGMwMTJhN2FhMzc5NDg0Zl8wLTctMS0xLTA_399a7667-cbb4-4179-9bfd-d2c2efdc395c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGFibGU6ZGUzYjM4M2RhNmFhNGZiZThjMDEyYTdhYTM3OTQ4NGYvdGFibGVyYW5nZTpkZTNiMzgzZGE2YWE0ZmJlOGMwMTJhN2FhMzc5NDg0Zl8wLTktMS0xLTA_faee4d86-6d06-4a9c-8f0c-c303ebc3d48c">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xNzQ0_a1cc0e96-aae2-48b4-933d-964a59283e14">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xODY1_d44166df-887b-40dd-96ee-f9849170a44f">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4571822fa95e433cb31fe3b268a0157b_I20200505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xL2ZyYWc6OTcwMWZhZTM1NmI5NDU2MDhmNDU4MjkxOWI1MmU0MTkvdGV4dHJlZ2lvbjo5NzAxZmFlMzU2Yjk0NTYwOGY0NTgyOTE5YjUyZTQxOV8xMDk5NTExNjMwMDYw_ef230efd-61aa-4da1-bf86-19c1aa835ee1"
      unitRef="shares">13650752</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNC0xLTEtMS0w_5dd91097-5bfb-4711-8e0a-e72201516bc5"
      unitRef="usd">9646940</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNC0zLTEtMS0w_c27e0247-02ab-48f0-a091-68250a150d4f"
      unitRef="usd">3738900</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNS0xLTEtMS0w_c1d40bb7-1ed7-43e3-bde5-3f0dc4c5496e"
      unitRef="usd">591129</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNS0zLTEtMS0w_9782c75c-0539-4c0f-b408-f5b1f630273e"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNy0xLTEtMS0w_ce9731f4-3c32-4940-ae0c-0f39236882e7"
      unitRef="usd">646360</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfNy0zLTEtMS0w_0603751a-a2d9-481d-9e07-5e7f351fb3f1"
      unitRef="usd">955899</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfOC0xLTEtMS0w_fb5098fa-a175-44ca-bb94-93630c899b28"
      unitRef="usd">10884429</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfOC0zLTEtMS0w_f57298e3-15c0-4e64-baa0-52cfd90f385b"
      unitRef="usd">4694799</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfOS0xLTEtMS0w_fee7b8a8-6c39-42a3-af71-46c43d1db6f2"
      unitRef="usd">21889</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfOS0zLTEtMS0w_79a7a2fe-65cb-47f2-9629-f3ab17ceb029"
      unitRef="usd">25016</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTItMS0xLTEtMA_a3f79247-7ad6-4729-a083-5614992d92f0"
      unitRef="usd">8865909</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTItMy0xLTEtMA_e476d52a-5cf3-42e7-965e-499c7b93b1a1"
      unitRef="usd">8865909</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTMtMS0xLTEtMA_30cfc71f-3041-44fc-b248-67827050d4d4"
      unitRef="usd">293147</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTMtMy0xLTEtMA_3957cab6-2d8c-4aff-bbe1-78d9baf727af"
      unitRef="usd">308674</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTQtMS0xLTEtMA_7284bf7d-e42a-48ec-bd59-ce06261fa58d"
      unitRef="usd">20065374</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTQtMy0xLTEtMA_3fa084cc-d14d-4347-af12-9d26b8240328"
      unitRef="usd">13894398</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTctMS0xLTEtMA_e28b2030-4903-485f-a46c-e66af7fd93d2"
      unitRef="usd">979823</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTctMy0xLTEtMA_2e16ad9e-ebcf-4f69-81b8-d7ee1694d23e"
      unitRef="usd">1790966</us-gaap:AccountsPayableCurrent>
    <flks:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTgtMS0xLTEtMA_27406edd-a930-4b1d-b56e-dc3c78febcf0"
      unitRef="usd">795567</flks:AccruedExpensesAndOtherCurrentLiabilities>
    <flks:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMTgtMy0xLTEtMA_87563e2f-4569-4ac2-bd76-d46b5ec53675"
      unitRef="usd">160783</flks:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:NotesPayableCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjMtMS0xLTEtMA_195788b1-dbb5-4e4c-9703-824a6b32577b"
      unitRef="usd">252679</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjMtMy0xLTEtMA_ff356518-ad92-411c-abde-0531442a182c"
      unitRef="usd">502332</us-gaap:NotesPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjQtMS0xLTEtMA_cbc45075-6025-42a5-a4c7-1fb0c6712f7b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjQtMy0xLTEtMA_bd410fd5-8f1f-4ffb-84cc-227467eb0aef"
      unitRef="usd">541701</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjUtMS0xLTEtMA_2c2aec3e-c1ab-41b8-8e19-ec86f6baa1ed"
      unitRef="usd">34692</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjUtMy0xLTEtMA_0f772696-2eea-4020-af32-c14406bf0f4a"
      unitRef="usd">317762</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjYtMS0xLTEtMA_2cb012ee-6459-4f4b-9e53-d0d503382eee"
      unitRef="usd">2062761</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMjYtMy0xLTEtMA_8519f2c8-85d1-40f8-8efb-9828a88632c4"
      unitRef="usd">3313544</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzAtMS0xLTEtMA_ce8f742c-c45d-43f6-a79c-e219895b6981"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzAtMy0xLTEtMA_90f972b9-6fe7-4fd0-9b7c-ec00304255f2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzIx_753a1b0d-bf11-418e-b024-a7a173f5fe73"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzIx_bf42d8ac-e9dd-470d-90d1-3168d5b01d8c"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzM1_32e9c7c1-ac44-49b9-a7b7-7bda47f4c36b"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzM1_4cccda8b-5477-4dbb-a9ea-0c8fa34335f2"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzU3_320732e5-1f86-4d0e-a557-06d48aeb9efe"
      unitRef="shares">468694</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzU3_7223a335-dce2-4eb2-9dd9-3b950c815024"
      unitRef="shares">468694</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzU3_a1a325f0-378d-47a7-adca-e843b6e80d06"
      unitRef="shares">468694</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmZjYzIyY2JmNmJjNjQxYTJhZmJhMGFkODgwYzY5MzIwXzU3_c9f160a0-c8f6-4a95-bd90-3b7aa21e487d"
      unitRef="shares">468694</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMS0xLTEtMA_0e06e732-7b3a-4489-bfc2-96da8b92a0bd"
      unitRef="usd">47</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzMtMy0xLTEtMA_144d591f-b1bd-4396-8ca1-12cea8ee7f13"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzE4_0fc468fa-cbf4-4b40-8f5c-70ca97fbe38e"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzE4_ac9d0309-5c29-483a-982c-2fc255db4d6b"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzMy_3aad688a-0221-4e70-90a3-c5446324db0a"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzMy_b8088a6a-9b24-4df3-babf-e95094f75ca2"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzU0_6e91fa8d-4af0-4313-9952-1f411494e2f8"
      unitRef="shares">13650838</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzYx_6e5d5910-b2f9-4b44-b898-fd6779d59fba"
      unitRef="shares">4519533</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4Xzk2_98fdc90c-4bf9-4faa-9b9e-fe17b707ef63"
      unitRef="shares">13645677</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOmE2NjA5NTYzMjI4NjQ1NzFiNmVhMDk2Y2Y4MGViZDQ4XzEwMw_0ac9dc1c-ce61-4cc8-a84b-3e668abd8e88"
      unitRef="shares">4511174</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMS0xLTEtMA_52013082-48ec-45bb-ab1a-9c31668cafa0"
      unitRef="usd">1364</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzQtMy0xLTEtMA_da853bdf-4712-4275-bbc9-617ebafbff02"
      unitRef="usd">451</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzUtMS0xLTEtMA_6d36717b-dcf9-4070-8b8c-c99c266bd14c"
      unitRef="usd">32161718</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzUtMy0xLTEtMA_c2a3f275-da1f-4244-ade1-58f86e5e2bf8"
      unitRef="usd">22657103</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzctMS0xLTEtMA_df00db5f-599d-4e95-9b72-910153750d03"
      unitRef="usd">-14160516</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzctMy0xLTEtMA_41e63c20-016a-436a-9430-600ae5e97ee0"
      unitRef="usd">-12076700</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzgtMS0xLTEtMA_1979f5f3-c037-4300-8991-8d0d45d8f455"
      unitRef="usd">18002613</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzgtMy0xLTEtMA_a8779e8f-3bf0-41df-a73c-346e4a6cda81"
      unitRef="usd">10580854</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzktMS0xLTEtMA_55005a9d-86ee-4878-9dc3-68a00a6fbdef"
      unitRef="usd">20065374</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xOS9mcmFnOjNlY2YyMDkzMzRmYTQxODdhMTFhOWRmZGVlYzVjMmM5L3RhYmxlOjlmOTc2M2MwYmU4YzRiODNiNDIxMTI5MWU2NjM2NDgwL3RhYmxlcmFuZ2U6OWY5NzYzYzBiZThjNGI4M2I0MjExMjkxZTY2MzY0ODBfMzktMy0xLTEtMA_7d46244f-f552-40d8-8f4f-b4a174ce03c6"
      unitRef="usd">13894398</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMi0xLTEtMS0w_0c1cf9d8-c720-411f-8c10-911997ac9515"
      unitRef="usd">1132830</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMi0zLTEtMS0w_c672dcfc-8123-48a5-a9c7-fc91644f132d"
      unitRef="usd">655635</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNC0xLTEtMS0w_b056b350-3261-4e1c-b413-ab15f5dc4114"
      unitRef="usd">1643371</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNC0zLTEtMS0w_7265851c-491a-426d-8320-b508b775ea33"
      unitRef="usd">699929</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNS0xLTEtMS0w_3c3eca60-a562-4ed2-854d-fca03298e9bf"
      unitRef="usd">1859017</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNS0zLTEtMS0w_97963191-e855-4858-89e6-1062b0df8e21"
      unitRef="usd">1488490</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNi0xLTEtMS0w_1131130e-0264-4daf-9d62-4b9bbcb20ddd"
      unitRef="usd">3502388</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNi0zLTEtMS0w_acf130f2-2d0b-481d-a508-57b758fcf567"
      unitRef="usd">2188419</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNy0xLTEtMS0w_fdf189de-366f-40fc-bd6c-49a4d7f22a6c"
      unitRef="usd">-2369558</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfNy0zLTEtMS0w_13cb9da4-4ce5-4694-8d6e-3e2d8ff215fc"
      unitRef="usd">-1532784</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfOC0xLTEtMS0w_52dfb0b8-2878-4ff9-a7c1-163ed91ab554"
      unitRef="usd">-283070</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfOC0zLTEtMS0w_cea4d865-4138-4887-a093-a0451f1a195b"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfOS0xLTEtMS0w_80312d9c-2aa1-4f2a-beef-d652ca87d8ae"
      unitRef="usd">2672</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfOS0zLTEtMS0w_db6a8ac5-e2f9-474b-8153-6442afd236cf"
      unitRef="usd">10708</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMTAtMS0xLTEtMA_a1429d2e-12b9-4afc-91c3-85322f0e4e10"
      unitRef="usd">-2083816</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMTAtMy0xLTEtMA_42578e81-5f90-4e28-94f7-b8456f34f2f8"
      unitRef="usd">-1522076</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMjEtMS0xLTEtMA_a574d433-fc9b-43a8-ac2f-f13e3e56c4d1"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMjEtMy0xLTEtMA_4e138149-2c35-4cc9-9d00-9ced9ba8e9e2"
      unitRef="usdPerShare">-0.64</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMjItMS0xLTEtMA_2f949f9c-ce9f-449b-8346-fa2374387d34"
      unitRef="shares">9534842</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yMi9mcmFnOjJmYzJiMDQ2MmZiMTQ1YTNhMzhiZmQ3ZmZkZTU0OGYwL3RhYmxlOjNhNTRlMzQ4YWE0MzQ1YmFiM2YyMDZlOWZlNDdhNjI5L3RhYmxlcmFuZ2U6M2E1NGUzNDhhYTQzNDViYWIzZjIwNmU5ZmU0N2E2MjlfMjItMy0xLTEtMA_f99bd2b3-7dbb-49c0-b76c-4800e09cfb28"
      unitRef="shares">2372940</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMi0xLTEtMS0w_cb9abbfe-3d02-4856-8260-4ea52db19226"
      unitRef="usd">-2083816</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMi0zLTEtMS0w_f952b459-f8a8-4019-986c-b537f01fb672"
      unitRef="usd">-1522076</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNC0xLTEtMS0w_790965ec-1189-4558-bf89-9167d5ca7043"
      unitRef="usd">4233</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNC0zLTEtMS0w_103d13a3-3d75-4f81-bdb9-0750775fd4ac"
      unitRef="usd">114707</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNS0xLTEtMS0w_c2b78535-5c70-4938-ad1b-87bc370e89de"
      unitRef="usd">38409</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNS0zLTEtMS0w_8b6c2b53-9c01-4ccf-969a-030fef4f33e5"
      unitRef="usd">35407</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNy0xLTEtMS0w_2094bd50-43c3-4e04-963b-7fba1eb87991"
      unitRef="usd">-283070</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNy0zLTEtMS0w_c3c35b0b-df83-492f-b00c-14bf8e54978f"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTAtMS0xLTEtMA_6adc4c95-fd4c-4f67-8aa8-8452df9ec3b5"
      unitRef="usd">591129</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTAtMy0xLTEtMA_c41171fe-8276-4dd5-a357-21dc4427fc1a"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTEtMS0xLTEtMA_d5f1294d-6f34-4d21-9e31-5af19e473313"
      unitRef="usd">-298959</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTEtMy0xLTEtMA_20f2d194-3c12-47ca-bd8e-f5b7ba46c8f3"
      unitRef="usd">-30743</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTMtMS0xLTEtMA_b63b4fbc-15d8-4705-8eab-0008e14b7ed0"
      unitRef="usd">-911301</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTMtMy0xLTEtMA_06cd015f-d125-4738-9248-d00e9a0f17f7"
      unitRef="usd">589700</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTQtMS0xLTEtMA_15a23f9a-b367-4efd-881f-a59a95b838ce"
      unitRef="usd">361382</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTQtMy0xLTEtMA_0d0c7642-b2ee-4f67-87ba-90ed6acf2498"
      unitRef="usd">-462816</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTUtMS0xLTEtMA_06695fc8-da86-423c-8512-419c95f535b1"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTUtMy0xLTEtMA_72dfc569-4eae-4a40-bd5b-df118e30f67e"
      unitRef="usd">1256</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTYtMS0xLTEtMA_fac28c56-640f-4381-8914-073f9393440b"
      unitRef="usd">-541701</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTYtMy0xLTEtMA_223185c7-874f-4935-9aff-62bbc3294244"
      unitRef="usd">-655634</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTgtMS0xLTEtMA_f5aa85a7-bb49-43ea-9ba0-f7b612e051b2"
      unitRef="usd">-3708034</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMTgtMy0xLTEtMA_b10619ac-19a5-403f-91db-f374abd24e38"
      unitRef="usd">-1868713</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMjgtMS0xLTEtMA_7f369767-5c93-4485-9f03-ef1d60652e62"
      unitRef="usd">9865727</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMjgtMy0xLTEtMA_707e690a-3e32-4f93-ae5a-693bd0b5aecb"
      unitRef="usd">1508179</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzAtMS0xLTEtMA_15dadfbf-f64c-4484-9ff5-d9b25a91205d"
      unitRef="usd">249653</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzAtMy0xLTEtMA_80308866-d57e-4321-bb25-c2ffc2c8378a"
      unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzItMS0xLTEtMA_ccef80cd-1754-4678-954f-fbc1831c7524"
      unitRef="usd">9616074</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzItMy0xLTEtMA_859dcedd-e19b-4f5c-9488-7da52c039c91"
      unitRef="usd">1508179</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzQtMS0xLTEtMA_828d8fb6-4569-4b07-895a-2840bb4d97ba"
      unitRef="usd">5908040</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzQtMy0xLTEtMA_c1f362e6-1f70-4c28-8b7a-a7aec8a58b95"
      unitRef="usd">-360534</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzUtMS0xLTEtMA_0da29106-3606-4216-a55d-d429753311de"
      unitRef="usd">3738900</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i70af0eeb6ae64595b3496e4f573820f7_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzUtMy0xLTEtMA_b9c3ab99-667e-4c9b-80d4-89a290a48ac5"
      unitRef="usd">6131781</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzYtMS0xLTEtMA_c1fdfc38-5284-4e35-8eb4-828885000330"
      unitRef="usd">9646940</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6632a88f72bd4dce912e8beda5728be8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzYtMy0xLTEtMA_23e91c79-bc2d-4b10-ab9d-2ead814dea5c"
      unitRef="usd">5771247</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzktMS0xLTEtMA_8aceab1d-db1d-49c7-8fe6-08a6869050bd"
      unitRef="usd">3061</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzktMy0xLTEtMA_78dd5b42-afb4-4f29-9cb1-47f869f916b3"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <flks:StockIssuanceCostsAccruedAndAmortized
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNDQtMS0xLTEtMA_cd0525ec-6903-4bcb-8bc0-dacc1ceea758"
      unitRef="usd">398561</flks:StockIssuanceCostsAccruedAndAmortized>
    <flks:StockIssuanceCostsAccruedAndAmortized
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfNDQtMy0xLTEtMA_9ae8dd8c-f235-4ce5-ae3d-345e6fc6bf33"
      unitRef="usd">0</flks:StockIssuanceCostsAccruedAndAmortized>
    <us-gaap:StockIssued1
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzQtMS0xLTEtMjEyOQ_b0f5fbe9-63ef-4c2b-9db4-908a83c02451"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzUtMy0xLTEtMTk2Mg_40a97a14-af81-4daa-9691-3ae88116425b"
      unitRef="usd">110474</us-gaap:StockIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzYtMS0xLTEtMTk1Ng_23fc7534-ab37-4980-a6d7-8790fde60801"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yNS9mcmFnOmJiMTJlNzZmNjE5NDQ2MWNiYTIzYmMxMmZlNzAwOTdkL3RhYmxlOjhkZTQ5ZGI2OWZjMDRhZTlhNjNlMmZjYTY5MTMyMDYzL3RhYmxlcmFuZ2U6OGRlNDlkYjY5ZmMwNGFlOWE2M2UyZmNhNjkxMzIwNjNfMzYtMy0xLTEtMTk1Ng_5c32e6ba-5f6b-4075-a881-ec8438509cb3"
      unitRef="usd">2869412</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:SharesOutstanding
      contextRef="i85b3036ab6d64f5c890474b22de3cea0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctMS0xLTEtMA_916d68d4-55fe-4f99-8592-24c7732cf90b"
      unitRef="shares">2032763</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i85b3036ab6d64f5c890474b22de3cea0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctMy0xLTEtMA_a45232c8-b2a8-4cfb-bf63-7ca108f29139"
      unitRef="usd">203</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i48e6839aa78b49d7a1b426193e822187_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMy01LTEtMS0xNjk3_5a9ff340-890f-463c-9b7c-44d336cbb198"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i48e6839aa78b49d7a1b426193e822187_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMy03LTEtMS0xNjk3_29c6a058-58ca-4310-8d6f-59490a069c03"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9544fb2f862e407388524ab0bccddac0_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctNS0xLTEtMA_1a8160b7-4f5f-4b30-a733-5e4ccfa2dd4c"
      unitRef="usd">3869120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i16fda578275a497fa39ffdae434647bb_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctNy0xLTEtMA_d4e7fbd6-e371-4510-a762-12bec70c3414"
      unitRef="usd">-5140437</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i70af0eeb6ae64595b3496e4f573820f7_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTctOS0xLTEtMA_934583e5-3d3b-47f5-a5da-56875a9dce7e"
      unitRef="usd">-1271114</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTgtMS0xLTEtMA_3f3c2197-7f42-45df-9cd2-72cb43aa66b1"
      unitRef="shares">960489</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTgtMy0xLTEtMA_b2233200-6149-4d19-bbf3-b4630bc887a7"
      unitRef="usd">96</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i296a0cb619044259822d223d39af65b2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTgtNS0xLTEtMA_65c57d25-f9ab-4473-92d1-d6f74a5a00d2"
      unitRef="usd">4377495</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTgtOS0xLTEtMA_e07946a1-f01b-4b94-98dd-3e1793dfbd05"
      unitRef="usd">4377591</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTktMS0xLTEtMA_b8b267a3-88a6-4585-91ed-82716e8dc611"
      unitRef="shares">12907</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTktMy0xLTEtMA_120a3fe8-eec8-40fd-be5a-69bf62703394"
      unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i296a0cb619044259822d223d39af65b2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTktNS0xLTEtMA_acf6d933-3950-4315-aa28-822fbd3a2b05"
      unitRef="usd">110473</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTktOS0xLTEtMA_e46cdc05-ab85-453f-afab-4a36fc30082c"
      unitRef="usd">110474</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjAtMS0xLTEtMA_392359ff-d8f8-4927-a58c-38bf0a7f9ad7"
      unitRef="shares">9550</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjAtMy0xLTEtMA_1f7baa89-3503-4249-a125-4672070b15ab"
      unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i296a0cb619044259822d223d39af65b2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjAtNS0xLTEtMA_4839433c-7c47-434d-88b4-1d4287b2f361"
      unitRef="usd">35406</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjAtOS0xLTEtMA_427468bf-744e-4c36-83aa-a761d0c9d431"
      unitRef="usd">35407</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="ic0351d160e9c47e49e8caea479d3bbb7_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjEtNy0xLTEtMA_60865ade-025a-46fb-b082-62dab2278c94"
      unitRef="usd">-1522076</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjEtOS0xLTEtMA_f69a0d48-4aa7-45e2-9a3b-9eb657d3cc3e"
      unitRef="usd">-1522076</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i029a4238195344ce9ca54a046028a734_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItMS0xLTEtMA_499aeba5-a46a-40bb-82bb-f5efafb5909e"
      unitRef="shares">3015709</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i029a4238195344ce9ca54a046028a734_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItMy0xLTEtMA_a3820351-ad2f-49bf-8a42-848d0afdbf93"
      unitRef="usd">301</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4cafa03bbcbf41e9af4d14448d9db3c5_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItNS0xLTEtMA_aad5830c-101a-4132-bc25-515996adbb6b"
      unitRef="usd">8392494</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9edcc8fcaab54e3aacded026cb8d9b22_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItNy0xLTEtMA_9c46f1b8-a4aa-4ad4-b7f0-e55174ba15ca"
      unitRef="usd">-6662513</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6632a88f72bd4dce912e8beda5728be8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjItOS0xLTEtMA_c4837b57-c229-4414-8d7a-ab5f5383a180"
      unitRef="usd">1730282</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ic9c5329d026f46fa9a0a9ab94fd1106c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtMS0xLTEtMA_ef976c3b-d428-4a90-9886-ef5c7ff3d5eb"
      unitRef="shares">4511174</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic9c5329d026f46fa9a0a9ab94fd1106c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtMy0xLTEtMA_8303a891-e99b-42e3-9902-9da01ee86ee0"
      unitRef="usd">451</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i7146557875c64c948bcec77e00b091b1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTAtNS0xLTEtMTY5NQ_7ce9d0ac-8cd5-4693-b3b9-deeb13824f03"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7146557875c64c948bcec77e00b091b1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTAtNy0xLTEtMTY5NQ_a2f2e8f9-90d1-4966-936e-fbbac569cff6"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7bd590e1573a4c41a8193d12224c9c3c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtNS0xLTEtMA_11438646-d64a-4c6c-96f3-7f7b32cd916c"
      unitRef="usd">22657103</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f3e1bbf23f94c92b05cbed3fcbff616_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtNy0xLTEtMA_7fc26b52-6ccd-4929-aa8e-7b60312a279a"
      unitRef="usd">-12076700</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjYtOS0xLTEtMA_32e66f49-e242-418e-880e-687307740cb4"
      unitRef="usd">10580854</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjctMS0xLTEtMA_b899acde-b2e9-4097-a0b0-446560ae309b"
      unitRef="shares">8353480</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjctMy0xLTEtMA_1b115917-1067-4776-b635-07ed65d56355"
      unitRef="usd">835</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTEtNS0xLTEtMTY5MQ_ce528552-93a2-452c-b5ca-7fbe3cb08ca7"
      unitRef="shares">1246519</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTEtNy0xLTEtMTY5MQ_0036f470-c71e-4f78-9a6e-1708ec405a56"
      unitRef="usd">125</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5df749b27e2e4ab594097b6f0dfcbbfb_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjctNS0xLTEtMA_870aad8b-6a6b-4b27-b7bf-81e6f9bd42cd"
      unitRef="usd">9466206</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjctOS0xLTEtMA_da1b3aee-d5ef-4400-86df-fbc1c57e4c1b"
      unitRef="usd">9467166</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjgtMS0xLTEtMA_e990fe60-50ab-4476-9c1a-854e55fc1edf"
      unitRef="shares">777825</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjgtMy0xLTEtMA_9e5ffdf6-0939-42f4-97d5-e061d837b7c8"
      unitRef="usd">78</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTItNS0xLTEtMTY4Ng_24c6f4ed-5003-4895-bdee-cd1a65d0534d"
      unitRef="shares">-777825</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i14aa9812cc5b4051a87447a059bc277e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTItNy0xLTEtMTY4OA_ea15a0d2-6151-4171-96c6-e5b343394c3f"
      unitRef="usd">-78</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjgtOS0xLTEtMA_9aab2991-a45e-46c8-8a48-f097a3e26136"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4ecd63b46b854324b0c2381978c0d0c7_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjktMS0xLTEtMA_12b7f438-6f6e-4f65-8191-2436f9096c4b"
      unitRef="shares">3198</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5df749b27e2e4ab594097b6f0dfcbbfb_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjktNS0xLTEtMA_6474963a-f65e-4d43-bec4-99f8b264c3df"
      unitRef="usd">38409</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMjktOS0xLTEtMA_cd43383a-8d54-4ab0-87c8-96868f575904"
      unitRef="usd">38409</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i139ce469438446e1aa69f17a3d9c7865_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTQtMTEtMS0xLTE3MDE_5c859466-2a01-40b8-9f2e-e4b133b5f027"
      unitRef="usd">-2083816</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTQtMTMtMS0xLTE3MDE_39b584e5-05e0-41fc-b5e2-ab6c5325ec76"
      unitRef="usd">-2083816</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ie9080f05ec45443fad3554f83e2eace9_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtMS0xLTEtMA_dd7d559c-347d-4c28-972d-19156acc8aa9"
      unitRef="shares">13645677</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie9080f05ec45443fad3554f83e2eace9_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtMy0xLTEtMA_80d6a1af-f839-4346-b7a1-5d8c1d3a9fa0"
      unitRef="usd">1364</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i48fe193ad62a4945adfc9947d631230b_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTUtNS0xLTEtMTY5Mw_e65415dc-dcdd-415d-afa5-fbeb62d27b7b"
      unitRef="shares">468694</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i48fe193ad62a4945adfc9947d631230b_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMTUtNy0xLTEtMTY5Mw_212d780c-c0d1-4aff-9b80-64f376934118"
      unitRef="usd">47</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2f7e69dbdb94177a53d56e0f77d4cf3_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtNS0xLTEtMA_6907b9fc-8aa2-4aa8-ab94-4986455d7f9b"
      unitRef="usd">32161718</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifd7aaa5165cb45d2809ccf6274968968_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtNy0xLTEtMA_7ba0c387-837d-4764-b15d-fb2fc6d27d4d"
      unitRef="usd">-14160516</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8yOC9mcmFnOjA3MTAyZjg1NWM2MDQ3ZjliOTMyMGQ4MWQxM2E0M2I5L3RhYmxlOjUzYTQwYjEyMTFjNzRmZWE4ZDA3YjAwMjcxYzk3NTg3L3RhYmxlcmFuZ2U6NTNhNDBiMTIxMWM3NGZlYThkMDdiMDAyNzFjOTc1ODdfMzAtOS0xLTEtMA_93f2c932-9395-4d7b-811b-462fe7812e05"
      unitRef="usd">18002613</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNC9mcmFnOjhiNDIwMmIzYjdjNDRhOTE5ZWJhODIwZWQ2ODZlYzA5L3RleHRyZWdpb246OGI0MjAyYjNiN2M0NGE5MTllYmE4MjBlZDY4NmVjMDlfMzI5Nw_eb97b43d-d158-48d6-8097-351e060e6875">ORGANIZATION AND OPERATIONS&lt;div style="margin-bottom:1pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Nature of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Salarius Pharmaceuticals, Inc. (&#x201c;Salarius&#x201d; or the &#x201c;Company&#x201d;), together with its subsidiaries, Salarius Pharmaceuticals, LLC, Flex Innovation Group LLC, and TK Pharma, Inc., is a clinical-stage biotechnology company focused on developing effective treatments for cancers with high unmet medical need caused by dysregulated gene expression.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Epigenetics refers to the regulatory system that affects gene expression and the Company's lead epigenetic enzyme technology was licensed from the University of Utah Research Foundation in 2011. The Company is located in Houston, Texas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Merger with Flex Pharma, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:1pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January&#160;3, 2019, Flex Pharma, Inc. ("Flex Pharma"), Salarius Pharmaceuticals LLC ("Private Salarius") and Falcon Acquisition Sub, LLC (&#x201c;Merger Sub&#x201d;), a wholly owned subsidiary of Flex Pharma, entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;). Pursuant to the Merger Agreement, Merger Sub merged with and into Private Salarius, with Private Salarius continuing as a wholly owned subsidiary of Flex Pharma. The merger was completed on July 19, 2019. After the merger, Flex Pharma was renamed Salarius Pharmaceuticals, Inc. The merger was accounted for as a reverse acquisition with Private Salarius being deemed the acquiring company for accounting purposes. See Note&#160;3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Risks Related to Covid-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:1pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The outbreak of COVID-19 has spread worldwide. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company&#x2019;s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&#x2019;s ability to access capital, which could negatively impact the Company&#x2019;s long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&#x2019;s liquidity, capital resources, operations and business and those of the third parties on which we rely.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxMg_7dcd2435-e651-4d48-9572-6ba5e6557290">BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As described above, the merger with Flex Pharma closed on July 19, 2019. The merger was accounted for as a reverse acquisition with Private Salarius being deemed the acquiring company for accounting purposes. Private Salarius&#x2019; historical financial statements have replaced Flex Pharma&#x2019;s historical consolidated financial statements with respect to periods prior to the completion of the merger with retroactive adjustments to Private Salarius' legal capital to reflect the legal capital of Flex Pharma. Flex Pharma (renamed Salarius Pharmaceuticals, Inc.) remains the continuing registrant and reporting company. Accordingly, the historical financial and operating data of Salarius Pharmaceuticals, Inc., which covers periods prior to the closing date of the merger, reflects the assets, liabilities and results of operations of Private Salarius and does not reflect the assets, liabilities and results of operations of Flex Pharma for the periods prior to July 19, 2019. The Company has retrospectively adjusted its Statement of Changes in Stockholders&#x2019; Equity (Deficit) and the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding common unit, profits interest common unit and Series A Preferred unit of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Private Salarius that converted into shares of the Company&#x2019;s common stock upon the merger, and to reflect the effect of the 25 to 1 reverse stock split of the Company&#x2019;s common stock which occurred upon the merger.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December&#160;31, 2019 included elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 23, 2020. In the opinion of management, the unaudited interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company&#x2019;s financial position as of March&#160;31, 2020 and the results of operations for the three months ended March&#160;31, 2020 and 2019. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December&#160;31, 2019 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Salarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:1pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At March&#160;31, 2020 and December&#160;31, 2019, Salarius also held approximately $0 and $1.0 million, respectively, which represents funds received from Cancer Prevention and Research Institution of Texas ("CPRIT").  These funds were used for costs for allowable expenses, primarily research and development expenses. The grant has a mandatory fund matching requirement. Subject to CPRIT review, the Company believes that all matching fund requirements have been met at March&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.  During the three months ended March&#160;31, 2020 and March&#160;31, 2019 , impairment charges related to long-lived assets were $0 and $110,474, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;value of goodwill has been impaired. There was no impairment of goodwill during the three months ended March&#160;31, 2020 or March&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Financial Instruments and Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In conjunction with the reverse merger transaction, the Company issued rights to receive warrants to purchase the Company&#x2019;s common stock. Further, on February 11, 2020, the Company issued warrants to purchase the Company's common stock in a registered public offering. The Company determines whether the warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within Change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s preclinical and clinical trials are performed by third party contract research organizations (CROs) and/or clinical investigators, and clinical supplies are manufactured by contract manufacturing organizations (CMOs). Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon its assessment of the status of each clinical trial and the work completed, and upon information obtained from the CROs and CMOs. The Company&#x2019;s estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CMOs regarding the status and cost of the studies, and may not match the actual services performed by the organizations. This could result in adjustments to the Company&#x2019;s research and development expenses in future periods. To date the Company has had no significant adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Grants Receivable and Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Salarius&#x2019; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grants receivable.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company uses the Black-Scholes option valuation model and the Backsolve method (which is similar to the Black-Scholes valuation model and produces similar results) to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The number of anti-dilutive shares, consisting of common shares underlying (i) common stock options, (ii) stock purchase warrants, (iii) unvested restricted stock, (iv) convertible preferred stock and (v) rights entitling holders to receive warrants to purchase the Company's common shares, which have been excluded from the computation of diluted loss per share, was 10,597,729 and 30,395 shares as of March&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Application of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Intangibles-Goodwill and Other,&#x201d; which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;years, and interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzI_f639e0ea-90d0-4446-9b36-9ac09821dd1f">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As described above, the merger with Flex Pharma closed on July 19, 2019. The merger was accounted for as a reverse acquisition with Private Salarius being deemed the acquiring company for accounting purposes. Private Salarius&#x2019; historical financial statements have replaced Flex Pharma&#x2019;s historical consolidated financial statements with respect to periods prior to the completion of the merger with retroactive adjustments to Private Salarius' legal capital to reflect the legal capital of Flex Pharma. Flex Pharma (renamed Salarius Pharmaceuticals, Inc.) remains the continuing registrant and reporting company. Accordingly, the historical financial and operating data of Salarius Pharmaceuticals, Inc., which covers periods prior to the closing date of the merger, reflects the assets, liabilities and results of operations of Private Salarius and does not reflect the assets, liabilities and results of operations of Flex Pharma for the periods prior to July 19, 2019. The Company has retrospectively adjusted its Statement of Changes in Stockholders&#x2019; Equity (Deficit) and the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding common unit, profits interest common unit and Series A Preferred unit of &lt;/span&gt;&lt;/div&gt;Private Salarius that converted into shares of the Company&#x2019;s common stock upon the merger, and to reflect the effect of the 25 to 1 reverse stock split of the Company&#x2019;s common stock which occurred upon the merger.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i88b3e077cd5846b99d7bad5be157bb53_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTkwMw_e61f8b89-3a2d-467e-982a-ca45f7bdd7bc"
      unitRef="number">25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzc_a4384e37-c083-4f17-bbb6-1f83d9f2b824">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzA_bb74579d-4995-4bae-a6da-400dbb54b15a">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzg_b57a4236-0053-4462-8a9d-3020df247e68">Cash and Cash EquivalentsSalarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfNDY3Mg_e453c91d-b8ff-4070-ab83-1ee32f60cb25"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfNDY3OQ_f9595e16-e070-4d7a-b090-0ded0432d7c5"
      unitRef="usd">1000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMTc_2ec7ec45-b904-4478-a6c8-d72b1fd30c6c">Impairment of Long-Lived AssetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfNjM4NQ_7499deed-da94-440c-acbf-03fc6ce94dd8"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfNjM5Mg_c949065d-a9ac-41a5-bbfb-9bfecbe0007b"
      unitRef="usd">110474</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxNA_820151c1-cd3c-4084-a8eb-82013ac33f09">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying &lt;/span&gt;&lt;/div&gt;value of goodwill has been impaired.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMjc_ffcc6eeb-4dbd-457a-987d-d17d60fe74aa">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Financial Instruments and Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxNQ_ff0670e4-a698-461a-84df-7b9ce0032b99">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In conjunction with the reverse merger transaction, the Company issued rights to receive warrants to purchase the Company&#x2019;s common stock. Further, on February 11, 2020, the Company issued warrants to purchase the Company's common stock in a registered public offering. The Company determines whether the warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within Change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxNg_6b3c372c-d0f4-42d1-bc19-8ab8a14dbbf7">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Grants Receivable and Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Salarius&#x2019; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grants receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMTk_27d01ec5-4403-41e8-bbac-7485cbb81dfb">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMjA_caffe2f4-3ff0-4ed6-ad72-a73c64ba7869">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Equity-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;The Company uses the Black-Scholes option valuation model and the Backsolve method (which is similar to the Black-Scholes valuation model and produces similar results) to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMjE_310c10a7-cd03-4b06-8ab9-5b0bfb918d42">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTI3NDY_2f32a1d5-ef7d-40be-9538-39a6156ce595"
      unitRef="shares">10597729</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTI3NTM_a9523ed4-b55c-4d90-8485-118d682c131a"
      unitRef="shares">30395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxNw_0f969298-4a5e-426a-87bd-fbb0688bd29f">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTQzMzY_173d2a66-a514-4304-aee2-4ec39d9bc132">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8zNy9mcmFnOmI5OWY5YzBlMDI4ZjQ5YmFhYzNkNmNhZjhiZWQ4M2FjL3RleHRyZWdpb246Yjk5ZjljMGUwMjhmNDliYWFjM2Q2Y2FmOGJlZDgzYWNfMTA5OTUxMTY3NjUxMw_7b5770e6-11be-4159-9051-813cdd06d747">&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Application of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Intangibles-Goodwill and Other,&#x201d; which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;years, and interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfNDkwMQ_e0f8cacf-fd06-4334-b6ab-a9c058244aa1">REVERSE ACQUISITION AND DISPOSAL&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Reverse Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January&#160;3, 2019, Flex Pharma, Private Salarius and Merger Sub entered into the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into Private Salarius, with Private Salarius continuing as a wholly owned subsidiary of Flex Pharma, with Flex Pharma deemed the legal acquiror and Private Salarius deemed the accounting acquiror, as described below. The merger was completed on July&#160;19, 2019. After the merger, Flex Pharma was renamed Salarius Pharmaceuticals, Inc. The merger was accounted for as a reverse acquisition business acquisition with Private Salarius being deemed the acquiring company for accounting purposes. Private Salarius, as the accounting acquirer, recorded the assets acquired and liabilities assumed of Flex Pharma in the merger at their fair values as of the acquisition date. Private Salarius&#x2019; historical financial statements have replaced Flex Pharma&#x2019;s historical consolidated financial statements with respect to periods prior to the completion of the merger with retroactive adjustments to Private Salarius' legal capital to reflect the legal capital of Flex Pharma. Flex Pharma (which was renamed Salarius Pharmaceuticals, Inc. in connection with the merger) remains the continuing registrant and reporting company.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Private Salarius was determined to be the accounting acquirer based on the following facts and circumstances: (1)&#160;members of Private Salarius owned approximately 80.7% of the voting interests of the combined company immediately following the closing of the transaction; (2)&#160;the majority of the board of directors of the combined company was composed of directors designated by Private Salarius under the terms of the Merger Agreement; and (3)&#160;existing members of Private Salarius management became the management of the combined company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The business purposes of the merger included, among other purposes, obtaining the following potential advantages: (i) the combined organization&#x2019;s resources would be immediately available to support Private Salarius&#x2019; research on Seclidemstat; and (ii) the public company status would allow the Company greater potential access to additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At the closing of the merger, each outstanding common unit, profits interest common unit and Series A Preferred unit of Private Salarius converted into shares of the Company&#x2019;s common stock (subject to the payment of cash in lieu of fractional shares and after giving effect to a 25 to 1 reverse stock split of the Company&#x2019;s common stock) at the conversion ratio formulae described in the Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, at the closing of the merger, the Company distributed one right per share of common stock to stockholders of record as of the close of business on July 18, 2019. Each right entitles such stockholders to receive &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;a warrant to purchase shares of the Company&#x2019;s common stock six months and one day following the closing date of the merger. See Note 8.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounted for the acquisition as a reverse merger using purchase accounting. Because the merger qualifies as a reverse acquisition and given that Private Salarius was a private company at the time of the merger and therefore its value was not readily determinable, the fair value of the merger consideration was deemed to be equal to the sum of the quoted market capitalization of the Company at the merger date, the fair value of the Flex Pharma options that fully vested upon the merger together, and the fair value of the rights to receive warrants that were granted to the pre-merger Flex Pharma stockholders. Total purchase consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.595%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.405%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Flex Pharma market capitalization at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,963,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of rights to warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,629,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of Flex Pharma outstanding options on the merger date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,724,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recorded all tangible and intangible assets acquired and liabilities assumed at their preliminary estimated fair values on the merger date. The following represents the allocation of the estimated purchase consideration:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,405,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,937,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,587,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable, accrued liabilities and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,862,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,862,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,724,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Unaudited Pro Forma Disclosure&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following unaudited pro forma financial information summarizes the results of operations for the three months ended March&#160;31, 2020 and 2019 as if the merger described above had been completed as of January 1, 2019. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the merger had been completed as of January 1, 2019, the transaction costs would have been expensed in the prior period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.423%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,132,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;655,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,083,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,415,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfMTQyNw_df526ce9-1b18-4c96-842a-5c7c9da63b33"
      unitRef="number">0.807</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i88b3e077cd5846b99d7bad5be157bb53_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfMjQzMQ_200b873c-e26f-4440-bda0-00913de016b2"
      unitRef="number">25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="if8e9ef7d321148bfa7e0fc99f44856d7_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfMjYyNg_1ea8ea08-4ac9-469a-ab76-bd98e4f05e65"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <flks:ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable
      contextRef="i9335e01552494ea4aeab4ed31281b503_D20190719-20190719"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfMjg0MQ_00e707e5-140d-4654-8ac1-e6ae9eb5df2a">P6M</flks:ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfNDkwMg_7e376e58-6324-46f7-abdb-eab3cb32ca4c">Total purchase consideration is as follows:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.595%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:34.405%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Flex Pharma market capitalization at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,963,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of rights to warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,629,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of Flex Pharma outstanding options on the merger date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,724,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmVlYjJhN2U3Y2MxNDRlZTlhYTgwYjY5Y2I4OGZkOGE4L3RhYmxlcmFuZ2U6ZWViMmE3ZTdjYzE0NGVlOWFhODBiNjljYjg4ZmQ4YThfMC0xLTEtMS0w_18f99bf6-eaa5-4751-ae2c-52fee10fd198"
      unitRef="usd">10963526</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <flks:BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants
      contextRef="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmVlYjJhN2U3Y2MxNDRlZTlhYTgwYjY5Y2I4OGZkOGE4L3RhYmxlcmFuZ2U6ZWViMmE3ZTdjYzE0NGVlOWFhODBiNjljYjg4ZmQ4YThfMS0xLTEtMS0w_607cb662-22c8-45f4-a55e-eeda2123d947"
      unitRef="usd">1629095</flks:BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants>
    <flks:BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions
      contextRef="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmVlYjJhN2U3Y2MxNDRlZTlhYTgwYjY5Y2I4OGZkOGE4L3RhYmxlcmFuZ2U6ZWViMmE3ZTdjYzE0NGVlOWFhODBiNjljYjg4ZmQ4YThfMi0xLTEtMS0w_93436273-8869-48c0-8264-9706980aa905"
      unitRef="usd">132227</flks:BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmVlYjJhN2U3Y2MxNDRlZTlhYTgwYjY5Y2I4OGZkOGE4L3RhYmxlcmFuZ2U6ZWViMmE3ZTdjYzE0NGVlOWFhODBiNjljYjg4ZmQ4YThfMy0xLTEtMS0w_501728b9-3a9d-434c-abab-27385f5b2be4"
      unitRef="usd">12724848</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfNDkwMw_095fd89f-08b6-4663-be54-264da26eaad0">The following represents the allocation of the estimated purchase consideration:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:60.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:35.059%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,405,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;122,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid expense and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;106,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,937,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,587,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accounts payable, accrued liabilities and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,862,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,862,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,724,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMS0xLTEtMS0w_543dc472-dc96-4f42-bc7c-d5bff49d1397"
      unitRef="usd">5405826</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMi0xLTEtMS0w_bb00562c-6b51-49b4-b48c-129f95e958ae"
      unitRef="usd">15168</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMy0xLTEtMS0w_f92cf9fb-bc74-4041-a6fe-7ff9273f13ae"
      unitRef="usd">122235</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfNC0xLTEtMS0w_cfaffd20-7e11-4df1-aebb-11e78642b001"
      unitRef="usd">106319</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <flks:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfNS0xLTEtMS0w_5d1d3c63-af3f-4c90-bdd7-18f9120dc69b"
      unitRef="usd">8937899</flks:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfNi0xLTEtMS0w_183d40b6-c84d-4dfb-91cb-58281766066a"
      unitRef="usd">14587447</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfOS0xLTEtMS0w_2c8eaf5e-6b2f-4788-9f55-62b5ba64c1b2"
      unitRef="usd">1862599</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMTAtMS0xLTEtMA_fc4aa921-ce95-4b3a-939f-8fb92d9f2f8a"
      unitRef="usd">1862599</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i291b51edb08c4a50ba7e783e980e810b_I20190719"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOmJhMDEzZDJhMTc4YjRjODhiMTFiNWI0MWFjYmE2OWNmL3RhYmxlcmFuZ2U6YmEwMTNkMmExNzhiNGM4OGIxMWI1YjQxYWNiYTY5Y2ZfMTItMS0xLTEtMA_14d17b41-db76-4954-8226-33f1b76e94d0"
      unitRef="usd">12724848</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RleHRyZWdpb246MDZkNGZhMjMyODg3NDkxZWFkOWRlOWI2ODhkMzQyNDZfNDg5OQ_a9fb34b5-e7c8-477e-8b18-9e7f7bb2423d">&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following unaudited pro forma financial information summarizes the results of operations for the three months ended March&#160;31, 2020 and 2019 as if the merger described above had been completed as of January 1, 2019. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the merger had been completed as of January 1, 2019, the transaction costs would have been expensed in the prior period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.423%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,132,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;655,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,083,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(9,415,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3.97)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMS0xLTEtMS0w_8494ee3c-0209-401e-99d2-63542f26477b"
      unitRef="usd">1132830</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMS0zLTEtMS0w_6b5797d8-96ce-4c9d-b2d9-bcc4ad7df68d"
      unitRef="usd">655635</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMi0xLTEtMS0w_c5cccc6c-9ec0-4de5-b48b-dcd90663b983"
      unitRef="usd">-2083816</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMi0zLTEtMS0w_486cba67-24d7-4df3-9e92-ea86f7659bc4"
      unitRef="usd">-9415074</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMy0xLTEtMS0w_bedcf97b-9721-42e9-ac3e-b8e2472c952a"
      unitRef="usdPerShare">-0.22</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80MC9mcmFnOjA2ZDRmYTIzMjg4NzQ5MWVhZDlkZTliNjg4ZDM0MjQ2L3RhYmxlOjUzNDI0NmE5ZjEzYTRlZWU4ODMxNzk4ZGM1NjY3OTg2L3RhYmxlcmFuZ2U6NTM0MjQ2YTlmMTNhNGVlZTg4MzE3OThkYzU2Njc5ODZfMy0zLTEtMS0w_7b9cde3a-23bd-4803-8a42-c4434a541dc7"
      unitRef="usdPerShare">-3.97</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMTE1L2ZyYWc6YTljZGFkYWJkZmNiNDJhMzg1ZmFmYjhiNmM2NWFmZDUvdGV4dHJlZ2lvbjphOWNkYWRhYmRmY2I0MmEzODVmYWZiOGI2YzY1YWZkNV8xMDk5NTExNjI4MTE0_e8d66aaa-1c88-41d7-a487-2783f3b39f0b">GRANTS RECEIVABLEGrants receivable represents qualifying costs incurred and there is reasonable assurance that conditions of the grant have been met but the corresponding funds have not been received as of the reporting date. Grants receivable balances are $591,129 and $0 as of March 31, 2020 and December 31, 2019, respectively.</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMTE1L2ZyYWc6YTljZGFkYWJkZmNiNDJhMzg1ZmFmYjhiNmM2NWFmZDUvdGV4dHJlZ2lvbjphOWNkYWRhYmRmY2I0MmEzODVmYWZiOGI2YzY1YWZkNV8yMTk5MDIzMjU1ODIz_c1d40bb7-1ed7-43e3-bde5-3f0dc4c5496e"
      unitRef="usd">591129</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMTE1L2ZyYWc6YTljZGFkYWJkZmNiNDJhMzg1ZmFmYjhiNmM2NWFmZDUvdGV4dHJlZ2lvbjphOWNkYWRhYmRmY2I0MmEzODVmYWZiOGI2YzY1YWZkNV8yMTk5MDIzMjU1ODMw_9782c75c-0539-4c0f-b408-f5b1f630273e"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMTA5OTUxMTYyOTI0Mw_6a8ffbf4-3c6c-45f1-86a8-d89e1c3be19d">PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets at March&#160;31, 2020 and December&#160;31, 2019 consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.423%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;202,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;617,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other prepaid and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;144,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;646,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;955,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Prepaid insurance is comprised of prepaid directors' and officers' insurance. In July 2019, the Company financed their directors' and officers' insurance premium with a short term note, the principal amount of which is approximately $0.9 million bearing interest at a rate of 4.61%. The note payable balances were $252,679 and $502,332, which were included within Current Liabilities on the Condensed Consolidated Balance Sheets at March&#160;31, 2020 and December&#160;31, 2019, respectively.</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMTQ2_3238adc9-4c30-4784-a3bb-1b6b36ee366b">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Prepaid expenses and other current assets at March&#160;31, 2020 and December&#160;31, 2019 consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.422%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.423%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;140,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;202,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;360,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;617,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other prepaid and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;144,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;136,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;646,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;955,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <flks:PrepaidClinicalTrialExpense
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfMS0xLTEtMS0w_22e5ffd8-d75a-407a-8cc8-a327c219888c"
      unitRef="usd">140964</flks:PrepaidClinicalTrialExpense>
    <flks:PrepaidClinicalTrialExpense
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfMS0zLTEtMS0w_db3a2777-5af6-4f3b-93d4-125917e07a45"
      unitRef="usd">202743</flks:PrepaidClinicalTrialExpense>
    <us-gaap:PrepaidInsurance
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfMi0xLTEtMS0w_8d235a3d-ab0a-4010-bf31-e9856615806c"
      unitRef="usd">360608</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfMi0zLTEtMS0w_afea2e52-94f8-4248-8742-3240cf1f2204"
      unitRef="usd">617096</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfNC0xLTEtMS0w_47e10e1c-cb0d-488b-9d8b-19ae28bb2fa9"
      unitRef="usd">144788</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfNC0zLTEtMS0w_30004eb2-3a54-458c-8765-63d6f090c0e2"
      unitRef="usd">136060</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfNS0xLTEtMS0w_1b605ee9-e92b-4d63-be51-ecc123f05cd7"
      unitRef="usd">646360</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RhYmxlOjE0YWJjMWY4YWQ3MDRhOTdhZTM0NTU2Y2MxMzY3MDI5L3RhYmxlcmFuZ2U6MTRhYmMxZjhhZDcwNGE5N2FlMzQ1NTZjYzEzNjcwMjlfNS0zLTEtMS0w_3dd07658-3be0-4c44-9093-c21012846cc8"
      unitRef="usd">955899</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3c3c4f1bd73a41ab8a2603386c7cd387_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMTA5OTUxMTYyOTI1OQ_b78ed048-eba7-4991-913f-ddd6fc2d45f0"
      unitRef="usd">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3c3c4f1bd73a41ab8a2603386c7cd387_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMTA5OTUxMTYyOTI2Nw_3a1538e0-8a3e-4669-bf60-f12d832c5952"
      unitRef="number">0.0461</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMjc0ODc3OTA3MDYzOA_195788b1-dbb5-4e4c-9703-824a6b32577b"
      unitRef="usd">252679</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80My9mcmFnOjg4YzAyOTQwYmEyNzQ4ZWNiMmUyZjQyNTRlOWQ2OTY5L3RleHRyZWdpb246ODhjMDI5NDBiYTI3NDhlY2IyZTJmNDI1NGU5ZDY5NjlfMjc0ODc3OTA3MDY1OQ_ff356518-ad92-411c-abde-0531442a182c"
      unitRef="usd">502332</us-gaap:NotesPayableCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjk5Mw_f0319540-d1a0-418d-9db5-5ca6a76bd06b">COMMITMENTS AND CONTINGENCIES&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;License Agreement with the University of Utah Research Foundation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In 2011, the Company entered into a license agreement with the University of Utah, under which, the Company acquired an exclusive license to and epigenetic enzyme lysine specific demethylase 1 ("LSD 1"). In exchange for the license, the Company issued 2% equity ownership in the Company based on a fully diluted basis at the effective date of the agreement and subject to certain adjustments specified in the agreement, granted revenue sharing rights on any resulting products or processes to commence on first commercial sale, and milestone payments based upon regulatory approval of any resulting product or process as well as on the second anniversary of first commercial sale.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Cancer Prevention and Research Institute of Texas&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Company entered into a Cancer Research Grant Contract with CPRIT. Pursuant to the contract, CPRIT awarded the Company a grant of up to $18.7 million to fund the development of LSD-1 inhibitor. This is a 3-year grant award which originally expired on May 31, 2019. However, a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgwMA_62016ce1-9c77-440a-be57-b02c9bb2a0fd"&gt;six&lt;/span&gt;-month extension was approved by CPRIT in May 2019 and an additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgxNQ_f84e63ce-cd9b-41a2-9e9b-5f34bd9cd7fe"&gt;six&lt;/span&gt;-month extension through May 2020. The Company has applied for an extension with a proposed contract end date of November 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract, up to a maximum repayment of certain percentage of the aggregate amount paid to the Company by CPRIT under the CPRIT contract. The payments are determined as a percentage of net sales, which may be reduced if the Company is required to obtain a license from a third party to sell any such product. In addition, upon meeting the foregoing limitation on revenue-sharing payments, the Company agreed to make continued revenue-sharing payments to CPRIT of less than 1% of net sales.&lt;/span&gt;&lt;/div&gt;The CPRIT grant is subject to funding conditions including a matching funds requirement where the Company will match 50% of funding from the CPRIT grant. As of March&#160;31, 2020, the Company has received an aggregate of $9.6 million from the CPRIT grant and there was $9.1 million of funds available for the Company to draw upon meeting certain requirements. There was no funding received from CPRIT during the three months ended March&#160;31, 2020. At March&#160;31, 2020 and December&#160;31, 2019, the Company had deferred revenue of $0 and $541,701, respectively, related to the CPRIT contract. At March&#160;31, 2020 and December&#160;31, 2019, the Company had grants receivable of $591,129 and $0, respectively, related to the CPRIT contract.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i93571fc75180447ba55229d7f09f1868_I20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjk0_e6440e8d-b539-4fe6-993c-b957f2b24140"
      unitRef="number">0.02</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <flks:RevenueFromGrantsMaximumAward
      contextRef="ic1d35ab3929b4fbe91e95df48a459f8e_D20160601-20160630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfOTI1_5c307293-a94f-4641-8255-82473a99e53b"
      unitRef="usd">18700000</flks:RevenueFromGrantsMaximumAward>
    <flks:RevenueFromGrantsAwardTerm
      contextRef="ic1d35ab3929b4fbe91e95df48a459f8e_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfOTc4_4c29b3d6-6a75-4585-bc91-d354b09ad612">P3Y</flks:RevenueFromGrantsAwardTerm>
    <flks:RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjM1OQ_1d1b9fbe-2de7-4b5f-bb8e-43b6882b8385"
      unitRef="number">0.01</flks:RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales>
    <flks:RevenueFromGrantsMatchingFundsRequirement
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjQ5NA_21dc9e0f-f0fc-4a77-b47d-f9ffd48f88f8"
      unitRef="number">0.50</flks:RevenueFromGrantsMatchingFundsRequirement>
    <flks:RevenueFromGrantsAggregateAmountReceived
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjU4MQ_02386baa-eb03-4052-bf8c-498c475084dd"
      unitRef="usd">9600000</flks:RevenueFromGrantsAggregateAmountReceived>
    <flks:RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjYxOQ_78cb199b-ddfc-467c-af8c-abcf1993c852"
      unitRef="usd">9100000</flks:RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable>
    <flks:RevenueFromGrantsCurrentFundingReceived
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjcxMA_ed1d7d16-9e10-4b2b-aa9f-048a1e7f81b7"
      unitRef="usd">0</flks:RevenueFromGrantsCurrentFundingReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjgyMg_5779557e-8829-44cb-bc1c-64ca5aeab764"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjgyOQ_8d345c4e-7236-4b48-a05d-1317f44c8aa0"
      unitRef="usd">541701</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjE5OTAyMzI2MDE0OQ_c1d40bb7-1ed7-43e3-bde5-3f0dc4c5496e"
      unitRef="usd">591129</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMjE5OTAyMzI2MDE1Mw_9782c75c-0539-4c0f-b408-f5b1f630273e"
      unitRef="usd">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGV4dHJlZ2lvbjpmOWJmMWY3NzYxZTA0YjIwYjJiYmQxNTYyZGY1NGFlM18xMDk5NTExNjI5NDE1_261c161e-2abc-4cb7-876c-f3f3713c5d9b">FAIR VALUE OF FINANCIAL INSTRUMENTS &lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-40.5pt;padding-left:76.5pt;text-align:justify;margin-bottom:3pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 - Significant unobservable inputs including Salarius&#x2019; own assumptions in determining fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrant associated with the Flex Pharma merger measured at fair value on a recurring basis for the three months ended March&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.532%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.080%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.450%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;317,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;283,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGV4dHJlZ2lvbjpmOWJmMWY3NzYxZTA0YjIwYjJiYmQxNTYyZGY1NGFlM18xMDk5NTExNjI5NDE2_02833243-d6d1-4272-970f-603c20eff849">&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrant associated with the Flex Pharma merger measured at fair value on a recurring basis for the three months ended March&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.532%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:23.000%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.080%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.535%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:22.450%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;317,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;283,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i72557c4fa44d4ba5b0d57686b7176435_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGFibGU6MTM5YWVkNWJjNWEwNDg0OWJjMzBjN2Q0ZjE2NGE2ZDkvdGFibGVyYW5nZToxMzlhZWQ1YmM1YTA0ODQ5YmMzMGM3ZDRmMTY0YTZkOV8xLTEtMS0xLTMxNTk_93347a45-8df1-47c8-82e0-e0c0155cb8cf"
      unitRef="usd">317762</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ib355700b35e94a5ba6f3b2d4a9975b06_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGFibGU6MTM5YWVkNWJjNWEwNDg0OWJjMzBjN2Q0ZjE2NGE2ZDkvdGFibGVyYW5nZToxMzlhZWQ1YmM1YTA0ODQ5YmMzMGM3ZDRmMTY0YTZkOV8xLTMtMS0xLTMxNTk_fd9a0294-5546-4bcf-9365-a7b52ccfab38"
      unitRef="usd">-283070</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i401548a97a504666ac77f37acd7d7032_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF8xMDkwL2ZyYWc6ZjliZjFmNzc2MWUwNGIyMGIyYmJkMTU2MmRmNTRhZTMvdGFibGU6MTM5YWVkNWJjNWEwNDg0OWJjMzBjN2Q0ZjE2NGE2ZDkvdGFibGVyYW5nZToxMzlhZWQ1YmM1YTA0ODQ5YmMzMGM3ZDRmMTY0YTZkOV8xLTUtMS0xLTMxNTk_148a4a6a-a2b3-462a-96ef-297e332a9e34"
      unitRef="usd">34692</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzk1OQ_66ea41c0-c9b8-4f32-abb4-03bfa9328b02">STOCKHOLDERS' EQUITY&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated statements of stockholders' equity (deficit) and the footnotes to the interim financial statements have been retroactively adjusted to reflect the equity structure (that is, the number and type of equity interests issued) of Flex Pharma, the legal parent (accounting acquiree) of the merger closed on July 19, 2019, with the retained earnings and other equity balances of the Private Salarius before the merger. Private Salarius' equity was restated using the exchange ratio established in the merger agreement to reflect the number of shares of Flex Pharma issued in the merger. Concurrent with the merger, the Company's shareholders approved a 1-for-25 reverse stock split, which became effective on July 19, 2019. Total shares owned by Flex Pharma pre-merger shareholders (net of fraction shares paid in cash) was 8,353,480 shares after reverse stock-split. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Common Stock and Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:1pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;On February 11, 2020, the Company completed a public offering with total gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase an additional 1,252,173 shares and warrants prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius. The offering is comprised of 7,101,307 Class A units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of common stock and a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUxNA_5df20bb8-eba1-4ed3-bcaa-a88042c57c15"&gt;five&lt;/span&gt;-year warrant to purchase one share of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:1pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;common stock at an exercise price of $1.15 per share, and 1,246,519 Class B units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of Series A convertible preferred stock and a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ3MA_5232e6f4-81eb-413b-ad84-cc43a3411329"&gt;five&lt;/span&gt;-year warrant to purchase one share of common stock with and exercise price of $1.15 per share. A total of 8,343,480 shares of common stock, 1,246,519 shares of Series A convertible preferred stock, and warrants to purchase up to 9,599,999 shares of common stock were issued in the offering, including the full exercise of the over-allotment option. The convertible preferred stock issued in this transaction includes a beneficial ownership limitation on conversion, but has no dividend rights (except to the extent that dividends are also paid on the common stock). The conversion price of the Series A convertible preferred stock in the offering as well as the exercise price of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In February 2020, 777,825 shares of Series A convertible preferred stock were converted to common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March&#160;31, 2019 the Company issued 960,489 common shares (4,035 Series A preferred units and 350 profit interest units of Private Salarius) for $4,377,591 (net of offering cost of $10,617).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2018, the Company agreed to issue an unrelated party 12,907 common shares (91 common units of Private Salarius) to acquire licenses for the DNMT1 inhibitor. The issuance was approved in January 2019 and the license was granted in 2018. . &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Right to Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Pursuant to the Merger Agreement (See Note 3), Flex Pharma distributed one right per share of common stock to stockholders of record as of the close of business on July 18, 2019. Each right entitles such stockholders to receive a warrant to purchase the Company's common shares on January 20, 2020. These warrants are exercisable, in the aggregate, into 142,711 shares of the Company's common stock with a 5-year term from January 20, 2020, and an exercise price of $15.17 per share. The warrants are subject to a cashless exercise, at the option of the Company, at the closing of an issuance and sale of the Company&#x2019;s common stock in certain qualified financing, upon the closing of which the holders of warrants shall be entitled to receive a number of shares of common stock equal to the greater of two formulae defined by the Merger Agreement, which are based on the volume weighted average price of the Company's common stock during the 10 consecutive trading days ending on the trading day immediately preceding the date of exercise. As a result, the warrants have been classified as a liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounted for these warrants at fair value using Level 3 inputs. The Company determined the fair value of this warrant liability using a Black-Scholes valuation model as the Company believes the value will closely approximate the value from the binomial asset pricing model that consisted of a conditional probability weighted expected return method that values the Company&#x2019;s equity securities assuming various possible future outcomes to estimate the allocation of value within one or more of the scenarios. Using this method, unobservable inputs included the Company&#x2019;s equity value, expected timing of possible outcomes, risk free interest rates and stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;price volatility. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Variables used in the Black-Scholes model are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:75.146%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.163%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.161%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.459%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.356%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.461%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.37%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.69%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.81 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.06 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113.17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103.07%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Wedbush Warrant&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 19, 2019, upon the closing of the merger, the Company elected to issue warrants to purchase 42,928 common shares to Wedbush Securities Inc. ("Wedbush") to satisfy $500,000 of the $1,000,000 success fee payable to Wedbush at the closing of the merger. The remaining $500,000 success fee was paid in cash. These warrants have an exercise price of $18.90 and a 5-year term. As of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;March&#160;31, 2020, all warrants issued to Wedbush were outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ib502bdc134494b80b87687b9029ffcca_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfNzA0_95f2c709-2577-4591-ad73-8b032ccab047"
      unitRef="number">25</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id08675e640c04365826f8bb18dab3ceb_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfODY5_5ed9baa6-3149-4647-9b8b-14e9561921df"
      unitRef="shares">8353480</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ide7180e8b2684c66b43dcb58cf485a4e_D20200211-20200211"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjM5NQ_e0682367-e4bf-47f5-978e-5e0017d30c97"
      unitRef="usd">11000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ide7180e8b2684c66b43dcb58cf485a4e_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ0MQ_5e358f69-a973-44a0-8b5b-d21f4b1d62d1"
      unitRef="shares">1252173</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8481df852a634528bdf8f167d58d97c5_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQxMA_a628f1f1-4c28-4049-904e-2399ae31f96b"
      unitRef="shares">7101307</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iaed98830a5f34cfda77f4a37fb71e8c4_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUwMA_c44352c1-bd83-42f1-89f4-331b03bea3d0"
      unitRef="usdPerShare">1.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUzNg_5d1cec89-58cd-4215-bc90-60e84e022298"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUyMQ_5a47bacc-6e41-4ddd-a523-849472e6a0a2"
      unitRef="usdPerShare">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8ec9f9e3c871475686ca302cf142454a_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ1Mg_d5af0b55-8082-4bc9-a6cc-a66c35718145"
      unitRef="shares">1246519</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ibea4f4bd11db4c879d27ce92ac6637d8_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ3OA_172be438-69e9-4d15-8a20-3dec8761daa2"
      unitRef="usdPerShare">1.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjU1MQ_eb6675cb-7c92-40c3-a25e-dd68266f237c"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ic6c7b8afaca84481a88ecafbf639cfbe_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ5Mg_b5390ad3-7271-4f3c-8618-22d5940f5470"
      unitRef="usdPerShare">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib4d806ab35a84b6ba717db59bba7315a_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjgxMw_423a26ff-7d62-41a0-a1d9-59862d64171c"
      unitRef="shares">8343480</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i82641346e1074588aae8bc99288365f9_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjgyNA_2fddfb90-530c-4e12-8d8a-db2278cd3039"
      unitRef="shares">1246519</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="iac9b8222fe3849c3a6894033394a49ec_I20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjgzNQ_0924faa2-ff36-4287-a76e-02095f26f5d2"
      unitRef="shares">9599999</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib1026e50b8014604b81db07f3826adb3_D20200211-20200211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUzMQ_ef7fe020-d884-4e1f-ae70-bf0526088b53"
      unitRef="shares">777825</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i549691aaaf6444ffb9149c55b9804d03_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfOTcy_a53fcc85-dc4f-4879-9d81-d6f28d8afc35"
      unitRef="shares">960489</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7f20b1ecfb964b37a76c0654fff02596_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfOTkw_357b0543-4002-4538-acc7-bd9b66de28a3"
      unitRef="shares">4035</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3b8ac8f09be5476299897cdf23a7a0c4_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTAyMg_74381f9f-b063-4d3f-ba37-054f019e2a8d"
      unitRef="shares">350</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA3Mg_f545bd69-f939-4031-a968-7ed63afe7abb"
      unitRef="usd">4377591</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia79974a3a9b44f219d2fc0d3952ebdd2_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTEwMA_19e4fe2a-5963-4724-a076-33b0413c7c4a"
      unitRef="usd">10617</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ibaf829e8bf7e456b9116404177f196c9_D20181201-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTM1Mw_8ffb5637-725a-444d-919e-48a408ec2849"
      unitRef="shares">12907</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="if9d5f52e15574141abe8b47621abead0_D20181201-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTM3MQ_cf0aad6f-e560-4e36-a802-d59156cd6902"
      unitRef="shares">91</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="if8e9ef7d321148bfa7e0fc99f44856d7_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTc1Nw_1ea8ea08-4ac9-469a-ab76-bd98e4f05e65"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i3eeda48ea55c43c3921c1333146fc953_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMjAzOQ_e8a546c4-21bf-449b-b3ee-5690cd513ac4"
      unitRef="shares">142711</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="id75dc2c494874c2590b7a7652f91ebca_I20190120"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMjA4Ng_250807c2-ea3d-4b98-827b-7900e004b5ce">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3eeda48ea55c43c3921c1333146fc953_I20190719"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMjE0Nw_650a5976-f7e6-49f1-84b5-94efcfc6b495"
      unitRef="usdPerShare">15.17</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <flks:ClassOfWarrantOrRightThresholdConsecutiveTradingDays
      contextRef="i9335e01552494ea4aeab4ed31281b503_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMjYxOQ_8d1c5470-a95f-4b03-8a21-fa5c192817a4"
      unitRef="trading_days">10</flks:ClassOfWarrantOrRightThresholdConsecutiveTradingDays>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzk2NA_4a0ecf34-da9a-421b-9e0f-f487feaafab2">&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Variables used in the Black-Scholes model are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:75.146%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:42.163%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.161%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.459%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.356%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:24.461%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.37%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.69%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.81 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.06 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113.17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103.07%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="i923938e66ee44ac4a3049da0fb812f9f_I20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMS0yLTEtMS0w_8b4a358f-bb0b-421e-90e2-ef51a8851439"
      unitRef="number">0.0037</flks:WarrantsOutstandingMeasurementInput>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="if3d35d901c984cd9a8b3c067ed4795b3_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMS00LTEtMS0w_9a8ad301-68cd-435e-92b5-16bd16fcd927"
      unitRef="number">0.0169</flks:WarrantsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMi0yLTEtMS0w_c733e389-d48d-4bc2-a012-88ff23412b70">P4Y9M21D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMi00LTEtMS0w_2ad205af-4523-4d8b-a33f-5cdc82a7a2d2">P5Y21D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="i18d0ed03a53041689adae6878926fead_I20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMy0yLTEtMS0w_da773777-87a1-40a5-acc9-3de611d6ed3b"
      unitRef="number">1.1317</flks:WarrantsOutstandingMeasurementInput>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="if5c08f3842d84b48b2fd04af17a3bc44_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfMy00LTEtMS0w_608137b0-f307-494b-b489-9c35b71c366d"
      unitRef="number">1.0307</flks:WarrantsOutstandingMeasurementInput>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="i6bbed367577c464aa83ed65a64104166_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfNC0yLTEtMS0w_4cf0c7a4-fcf0-463f-8e0e-cf637db2fc3c"
      unitRef="number">0</flks:WarrantsOutstandingMeasurementInput>
    <flks:WarrantsOutstandingMeasurementInput
      contextRef="i2e818517cf6e4951b3588a8d6e0e57a8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RhYmxlOmE3YjFmNWJjYTMyMTQ0YWVhZDViODJkNGIzYjc5ZDdiL3RhYmxlcmFuZ2U6YTdiMWY1YmNhMzIxNDRhZWFkNWI4MmQ0YjNiNzlkN2JfNC00LTEtMS0w_3386ca6f-1ebf-4b4f-99a2-7fc83991e79c"
      unitRef="number">0</flks:WarrantsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzY1MA_5fc59672-c147-411e-9992-9d0a114d978b"
      unitRef="shares">42928</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzcxNw_c69aa001-086c-4f2f-b0cd-1ed1e2828cbf"
      unitRef="usd">500000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzcyNw_0983cee3-f07f-4655-ae01-adc943c12bd0"
      unitRef="usd">1000000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="i2defc6da5b484ddc838a55ab137797ca_D20190719-20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzgwNQ_1d409471-89f7-48ce-b74a-d2c883a423e3"
      unitRef="usd">500000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzg3OQ_4982e9f9-a262-4477-89a8-881fc51bfc23"
      unitRef="usdPerShare">18.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i71357db1c2cb48d4a167d650fea320cc_I20190719"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMzg4OA_6c3f0d04-f749-4769-8cc3-c0a4b966cec7">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMjg2MA_a381cb55-97ce-4216-907e-04b69fef14a6">EQUITY-BASED COMPENSATION &lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has granted options to employees, directors, and consultants under the 2015 Equity Incentive Plan (the "2015 Plan"). On July 19, 2019, the Company completed a merger with Flex Pharma and Flex Pharma had fully vested options to purchase 90,279 common shares outstanding as of the date of the merger that continue to be exercisable.  The 2015 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options, restricted stock awards, restricted stock units, stock appreciation rights, performance-based stock awards and other stock-based awards. Additionally, the 2015 Plan provides for the grant of performance-based cash awards. ISOs may be granted only to the Company's employees. All other awards may be granted to the Company's employees, including officers, and to non-employee directors and consultants. As of March&#160;31, 2020, there were 34,087 shares remaining available for the grant of stock awards under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On March 23, 2020, the Company awarded 182,000 stock options to its employees and directors, pursuant to the plan described above. Stock options generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTk0Mg_3e677467-eb4d-4c5e-916f-d6b12ec0b478"&gt;one&lt;/span&gt; to four years and have a contractual term of ten years. Stock options are valued using the Black-Scholes option pricing model and compensation cost is recognized based on the resulting value over the service period. Expected volatilities utilized in the model are based on implied volatilities from traded stocks of peer companies. Similarly, the dividend yield is based on historical experience and the estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected term of the options is based on the average period the stock options are expected to remain outstanding. The fair value of the option grants of $92,007 has been estimated with the following assumptions for the three months ended March&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.701%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:30.427%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.847%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (years)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.901%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.965%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.965%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.965%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.969%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, there was approximately $489,641 of total unrecognized compensation cost related to unvested stock options. Total unrecognized compensation cost will be adjusted for future changes in employee and non-employee forfeitures, if any. The Company expects to recognize that cost over a remaining weighted-average period of 3.27 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3eeda48ea55c43c3921c1333146fc953_I20190719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTA5OTUxMTYzNTY0Mg_752f2a49-5f37-4479-ac5f-1440bf825ed9"
      unitRef="shares">90279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i8ee10a83c58c467499b54edfb3d4578c_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTcwNg_6dcc9188-0d23-409d-a50b-255a30013382"
      unitRef="shares">34087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0229b2e923e041fe8797ef1f87ddd7eb_D20190910-20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMzg0ODI5MDcwMDk4Mg_478b60a7-0c14-4d25-8e80-8500c7d5a3cc"
      unitRef="shares">182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i63ca0eae144c4e4a86b4c93b3bcd23ed_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTk0OA_9ddc7c05-294c-4c6e-9038-dc07ba2d4918">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ifc382e1599924272a66a5f62e9b3fb2e_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTk4Mg_1f0cd44f-d24b-425b-8326-9ec6c7352302">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTA5OTUxMTYzNTYyNQ_9d9157f3-d652-435c-b360-a58204948f57">The fair value of the option grants of $92,007 has been estimated with the following assumptions for the three months ended March&#160;31, 2020:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.701%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:30.427%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:64.847%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.526%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Volatility&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;113.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected life (years)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected dividend yield&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMTA5OTUxMTYzNTYyNw_3d8dae91-1078-4ba8-bf85-8da2907773de"
      unitRef="usd">92007</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOjAyMTlmZWU0OWU0NTQ0NjBiNzYzZTM0N2JkYzdkNTFmL3RhYmxlcmFuZ2U6MDIxOWZlZTQ5ZTQ1NDQ2MGI3NjNlMzQ3YmRjN2Q1MWZfMC0xLTEtMS0xODc3_9cd6180f-13df-4498-8ce9-f608a15377ad"
      unitRef="number">0.0048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOjAyMTlmZWU0OWU0NTQ0NjBiNzYzZTM0N2JkYzdkNTFmL3RhYmxlcmFuZ2U6MDIxOWZlZTQ5ZTQ1NDQ2MGI3NjNlMzQ3YmRjN2Q1MWZfMS0xLTEtMS0xODc3_76a74d95-bc93-4ad7-a779-7f322c8ad3e5"
      unitRef="number">1.1317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOjAyMTlmZWU0OWU0NTQ0NjBiNzYzZTM0N2JkYzdkNTFmL3RhYmxlcmFuZ2U6MDIxOWZlZTQ5ZTQ1NDQ2MGI3NjNlMzQ3YmRjN2Q1MWZfMi0xLTEtMS0xODc3_ca52400c-db8c-4cae-b67b-5f978c13618d">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOjAyMTlmZWU0OWU0NTQ0NjBiNzYzZTM0N2JkYzdkNTFmL3RhYmxlcmFuZ2U6MDIxOWZlZTQ5ZTQ1NDQ2MGI3NjNlMzQ3YmRjN2Q1MWZfMy0xLTEtMS0xODc3_e049acef-d462-4c27-875c-91829ada8f28"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMjg3MQ_ef1a4bc8-5584-4124-b4ca-d6fe3c735e4f">&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:43.901%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.965%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.965%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.965%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.545%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.969%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;84,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;59.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMS0xLTEtMS0w_5040eb58-5e7d-4ec2-abdc-f0affdc729f6"
      unitRef="shares">166233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMS0zLTEtMS0w_401c1c18-5f2a-45d8-9c97-e70c3166e382"
      unitRef="usdPerShare">34.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib0e99be21eb64f78a76597b9daad23be_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMS01LTEtMS0w_9709e140-0a8a-4d7e-976c-f0a1fd6c4055">P6Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i316105bb8a4240588ac05a8d48949e71_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMS03LTEtMS0w_05ae42c7-e2fc-42cf-9210-417687914af6"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMi0xLTEtMS0w_4ee46765-54ca-4a8a-b430-8b2241d90091"
      unitRef="shares">182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfMi0zLTEtMS0w_8f9d329d-3cbe-4072-a1e3-5ddaa75a0c17"
      unitRef="usdPerShare">0.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNS0xLTEtMS0w_91793b0a-201f-47c3-86dd-76f0cadd657b"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNS0zLTEtMS0w_8108323b-e752-4fcd-9185-a43d7d586f01"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNy0xLTEtMS0w_1f1c1324-3f51-4aab-b35f-281a37fda22e"
      unitRef="shares">338233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNy0zLTEtMS0w_e752b765-05fa-4154-884b-f01d1bda0803"
      unitRef="usdPerShare">17.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNy01LTEtMS0w_f9b00f5d-dd2a-4717-b759-af699f5b1e2c">P8Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfNy03LTEtMS0w_4529dcfb-61a2-40c9-b6ca-0a4075109c8d"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfOC0xLTEtMS0w_1ec20289-c3d5-446b-8c7a-dcade979ea3a"
      unitRef="shares">84711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfOC0zLTEtMS0w_f0c4d2ef-a5a4-4b55-8ea0-6f77a9609047"
      unitRef="usdPerShare">59.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfOC01LTEtMS0w_5cd3cb6f-e7b5-4a4f-9e3a-4f7708a5630a">P3Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RhYmxlOmM5YTVkNWJjYjk4NjQ3YWRiMTE4OGFlMGI0ZGM1MDg1L3RhYmxlcmFuZ2U6YzlhNWQ1YmNiOTg2NDdhZGIxMTg4YWUwYjRkYzUwODVfOC03LTEtMS0w_d10a0b65-c3af-4e5b-b4b7-24439dd6463b"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="idff75338ab954067833daa55353126e4_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMjI5OA_c469ba51-9455-463d-bf44-d1ca181b4c90"
      unitRef="usd">489641</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF81Mi9mcmFnOmRjZTBkMDNkYWU4ODQ2NjVhMDkxYjczNWQ5OWM4ZTNjL3RleHRyZWdpb246ZGNlMGQwM2RhZTg4NDY2NWEwOTFiNzM1ZDk5YzhlM2NfMjU4Ng_4c9d9f8f-6e23-4231-bf15-14cfc6c1f38d">P3Y3M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF82MS9mcmFnOjU3OTAxNjcyY2UxMzRlZGQ5NjVmZWQyNjU4ODcwNDhlL3RleHRyZWdpb246NTc5MDE2NzJjZTEzNGVkZDk2NWZlZDI2NTg4NzA0OGVfMTA5OTUxMTYzOTQ2OA_14a40bfa-746d-4402-a627-863bcec00a06">SUBSEQUENT EVENTS&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 9, 2020, the Company was notified (the &#x201c;Notice&#x201d;) by Nasdaq Stock Market, LLC (&#x201c;Nasdaq&#x201d;) that on April 8, 2020 the average closing price of the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;) over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the &#x201c;Minimum Bid Requirement&#x201d;). The Notice has no immediate effect on the listing or trading of the Company&#x2019;s common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, to regain compliance with the Minimum Bid Requirement. To regain compliance, the closing bid price of the Company&#x2019;s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during this 180-day period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 20, 2020, the Company was notified by Nasdaq that it has determined to toll the compliance periods for bid price and market value of publicly held shares (&#x201c;MVPHS&#x201d;) requirements (collectively, the &#x201c;Price-based Requirements&#x201d;) through June 30, 2020. In that regard, on April 16, 2020, Nasdaq filed an immediately effective rule change with the Securities and Exchange Commission. As a result, companies presently in compliance periods for any Price-based Requirements will remain at that same stage of the process and will not be subject to being delisted for these concerns. Starting on July 1, 2020, companies will receive the balance of any pending compliance period in effect at the start of the tolling period to regain compliance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accordingly, since the Company had 173 calendar days remaining in its bid price compliance period as of April 16, 2020, it will, upon reinstatement of the Price-based Requirements, still has 173 calendar days from July 1, 2020, or until December 21, 2020, subject to any extensions granted by Nasdaq, to regain compliance. The Company can regain compliance, either during the suspension or during the compliance period resuming after the suspension by evidencing compliance with the Price-based Requirements for a minimum of 10 consecutive trading days.&lt;/span&gt;&lt;/div&gt;On April 13, 2020, the Company was granted a loan of approximately $180,000 from Paycheck Protection Program established under the CARES Act. The loan matures on April 13, 2022 and bears interest at a rate of 0.5% per annum. The loan will be forgiven if the Company use it to pay payroll costs including benefit, mortgage interest, rent, and utilities payment over the 8 weeks after getting the loan</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i82289f6d72fc4019908f2649c6567ffd_I20200413"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF82MS9mcmFnOjU3OTAxNjcyY2UxMzRlZGQ5NjVmZWQyNjU4ODcwNDhlL3RleHRyZWdpb246NTc5MDE2NzJjZTEzNGVkZDk2NWZlZDI2NTg4NzA0OGVfMTA5OTUxMTYzOTQ3MA_ad3ddb40-066b-4309-af7b-8f08b06a84f0"
      unitRef="usd">180000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i82289f6d72fc4019908f2649c6567ffd_I20200413"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF82MS9mcmFnOjU3OTAxNjcyY2UxMzRlZGQ5NjVmZWQyNjU4ODcwNDhlL3RleHRyZWdpb246NTc5MDE2NzJjZTEzNGVkZDk2NWZlZDI2NTg4NzA0OGVfMTA5OTUxMTYzOTQ4MA_b4414a56-42ae-4753-b38a-c75407069af9"
      unitRef="number">0.005</us-gaap:DebtInstrumentInterestRateStatedPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6857009120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 19, 2019</div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Grant contract amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charges of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 110,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,597,729<span></span>
</td>
<td class="nump">30,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 220<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873921&amp;loc=SL114875236-224282<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762837296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE ACQUISITION AND DISPOSAL - Schedule of Unaudited Pro Forma Results (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenues</a></td>
<td class="nump">$ 1,132,830<span></span>
</td>
<td class="nump">$ 655,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,083,816)<span></span>
</td>
<td class="num">$ (9,415,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (3.97)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6847498080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text">The fair value of the option grants of $92,007 has been estimated with the following assumptions for the three months ended March&#160;31, 2020:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:80.701%;"><tr><td style="width:1.0%;"/><td style="width:30.427%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:64.847%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.526%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.48&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Volatility&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113.17&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.80</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend yield&#160;</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes stock option activity for employees and non-employees for the three months ended March&#160;31, 2020: </span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"><tr><td style="width:1.0%;"/><td style="width:43.901%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.965%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.965%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.965%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.545%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.969%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.42&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.53</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.61&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.01&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.18</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59.85&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.23</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6856976080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVERSE ACQUISITION AND DISPOSAL - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - Flex Pharma<br></strong></div></th>
<th class="th">
<div>Jul. 19, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 5,405,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">15,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">122,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other current assets</a></td>
<td class="nump">106,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets', window );">Goodwill and intangibles</a></td>
<td class="nump">8,937,899<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total fair value of assets acquired</a></td>
<td class="nump">14,587,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Accounts payable, accrued liabilities and other current liabilities</a></td>
<td class="nump">1,862,599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total fair value of liabilities assumed</a></td>
<td class="nump">1,862,599<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 12,724,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flks_FlexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flks_FlexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>24
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *Z#KU ?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ KH.O4"?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O)NR\L0?[CXVO@K*%7W<AOP!02P,$%     @ KH.O4)E<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M$%U YSX(XAE\V1$FH+O ]A629_"51YB ] *[7' 3DR\^PH18L-4%=S)-?!:
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M,SEGP^TR+ 3MQIL33-?W]B]02P,$%     @ KH.O4 ]W'4_9 @  R0D  !@
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M42DM#2>Z-X1G<Z^:)I4\:CO,S;@;+A?#1*MVO#@ET^UM\Q=02P,$%     @
MKH.O4*OC3>CQ P  "1$  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q]
M6-N.XS8,_17#[UE+E'4;) $F4Q0MT *#+;9]]B1*8JPOJ>U,MG]?^;+9K$C-
M2VPKA]0A)1Z+7M_:[FM_=FY(OM55TV_2\S!<GK*LWY]=7?2?VHMK_#_'MJN+
MP3]VIZR_=*XX3$9UE0%C*JN+LDFWZVGLM=NNV^M0E8U[[9+^6M=%]]_.5>UM
MD_+T^\#G\G0>QH%LN[X4)_>7&[Y<7CO_E-V]',K:-7W9-DGGCIOTF3^]@!T-
M)L3?I;OU#_?)&,I;VWX='WX_;%(V,G*5VP^CB\)?WMV+JZK1D^?Q[^(TO<\Y
M&C[>?_?^ZQ2\#^:MZ-U+6_U3'H;S)C5I<G#'XEH-G]O;;VX)2*;)$OT?[MU5
M'CXR\7/LVZJ??I/]M1_:>O'BJ=3%M_E:-M/U-O^CU6)&&\!B '<#/_='!F(Q
M$#\,\BGXF=D4ZB_%4&S777M+NGFU+L6X*?B3\,G<CX-3[J;_?+2]'WW?<L[7
MV?OH:,'L9@P\8NZ(S'N_3P'4%#M YO#S!"\880T]@R"#$).]^"D(H!WDI(-\
M<I _.F FR,*,41.FF3 K8$88KH)H"""7 $PKFI(D*4DB)D$[4*0#A6/B>1#3
MC)$/5',0(H@'@[PCS31-1I-D-$%&!F0TFD>8G-F #8&2>8R,(<D88K6#1=P9
M-,T*C&":!70PCM%4+$G%$JL<V2:<T07,B-3JL((9#D=:7R1A=@E@)!X>T1..
MZ*APH1?,XR1@C96(#,;Y%<@C5<!)]7GF@ AI" D!3H_/CF \9(2!TEC-8CFB
MY8H+3$F$E 2.77%A0NDD<*M<@8GN(EH .:& /%3 !41OCH4.AG"0,2ZT\G&)
MTX.VD"0V=,XU7C$"J*14(H]PHL644VIJ0U)8*5=",\-$'K(BD-PHHV,2SVE9
MY1KK!\0V(RV&G%!#0"< +'/6**E!AX%A()?,<&TCI&A9Y)8@A:K6$AJ=6R7#
M%Q@!C.0(:(T%0F,AK%C TFD55UZPPM,.!GZ8(Z"5%K#2<@A?\( E5%J_(_.P
M< G@2B@F8W4"M-H"5EM?_R$IK*)""V,9(H6!7@.Y-K'S)ZVW@/660_C"!RRD
M5N7*XDQAH-3:ISYR!@%:<2$G2C?F@A9*P$+)(11MP (HF IEDD#%2H062%!$
M.+$-38L9$(=$P<)PB/.?-1('A'&Q@&A=!$(71:B+\-'Q;R%"*")GN8[5%2V(
M0 BB" 5Q :F/V& (&+_)4;N4/320M>M.4Z_=)_OVV@QCJ_8P>N_GGV%L0(/Q
MG>_SYZ[\AYOY(\&?17<JFSYY:P??WDY-Z+%M!^=YLD\^7V=7'.X/E3L.XZWV
M]]W<G,\/0WM9/CQD]Z\?V_\!4$L#!!0    ( *Z#KU#LV>8#+P0  - 2   8
M    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULC5A=;^I&$/TKB'>N=_;;$2 U
MD*B56BFZ5=MG!Y: KHVI[83;?]^U<;AX9IR;%_S!F9FSL[OGV)Z?R^I;O0^A
MF7PO\F.]F.Z;YG27)/5F'XJL_E*>PC'^LRNK(FOB9?62U*<J9-LNJ,@3*81-
MBNQPG"[GW;VG:CDO7YO\< Q/U:1^+8JL^N\^Y.5Y,87I^XVOAY=]T]Y(EO-3
M]A+^#,U?IZ<J7B77+-M#$8[UH3Q.JK!;3'^!NT=IVH .\?<AG.N;\TD[E.>R
M_-9>_+9=3$7+*.1AT[0ILGAX"ZN0YVVFR./?/NGT6K,-O#U_S_[8#3X.YCFK
MPZK,_SELF_UBZJ>3;=AEKWGSM3S_&OH!F>FD'_WOX2WD$=XRB34V95YWOY/-
M:]V419\E4BFR[Y?CX=@=SWW^]S ^0/8!\AH ZL, U0>HSP;H/D#_"+ ?!I@^
MP%P#I/LPP/8!]D= -^CDTJRN^^NLR9;SJCQ/JLL".F7M.H4[&^=WT][LIK/[
M+TY '>^^+4&I>?+6)NHQ]Q>,'&#T$+/B,&:(67,8.\0\<!@WQ#QR&'_%)'&\
MUT%+=M"R2Z '"5(TH O&=)ACAY%"26=1<]84)W@JBJ6B*!4M4/\O&'M38@;2
M 0">! J,G!%?BD'E'BA">9N"1+A'AI:)Y/7-? T:H-D&Z"Z+&C0 ^ 2&36"8
M#DK4&$,F*;5"^Y2O8]DZEJF#=XHE=6(WG$D!\;&D=2G>"'PJG1J>LV,Y.X8S
M7C2.% *9BI$Y]&P9SY1!F__>TS(@M,-L/.D,ZMW#2"+%$TY9PBE#&$W *J5K
MQIB1O0V"%U=!ZP!N3 ^Z+:2,%@X+K/AI9T8RV1'.(X8 E+/PF#.02C,P4@IG
ML59_ CFDQ4LV,)JM28^H&"L!QHF1C0Z\)@,GRJ0%BJY#IX3T6'N T5-!IHYF
M\RJ5.M6XGQ0XL]9* R,; 'C9!<V,$7M@#QJ(D(F^@W?MF@&.[11>Q(%1<8-]
M$*B,@S!>>$.>1@SI>22.25,0MD*FHI36.,"V^L@@HTG'5>[$6"=XFP'[>4,$
M7O6!DWVR+*GN>V64]@*WB3,(;0V,;2K>(X S"?*D2<4]U=:!Q>(,U"<\?=YD
MS$0:/,5L22M'99-W%& L!:^X%5!/<<YYS&G-X&8(.'S*Y>U',O9CT#JXE]0T
MT I826H]#LGAFL',W-A#.>\\DG$>XLJ2^HF"=*S0R.,_XR7$EB7C)5X+))$/
M/X4-"?&&(QG#(9XK&>67PBL/V',_@QS2XCU",AYA%)X0*OWQK4X;ZQQ>(HR;
MV/AFH4=(\4XA.:?0N%=4VL$+(2T0^@PRTL?4&3]Q>"50C))@P8''\T.1LZCQ
M5A@R0<G->WS[K>>/K'HY'.O)<]DT9=&]N._*L@DQK?@2T^Y#MKU>Y&'7M*<N
MGE>7;RR7BZ8\]=^/DNM'K.7_4$L#!!0    ( *Z#KU#_*["NL0$  -(#   8
M    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?5/;;MLP#/T501]0)4K2#H%M
MH.DP;, &!!VV/2LV;0O5Q9/DN/O[4;+C>9VQ%XND>0X/*2H;K'OQ+4 @KUH9
MG],VA.[(F"];T,+?V0X,_JFMTR*@ZQKF.P>B2B"M&-]L[ID6TM B2[&S*S+;
M!R4-G!WQO=;"_3J!LD-.M_06>)9-&V* %5DG&O@*X5MW=NBQF:62&HR7UA '
M=4X?M\?3/N:GA.\2!K^P2>SD8NU+=#Y5.=U$0:"@#)%!X'&%)U J$J&,GQ,G
MG4M&X-*^L7](O6,O%^'AR:H?L@IM3M]14D$M>A6>[? 1IGX.E$S-?X8K*$R/
M2K!&:95/7U+V/E@]L: 4+5['4YIT#A/_#;8.X!. OP&PL5!2_EX$463.#L2-
ML^]$O.+MD>-LRAA,HTC_4+S'Z+78'@X9NT:B*><TYO!ESIS!D'TNP==*G/@_
M<+X.WZTJW"7X[B^%]^L$^U6"?2+8_[?%M9R'-T788J8:7).VR9/2]B9M\B(Z
M+^PC3W?R)WW<]B_"-=)X<K$!;S;-O[8V $K9W.$*M?C 9D=!':+Y@+8;UVQT
M@NVF%\3F9US\!E!+ P04    " "N@Z]0ZF;SY+8!  #2 P  &    'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;'U3VV[;, S]%4$?4#E.TF:!;:#I,&Q "P0=
MMCTK-FT+U<63Y+C]^U&RZWF;L1=)I'@.#RDJ&XQ]<2V )Z]*:I?3UOONR)@K
M6U#<W9@.--[4QBKNT;0-<YT%7D60DBQ-DENFN-"TR*+O;(O,]%X*#6=+7*\4
MMV\GD&;(Z8:^.YY%T_K@8$76\0:^@O_6G2U:;&:IA +MA-'$0IW3^\WQM OQ
M,>"[@,$MSB14<C'F)1A?JIPF01!(*'U@X+A=X0&D#$0HX^?$2>>4 ;@\O[-_
MBK5C+1?NX,'('Z+R;4X/E%10\U[Z9S-\AJF>/253\8]P!8GA00GF*(UT<25E
M[[Q1$PM*4?QUW(6.^S#>[ \3;!V03H!T!AQB'C8FBLH_<L^+S)J!V+'W'0]/
MO#FFV)LR.&,KXAV*=^B]%IO](6/70#3%G,:8=!DS1S!DGU.D:RE.Z3_P=!V^
M756XC?#M'PH_K!/L5@EVD6#WWQ)78FZ3OY*P14\5V"9.DR.EZ76<Y(5W'MC[
M-+[)[_!QVI^X;81VY&(\OFSL?VV,!Y22W. (M?C!9D-"[</Q#L]V'+/1\*:;
M?A";OW'Q"U!+ P04    " "N@Z]0%EH I+,!  #2 P  &    'AL+W=O<FMS
M:&5E=',O<VAE970Y+GAM;'U386_<( S]*X@?4"[DUE6G)%*O4]5*FW3JM/4S
MES@)*H04R*7[]S,DS;(MVQ? QN_YV9AL-/;%M0">O&G5N9RVWO<'QES9@A;N
MRO30X4UMK!8>3=LPUUL0501IQ?AN=\VTD!TMLN@[V2(S@U>R@Y,E;M!:V!]'
M4&;,:4+?'4^R:7UPL"+K10-?P7_K3Q8MMK!44D/GI.F(A3JGM\GAN _Q,>"[
MA-&MSB14<C;F)1B/54YW01 H*'U@$+A=X Z4"D0HXW7FI$O* %R?W]GO8^U8
MRUDXN#/J65:^S>D-)1748E#^R8P/,-?S@9*Y^,]P 87A00GF*(UR<27EX+S1
M,PM*T>)MVF47]W&Z2=,9M@W@,X O@)N8ATV)HO)/PHLBLV8D=NI]+\(3)P>.
MO2F#,[8BWJ%XA]Y+D5PG&;L$HCGF.,7P=<P2P9!]2<&W4ASY7W"^#4\W%:81
MGOZF\!\$^TV"?238_[?$K9CTCR1LU5,-MHG3Y$AIABY.\LJ[#.PMCV_R*WR:
M]B_"-K)SY&P\OFSL?VV,!Y2RN\(1:O&#+8:"VH?C1SS;:<PFPYM^_D%L^<;%
M3U!+ P04    " "N@Z]02R&[PK0!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q]4]MNW" 0_17$!X1=UME$*]M2-E'52JFT2I7DF;7'%P48
M%_ Z_?L"=ARWM?H"S##GS)EA2 <T;[8!<.1=26TSVCC7'1BS10-*V"OL0/N;
M"HT2SINF9K8S(,H(4I+QS6;/E&@US=/H.YD\Q=[)5L/)$-LK)<RO(T@<,KJE
M'XZGMFY<<+ \[40-/\ ]=R?C+3:SE*T";5O4Q$"5T;OMX9B$^!CPTL)@%V<2
M*CDCO@7C6YG131 $$@H7&(3?+G /4@8B+^/GQ$GGE &X/'^P?XFU^UK.PL(]
MRM>V=$U&;RDIH1*]=$\X?(6IGFM*IN(?X0+2AP<E/D>!TL:5%+UUJ"86+T6)
M]W%O==R'\8;O)M@Z@$\ /@-N8QXV)HK*'X03>6IP(&;L?2?"$V\/W/>F",[8
MBGCGQ5OOO>3;?9*R2R":8HYC#%_&S!',L\\I^%J*(_\'SM?ANU6%NPC?_:'P
M>IT@625((D'RWQ+78O9_)6&+GBHP=9PF2PKL=9SDA7<>V#L>W^0S?)SV[\+4
MK;;DC,Z_;.Q_A>C 2]E<^1%J_ >;#0F5"\<;?S;CF(V&PV[Z06S^QOEO4$L#
M!!0    ( *Z#KU"8[RWDM0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;'U3VX[3,!#]%<L?L&[=LBU5$FF["($$4K4(>':326*M+\%VFN7O
M&3O9$"#BQ?:,YYPY,QYG@W7/O@4(Y$4KXW/:AM"=&/-E"UKX.]N!P9O:.BT"
MFJYAOG,@J@32BO'-YIYI(0TMLN2[N"*S?5#2P,41WVLMW,\S*#OD=$M?'4^R
M:4-TL"+K1 -?('SM+@XM-K-44H/QTAKBH,[IP_9TWL?X%/!-PN 79Q(KN5K[
M'(V/54XW41 H*$-D$+C=X!&4BD0HX\?$2>>4$;@\O[*_3[5C+5?AX=&J[[(*
M;4Z/E%10BUZ%)SM\@*F>-Y1,Q7^"&R@,CTHP1VF53RLI>Q^LGEA0BA8OXRY-
MVH?QYG"88.L /@'X##BF/&Q,E)2_$T$4F;,#<6/O.Q&?>'OBV)LR.E,KTAV*
M]^B]%=O[0\9ND6B*.8\Q?!DS1S!DGU/PM11G_@^<K\-WJPIW";[[0^%QG6"_
M2K!/!/O_EK@6\_:O)&S14PVN2=/D26E[DR9YX9T']H&G-_D=/D[[9^$::3RY
MVH OF_I?6QL I6SN<(1:_&"SH: .\7C LQO';#2"[:8?Q.9O7/P"4$L#!!0
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M?!/.=AJSR?#8SS^(+=^X_ 502P,$%     @ KH.O4+G9%M!\ @  <PD  !D
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M3 2+I*!(ZA#$RRUQ(3B-80T<P 44 !3;905!H&1%9Z50,4"1+G5<D#Z@5W3
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M;_=J&IC),+*?WP*R/$CY'U!+ P04    " "N@Z]0W$])L+<!  #2 P  &0
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M9S..V6@X[*8?Q.9OG/\#4$L#!!0    ( *Z#KU"6$VN&MP$  -(#   9
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MU9DW)_/(F 0E%SPHI4I]#<:"PE'J;JKZ?+@3AT*RSE[W:/SFE'\ 4$L#!!0
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MTUN<V_&2C84W_?1^V/R(JS=02P,$%     @ KH.O4,$\H6(% @  @P4  !D
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M+?4V4WL^38,ID&RP@P[-T[;\ U!+ P04    " "N@Z]04&PF$+P"   ^"@
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MN$T4V9::5E57VI6BKG;[3.QQC,K%!1)W_WZYN%::^@5FAC/GS Q0CMJ\V1[
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M9)Q/5C5\%%YC=_&ODWX/[TVR %3XE,U"8 )0IK36I_EM-0NN\\7U?P6_R<P
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MW/RRZ=9A][.LJ'-*/9N<U;/8V:Z5&#N^W_2SS;'J!4,\]Z6C3C#=F!!QP$L
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MSSH@#N@K(^8^S%.%&.^)G0EIX)F&(P4^2Y3.H?U$]UI(3,X?99GN:;QX:/>
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M0W:4L9PLA)_-OLF*C-@7R%23/=C_8J6:@$/XG(&1"M=3*^*<&HO?J6OQ\^S
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M6I4<F1AKH(YVHV'C%//+/-DGZILN,VWK31)P_FA+LDJXH02?&R.DS4+#>XT
M=CMIMP'\S!L >4E::1!]4B1YQWM]^/?AP4%Z"+?1=(O:VDW[QWOI\>!P.]DZ
M2??A_O:/]K>36#NI?F\7E,"MO=[)T7;0$?'=]1!;G%R?GYZ/OA^^N0B:T%X[
MCJLU;<+:PX0-/!U"%Z:>_#.28LC7(!X*)S6$LT_H38YMRDLG#\4,Z#OF3)*1
MLR%;"0Y+61R<P(%)*"G6M7A!L)(73!ITH+@^OQJ.SI+S_[K"+C5C[J1P\]WY
M=7+Z\?KZ'$O>CL?G-T%Q7=.@\Y03/DZ5IZ-R*V0]M1$M6FO%(4LOM%AOO-(V
M4^GNV!H6BXG#4..B<Y,M8<CI-^T!PH]U.:V$0;,ZN(O[*/3LP[]@B/1H?\]\
M4Y@4_;W#?GK8/TX.!T<@\1P*5!?R'IF.6AQS?S\].CX&R>8P[1_V5;+9&#9
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MTBM/177B5$8U@?E <T!=KYYR+K\JN6K:\("*'A,\K/L3</4@/AV:O?+D%;V
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MG/PN^;[-0),N3GS0.^Y'F"I7A>[#9U$OD(WO=T&@A>0Y^]Z'@WON+_+.C/F
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M<^,#[@#&/YC/HP",O6DFF30V=6,O3 LN4_[=J26HN5].:U]TOCEY"YR.P6J
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M%($\/2)D;R;/$,BS8T+Z!N0(@1S9A8R3:1"Q;T'*XH@$44CB!4W:$C< SQ'
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M:Q8JVT.>3Z N+F=5UOXU:/IX_O-R]1M02P,$%     @ KH.O4*VBQXV8 0
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MU?"[1Y,CN'VX5/;Q&</4N_M'2H=^BS7#]>$V#U-_(\S5.?WV!U!+ P04
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M61[JL^ZGP.P+4$L! A0#%     @ KH.O4!\CSP/     $P(   L
M     ( !     %]R96QS+RYR96QS4$L! A0#%     @ KH.O4"?HAPZ"
ML0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " "N@Z]0YOFU N\    K @  $0              @ &9 0  9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " "N@Z]0F5R<(Q &  "<)P  $P
M        @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *Z#
MKU#;M[E.3@,   80   8              "  ?@(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " "N@Z]0/O*"#ZL#  "E#P  &
M        @ %\#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ KH.O4.1&-@1- @  R@<  !@              ( !71   'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *Z#KU /=QU/V0(  ,D)   8
M              "  > 2  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " "N@Z]0J^--Z/$#   )$0  &               @ 'O%0  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ KH.O4.S9Y@,O!
MT!(  !@              ( !%AH  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( *Z#KU#_*["NL0$  -(#   8              "  7L>
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "N@Z]0ZF;S
MY+8!  #2 P  &               @ %B(   >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ KH.O4!9: *2S 0  T@,  !@
M ( !3B(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( *Z#
MKU!+(;O"M $  -(#   9              "  3<D  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ KH.O4)CO+>2U 0  T@,  !D
M         ( !(B8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " "N@Z]0YT)B*K(!  #2 P  &0              @ $.*   >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *Z#KU#5Q!94M $  -(#
M   9              "  ?<I  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ KH.O4/4V,0ZT 0  T@,  !D              ( !XBL
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "N@Z]0!+N
M![4!  #2 P  &0              @ '-+0  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( *Z#KU#)+A%&LP$  -(#   9
M  "  ;DO  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
MKH.O4+G9%M!\ @  <PD  !D              ( !HS$  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " "N@Z]07Y[+:=0!  "<!   &0
M            @ %6-   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( *Z#KU#<3TFPMP$  -(#   9              "  6$V  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ KH.O4)83:X:W 0
MT@,  !D              ( !3S@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " "N@Z]0;&)=>+<!  #2 P  &0              @ $]
M.@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( *Z#KU#L
M7D@(Q $  #<$   9              "  2L\  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ KH.O4#^G[8 @ @  ?P8  !D
M     ( !)CX  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Z#KU"G=UX4LP$  - #   9              "
M 6-)  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ KH.O
M4,$\H6(% @  @P4  !D              ( !34L  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " "N@Z]0$26@RO0!  !Y!0  &0
M        @ &)30  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( *Z#KU!0;"80O (  #X*   9              "  ;1/  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ KH.O4,1&<?$B @  ' 8
M !D              ( !IU(  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " "N@Z]0^:SYT"D%  !['   &0              @ $ 50
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( *Z#KU"0/RUC
M* (  ','   9              "  6!:  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ KH.O4)2;]*F9 @  ( H  !D
M ( !OUP  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "N
M@Z]0[LJQ-.0!   !!0  &0              @ &/7P  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( *Z#KU#W&=]AP0(  (L*   9
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *Z#KU!VP/Z<GP,  /T9   /
M      "  ;.Q  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "N@Z]0K:+'
MC9@!  "W%P  &@              @ %_M0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " "N@Z]0R5/E^*(!   <&   $P
M    @ %/MP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     +P O +L,   B
%N0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6655716832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE ACQUISITION AND DISPOSAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Summary of Purchase Consideration</a></td>
<td class="text">Total purchase consideration is as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"/><td style="width:61.595%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:34.405%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Flex Pharma market capitalization at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,963,526&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of rights to warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,629,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of Flex Pharma outstanding options on the merger date</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total purchase consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,724,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The following represents the allocation of the estimated purchase consideration:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:60.941%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:35.059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of assets acquired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,405,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expense and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill and intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,937,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,587,447&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable, accrued liabilities and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,862,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of liabilities assumed</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,862,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,724,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Unaudited Pro Forma Results</a></td>
<td class="text"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following unaudited pro forma financial information summarizes the results of operations for the three months ended March&#160;31, 2020 and 2019 as if the merger described above had been completed as of January 1, 2019. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the merger had been completed as of January 1, 2019, the transaction costs would have been expensed in the prior period.</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:64.422%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.422%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.423%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,132,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">655,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,083,816)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,415,074)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.22)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636468208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GRANTS RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">GRANTS RECEIVABLE</a></td>
<td class="text">GRANTS RECEIVABLEGrants receivable represents qualifying costs incurred and there is reasonable assurance that conditions of the grant have been met but the corresponding funds have not been received as of the reporting date. Grants receivable balances are $591,129 and $0 as of March 31, 2020 and December 31, 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6610033344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS' EQUITY<div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated statements of stockholders' equity (deficit) and the footnotes to the interim financial statements have been retroactively adjusted to reflect the equity structure (that is, the number and type of equity interests issued) of Flex Pharma, the legal parent (accounting acquiree) of the merger closed on July 19, 2019, with the retained earnings and other equity balances of the Private Salarius before the merger. Private Salarius' equity was restated using the exchange ratio established in the merger agreement to reflect the number of shares of Flex Pharma issued in the merger. Concurrent with the merger, the Company's shareholders approved a 1-for-25 reverse stock split, which became effective on July 19, 2019. Total shares owned by Flex Pharma pre-merger shareholders (net of fraction shares paid in cash) was 8,353,480 shares after reverse stock-split. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Common Stock and Preferred Stock </span></div><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On February 11, 2020, the Company completed a public offering with total gross proceeds of approximately $11.0 million, which includes the full exercise of the underwriter's over-allotment option to purchase an additional 1,252,173 shares and warrants prior to deducting underwriting discounts and commissions and offering expenses payable by Salarius. The offering is comprised of 7,101,307 Class A units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of common stock and a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjUxNA_5df20bb8-eba1-4ed3-bcaa-a88042c57c15">five</span>-year warrant to purchase one share of </span></div><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">common stock at an exercise price of $1.15 per share, and 1,246,519 Class B units, priced at a public offering price of $1.15 per unit, with each unit consisting of one share of Series A convertible preferred stock and a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80OS9mcmFnOjE3ZDA4M2NlZDY3ODRiMzY5YWVhNGVjYzE0NmMyNTBjL3RleHRyZWdpb246MTdkMDgzY2VkNjc4NGIzNjlhZWE0ZWNjMTQ2YzI1MGNfMTA5OTUxMTYzNjQ3MA_5232e6f4-81eb-413b-ad84-cc43a3411329">five</span>-year warrant to purchase one share of common stock with and exercise price of $1.15 per share. A total of 8,343,480 shares of common stock, 1,246,519 shares of Series A convertible preferred stock, and warrants to purchase up to 9,599,999 shares of common stock were issued in the offering, including the full exercise of the over-allotment option. The convertible preferred stock issued in this transaction includes a beneficial ownership limitation on conversion, but has no dividend rights (except to the extent that dividends are also paid on the common stock). The conversion price of the Series A convertible preferred stock in the offering as well as the exercise price of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, 777,825 shares of Series A convertible preferred stock were converted to common stock. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2019 the Company issued 960,489 common shares (4,035 Series A preferred units and 350 profit interest units of Private Salarius) for $4,377,591 (net of offering cost of $10,617).</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2018, the Company agreed to issue an unrelated party 12,907 common shares (91 common units of Private Salarius) to acquire licenses for the DNMT1 inhibitor. The issuance was approved in January 2019 and the license was granted in 2018. . </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Right to Warrants</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Pursuant to the Merger Agreement (See Note 3), Flex Pharma distributed one right per share of common stock to stockholders of record as of the close of business on July 18, 2019. Each right entitles such stockholders to receive a warrant to purchase the Company's common shares on January 20, 2020. These warrants are exercisable, in the aggregate, into 142,711 shares of the Company's common stock with a 5-year term from January 20, 2020, and an exercise price of $15.17 per share. The warrants are subject to a cashless exercise, at the option of the Company, at the closing of an issuance and sale of the Company&#8217;s common stock in certain qualified financing, upon the closing of which the holders of warrants shall be entitled to receive a number of shares of common stock equal to the greater of two formulae defined by the Merger Agreement, which are based on the volume weighted average price of the Company's common stock during the 10 consecutive trading days ending on the trading day immediately preceding the date of exercise. As a result, the warrants have been classified as a liability.</span></div><div style="padding-left:18pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounted for these warrants at fair value using Level 3 inputs. The Company determined the fair value of this warrant liability using a Black-Scholes valuation model as the Company believes the value will closely approximate the value from the binomial asset pricing model that consisted of a conditional probability weighted expected return method that values the Company&#8217;s equity securities assuming various possible future outcomes to estimate the allocation of value within one or more of the scenarios. Using this method, unobservable inputs included the Company&#8217;s equity value, expected timing of possible outcomes, risk free interest rates and stock</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">price volatility. </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Variables used in the Black-Scholes model are as follows:</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:75.146%;"><tr><td style="width:1.0%;"/><td style="width:42.163%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.161%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.459%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.356%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.461%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.37%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.69%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.81 years</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.06 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113.17%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.07%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Wedbush Warrant</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 19, 2019, upon the closing of the merger, the Company elected to issue warrants to purchase 42,928 common shares to Wedbush Securities Inc. ("Wedbush") to satisfy $500,000 of the $1,000,000 success fee payable to Wedbush at the closing of the merger. The remaining $500,000 success fee was paid in cash. These warrants have an exercise price of $18.90 and a 5-year term. As of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">March&#160;31, 2020, all warrants issued to Wedbush were outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6847549280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE ACQUISITION AND DISPOSAL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">REVERSE ACQUISITION AND DISPOSAL</a></td>
<td class="text">REVERSE ACQUISITION AND DISPOSAL<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reverse Acquisition</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January&#160;3, 2019, Flex Pharma, Private Salarius and Merger Sub entered into the Merger Agreement. Pursuant to the Merger Agreement, Merger Sub merged with and into Private Salarius, with Private Salarius continuing as a wholly owned subsidiary of Flex Pharma, with Flex Pharma deemed the legal acquiror and Private Salarius deemed the accounting acquiror, as described below. The merger was completed on July&#160;19, 2019. After the merger, Flex Pharma was renamed Salarius Pharmaceuticals, Inc. The merger was accounted for as a reverse acquisition business acquisition with Private Salarius being deemed the acquiring company for accounting purposes. Private Salarius, as the accounting acquirer, recorded the assets acquired and liabilities assumed of Flex Pharma in the merger at their fair values as of the acquisition date. Private Salarius&#8217; historical financial statements have replaced Flex Pharma&#8217;s historical consolidated financial statements with respect to periods prior to the completion of the merger with retroactive adjustments to Private Salarius' legal capital to reflect the legal capital of Flex Pharma. Flex Pharma (which was renamed Salarius Pharmaceuticals, Inc. in connection with the merger) remains the continuing registrant and reporting company.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Private Salarius was determined to be the accounting acquirer based on the following facts and circumstances: (1)&#160;members of Private Salarius owned approximately 80.7% of the voting interests of the combined company immediately following the closing of the transaction; (2)&#160;the majority of the board of directors of the combined company was composed of directors designated by Private Salarius under the terms of the Merger Agreement; and (3)&#160;existing members of Private Salarius management became the management of the combined company. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The business purposes of the merger included, among other purposes, obtaining the following potential advantages: (i) the combined organization&#8217;s resources would be immediately available to support Private Salarius&#8217; research on Seclidemstat; and (ii) the public company status would allow the Company greater potential access to additional capital.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the closing of the merger, each outstanding common unit, profits interest common unit and Series A Preferred unit of Private Salarius converted into shares of the Company&#8217;s common stock (subject to the payment of cash in lieu of fractional shares and after giving effect to a 25 to 1 reverse stock split of the Company&#8217;s common stock) at the conversion ratio formulae described in the Merger Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, at the closing of the merger, the Company distributed one right per share of common stock to stockholders of record as of the close of business on July 18, 2019. Each right entitles such stockholders to receive </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a warrant to purchase shares of the Company&#8217;s common stock six months and one day following the closing date of the merger. See Note 8.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounted for the acquisition as a reverse merger using purchase accounting. Because the merger qualifies as a reverse acquisition and given that Private Salarius was a private company at the time of the merger and therefore its value was not readily determinable, the fair value of the merger consideration was deemed to be equal to the sum of the quoted market capitalization of the Company at the merger date, the fair value of the Flex Pharma options that fully vested upon the merger together, and the fair value of the rights to receive warrants that were granted to the pre-merger Flex Pharma stockholders. Total purchase consideration is as follows:</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.391%;"><tr><td style="width:1.0%;"/><td style="width:61.595%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:34.405%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Flex Pharma market capitalization at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,963,526&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of rights to warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,629,095&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of Flex Pharma outstanding options on the merger date</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total purchase consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,724,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recorded all tangible and intangible assets acquired and liabilities assumed at their preliminary estimated fair values on the merger date. The following represents the allocation of the estimated purchase consideration:</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"/><td style="width:60.941%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:35.059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of assets acquired</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,405,826&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,168&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,235&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expense and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">106,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill and intangibles</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,937,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of assets acquired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,587,447&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable, accrued liabilities and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,862,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of liabilities assumed</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,862,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,724,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Unaudited Pro Forma Disclosure</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following unaudited pro forma financial information summarizes the results of operations for the three months ended March&#160;31, 2020 and 2019 as if the merger described above had been completed as of January 1, 2019. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the merger had been completed as of January 1, 2019, the transaction costs would have been expensed in the prior period.</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:64.422%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.422%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.423%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,132,830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">655,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,083,816)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,415,074)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.22)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6857033264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER PAGE - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SALARIUS PHARMACEUTICALS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001615219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,650,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $ 0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2450 Holcombe Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite J 608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5087339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">772-0346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6846634832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION - Summary of stock option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 10, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">182,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,233<span></span>
</td>
<td class="nump">166,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Beginning Balance (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted-average exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, Ending Balance (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.01<span></span>
</td>
<td class="nump">$ 34.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 4 days<span></span>
</td>
<td class="text">6 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6860904064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 11, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 19, 2019 </div>
<div>USD ($) </div>
<div>trading_Days </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 20, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,645,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,511,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,467,166<span></span>
</td>
<td class="nump">$ 4,377,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 21 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays', window );">Consecutive trading days | trading_Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value | $</a></td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,252,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">8,343,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,353,480<span></span>
</td>
<td class="nump">960,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of rights per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants</a></td>
<td class="nump">9,599,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred shares converted to common shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of equity securities for license (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of rights per share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Flex Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,353,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred shares converted to common shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(777,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A | Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">7,101,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share) | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B | Preferred Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">1,246,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share) | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred shares converted to common shares (shares)</a></td>
<td class="nump">777,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,246,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=flks_ProfitInterestUnitsMember', window );">Profit Interest Units | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=flks_CommonUnitsMember', window );">Common Units | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of equity securities for license (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flks_WedbushSecuritiesIncMember', window );">Wedbush | Satisfy success fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related party | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Cash payment to related party | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=flks_FlexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=flks_FlexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=flks_ProfitInterestUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=flks_ProfitInterestUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=flks_CommonUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=flks_CommonUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flks_WedbushSecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=flks_WedbushSecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=flks_SatisfySuccessFeeDueToRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=flks_SatisfySuccessFeeDueToRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6857281712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,083,816)<span></span>
</td>
<td class="num">$ (1,522,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairment</a></td>
<td class="nump">4,233<span></span>
</td>
<td class="nump">114,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">38,409<span></span>
</td>
<td class="nump">35,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(283,070)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Grants receivable</a></td>
<td class="num">(591,129)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">298,959<span></span>
</td>
<td class="nump">30,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(911,301)<span></span>
</td>
<td class="nump">589,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">361,382<span></span>
</td>
<td class="num">(462,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Due to/from related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(541,701)<span></span>
</td>
<td class="num">(655,634)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,708,034)<span></span>
</td>
<td class="num">(1,868,713)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of equity securities, net</a></td>
<td class="nump">9,865,727<span></span>
</td>
<td class="nump">1,508,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
<td class="num">(249,653)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,616,074<span></span>
</td>
<td class="nump">1,508,179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">5,908,040<span></span>
</td>
<td class="num">(360,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">3,738,900<span></span>
</td>
<td class="nump">6,131,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">9,646,940<span></span>
</td>
<td class="nump">5,771,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_StockIssuanceCostsAccruedAndAmortized', window );">Accrued issuance costs for public offering</a></td>
<td class="nump">398,561<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of shares for license</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">110,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of liabilities to equity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,869,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_StockIssuanceCostsAccruedAndAmortized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Accrued and Amortized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_StockIssuanceCostsAccruedAndAmortized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>74</ContextCount>
  <ElementCount>265</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - COVER PAGE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/COVERPAGE</Role>
      <ShortName>COVER PAGE</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION AND OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS</Role>
      <ShortName>ORGANIZATION AND OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - REVERSE ACQUISITION AND DISPOSAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL</Role>
      <ShortName>REVERSE ACQUISITION AND DISPOSAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - GRANTS RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/GRANTSRECEIVABLE</Role>
      <ShortName>GRANTS RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119107 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122108 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126109 - Disclosure - EQUITY-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION</Role>
      <ShortName>EQUITY-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131110 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - REVERSE ACQUISITION AND DISPOSAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables</Role>
      <ShortName>REVERSE ACQUISITION AND DISPOSAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2320303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails</Role>
      <ShortName>REVERSE ACQUISITION AND DISPOSAL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Summary of Purchase Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails</Role>
      <ShortName>REVERSE ACQUISITION AND DISPOSAL - Summary of Purchase Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>REVERSE ACQUISITION AND DISPOSAL - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Schedule of Unaudited Pro Forma Results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails</Role>
      <ShortName>REVERSE ACQUISITION AND DISPOSAL - Schedule of Unaudited Pro Forma Results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - GRANTS RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails</Role>
      <ShortName>GRANTS RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/GRANTSRECEIVABLE</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails</Role>
      <ShortName>FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - EQUITY-BASED COMPENSATION - Summary of stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION - Summary of stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="flks-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.flex-pharma.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q/A" original="flks-20200331.htm">flks-20200331.htm</File>
    <File>flks-20200331.xsd</File>
    <File>flks-20200331_cal.xml</File>
    <File>flks-20200331_def.xml</File>
    <File>flks-20200331_lab.xml</File>
    <File>flks-20200331_pre.xml</File>
    <File>slrx20200331ex-311.htm</File>
    <File>slrx20200331ex-312.htm</File>
    <File>slrx20200331ex-321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6847610096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Level 3 Liabilities</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrant associated with the Flex Pharma merger measured at fair value on a recurring basis for the three months ended March&#160;31, 2020: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.532%;"><tr><td style="width:1.0%;"/><td style="width:23.000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:23.000%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:22.080%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:22.450%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">317,762&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">283,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6846404400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVERSE ACQUISITION AND DISPOSAL - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 19, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable', window );">Period the right is unexercisable</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of rights per share</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=flks_FlexPharmaMember', window );">Flex Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interest acquired</a></td>
<td class="nump">80.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Period Warrants or Rights Unexercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flks_FlexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flks_FlexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6844139504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GRANTS RECEIVABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Grants receivable from CPRIT</a></td>
<td class="nump">$ 591,129<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6844065264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">468,694<span></span>
</td>
<td class="nump">468,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">468,694<span></span>
</td>
<td class="nump">468,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">13,650,838<span></span>
</td>
<td class="nump">4,519,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">13,645,677<span></span>
</td>
<td class="nump">4,511,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6854722016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 10, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 19, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,233<span></span>
</td>
<td class="nump">166,233<span></span>
</td>
<td class="nump">90,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (shares)</a></td>
<td class="nump">182,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant of stock awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=flks_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6858027008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsAwardTerm', window );">Award term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsExtensionTerm', window );">Extension term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales', window );">Continued payments, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsMatchingFundsRequirement', window );">Matching funds requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsAggregateAmountReceived', window );">Aggregate amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable', window );">Current funding available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_RevenueFromGrantsCurrentFundingReceived', window );">Current funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 541,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Grants receivable from CPRIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 591,129<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=flks_UniversityOfUtahResearchFoundationMember', window );">University of Utah Research Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsAggregateAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Aggregate Amount Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsAggregateAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Aggregate Amount Received, Current Funding Available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Award Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsCurrentFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Funding Received During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsCurrentFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Extension Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsMatchingFundsRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Matching Funds Requirement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsMatchingFundsRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsMaximumAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Maximum Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsMaximumAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=flks_UniversityOfUtahResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=flks_UniversityOfUtahResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6847555984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND OPERATIONS</a></td>
<td class="text">ORGANIZATION AND OPERATIONS<div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Nature of Business</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Salarius Pharmaceuticals, Inc. (&#8220;Salarius&#8221; or the &#8220;Company&#8221;), together with its subsidiaries, Salarius Pharmaceuticals, LLC, Flex Innovation Group LLC, and TK Pharma, Inc., is a clinical-stage biotechnology company focused on developing effective treatments for cancers with high unmet medical need caused by dysregulated gene expression.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Epigenetics refers to the regulatory system that affects gene expression and the Company's lead epigenetic enzyme technology was licensed from the University of Utah Research Foundation in 2011. The Company is located in Houston, Texas.</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Merger with Flex Pharma, Inc.</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January&#160;3, 2019, Flex Pharma, Inc. ("Flex Pharma"), Salarius Pharmaceuticals LLC ("Private Salarius") and Falcon Acquisition Sub, LLC (&#8220;Merger Sub&#8221;), a wholly owned subsidiary of Flex Pharma, entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;). Pursuant to the Merger Agreement, Merger Sub merged with and into Private Salarius, with Private Salarius continuing as a wholly owned subsidiary of Flex Pharma. The merger was completed on July 19, 2019. After the merger, Flex Pharma was renamed Salarius Pharmaceuticals, Inc. The merger was accounted for as a reverse acquisition with Private Salarius being deemed the acquiring company for accounting purposes. See Note&#160;3.</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Covid-19 Pandemic</span></div><div style="text-align:justify;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The outbreak of COVID-19 has spread worldwide. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company&#8217;s operations and those of third parties on which the Company relies. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company&#8217;s ability to access capital, which could negatively impact the Company&#8217;s long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing or other activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on the Company&#8217;s liquidity, capital resources, operations and business and those of the third parties on which we rely.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6609925680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">License Agreement with the University of Utah Research Foundation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2011, the Company entered into a license agreement with the University of Utah, under which, the Company acquired an exclusive license to and epigenetic enzyme lysine specific demethylase 1 ("LSD 1"). In exchange for the license, the Company issued 2% equity ownership in the Company based on a fully diluted basis at the effective date of the agreement and subject to certain adjustments specified in the agreement, granted revenue sharing rights on any resulting products or processes to commence on first commercial sale, and milestone payments based upon regulatory approval of any resulting product or process as well as on the second anniversary of first commercial sale.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cancer Prevention and Research Institute of Texas</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Company entered into a Cancer Research Grant Contract with CPRIT. Pursuant to the contract, CPRIT awarded the Company a grant of up to $18.7 million to fund the development of LSD-1 inhibitor. This is a 3-year grant award which originally expired on May 31, 2019. However, a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgwMA_62016ce1-9c77-440a-be57-b02c9bb2a0fd">six</span>-month extension was approved by CPRIT in May 2019 and an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjMzMGVmNjM0ZDc5YTQ2MDk4NTM1YjkzZWVkYjJmYTU0L3NlYzozMzBlZjYzNGQ3OWE0NjA5ODUzNWI5M2VlZGIyZmE1NF80Ni9mcmFnOjgyZmNmMjA1ZGU0YTQzNWE4NzYyZjQ4Yzc4N2U3NzQxL3RleHRyZWdpb246ODJmY2YyMDVkZTRhNDM1YTg3NjJmNDhjNzg3ZTc3NDFfMTA5OTUxMTYzMTgxNQ_f84e63ce-cd9b-41a2-9e9b-5f34bd9cd7fe">six</span>-month extension through May 2020. The Company has applied for an extension with a proposed contract end date of November 30, 2020. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will retain ownership over any intellectual property developed under the contract ("Project Result"). With respect to non-commercial use of any Project Result, the Company agreed to grant to CPRIT a nonexclusive, irrevocable, royalty-free, perpetual, worldwide license with right to sublicense any necessary additional intellectual property rights to exploit all Project Results by CPRIT, other governmental entities and agencies of the State of Texas, and private or independent institutions of higher education located in Texas, for education, research and other non-commercial purposes.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is obligated to make revenue-sharing payments to CPRIT with respect to net sales of any product covered by the contract, up to a maximum repayment of certain percentage of the aggregate amount paid to the Company by CPRIT under the CPRIT contract. The payments are determined as a percentage of net sales, which may be reduced if the Company is required to obtain a license from a third party to sell any such product. In addition, upon meeting the foregoing limitation on revenue-sharing payments, the Company agreed to make continued revenue-sharing payments to CPRIT of less than 1% of net sales.</span></div>The CPRIT grant is subject to funding conditions including a matching funds requirement where the Company will match 50% of funding from the CPRIT grant. As of March&#160;31, 2020, the Company has received an aggregate of $9.6 million from the CPRIT grant and there was $9.1 million of funds available for the Company to draw upon meeting certain requirements. There was no funding received from CPRIT during the three months ended March&#160;31, 2020. At March&#160;31, 2020 and December&#160;31, 2019, the Company had deferred revenue of $0 and $541,701, respectively, related to the CPRIT contract. At March&#160;31, 2020 and December&#160;31, 2019, the Company had grants receivable of $591,129 and $0, respectively, related to the CPRIT contract.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6847549824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 9, 2020, the Company was notified (the &#8220;Notice&#8221;) by Nasdaq Stock Market, LLC (&#8220;Nasdaq&#8221;) that on April 8, 2020 the average closing price of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the &#8220;Minimum Bid Requirement&#8221;). The Notice has no immediate effect on the listing or trading of the Company&#8217;s common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, to regain compliance with the Minimum Bid Requirement. To regain compliance, the closing bid price of the Company&#8217;s common stock must be at least $1.00 per share for a minimum of ten consecutive business days during this 180-day period.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2020, the Company was notified by Nasdaq that it has determined to toll the compliance periods for bid price and market value of publicly held shares (&#8220;MVPHS&#8221;) requirements (collectively, the &#8220;Price-based Requirements&#8221;) through June 30, 2020. In that regard, on April 16, 2020, Nasdaq filed an immediately effective rule change with the Securities and Exchange Commission. As a result, companies presently in compliance periods for any Price-based Requirements will remain at that same stage of the process and will not be subject to being delisted for these concerns. Starting on July 1, 2020, companies will receive the balance of any pending compliance period in effect at the start of the tolling period to regain compliance.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accordingly, since the Company had 173 calendar days remaining in its bid price compliance period as of April 16, 2020, it will, upon reinstatement of the Price-based Requirements, still has 173 calendar days from July 1, 2020, or until December 21, 2020, subject to any extensions granted by Nasdaq, to regain compliance. The Company can regain compliance, either during the suspension or during the compliance period resuming after the suspension by evidencing compliance with the Price-based Requirements for a minimum of 10 consecutive trading days.</span></div>On April 13, 2020, the Company was granted a loan of approximately $180,000 from Paycheck Protection Program established under the CARES Act. The loan matures on April 13, 2022 and bears interest at a rate of 0.5% per annum. The loan will be forgiven if the Company use it to pay payroll costs including benefit, mortgage interest, rent, and utilities payment over the 8 weeks after getting the loan<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>45
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "flks-20200331.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 74,
   "dts": {
    "calculationLink": {
     "local": [
      "flks-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "flks-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "flks-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "flks-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "flks-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "flks-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 311,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 3,
    "http://www.flex-pharma.com/20200331": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 7,
    "total": 12
   },
   "keyCustom": 17,
   "keyStandard": 248,
   "memberCustom": 7,
   "memberStandard": 19,
   "nsprefix": "flks",
   "nsuri": "http://www.flex-pharma.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - COVER PAGE",
     "role": "http://www.flex-pharma.com/role/COVERPAGE",
     "shortName": "COVER PAGE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - GRANTS RECEIVABLE",
     "role": "http://www.flex-pharma.com/role/GRANTSRECEIVABLE",
     "shortName": "GRANTS RECEIVABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119107 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "role": "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122108 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126109 - Disclosure - EQUITY-BASED COMPENSATION",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION",
     "shortName": "EQUITY-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131110 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.flex-pharma.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - REVERSE ACQUISITION AND DISPOSAL (Tables)",
     "role": "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables",
     "shortName": "REVERSE ACQUISITION AND DISPOSAL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320303 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - EQUITY-BASED COMPENSATION (Tables)",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables",
     "shortName": "EQUITY-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i9335e01552494ea4aeab4ed31281b503_D20190719-20190719",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "flks:ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Narrative (Details)",
     "role": "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
     "shortName": "REVERSE ACQUISITION AND DISPOSAL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i9335e01552494ea4aeab4ed31281b503_D20190719-20190719",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "flks:ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Summary of Purchase Consideration (Details)",
     "role": "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails",
     "shortName": "REVERSE ACQUISITION AND DISPOSAL - Summary of Purchase Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i86ef8930d7f44b2196a87ca7c8b21ba4_D20190719-20190719",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i291b51edb08c4a50ba7e783e980e810b_I20190719",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "REVERSE ACQUISITION AND DISPOSAL - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i291b51edb08c4a50ba7e783e980e810b_I20190719",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - REVERSE ACQUISITION AND DISPOSAL - Schedule of Unaudited Pro Forma Results (Details)",
     "role": "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails",
     "shortName": "REVERSE ACQUISITION AND DISPOSAL - Schedule of Unaudited Pro Forma Results (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - GRANTS RECEIVABLE (Details)",
     "role": "http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails",
     "shortName": "GRANTS RECEIVABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "flks:PrepaidClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "flks:PrepaidClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)",
     "role": "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i3c3c4f1bd73a41ab8a2603386c7cd387_I20190731",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ic1d35ab3929b4fbe91e95df48a459f8e_D20160601-20160630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "flks:RevenueFromGrantsMaximumAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ic1d35ab3929b4fbe91e95df48a459f8e_D20160601-20160630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "flks:RevenueFromGrantsMaximumAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)",
     "role": "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails",
     "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i72557c4fa44d4ba5b0d57686b7176435_I20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i3eeda48ea55c43c3921c1333146fc953_I20190719",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)",
     "role": "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i923938e66ee44ac4a3049da0fb812f9f_I20200331",
      "decimals": "4",
      "lang": "en-US",
      "name": "flks:WarrantsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "idff75338ab954067833daa55353126e4_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - EQUITY-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "EQUITY-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i3eeda48ea55c43c3921c1333146fc953_I20190719",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails",
     "shortName": "EQUITY-BASED COMPENSATION - Schedule of Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i316105bb8a4240588ac05a8d48949e71_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - EQUITY-BASED COMPENSATION - Summary of stock option activity (Details)",
     "role": "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails",
     "shortName": "EQUITY-BASED COMPENSATION - Summary of stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i82289f6d72fc4019908f2649c6567ffd_I20200413",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i82289f6d72fc4019908f2649c6567ffd_I20200413",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i85b3036ab6d64f5c890474b22de3cea0_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)",
     "role": "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "i85b3036ab6d64f5c890474b22de3cea0_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION AND OPERATIONS",
     "role": "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS",
     "shortName": "ORGANIZATION AND OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - REVERSE ACQUISITION AND DISPOSAL",
     "role": "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL",
     "shortName": "REVERSE ACQUISITION AND DISPOSAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "flks-20200331.htm",
      "contextRef": "ia77ed32700ac4550a8fe9da73f7138fd_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 27,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COVERPAGE"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "flks_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Expenses And Other Current Liabilities",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Fair Value of Outstanding Options",
        "label": "Business Combination, Consideration Transferred, Fair Value of Outstanding Options",
        "terseLabel": "Fair value of Flex Pharma outstanding options on the merger date"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Fair Value of Rights to Warrants",
        "label": "Business Combination, Consideration Transferred, Fair Value of Rights to Warrants",
        "terseLabel": "Fair value of rights to warrants"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets",
        "terseLabel": "Goodwill and intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Period Warrants or Rights Unexercisable",
        "label": "Class of Warrant or Right, Period Warrants or Rights Unexercisable",
        "terseLabel": "Period the right is unexercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "flks_ClassOfWarrantOrRightThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Threshold Consecutive Trading Days",
        "label": "Class of Warrant or Right, Threshold Consecutive Trading Days",
        "terseLabel": "Consecutive trading days"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightThresholdConsecutiveTradingDays",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "flks_CommonUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Units",
        "label": "Common Units [Member]",
        "terseLabel": "Common Units"
       }
      }
     },
     "localname": "CommonUnitsMember",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_EquityIncentivePlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Incentive Plan 2015 [Member]",
        "label": "Equity Incentive Plan 2015 [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2015Member",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_FlexPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Flex Pharma",
        "label": "Flex Pharma [Member]",
        "terseLabel": "Flex Pharma"
       }
      }
     },
     "localname": "FlexPharmaMember",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_PrepaidClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepaid Clinical Trial Expense",
        "label": "Prepaid Clinical Trial Expense",
        "terseLabel": "Prepaid clinical trial expenses"
       }
      }
     },
     "localname": "PrepaidClinicalTrialExpense",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_ProfitInterestUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit Interest Units",
        "label": "Profit Interest Units [Member]",
        "terseLabel": "Profit Interest Units"
       }
      }
     },
     "localname": "ProfitInterestUnitsMember",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_RevenueFromGrantsAggregateAmountReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Aggregate Amount Received",
        "label": "Revenue From Grants, Aggregate Amount Received",
        "terseLabel": "Aggregate amount received"
       }
      }
     },
     "localname": "RevenueFromGrantsAggregateAmountReceived",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Aggregate Amount Received, Current Funding Available",
        "label": "Revenue From Grants, Aggregate Amount Received, Current Funding Available",
        "terseLabel": "Current funding available"
       }
      }
     },
     "localname": "RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_RevenueFromGrantsAwardTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Award Term",
        "label": "Revenue From Grants, Award Term",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "RevenueFromGrantsAwardTerm",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "flks_RevenueFromGrantsCurrentFundingReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Funding Received During Period",
        "label": "Revenue From Grants, Current Funding Received",
        "terseLabel": "Current funding received"
       }
      }
     },
     "localname": "RevenueFromGrantsCurrentFundingReceived",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_RevenueFromGrantsExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Extension Term",
        "label": "Revenue From Grants, Extension Term",
        "terseLabel": "Extension term"
       }
      }
     },
     "localname": "RevenueFromGrantsExtensionTerm",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "flks_RevenueFromGrantsMatchingFundsRequirement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Matching Funds Requirement",
        "label": "Revenue From Grants, Matching Funds Requirement",
        "terseLabel": "Matching funds requirement"
       }
      }
     },
     "localname": "RevenueFromGrantsMatchingFundsRequirement",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "flks_RevenueFromGrantsMaximumAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Maximum Award",
        "label": "Revenue From Grants, Maximum Award",
        "terseLabel": "Award amount"
       }
      }
     },
     "localname": "RevenueFromGrantsMaximumAward",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales",
        "label": "Revenue From Grants, Revenue-sharing Payments, Continued Payments, Percent of Net Sales",
        "terseLabel": "Continued payments, percent of net sales"
       }
      }
     },
     "localname": "RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "flks_SatisfySuccessFeeDueToRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Satisfy Success Fee Due to Related Party",
        "label": "Satisfy Success Fee Due to Related Party [Member]",
        "verboseLabel": "Satisfy success fee"
       }
      }
     },
     "localname": "SatisfySuccessFeeDueToRelatedPartyMember",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_StockIssuanceCostsAccruedAndAmortized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issuance Costs Accrued and Amortized",
        "label": "Stock Issuance Costs Accrued and Amortized",
        "terseLabel": "Accrued issuance costs for public offering"
       }
      }
     },
     "localname": "StockIssuanceCostsAccruedAndAmortized",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "flks_UniversityOfUtahResearchFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "University of Utah Research Foundation",
        "label": "University of Utah Research Foundation [Member]",
        "terseLabel": "University of Utah Research Foundation"
       }
      }
     },
     "localname": "UniversityOfUtahResearchFoundationMember",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "flks_WarrantsOutstandingMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Outstanding, Measurement Input",
        "label": "Warrants Outstanding, Measurement Input",
        "terseLabel": "Warrants measurement input"
       }
      }
     },
     "localname": "WarrantsOutstandingMeasurementInput",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "flks_WedbushSecuritiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Wedbush Securities Inc.",
        "label": "Wedbush Securities Inc. [Member]",
        "terseLabel": "Wedbush"
       }
      }
     },
     "localname": "WedbushSecuritiesIncMember",
     "nsuri": "http://www.flex-pharma.com/20200331",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r81",
      "r210",
      "r216"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r34"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r123",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Voting interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Unaudited Pro Forma Results"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofUnauditedProFormaResultsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r163",
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total purchase consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Flex Pharma market capitalization at closing"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "REVERSE ACQUISITION AND DISPOSAL"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSAL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total fair value of assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expense and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total fair value of liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r21",
      "r51"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r6",
      "r52",
      "r58"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r45",
      "r51",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r45",
      "r187"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of rights per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r29",
      "r95",
      "r213",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 100,000,000 shares authorized; 13,650,838 and 4,519,533 shares issued at March\u00a031, 2020 and December\u00a031, 2019, and 13,645,677 and 4,511,174 shares outstanding at March\u00a031, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r74",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments and Credit Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r168",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r167",
      "r170",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r112",
      "r113",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Grant contract amount"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r112",
      "r113",
      "r116"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of liabilities to equity"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails",
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r49",
      "r80"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation, amortization and impairment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r66",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "EQUITY-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r65",
      "r190",
      "r212",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r69",
      "r70",
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Employee stock option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r49",
      "r98"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "negatedTerseLabel": "Change in Fair Value",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited",
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Variables used in Black-Scholes Model"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r117",
      "r118",
      "r120",
      "r179",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r181",
      "r182",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r117",
      "r118",
      "r120",
      "r179",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r183",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r183",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value of Level 3 Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at March 31, 2020",
        "periodStartLabel": "Balance at December 31, 2019"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r184",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r86",
      "r87"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r58",
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r49",
      "r90",
      "r92",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment charges of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r89",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r58",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties",
        "terseLabel": "Due to/from related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Grants receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r44",
      "r46",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r211",
      "r218"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "GRANTS RECEIVABLE"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/GRANTSRECEIVABLE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loan Payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r28",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected dividend"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by noncontrolling Owner"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r45",
      "r47",
      "r50"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r36",
      "r37",
      "r39",
      "r50",
      "r70",
      "r214",
      "r223"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Application of New Accounting Standards and Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Note Payable"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss before other income (expense)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/ORGANIZATIONANDOPERATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other prepaid and current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r123",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 468,694 issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r19",
      "r20"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r2",
      "r4",
      "r84",
      "r85"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from issuance of equity securities, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r91",
      "r220"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r12",
      "r18",
      "r219",
      "r224"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Grants receivable from CPRIT"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.flex-pharma.com/role/GRANTSRECEIVABLEDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r119",
      "r191",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r119",
      "r191",
      "r192",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payments on note payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "terseLabel": "Cash payment to related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r148",
      "r227"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r58",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r109",
      "r217"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Grants Receivable and Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALSummaryofPurchaseConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Summary of Purchase Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r123",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r129",
      "r134",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r30",
      "r61",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for grant of stock awards (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (shares)",
        "verboseLabel": "Number of stock options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r131",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending Balance (shares)",
        "periodStartLabel": "Outstanding, Beginning Balance (shares)",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails",
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, Ending Balance (in usd per share)",
        "periodStartLabel": "Weighted-average exercise price, Beginning Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r121",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r58",
      "r123",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r139",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONScheduleofFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONSummaryofstockoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/EQUITYBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (shares)",
        "periodStartLabel": "Equity, beginning balance (shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r32",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of shares for license"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r31",
      "r102",
      "r103",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Preferred shares converted to common shares (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of equity securities for license (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r102",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of equity securities (shares)",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r10",
      "r11",
      "r102",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation expense (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r32",
      "r102",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Preferred shares converted to common shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of equity securities for license"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r102",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of equity securities",
        "verboseLabel": "Shares issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r10",
      "r11",
      "r109",
      "r122",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r15",
      "r16",
      "r82"
     ],
     "calculation": {
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYDEFICITUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://www.flex-pharma.com/role/REVERSEACQUISITIONANDDISPOSALNarrativeDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r72",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/BASISOFPRESENTATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant value"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.flex-pharma.com/role/STOCKHOLDERSEQUITYScheduleofVariablesusedinBlackScholesModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of common shares outstanding\u00a0\u2014 basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591554-111686"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(a)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r228": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r229": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r231": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r232": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r233": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r234": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6857776496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,646,940<span></span>
</td>
<td class="nump">$ 3,738,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Grants receivable from CPRIT</a></td>
<td class="nump">591,129<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">646,360<span></span>
</td>
<td class="nump">955,899<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,884,429<span></span>
</td>
<td class="nump">4,694,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,889<span></span>
</td>
<td class="nump">25,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,865,909<span></span>
</td>
<td class="nump">8,865,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">293,147<span></span>
</td>
<td class="nump">308,674<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,065,374<span></span>
</td>
<td class="nump">13,894,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">979,823<span></span>
</td>
<td class="nump">1,790,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">795,567<span></span>
</td>
<td class="nump">160,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">252,679<span></span>
</td>
<td class="nump">502,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">541,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="nump">34,692<span></span>
</td>
<td class="nump">317,762<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,062,761<span></span>
</td>
<td class="nump">3,313,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 468,694 issued and outstanding</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 100,000,000 shares authorized; 13,650,838 and 4,519,533 shares issued at March&#160;31, 2020 and December&#160;31, 2019, and 13,645,677 and 4,511,174 shares outstanding at March&#160;31, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">32,161,718<span></span>
</td>
<td class="nump">22,657,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(14,160,516)<span></span>
</td>
<td class="num">(12,076,700)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">18,002,613<span></span>
</td>
<td class="nump">10,580,854<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 20,065,374<span></span>
</td>
<td class="nump">$ 13,894,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6846755376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Schedule of Variables used in Black-Scholes Model (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 20, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected life (years)</a></td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
<td class="text">5 years 21 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_WarrantsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.37%<span></span>
</td>
<td class="nump">1.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_WarrantsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">113.17%<span></span>
</td>
<td class="nump">103.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_WarrantsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_WarrantsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Outstanding, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_WarrantsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6857102208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="nump">$ 252,679<span></span>
</td>
<td class="nump">$ 502,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Note Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.61%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6854856656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,032,763<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2018</a></td>
<td class="num">$ (1,271,114)<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,869,120<span></span>
</td>
<td class="num">$ (5,140,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of equity securities (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity securities</a></td>
<td class="nump">4,377,591<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,377,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of equity securities for license (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of equity securities for license</a></td>
<td class="nump">110,474<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation expense (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">35,407<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,522,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,522,076)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,015,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2019</a></td>
<td class="nump">1,730,282<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,392,494<span></span>
</td>
<td class="num">(6,662,513)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,511,174<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2019</a></td>
<td class="nump">10,580,854<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">22,657,103<span></span>
</td>
<td class="num">(12,076,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of equity securities (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,353,480<span></span>
</td>
<td class="nump">1,246,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of equity securities</a></td>
<td class="nump">9,467,166<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">9,466,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred shares converted to common shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,825<span></span>
</td>
<td class="num">(777,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Preferred shares converted to common shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Equity-based compensation expense (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="nump">38,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,083,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,083,816)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,645,677<span></span>
</td>
<td class="nump">468,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 18,002,613<span></span>
</td>
<td class="nump">$ 1,364<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 32,161,718<span></span>
</td>
<td class="num">$ (14,160,516)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6610112000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event - Loan Payable<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 13, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6762862000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE OF FINANCIAL INSTRUMENTS <div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, are used to measure fair value:</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-40.5pt;padding-left:76.5pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 - Significant unobservable inputs including Salarius&#8217; own assumptions in determining fair value.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company believes the recorded values of its financial instruments, including cash and cash equivalents, accounts payable and note payable approximate their fair values due to the short-term nature of these instruments.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrant associated with the Flex Pharma merger measured at fair value on a recurring basis for the three months ended March&#160;31, 2020: </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:79.532%;"><tr><td style="width:1.0%;"/><td style="width:23.000%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:23.000%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:22.080%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.535%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:22.450%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrant liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">317,762&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">283,070&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,692&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6857977120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standard Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As described above, the merger with Flex Pharma closed on July 19, 2019. The merger was accounted for as a reverse acquisition with Private Salarius being deemed the acquiring company for accounting purposes. Private Salarius&#8217; historical financial statements have replaced Flex Pharma&#8217;s historical consolidated financial statements with respect to periods prior to the completion of the merger with retroactive adjustments to Private Salarius' legal capital to reflect the legal capital of Flex Pharma. Flex Pharma (renamed Salarius Pharmaceuticals, Inc.) remains the continuing registrant and reporting company. Accordingly, the historical financial and operating data of Salarius Pharmaceuticals, Inc., which covers periods prior to the closing date of the merger, reflects the assets, liabilities and results of operations of Private Salarius and does not reflect the assets, liabilities and results of operations of Flex Pharma for the periods prior to July 19, 2019. The Company has retrospectively adjusted its Statement of Changes in Stockholders&#8217; Equity (Deficit) and the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding common unit, profits interest common unit and Series A Preferred unit of </span></div>Private Salarius that converted into shares of the Company&#8217;s common stock upon the merger, and to reflect the effect of the 25 to 1 reverse stock split of the Company&#8217;s common stock which occurred upon the merger.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Principles of Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsSalarius considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Goodwill</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill is not amortized but is tested at least annually for impairment at the reporting unit level. The Company has determined that the reporting unit is the single operating segment disclosed in its current financial statements. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. The first step in the impairment process is to determine the fair value of the reporting unit and then compare it to the carrying value, including goodwill. If the fair value exceeds the carrying value, no further action is required and no impairment loss is recognized. Additional impairment assessments may be performed on an interim basis if the Company encounters events or changes in circumstances that would indicate that, more likely than not, the carrying </span></div>value of goodwill has been impaired.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Financial Instruments and Credit Risks</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Warrants</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In conjunction with the reverse merger transaction, the Company issued rights to receive warrants to purchase the Company&#8217;s common stock. Further, on February 11, 2020, the Company issued warrants to purchase the Company's common stock in a registered public offering. The Company determines whether the warrants should be classified as a liability or equity. For warrants classified as liabilities, the Company estimates the fair value of the warrants at each reporting period using Level 3 inputs with changes in fair value recorded in the Condensed Consolidated Statement of Operations within Change in fair value of warrant liability. The estimates in valuation models are based, in part, on subjective assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk-free interest rate and the fair value of the common stock underlying the warrants, and could differ materially in the future. The Company will continue to adjust the fair value of the warrant liability at the end of each reporting period for changes in fair value from the prior period until the earlier of the exercise or expiration of the applicable warrant.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Grants Receivable and Revenue Recognition</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Grants Receivable and Revenue Recognition </span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Salarius&#8217; source of revenue has been from a grant received from CPRIT. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that conditions of the grant have been met. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as revenue when qualifying costs are incurred. When grant funds are received after costs have been incurred, the Company records revenue and a corresponding grants receivable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs consist of expenses incurred in performing research and development activities, including pre-clinical studies and clinical trials. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, the costs of laboratory equipment and facilities, license fees and other external costs. Research and development costs are expensed when incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-Based Compensation</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Equity-Based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Salarius measures equity-based compensation based on the grant date fair value of the awards and recognizes the associated expense in the financial statements over the requisite service period of the award, which is generally the vesting period.</span></div>The Company uses the Black-Scholes option valuation model and the Backsolve method (which is similar to the Black-Scholes valuation model and produces similar results) to estimate the fair value of the stock-based compensation and incentive units. Assumptions utilized in these models including expected volatility calculated based on implied volatility from traded stocks of peer companies, dividend yield and risk-free interest rate. Additionally, forfeitures are accounted for in compensation cost as they occur.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Income taxes are recorded in accordance with FASB ASC Topic 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. The Company has evaluated available evidence and concluded that the Company may not realize the benefit of its deferred tax assets; therefore, a valuation allowance has been established for the full amount of the deferred tax assets.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. As of March&#160;31, 2020 and December&#160;31, 2019, the Company did not have any significant uncertain tax positions and no interest or penalties have been charged. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company is subject to routine audits by taxing jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Subsequent Events</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s management reviewed all material events through the date that the financial statements were issued for subsequent event disclosure consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Application of New Accounting Standards and Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Application of New Accounting Standards</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Intangibles-Goodwill and Other,&#8221; which is intended to simplify the subsequent measurement of goodwill. The pronouncement allows an entity, during its annual or interim goodwill impairment evaluation, to compare the fair value of a reporting unit with its carrying amount. An impairment charge is immediately recognized by which the carrying amount exceeds the fair value. This ASU is effective for fiscal </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">years, and interim periods within those years, beginning after December 15, 2019. The Company does not expect adoption of this ASU to have a material impact on its consolidated financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Pronouncements Not Yet Adopted</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The guidance eliminates certain exceptions for recognizing deferred taxes for investments, performing intra-period </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">allocation and calculating income taxes in interim periods. This guidance also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its consolidated financial statements.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement of all expected credit losses for financial assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses guidance. The FASB also subsequently issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Derivatives and Hedging (Topic 815), and Financial Instruments (Topic 842), which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019 for public business entities, excluding smaller reporting companies. Early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of assessing the impact adoption will have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001615219-20-000061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001615219-20-000061-xbrl.zip
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M$"Y- '[@Z)8$SJ5(73;[#)D%Q7H2UBC&A,=$" K>HH]%X;2)^_\(E:!$^"7
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M7K>/]$FQ\.X"F2[1_49R=G1_+^^6^B_AOO'7,1OD586^.W5#N#UUU6V(6TH
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M!<>QUI9/@]T2B"E08ZG5EP3E,1_>.(DY"$:BH&\//0@WPY#K<U2&(R<O=BS
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M(-D9#^IDU25,U%<^QR)I79V;G]DD,;E[97<#&UQ&]/HIW/Q!#ZD&B,Y#Y[]
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MD[ZS\!JPPD/;7>W[.WG=A@RS(0@OD1\]$.%%[ K&G@+AA7[/D_W=6U!G_-V
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M."5<*/]H7_&C]AY8=R?71WMG- FB.$XIT6D:$&&$(DF$Z*5,R##E++#]"%G
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M<"(3D1$1"DIBH&(,?T1<)HD)>+KSFL:[RWU;)H%1V'8$!+>$H6&INX.A%=Q
M%&!#$ JTV,G3'(0>ALY \*/LO]7]>A!ES- "\)7Z78^+*R#ZVRG!DD#;%+U?
M;O,5^.H*UI?KD("S%6"B:4!2E5 "BR]2/Y$ZI&SG-5]TD@@N:\7X5BA401&P
MOL[SOD1%;[X-K44*U-&45Q/<L5WO/X-+V(*B@00P*U9QQTC^C71RK4W_]U]F
M'V9BT]?-]OEE<^\L1))6AI)$11$!VTQB"E-$4I^I)$V9]#.]\[K,OU5:C/2
M=3JPY".PR)$?+V5U8H5H_.E5);YSMQ46ME1:P\'#8UED93 3MINQO!G?6A_.
MLEB8D"M#E$Y2(JADV(TU)4'&1:H3!7Z*N74S1ATP%LX[U=HSWYT>U/JSX[:J
MBZ8KNE;6@YOLHSNNA(T<#M" K!4RZ'@]L95;L,L.V\]O5 ,\P+KY2<RBV:6]
M!.T$-K7U%:8>"JQ68:UM/,7K=L&G&-ODYL$0W(JK6GVAM6Z][5D["%SB]\7
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M:B=6JPM<B<NL'+DEI?@QVW-O)/OMK]<-DB9S.;N5WEB/8[&[5T*EE%DHA,C
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MK)\G$V&*MB[/J)&QD7Y,A%0(^I!((E,P %.=Q& :^H$)@QLR?>R!T#2)8^E
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M5M/_5C']@HJI#GY-B6.KFM963<<+JBD*921T$I!4)9P(J2,"1)"0*..,*01
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M?[H\VO][-O_F\BSPA6_2(":!B301!KOMIEJ1S)=9IE7$DBS<>4W#L,$X?_J
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MFHB ZHBIJ/H;<&&.706OAYTS!TXDHAZ(IA:_6HOQZ_X1[./Q +;DWDN#3+5
M,; $KH.D@^JP+K\Q3G*AGB<_B?8H%5QD'"=.5@"+RW=ENZ!?_ 400LN>M6%S
MU.#E-$==I"&9:"!1J!(<#^L*+#(_E+TR-["CX1@N <KYI0AN^5CQEP^PRTB
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M7W\[)RHP^C-!?%/!4+.^H!%A1$4S1GYU$1=359@Y24SQ+)6&<RE$I#+_+J7
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M-U=.'Q"#[,&Z39*@"DPKBXQUM"/VI/,2\!([SA^3,!*Z+0GC*"9T.TW&,@+
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M99&E]8-R'.?<8)HH)QO9.<.F'ZZ8]>9LF2#H6P'O98\>V"M&S)$I[,PD4YQ
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M?\N<?Q1>"G=$\X9$[C]HC!6*L3_Y*H>;O#F1.^BIZ>4\J"CG >G_^^[Z5^=
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M=]JULHMET%O>5/=VE 1S^,\DGT8__7]02P,$%     @ KX.O4#[Q2!56"P
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M4H,3+L@*T#W9F#V[3EF7:HZ?TYBMK*V-K2%1+@U:TY .OA->:F+0FR8UX]J
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M=T^K+\GS0P:M#1%&T9*1RR1$SS$VT53;J$(P= \++,VL&,CL0LJ*\*2 2 Y
MO+2:V*BS5DQ29NI%Q@^L&.RP>'SAT5E"%RF"Y%D3QS,*EJTD/N=(A T!C F1
MVN7ED$TM'$]@-/C@WBE!KKXFNH,NERUTO9H6E/XC]@8XV/_TPWAX!=_>'/3'
M\'5\U)O<\*<?1O"QO&B,#E-VE1EFT,=_C@Z^=D<=!U&SDE#@.AD<I)PEP;!
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M*!&X8B1'B_$= XZC);7$B\20-\)$J%+FM37B]B>MI\/G^:FO';,WW43^#+Y
M_PK>HJ)_GG0<_]5_[5Y>71[\Z8<)]>&IL2R2Y$I;:)PNB!6(D4ONN-,T\OCH
M6/WX;5Y8U+@QFBY 7$ V@52<QPY(G81/FD2K-)%.4F*M2"1F4P*'()E=[]3L
MU?=X(4BS9FCZQ/4%6$?%#2JAZ 2:X&"S#I&@%VI*_:8A*+PD())R4B$)I-^.
M(??N\\*2YLW1=&^.!6BS-\[1[\8)$2/'DAH>H6+'77P[W;PQFT-/,VKHW)<^
M4EQ*&XREQ.M2[.T3)\YC/&F$\(JGB"ZWWHY4VT)ZX=]>C=Q@"XY5D_$X?D+\
M;Z_Z"46:E*@7W!TP##6"<[(Q%A\H:8 $AOX;XS'A#)VCL.L5XZ]]RQ>J5352
M@STQ5DS;'S\.X:,?STHWIOWQ('6$2)%[S0B4UM12.$V\M^7\/^DXZD:9M.5,
MN>*.+T2J::(&NT]L!'*VO%^> 7P4#K[X;F^R])<R4UP8@1%$C*0<-(B!)@\D
M9<\B!IE<J=0HO58 >6'='@S:8 >)Y=CO@[Q]8)RG.G.I"-.H(2E$("&Q0 35
M1GM# \2X'>F6W_"%7!4-5*&K0W$#ASZ.?^^./QU>C<:#2QC>M)^XOBE4XC$S
MX)H2YD(Y$Y<Z8C'@)4@1#BJD2&V5$T;7 ?="N(K&7"2<VY5P=[H1H]RWI7 R
M)JT2(\%P4X;23'SVBN!#H!AC05%?I87O4C0OE&K27$N2H3M7.]?0U[0^BQD6
MM+6:B! "D2GC< Q*HZ#:8_S"O/%5^H!5DZBMHLFG2^&G099]%VZ.AN/.K62S
MBB/O,.Q&]U6+2?OLC&%4\"1ZQ:P/B1J]SCX O/ =FN._YBF^<.=]%68^$2(,
MFC!(@TM,]X#<EA$^#F6#ZLW-.+*/2LT=K;',ICNHLK)U-7 )BDEB YN,II)X
M#%9)= [Y&KW(<1U__NE8=47%93VC;J+!IE>#/_0Q<!R.T*4_S1_&_M,9C "O
M_NGM $/+R=@V*_KC/G@3O2-13 [[D)HX(QQ)QHJ<>9:!K7>V_+IW;,]QWMDF
M@]H*;:V*\NW!\=EO!^\^')V^?7M\<G!R>'SP[OCD_.+LPZ2P;9L"O\<NV4QU
MWT; YS>6<T\QR/!&B2P34)=4U(QE+;2VSD-G Q&:UOCV'2'6NW KVE^C#X0*
M(&.4/*K@I>/,!A$@,R<9X]2'\)@-&F@!\<@==JAQ7?/*K=ABK>WW')SRQ22"
MR:Q2""R%9&1DTN'89QXS1C/UKF]]=_B;[UW!G0ZVOX(?70TAG9;NMU?#L@;]
MVH^ZHP_]01C!<));..Y_OBKI]D$_XJ_\_=:H*CME@&'LQS6.Z]Y(XG+RA'J6
ML\@X"- JN:$:PNR:^&@0TZ'OQ:O>M"TQAD!O!\-)G9LQV82<$HG!J-)EF)*@
MLR0,ISMA\<FF=7;H5)>L_:S>WI^&^4S(TV)/A2X(MP+.I"H)DY(,7Q!F=%^:
MT7W9;W/FDVMUF%:6JYP)8Y02"<83J\$3J:W@7GE-H<KR1Q5IONO'H G6K7HF
M]D:9"COO;H4Z2/_O:C2^G-1U_5Z:ZY1#3T/D1BD%Q'B0.(3X1'QI/%'ZVXE
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M"5(0:Z,G*$OTCMH47)V33'>"_1QXUZ+A:C29NVF,/M-)$<3W(QP.1OA, +<
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MS?B_#JB:H?E25'N.SG>WWJ"6ZBNX<LO!19FBHLH3"U$C.(GA:*0XF*G@J*?
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M#5.":%4"$^I*/T1O"(V>">%CC.UX+DO1/5NV[&Z+%@:6HZ^?(8XAO>E^Z2;
MR/8;M:/PRBNG"4@JB,Q*D<!#)*!2A$E[1E-E!6)]B,^6.@U99>6FKZ;7)J;9
M\-<'YT=O#D]_?7]T<GYP<7QZLLUZPZI+-;.&L!;0N76!E)@I[82-H4;F%#&R
M!@RT0]02&,^LLP;DIC0Z.\2^.;W.+EA5N\M S^DX"%0I4*H\*RFS' !XR):!
MH(:QZ%?I>!%^4YI>.+J^.9TO7+JJ]A\69-X.JAS1 ,()$W#PLE9%'K/2P5#(
MBNM5=EBXR8X%%.5DB==^!*D496.(X*?#^M#W/TY&R=?7W[XR.]/DX$\_3-]R
M8A&HX3DIDE ('"<#)4X$3@3%.9:CA%[7.9=X9^@[5Y]LBV"Z!GXWK3T]Q:H#
M%GU:JU#<[#DZN?C*ES-"H22UN;)LH9_3GG6Y2I(]U#"TR^2%"IB]<J%&I>:V
M MT___C@"XY29>YX.QC^7%9U.H+'Y'Q #E+&B'0V$2<C_E,IFEP2H'V=4X8K
M"?1"]7TPHT8QX8Z/\$2(T7%_>F;3S\/!:-0!+;6R)I.,#S"1%O_8:  YZIPR
MW$7EZW3J:%Z6%YZWS(<*#6JW%FGRYS<8C6_/)&,=ZI(/GAJB2N\,*6,D3N-4
MA3$X")9D-O9I.2M+A'@A=5L,J- '<0(T/"Y+F)?EZ.OG[G#RY:DDG92TYL%X
M$DI7&$E++Y@<# %I4+,Y>*>KG"#4F 1_31ZW;OL:366V%60VRY1'$M+-+'-;
M,L ZR2E0+#B"_TDB$\8/@5%++.=4Y>1XTG4V5%42Z(7B^V!&@SNH;YL 7'[N
M#:X!9L>8+M?R23E*N>"?2#2Z&(Q][^[GY2#=D\'XOV%\!G'PL=_]GUD+@)GP
M'2:\I))S$K01^%@K1G"F B)"H")YP1FK$F:V(MU?[EEX>IRIL!&RFI"S$6 P
MG+U5OL<Z03B7P IB[$3:D(BEI1^N\6 =.,-DE=BT73%?'I6GPZ+%9\8T> SD
M8VH?K=+[M"#2Z415<C@K<H6"J'*JD.&ELEQIRH1EB=7IW]>4!&U56>_;+=J+
MQ9]*T?3[GN^7/9K3H]*R9"F54[VS3R@ !X(3E2<R@%->,@S+JV1@[H)X FT2
MVJ3!?/NI;<U1(7]]@^7F+,0UT-2L>+X/9S]5SMN;9X6==]!M?8M'KE7"P;2<
M;8!8?':EXUDID2K[J8VQP=;I+=>"I1^I6JYEZ$U4VG1GHVFSO.-^Q.&J^P4*
M,C2 NNE)GE..5I>,5<8@ODRF@:,;%@QG.H5DC9U+6:[8!_O@;=KWGG<QP*"*
M]AI<7!\-QYVS,BU->V\AH,@9+8T.D:P.PTW'9"P+_O@/#ISJ=4YPPHO>>5;Q
M7_//Z;V[_C7GZ^T5W^ JW"V(FS;T:\#88(9>GP?-/]N/3\D[6&#>ACNHK\$Q
M>AZ.ET$DXPW)6G$B+4XX/MBRF*!#3,*5XN'OQHHKIMOFC;B)UAHVWJ^HJ<NK
MRQD0%@WSU$:2 BOEWMP09X$1)75TR08IQ3J')ZUEOGMW;F^*W4GW@R84U_!4
M^JO_>@>(UUQ'(Q51U.#$'DNG9V43*3M=C1.*ZMS8='KOSM^A!;=67(4H9CJU
MWVPSY-SYR:$>9G*X-]64>"X" 1TD%4EPEZL<8G8/Q5_32=K=(+6*/+92Q#<Q
M^FDNJEA'IJK])"L(M9\,RPY<V;0RJ2U#[Z.T=!O90%$J8Y0D.E^: G..LLE$
MN(E4*0?<B"K[DK\?\CZ2-'KBW-W$OC5.K;E91_RV0C[S%[(R*6;K2/"H) D0
MB==>H,>7 XM D]!U2ROF$3W!-=[J!E^UZKN3M5KKL;EB=]NW-H]W>]]<74[K
M,YK?(+C>_:KN&MQ"Y+FMA)99*T+BH*R2S%GK,?164:5@8Z#2KMI*N+'PC5GY
MZO+2#Z\'>53(.IC<KS2;_5(:WC=OXS7N5M?"FXH[9U\9;! *(,L$DG,,Z4**
M('!.TE9[X"OMNYG@F_?)_?"Z=&<].KDX^@W_G&]CLX5K--3!]D%H<_IE&/&*
MZ"F'8"33(B@.B$\8T"S[:#H/@=Q9:[MT#%YQJ3HZ7(>J6D"@,3KA$Y5!.P],
M)4Z5SLI1P_F"*AO:Q7P51O"O*YQBC[[@GW>W=2:,&>NSI 3#74>D=9%8S3/1
MH+-G@I;M955<Y!6 =O7)WD 8'_='X^%5\2?>^@@'EZ5/3L?+' W+ABA;FE48
M[HAE)A&O4/Y(1::NRDERJP#MP2-K@@/S7E4C^JZP.?<^KILCCDOSDLF9BJ54
MKZQ[^H_08=P'&K(B(&(D,D5'?/**4 U<**^C5U6VMJP/\5ERI3&;U,A&W!=_
MFC!DGB*E=2RYPHQA @;" ;0@1G.I9% >8I7C2)>!::V2L08/=M;N4RDUG!?D
M)E$"0B9O2_&F%Z@<D(QXGP*AR.I$M;3)5YEK5N#96ZY^9SL_0IQM]-W":/&M
M$=<ZP*IFT5<AV]]A3#O;[W%.[*#\5MFAHN$T14FH4?@\&(:/0N2)4,^XTYPK
M6:=M9LNL6..\I?9(L8G.ZY-AEH!4@K. ,2'!L) 3Z1,G(3!/%/,@8S)&5VH0
MM0S-WIW-;:WU, >V4'6%L.3=H/\1W=[+X@K?,EV5HWVB  (^%J8K2CR5"8$9
M([)Q5KLJX\ R,,_&5]A9TQ6:B\QCNF'Y&JAJ>@G+8>W'1=C=;(_P8 >=5Y@/
M5J!C5#.F121)<T!TR1,;O2 TF<!C4-RY=0JUGC03'G$+VB+")JJN0@#?'[WW
MUV6\FTU1P@?)!#.$AK(<F;(G+G&<HE) =RA8BO-5'>//0VG?%6C"2 MVWTG#
MFR[XSMXN?TK;B7_^[?\#4$L#!!0    ( *^#KU ILQ.LZ(L  ,;S!0 5
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MF#.8Z0PE.L.,<J_3>E\!QL8LM\_/1K[:%;+0P*@#-OJ STMC>;-"UDZ37?6
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MGB[--N4X#FY4$1[=GOECK]QV=192%72LI&XVJ$;N^O9YR,*./D"%+>[HU//
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MPLM3@+$1QT8^FXEKNO#T5OC"[^C,Z!'4OGT=6Z+_4U-JWH9/JYMZ\P(J!6[
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M2&2@S0E$,::0Y"B&F4!<RS2*9.QU^./9_]@(924^^&ZEP/=@.@?;.OP3J+4
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M123.E3%8XIQA&UBK(9=*P01Q1%4DC"TC)W/UP)9*?AGN6L4149WF'*WGW('
M_<V_1E(S^ZYSN^+8H/;LG[IPC/XP;JKU#8LM36V1M-$XK,X/Q"C\5BUBCH#"
M@^ <^J9%6U?=2[R]GY:"S>KFWIN?E1-*<XS3.(=IDB40I7D":2QS2'E.2,X9
ME[E3DO367L9F7Z[KF-62-O,95++Z5WH[!/6\$RL(5#T3:">4.A5\.XE"@))O
MAVT/7O3MI'K'RKZ=?KB;S=APRRHMY%U9OC C^9M%:3-C9QE#1*10BB@ULU^E
MD. X@@Q3S#(M<\2(S_:RK;.QD<"]UJJZSB^L='XV6RNH;L97**AZ)H&5F!OG
MU$I2\*85-V\CR 60D-9,:W^#FB4NFN_;%T[O="XWO7A27]C7_?1.'&6",,,1
M"4?&5B"<0"9C#).$)%D49R*-O*[>G^IH;$S17 HT@OK6A#P)I1M'A "H9W[8
M8#-,-JQSD 0N'GV\KZ%K1K=J?*14=/OS7>\R-32CY-N78GW$7B4?.>%@52BG
M--(((BDT1")!-L8QABJ/*(ED+GGJ55?67X2Q,4EHQ[;_F#AZAGI%>@C'3PEJ
M\6]6:9W.NLF9-E_ EJ<GY#VJKFB&O5WE+<7 =ZZZHG1X$ZMS2Q=F_6M2+]D/
MZI?I\O$@XU*YFW*IW$W0M,KA]*UJ:T*E%$D<<2@P5H9#L:%/G7$8QUA$49ZJ
M2$G_8E2]R.HS^X<K4O4CFU4;%;8$;Y5053;W-+X!=H)TS,D7=(!%RJ-$XA3&
M&-O#72$@M3' !"4J23(1DXC[UJ4:R?#V7Z]J:W#_9B;L8S.R232&D75;9:\^
M5CTOQ-M9%;=4!+\;'8]D3RP/TB<>I%Q<JUHWVT,2Q3Z&HI?$B4$%O4ZRQ#ZP
M/ID@L9?. M2KM55P;[].RPG)54J9K3B).#:[):XA29""A%!%N11Y'*G.Y6I7
MO8QM0[17A755D]F*>DFUVC6HK@?A%T+5^XZF TJ7U:K=1Z&W4K7KCJY7J79?
MU]9"M0</=^0 \:CD2Q54>/08N-K#-&?!EG/JXV.SIWFJ?_;%$M?&GYCB2*:8
M1S#)M("(1!@2&2N8B$S)!.$X\G2U!!5O=*S3:&</-39&"MB2WY-[P@ZF(VE=
M;8CZ9KNMT6D)SJE/H]8A.FL5MX<1_%IIV8\KNI\!"$JT824<EJ%[0?> VOOI
MQ6]-T+/?RG4VPS>+)SZ=UVFXC47Z,+=YR.ZD$6BJI[8WT[M:UDD/"R5OS49[
MD_J[DDS)ORX6\O?I;&9^>3=?FKDU7;\W21B+,F'L2L426^(<Q\;@U,C,,;-0
M$(4CP9U2!@TI]-C6CY6H5568Z5I8QU5CT.%N7TO&.H@]KS#K3+!;*E?>AD9I
ML*TUJ,4'*[VK0=\N$M&H?@-V/HN-^DT#(_PX9!-SU!S7_<$^DAWI___RL3A;
M*=<8M=IVL3U#ZXF-TL8>&5260:R4:Z"[LEVNTG>X7>Z)>.CR5$!T96)-F$R$
M%'D*,<(((A3;DM*"0X5UFF9:J<2OF%\PR<9FFYS:/9VZ E&VWH%H-E"^OKA@
MP]Y]*]S[8%YI%]S3. ;9_5Z$>=\;WV["77W/>Q&F+MO=RSJX>IG$G\PR>+=4
M3^4DSA.2T=36P];8QIP)R(@P>UR42(7,;UCJ=)6E3R''MEKT4_@._&H5!I7&
MUZM^N/DR/(_CKS3> Y[&#SW4URQJ># 6(ZUCN)'SCUJZ\ #I'JL5'O9UZ0[E
M?OFHBC=& KO059N?O6.9*.4HRR2'N8C,^J(B!2F.$=19RG+)D:9QU&T+<J[K
ML:T:V[;IQT(]LZE<99<H*W]&I1!H-/+R?W48%]\]0DBT!]P$',-TH/,M5\3Z
M,>'/]GXE&]T5E=-&N',+W;CM_ED5S&9#W"KOIE"<$)T3R!$1QDBF&I(LS0SZ
MN>893PA18K)<+-G,C<2.].'%5NN>^IM$5B; E5X49AY5DVC:5'EK+EUX)NPX
M!JL;!UT(5L]DLY:NKRIX+>J'9(YCW0Q*$2UZ[G-!VZ/=)OW*F3M1.$LRDD<0
M)5$.$28)9 S'$/.$Y3&.$V/*^)@KJX;'9HRLY/*;Q&N8W&9N%^5[GJYG]?:>
MG_M*AIR4Z[8'G8G[&NU/OX/?=\RQ8(!29A676T7DZOM'$RTU3U/)(-4L@2CF
MPA9G2F&B,Z&9UAPSKP1^I[L:V[Q<2[I7(G):2>N9;^$TP&[S-PQL/<_H#6*[
M]2'OVA'SS[1P%HR@>19.]S9LEH6S6A_D6#C_1C>^^*1*9>\LW<[E6_6J9HMG
MZUUO=M#UM>T)5CQ)<9[#-!<4(I8B2)(D@8JBA/(441YC'^)PZ'-L#+(2N7(I
M; E])O-(9\C=J"0PD#USRDD,&X&'R=K@@5E(ZG'I=E .\L!AGXQ\7@UWB_E]
MH?[C1<W%MR;U-LIUK*G ,,IR!9'.$&22QI G4O$XQ22E7@4G'?H<&RMMWV1<
MB]HQV;D+Y)Z'5V& [)F5.F(8Y%KG"53ZOJ2YW^W5KUR>P,'E N6I5R^LDKT^
MTYE(3;@M8PDCFF0012R%/!7&%E(18RA3VM@_G6IC'QP;C855-G6=NY^='P'2
M\6SD(GCZ/@/Q0Z9[E>L#Y7NI;?W3=8YY3VMYLH[UX9/=YO<6<50'N>O+N32G
M"DE$H>1Q#I'(,*2YF>743'J2X8AHY75I\51'8YOKVZM?'5/1^=;S26S=)GX(
MQ 8T%=S!\F:!<TB$Y(*3?0W*".<TWN>%L\]W]86\JOF+>F_D>[.PE3I%E9_A
MS4NY7#RIXMU7,7N1T_F#/1\U_Y-?V%=C'F0HCJ,,8LL>2*"*.#)HX\"E4AI3
MX76TT4&&L7'*7PMF)DA1*^+K&O$? 5=72:^X]NXZJ:0'=NJ E?QU\IJ5!C=@
MK0-8*6%S88;TG'2&,*PGQ5^,@3TKG7$Z]+1T;ZH;!VY?R9G7WN;'Q<R\7]8)
M(V]Y68DQ25B$4)JE$.7:!C9C!HDT?U!!A1 R09I*'^)S[7AL;+<=OVH=F^66
MY/\$5"4[^$XJ/173I6=XA_-@N'%@'Q#W3'S[Z-:"&I.K$36@V>6+3DA.<^Y[
M4"+S162?O;S?#YH.N#XD.Y%[EA"6I3%C4!"D(:(VN54D,11Y+B6A1">17X%,
M?QG&1F1G$P)W+2K587A<?46]@MZW,VDW-W#]SS$F!W;!<X#LP*UBC"$]L M.
MCOF!G9KJ&(EKPT[K"%];C;&.^)U(%N49TP3R-#/;V!CED&59 F.<:DHE3O,\
M]N'#H[V,C?'J,';6X4K <1#=6.MB:'KFI1J56L"Z8F<M8L#@VS8$@H;?'NUH
MV #<-ET/0G!;'[[P*/WMM!2SA?6;E>M] ^6)V;/E*=0X9Q#)S&9\CC',4I;*
M-.<Z2KS*J+1U-K;9OY5M;TM:EZV%/\Z>!^<7HM<S070'KONA>0LBO9R6'^OO
M.L?D+9J?/!]O>Z<;BWQ0RS>L?/Q8+%ZG4LD?O_ULK)*[^?OIG,V%=4")Y?2U
MWNFMOGD>Z2BS)9J(2!%$*<H@25-A4!>9C#4F7'C=4?07872,LQ(5L+6L?B33
M81C<J*=?<'LF)",\L-*#E?@V_\AW5@,PG7\/-K!OM.B%K;J#&)+#.D@Q*+-U
M1VF?[RYHZ3I%S^]?EN62S:W'_A<U?7A<*GG[J@KVH-Y]5868ENIC,15J0F(J
MHTC&,#*,"9'6"A*5F#_B-.%"8AS%J7^YE8&D]R&&X0JPK"2&K!89J$9F\&R%
MO@$_JH?I?%[GFZC+>7PWG8.74@(C9'UA9.!JZJY?"TT,H)IA2$5JZR:G$>0D
ML2?2%$FDDYCAU+=VRVB_E?ZKN9S]4MY5:OWA/A-'G^KX!GX(/^R9C&:M"<UN
M-IF_M[2_ 2O]00, 6"$ *@A"5DL8=,S"UE\81O2!*SH,.AZ'-2*&[;ZC'[IX
M8//I?U:RO3&]+F9360LZEQ_-_%YET[W7C3W'9NMPT,WNQFPM44XB#6F<V41K
M+(.4BLAZL93 0L:9SKW\UB&D&MN^<UNI&["C5G6HOJU858=BI1K8Z-;9+Q9F
MG!U=ZT./7M^N^($&SM^#'Q+HH![_(((->T(0$LN#$X6@C7=C^G>LL/NJ\J,J
MJG5GOP"YQIF(B"T8E*H<(BKL(42N84(CB7.E,B6]SA[/]#<V=JYR AE9:P/3
MCUS/0>M&FP$!ZYD05Y)N\!KFTK C0B&9[%R7@W*4H_[[[./Z6L=4)^;3^& ^
MENJ228ZS5.K8&()"(H@B12#!E$&>4B726*-4>F7<W6Y\;(QA90-6N$[W='9@
M<R.(KF#TS ;../BG)3FB<-!$)-OM#YMZY(AF!\E&CCW3T6/^PLOJ@N[RW:OY
M8WTG+,8X3C4B,%4T@XA'$E*=(HA1A%+-<Y10OR*!Q_L9V\S=B DJ.2^H,7H"
M6$<OW^5P]>V5ZX*4O^>L'8>@GJX370WKF6K7]\"3=.;QCIZ?5U7<SF:+I=UD
MU#ZGOZDGKHH)R0152<:@RDD,$9(*<FGV!$EF?ACGJ9#$SYMSJJ>Q\8(5%*XE
M;?S)GGZ6DZ@Z^DY"8-6W/^083.#76LZ0[HUS6 1U69SL;%@WQ#F=#UP+9U^X
M, ?'O6ZY\92GTE@) ALK/],0V5SH%/,$QF87D/.4Y'GFE?W'J=>QT<8F'X6M
MS+-S\<S]HM0%@^!H;(2&MF_3(P2JW7-_N*#42SJ0UHZODR'$!8N324.<7O;C
M**FFDUO3MJQ2#\W8PR1.HP31G$#--((H3P2DD910*XRQ2",4<2?GY4'+8^.:
MM7# 2N?&)H=PM3/&12#TS J.^CO/^Y.Z;N9VN9K<I1)_?EB\_F#>J>>U^<O^
M=#YL;Y I>U*-U;0\_4"XU(#E^H?_-E6%34VXREA'J29*J CJU.;U441#CA6'
M::X2H7F4"NZUH_#J?6Q3>"MP?RUI=8[XX?;O ;,&GAX--WNA-XQ[9HC+X V2
M4/ L3'VG%CPMP-63#)[%QB7=X/E&1AU9_&DQF^E%85^<)$ID2G-DKWPJB*(X
MAM3>_1((HT0CIG!.O'90@ZLP-GY=1XYZ!OR-Y8MPW,Z->IS[WAM>*5BTGRWG
MU4;R#QA"NJW%?\5HTB.C=*7 TF.2=%M5[^:B,&NW>JOJ_][-UT6.WK#GZ9+-
MUJXLLQ?05&024FZSB:/4K(M""R@P09F2"J?8J\:!>]=C6\7>/-KA+,%T#A;K
M,EQUDH3*FIUMLOK\Q6])\Q@.MZ6H'Y![7D)60H/O5F)_;['>E#QK1.^%\OT1
M"TG5'KT/2K'^J.Q38X<6NE&:8=ZGQ7RK"LP6J4X,4:5,:D-=7'.($H0ACW,.
M:9RPG(@L,2SG0V)MG8V.MBI9]PH\+3;R^E%5*\QNY!0*O)[IJ,%MI\S3CFT:
MCGQ<$ E)-ZW]#4HP+IKO4XK3.WXDHF>_E=LY1:M,O653]?7]2]7T)R74]%7)
MB2!:BXP*2'.20$1B0R8LCR$6(HV%I!G"3A&5/IV.CE2:$L>Z%A,4C9QN9.(%
M=SNI] 5BS^2RREML10:US#?KNM&-V.!3?Z#*A7AY6MUQ&!S<G=X'!GD?7%"G
MEP-U?KG+.;T+9C6WVS<-8UN8&K[V:FL0WNZBW8J_.[W;\6;-T_-L\4VISZIX
M-1OGX_OS#XOYJRKM7MONJ,LOMLSU]N]M!;L/B^6_JZ61:O$PG_YG4V6PV;5/
M5,PRS&,)%<$11$HED-O:&"A-B)(1HAPKK_LY0T@]MI7DYWFQEG,WNZHPFMR8
MK78EMN?UGT'&W\W<'=VH#N@)/IJG=:WKKN/WIBH9:7Z[!-_4$FSTO &W3XN7
MD'D6!QV2H'>?!A%\V!M40X[%P3VL03N_,.SSS8R591.[55UID#1'*4\B6W>-
MF/4'2\APE$)*6:*P8"FFW2JP[?<TMC6CDF\=A-CMFLA)5!T/^T)@U;<'PPNF
M[H&9IR#H)1CSH+/K!&">TOEDT.7)%[JQPH\OY72NRM(0$9_.U]?8I[)RKB[F
M7\R"6]:5L>L S[NYF9F&QIKJV+=S:?_"^$Q-LBC):*05E)@:'F&(0Y9I!I,8
M*8&P)#+UROD?4+:Q,<_[F?H*/IIEXHF!)U;\9@P54;NQFUP"@)F?S!:EMV,U
MY("Z4=B5AJEGTEMI!;;4JE.$K!4#6YK=K$+7U\HUA0>J([V5?N%(LP?00])L
M2/$&)>8><-VG\CZZN.R"?Q,]RB2.,$I2R")[Y8?&#+*<"IB++$VUQFF$TBY7
M_,<9K+MUN;U39.X>>&Y<V1V2GNG. XW.E_W[BY3=Z^$J%_[;8UU//'5!0::=
M:S=FW[B5E'R3GR81(I=2*)AEMI*<S05 59S!#$6)-G-;IMB_#)-+SV.;[9^_
MW+_YG_]V_]/;=Y\^_Q-X][]^OOOR[QW*+#F![KKSZP'*OGURQR[K6;&W"A6
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M/"<8IF8AB#)-(IK1+N=H@VHQME5CK[ANH+JNU_E _ X 1SOL0YTL[H1.;2
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M9CK6\95S-+5@<3Y74]O+%^]\3(/WA:W<K.3?V>Q%?51%Q7^&CSCEE K(8Y)
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M\R6-F5(\!%&D_T 2AX#)!(&08J'_3B1SU$([T]#4>.#$N97+*?=NT-IQP1"
M>::#3ECU/N'C5>;L7%OO>K[GHL39I>L[1@=T;:(.\Y<13OM)GXJ';Z[I:O6:
M+[Z7JW<HT7.-#,4@X]*DB3$C>\0AP%!/,Q3"&:1.&T96K4Z--8RU1>S,S0]R
M;[=C[&"%N&4L,32.OF.+&L+BAX;),[,\75M=KJX.&&RXH#1H\&'5\+C!B L6
M1\&)T\U=ESPV5,<]XH:N%OJ1ZVJ%D& $990A$+-0SU=@HN<K,66 $DH)YCRF
MQ(F!3C<S-<JYXGS[O'VBQ6)A*=3JNKYQ$DW;A8V^&'E?T2@-#&H+/:RAMH,P
M["+&R99&7KUH\_9XV:+UZD%F*R8=II+E@E+%:9+$@')3=33&&! 4(< %PS1"
M&>;0B0/.MC0U&G@;@_>J$G\6WDY3EFZ@C3QG\5:Z_1(6'J<MC<;><]YR[/.%
MB<N)&]QX0CW]]UHSCW[65G[2YI4%BWZE&_Y#<]"G[4*L'TUP7N[/S*.8LTS(
M"'":48"DX  GL00Q3@AA6<(28B6-Y-;LU!BDMC-0QM!@M;?4CCT<06^G$G]0
M>H\W"IL#8W15_VT6[* M# \>/4,K*A%D6NH1CP[Q0?O3A]J:T[LA5A*\N1>8
M;"H85Z3M^+11&+R;AS6==[Q[D!APO\7"*>&AB@B(8R$ 2F@(J* (0!5E/%7Z
MX]A)Z.Y<0U/C[Z.(IOO>U5EL.\5_G1 ;._SSLX=U"0F/P=_G]]G)NN3QA=#O
M^/H.D5^EC'.M/\\Y??JZRNE3G:^!"8LRE&(0$969"F$,D!1!(%1*18AC'MG)
M75]J:&KL4)D:\,K68&.,#61IK>7Z]$5T+8*Z@3#SS \U7+6906'GQ308-[0<
MXK2!4!LI,NN(GEL@9@%):^C5=O]XP9:%%P?AE<WU'0.J2V6!+U0%OA(B-S_0
MI_VYTOUFM]#$BT2*@$0, 02C#!"*,B#26+$,9:$43HF(7JV=&GG;%"6WK4F^
M=[QQ?KM'=H/7;XUEO#F5[X+OH'427X/A2]$/T3VC%I_O9?"TRLT/@;US@?E!
M&NU:]I-N"AO*&H#&P.6BV*(VY^Y39,2J8PQ"+J0IAJ.'D?DC(DP@BM(HY&YO
MJ;;6IO:6J6I7[HWL)&30#K EH0\%FV="=D:L0W5/"R2&+?#9UN#(-3XM?#\N
M\VES4_=*GV5)\YN%^*C;F6,:1R2E$<"(FITCC@ 3% (A5<)3_9,,K=8:S[8P
M-8[85;$LK0QNS#D1;:=[C<]#(-MY81!X/'.!,S*=JGN>]'Z VIZ'SQV]LN=)
MMT[5]3Q]80_YDU(+H1)&F*LT0F8W&' &%4 X4H J#D$J5:80@9QBI_?_<1-3
M&]"E6L=+M6!3I*Y6RAVT,+N#QLDAI'9O_'Y >1[:31'^6:UL,K"*R4G?!Q<O
M.6QE?,V2DUZ>E"HY?67/F+\L\<8H45F2,<#2+-.#''+ 6)@ +/785QEG.'*2
M)3M\_-0&^,ZZCK7R#K%SC-\G5Q'/&HSND;J_FG>'+;Q/+-Y>V>[T5>[1]LUB
MHX/W1_D]-Y/^Q>9.]^E<X1ARDF&@"(X!(G$,:)*D($PER[)8)4EFE=MYKH&I
MC=S2QF!O9&"LM(^T3X)X.=#N"XWO.;<;*DY1=IOK/8+LDX\=+<9N<ZH98K=>
MU^W%>_NLH\J5(83[U<=\_;)<TZ=[]7FY^/XY_RE%^8XO"P?NM? 4R@1,< BB
MC.C7LQ$28U&: )$A%<LXYBEV$B_N8L34J&#O@SEU;6P'A?%54.KV2N_4*W8O
M?M]8>^:6)LRKH';@).3C%+[L@^>0H4<G.T8-4/H@]3:,Z?6LKE,4_8P?RR=]
MQ[I<N9P3"D7,- ]"&5* :*H T6$.").(9Q$A6:ABE[H+QTTXL=QHY1?6#3O_
MK3A#NW%4%CP!9AHGH1)* B2C%"!%$6!4?\]#'@DH".=9G,Y?BL4E'<2N-F-
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M/P6?;N^N[JYOKSX'MW=?OCY^^_7FSK7V?#O6=CPW&(*>^6R_NWFH;..%L:Q
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M=9FFX1.H+>#QD07=UNR[I#);X' N']GFULYR+WHR;9:YB\A^MQ0F18))%$9
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M9_W3?_Q+_1O]AXG^_N-?_C]02P,$%     @ KX.O4,E4Q/.C4P  #<$# !4
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M1W#SWJ<IY'_^2Q[],2-%M50LG_L_;__XYUL2/D]AAJA9L/P>WUA]1WG:SN3
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MJJ45!]-"BTP]X2&[TOJ:$^=Y(CHQPZEA-II*%9GWZ.CYZF,-73_1&&47P3>
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M&<![ONQ#7D1PAF:#*+"Y7.:20()'<8F4+;4BEXG;-5#V'%']EG)7PE9G6F@
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MFPVZ><I!Q'!ZMB@@G[VYOO.O.U5*N$:$UP9I38Q(QRD)')<-5TP*+ZEEK,Y
MKQV(;=BB;8.GI\\<*^FM@5CBEL?5I8;_@G2<2EUO'MY$2@L^D;2#<;J)S<NQ
M[FQV=0EI82ANV0_9)<\#QY#=H[P%$\1J$XB.C',9L\^ZROKMF(]^\RPO@.B7
MUW8#8%^SC#],)^\FN"T>CW/YS_VU["!;H#23TF@8'19NT%>1FC"65)3(=X J
M+3NVI+/?I$TUL-;4UFOU+$_\=+JXV;A'-=MV#W@1;_-YME["[[0B!H8_<"F*
M<K?  O$)<>O0D 6A8Q+FU47+V_@OBZ-))24(C^:<6J=Q!6E/G#&"L*1IYLY[
M8>J,2-J2T(;]S6UPM(^_N;6^VMQ^%[4WRDMEO<@D29"E0Z8F+FM.) 21#$^1
MIRH7_9Z@IY5BMQH@^/X6N[5&&@76THN%5;F.C%H(Z@UAUEDBHT(7!$PBGKF8
M.&ADJDJ9[G<I:\.4[:7_#3"UNS)Z1%?QG ;OT)?YL'!E5J5:EBN7#/4D8EB/
M'FU XJU!^8"D8%3((:KO>6!KO[D]).RAM4E7(FS NCQ?.(I1KE/>&$*S0;%@
M1$-<D)Y0+T&!]%3S.GFZO>NU7Z#Z[06VL.ZTTP#4UM>:)N0 Q6.(,J)<$&.4
ME*)D7(C4"L-IBKE*)=*K*^+>2ML;%7%O(_H&\/.XLEA(*B%321S5BR: G@2'
M# 01I:*9>I6KA'2OHHA[*^U^MXA[&U$W@)4UMOG]MUH6#LG&TELAE>$PTCB4
M3,J"F"@<>!84"R^5^?Q&5+]ISK[CLMUTTR;./L"TM([Q'U&:?Y^4NX+'8WP@
MS&Y/'P80LY4TE_Z1 ;G,4N-"X@;C$),BKJ5HZI:O;$=N<\[[CG#9( 7?L>X:
M0.C6=>Y<@K9E;C/3O.P;/! GT>- 0R\I#S&:$%_-A83JIYB=H[*JOAK XZJ\
M]/=R*%(Z/I\-/WZ:GUP5)^,TWU:''OK1"-*;ZR,?/]W_[$!X8 KW%Q*4+[,W
M/$.G! 013A@1&>56U6E;NR_E;1QE=H[8E]5HWSFSM=PNIXVOWINMWIS]-H:O
MN*$,9PN720<F0TJ.J&Q*^:&7) #Z32'G&)0L6:8'=9M/Y-9VI:#?LO+.X?=R
MVGBMY^GG5Y>7?GH]R1^NIO&3GT$90#-$-2_K5RL=LF_VU!<Y>=]! "]R'!\M
MQLP&@R=96LA;9]#P14=RR,S$Q'A@/_YQ/$U)&,70TH/5Y3JE));B%L #-2ZX
MS+G\_\?QW>%H[^/X;?35@)OYU.%?=#Z"\Y905>R^213M?D&)H+9< >!25BW!
M?MW'\5N!8,/C^&TTTBBP[I\E>A.-EI$26UP8*9(B(=I(8K!"^)!,<NRE(/8*
MCN.WTO_6Q_';**/OT.+16;(/-F3N7!D.$HE,1A!G+2/,T1 2Z,R!;Q0RO+;C
M^*VT]NQQ_#8B;-.ZW(F2+,B00R!9.Y2*39*X$#E!1J+A(8-A5?I=[7UNT<YA
M?,<;V&ZZ:0AG=_S*>['1!8;.LR5ERR3DMSSX\6QVM;@_45XL9"JCA2@@$>Y2
M:?R#8;RU,1!-<1&CP%EB53SY#GEHSA[N"*SOWUI]$2WWO9%NP?<[/YS^W8^N
MRJVA19KH8G*3.!I$RIB2QI61O"AZ,&@L6!(D<Q4EI.S@8=G\$]MO-_2T?."Q
M TC[TM3K!.?IU7PV]^,T'']<SBB9#9+1PFB+*S++TE=/6G22.'(NT>71EJ*/
MQ"K"\S%%+9]OO"Q ]]36ZW(0V( &:DLC=Y(24"*U0+:<<B3'Y$!R;62NTAQQ
M&R);/OUXF2U^.SWMCL')W(]Z//18A023#6X!^W6W@*N=BW1%V,L<G501XXLT
MV3#69(WF546$MLR:$N<])TEF%0W37/,JK;^:.ET1WB4N0!%%%5U.T'/)>B)9
M"#'@\H^LBA!^H-.5;7"T]^G*-OIJR#MXF,MU B1-5!+..,K,:4-<Y)%XD9,%
M$-34&1CQ8YRN; 6"#4]7MM%(H\"ZGQK&#5=I&31!G]F6(<>:>!0-NC0Y4A21
MHW7-^RL[7=E*_UN?KFRCC+[C[D=' R"]X,8&8CW#B R\(:'D$)SETF5GD ?Q
M/8_O59ZN;*6U9T]7MA%AF];E-@JS.D>5>"#,Q$ DS0F#(\>(IQI RQQ\W33V
M#W"ZTO$&MIMN&L+9';_R<115)+9!4ZI#/RNSLDM^_HL?E=N  PB)Z\ "H2*5
M\1R6$V]Q$8("Q9VV@;(J5R;KLM6<U=P1?M]/T/2%A1]M95Q-BV:7G\1O 11*
MZ>LY8,F':%4D296II)ZBNF(0)$0O@&EA!7NI=&3GS#5\"-3,*ND"%S_86CD>
MERF^D^GU(  8QJ(BE+IR74@+8J$<FBGK$U6.4OY2[:/WYZ;A$Z=65L-NFO_!
MX'_/)'R8PF<_3$=?/\-X!OCYT_DGF"Y_-_!)<%:&61L%&-'HTN%6<%M&GP&*
M2 =+7>O+8V-N&SX3:V7YU$%.W[F0+B7TRV22_AR.1J58"-$S_CC\]G<#IY1)
M5'N2%M._K2\'CKY<[O*6R9BS"IL5L+X0P1LMB&ICU#M?$,WJ^@?;7E82,)%1
M@\P2@.")3,FB!#(C";S4E$:G4Y5N6=VSLM$ZT*]F'32B\\Y**MI _6IKO/.+
M@3(J!JDR :%0&E$[$O MHH4.#%10P57I'5&7K8U6@_EOO1KVQ,(/MA_<%8-T
M8,MP(:)8N:3IF"=>1T%<B;J\BUFFYI-1VZX%^]]Z+>RJ_1]L>SB!^2 FZ1WE
MAF@)Z!.*:(@MO9),EE$PF[7.5>M!.N)C(]"[_]:@WU;;K[^\]+>QOTK#.:2;
MN1UG,+M";-:O'_W>DU^X0'0K0;Q$!2@HK=$3C\1J**/XI"&.L8RRECY'8X.%
MESH?[7PXY-T3^%MY?X'Q%0R"STFC>X4++EHBLP>"7Y2)98P++ERF^J7NASZD
MK8W#W;W1LD'1PEY::<@/7L<2&OGC,9H'>#^9S0944^^*1P..+@:8.^(@J&+2
MA#82C,A5@[WO4MC&6>F+@FYW#;4)O1N^'LZ$?N-GPS@0.2NM=$1WNO2-8^A8
MVQ)B>AY"]%F9$*H>UFQ*:!O'E"\!Q.[TU7#3M5_.#DXNSL^.#H^._W[PYOW1
M+J[>H^_HRFE[GKB.W*\[517?D,2UC+'L;DQ#1&.#D8CCB1$=HJ2)BQA4E>U@
M#2W[&J+W$S^>E;:KLXNI3]\.^NX\:>WP9R,Y:,5(YHRA  0*0&1)>/3:4!T-
MEU7:BN]$;;\.V;[X>6B)ZBOL%9FC/0+0I[ZJEG&J&2*NPY@2*F>.>YQ5KJ3C
M@!)'!2-<6@#-0?%091A;!1MUYRO1Z5OEWP=*!AJHH2127UH"@B8^.TX ,2V-
MMXG5:2R_EIKV;,PV^G]H8_87>,,VY,/9T8>#X[='__[AZ.3\Z/S@Y.WIQ=^.
MS@Y_.SL[.KDX.#\_NCC?Q:!L]+U=69?MF>C(U+Q=*?-P,IO/#OWGX=R/2@YU
M52]TOU#H=B?Z!LL@/<\A4J(R340BBLIP%4XX4$=-5(RE*FGR/>G>UX0MOOQ>
M@=7MW@Q2!R&4(X(&C$NDD<13E) 3,0G'P7I?I9;B&9KZ-6<OB;&'IJ\K1;UR
M WBQK,"O9 8O[M3WOY Q7,=0*R8Q2:]Q8R66IU)7DQWQ$K=K84NR@#G\?94A
M#SV;Q-LK=VO67-'6G>A%:NW+1"Z;2D,V$2())D>BM \I9.I UYG3LC&)K]Q@
M;H' I_L_=*K&5VX_;X\,[Q=2S_Q*%_?DM$<86X^8E[3.'8BK$6/.A0-<.IS8
MF-!'L&A4O-"2: S#G-/<T1_*OUV47:^><8B_'$8_NI@._6BEP($UI0>M 12%
MBD0R08DW-!*NC>&6"9_29HTEGWG(ZS:^VR#F7K5[5V)OX#ALQ<KQ&"7CQQ$&
M1FL90T@$'&<$7Y86<9!)H@RHTEP[6R4F>DA(O^>J?4"K$Y4T *D[DKE)8 43
MJ M<$988BB.#(4$C&X+*H#W+2>=Z@?8]4OH])>T35GNJI0%@/7<S[H8E0RFC
MRD=B/#@BJ5'$E^DU.BB=,OY6Q2I>P :T]7L1L@&+UIGB&J[KW,3G/BD=I>?#
M+U Y^GCTG)<,+)YGLI&801F>< O%U<QQ>Y4Z>H2W0H_-N9!]DDK:*O<FFDD
MG7^:3.<7,+U\"V&^[*^4R]1"0+)YUN5*#;[R5AK"3-"*"A-BG8J[YXAZW7'&
M-BA[.LFSIZH:V+_O<X!_M&@>&(*1K SCY#Y+(CE-I3$U$)&I%2Y*G7F5T^2U
MU+32S'-?93]$T=Z2;Q$^JTZ#,4DA1:&;,4%D<))X $8BDJF20I^"UAGRN)Z>
MGB&TOZ:_AYT=Q-X >A:%6Q_\]2(Q/GGCQW_,5OTE'=>JE'X1:XS!A970LU49
M".,QBI2T=ZS*AO<D18TA:!=]3VH(OP$4W1/.^SNCI8,MMRQ)")H1*=! >WP\
MT<)I9857"JK4B*\GIY6&GC4WL=UDWP"""O''8_0,KRY1F.]\A(/+R14&P !4
M2 V*1 :Y7+*TQ(?L"&/)RZ R+H<JV]A3!#5DA794]J2"Y)M#T,TTM3,_AW/4
M#X8E,(U%51]AX,NMBZ \4;8T[J26DI!,&=YLC0[!!\XKG8EM2F+/MJHVRCK3
M3@.XN[N)WV3M-)@HG=8$M,#0UGA-@N2>4"NCCYDF\W \6/>^4Q.9_0I(VE?>
M#1=R')[^^NOQQ:]')Q<E>7AX>G)Q?/++T<GA\=%.!<#/?5U7.<^-2>XHM7DX
MN;P<SHL-F1V,T^%D/!^./\(X#F%MBDD(93*+!/>RTA5!XA;&F";"6@4106$?
M#G'N9AUN1>6^!FBCA]T6/7FJ0DY2DUR&/$OPDH3%\  >!=I61X&IWF322/U:
M/90]M&85E?<Z#=T>AS\;?.L+F+V:!SO;X9(:!D%F3X00CDA&%ZUI&'%,\90Y
M]ZK.C:L7MG[CV60T3$L]PFQV\<F/?_\T&8VN3_\<0SJ_"K-A&OKI]8?%TB]O
M3F>?AI]O?-"CG"'.9Z?Y$/_PX^*"T3(H9X8%;2VNXQ!"*4(-N-84>A9&>X?1
MNC>^RBE8-8Y>DTW=!KN/;6H+D.@Q-)E-YX-O3*TRW=X)*P1)6BRZCF<27/ D
M>L6L#XD:O8DCA%]\!\?XKX<8?O3DOC'7!!(F7:BE%3RM\MX:N 3%)+&!92*Y
MDAC"*46B<RB!Z$6.FS0\V@Y1?1XE[:F]=1C8091]=R__;3S\@M\TG%^?YM_F
M_M,9"A^I^?1N<C5>+K/5"0;WP9OH'8EB,? #?59GT)0G8T7./,O -JNSWO2)
M#:!B%WU.:@NW@119#3-\FTQ*EJ+)X)QD8Q?B=L0GEHC-PKK@4M*Z2A5M5:[Z
M30"WM6^V!Z,&UM2OP_%DBI;BAK=OS-YFTM]<GTS&$1UM?#1^S<?E1P8J.AUX
M:;T2+4/7&CBQAEKB16)")6$B5)GBNC/%/YX/N2/J)GU H&^/8]7+\1TJYI>I
MQ^CQ5_]U>'EU>?"GGR:4GZ?&LD@26@^4GQ?$"ENZBG#'G::1Q^_FC;[_F!_/
M&N^'P(X5TQS$%BR48ZO28B$)GS2)%G<IZ20EUHI$8C:E2"Q(9N5N^/KVC'Y/
MZ%X+N'9327/(.BJ)X%F9VEM8$1QLUB&2R((ITZ -06%) B(I)Q4"2/K=T'7O
M.?U>L7DM"-M=-<VA;/5&:?^)F_X'?[U(NRYSKE>0;MY8^0FG&25Z[LN83BZE
M#<92XG496>\3)\YG($8(KWB*YE'KGTT!N2M)_8X%>RW8?1&%-P?S7_T<]3?^
M^.YJG% $BQ$)A<\!&(821+_#&&M*8R0@@:%_RWA,Z(7D**S8U2M<_\A^IW:]
M%IAVHK#F8'CP\>,4/OKYJG!RV:P0TD"(%+G7C(!)E$CA-/'>>A*<=!QEJ4S:
M<7=_XHG]#LMZ+2#L0EVO!8.K KFRWG#9'7SQP]$B#9<R4UP8@=%97+3C &(-
M#R1ESR(&_URIU"DTGR"DWY%6KQRQ72BW.2#?9^K;XG2>ZLRE(DRC1*40@83$
M A%4&^T-#1#C;H!=_\!^QTZ]%F!VH*P&4NG%32Y%)[\/YY\.KV;SR25,;Z9L
M7=^4&/.8&7!-"7.EUZ:ACEBI$T%Z.*B0(K55!OQL0MQF"7+ZWP>MU33; %K7
M]\+6,B:M$B/!<%-L?B8^>T5PQ2G&6%#4RQKPW*/Y^'_#$YO]===P4>^[@^.S
MOQ^\_^WH]-V[XY.#D\/C@_?')^<79[\MZF1WJ>C]WE=V5<Z[%>D=U?*^\\/I
MW_WH"FZK'V^;Y>? $O<.O3>$ )$6K9.5RA,#(?)H8HBV2I'^<T3M:[C6??=M
M9;OVV5J:(]&PL,*A7(&E@J )=HS&Y&V=IL//4M7OR7-G"'EHAKK3Q.LU1[LW
M%-_LBU_(-%5L(_XL_+05VCLA".5E]FV*Z#0I?*64LYH[85B=.9\O8J#NC-C]
M%7QY1CHMXWEQO\8PI\Q3F_TVGH093!=[^?'X\U4)RB?CB'^U4/.='OU<8/"-
M^SK0@(O5.TZ"Q(@\9ERH+L<D917'K 8S#9O#;?#XI#GL2^^OUXKN<5MKPV]^
M(3M:\];6L\ -AC(3K2&^)$QD8)2X7.Z]<ZVIC4F J))7>"V&=)'1C #11FT)
M]=03Z;C'< L"!EY.."ISRJRN<]@1(PT;T&UP6-. ;JWO!E(RW_A_<_WMY=^&
M,"VU^]?OX0N,%O=%LF T.!,)N)C1L=::V* YB2F);%P, :H4JF]&7B/8[ 5"
M3^&Y.WVVA-*57!<5(8_YN[G$(CT53I:)G!&0.<&)95X2X ;0L[+,BBHM3+:B
MLA',=@B3IY#8N<Y: N1B$<\6$A.K&TXY>@6@!0%F<3NR)A '$@&CHO""6@>5
M$V"/:6H$;-TCX2G,[:F6EA#VYOJ.V-Y-X3^O8!RO%\O3)!9XHF7VNBCY_!!(
MH!@^ C4ZF&!#H%6N^6] 6[_7#EK=DCO19$O@7,?0:AV'X)7($M>;%;C>&+X*
MTEDB-+,N"DD-K6L&GZ:M$7/8%1XVV'CW44ZC>)M]6\8K Q]%#B(G31C+M!1B
MZK)&'9$J*6"2"BY>#' /B6L$<5TA8A-7;Q_UM 2Y_;>0VP-XE9TRP#C)7..R
M]D:63(7'787E+++WAK:>47^_U37O:G>_VMSA^\+*C[5>#OTH7HT6+\\FH]&[
MR71Q+=.8;$).B<1@T$*)2$G061(FO126(5-UI@)4YZR1S:$W\-9;31T@J:6E
M=6=[+66!CYB?W>=^=E]6WZH'%]\U8%I9KG+&_9B6?HP&#9X&-'W:"NZ5UQ3J
MGMYTR<T/LX2Z0.P&WMG+PF?G-?09IL-).I_[Z;S;E720_N_5;-'1[S3_7N::
MH<,Z")$;I124@742C99/Q)<^W@RD%8&J:'3=O/$ZJGZ81$I-9.^MSNT1ZI8(
M'2\NMY3;_4T;>RF2SE1J HZ5<4%E5ID-AM <J T^X8+]P8S]:X@\7HVQWP8^
M>QK[HW&J6A5T?G%Z^*]_.WW_]NCL_.C??CN^^(]=*H#6?$M7U3[?(["CRIZC
M_[Q"]7ZKH8C!00(,>H75NIST%0U'3TSDJ&(%.=@J>]]],O8>YC2?Q#\^349H
M 6;+;RXC%]9U(\\A9QZD(\R7'AF4 ?%91R( /'+K4M!U9A1N2F&_'NT>Z'@T
MY*F*3AJN.WR\@'<OV'[RN^I9FXIEV0]09;VGT?E,J!&6R*@5L0G5+YU5V5,/
M0E09T]>MS;EU0A?38@]P_WK6,< /G$S&TWO;;?G[51%N_#0>_N<5S!9JN%T;
M+C&%[ B4%6"X97 ;]EI$XDV@4FE:VK/6C4TJ<M>4K=L&E4\')*U@X579R2[&
MJ&_PK?5LYXN,2'^ 5V]4R@I*;E655*LS)$2'NR8ZY\PPX7*L<IVE8\_M=L9D
M\1?>7!^._&RV.II1 )8'19POW4T\H\0R%HC+TGJFI3>^RC"09VAJRF)M@X!G
MII'O)?<&TN1G,%J,X_/3^?7%U(]G*)L2V;ZYOON;17F%UJ",YT X+D<B(7+T
M9QT0S03&WMXRF:JLF<U);&9L^7ZH>'2)O(J*&@/?JJ)">LF3+I./-3 B@\>@
MB3E%..BLLZ&>B2KGE8])Z1=,M93^#+9VT$#?W81^AQ2N9I_.BR^X<!>/Q_%F
MHG8*$6+"P)N6 Y;2<]Y2ETA6.6KA?53<?,\M^LXSVD'(+JJ;="_'QDS*G76S
M6"A,<F\L ,D^E;E]/!*K8RXUTUXE"%F&2CU3GJ2IF1GE+[%C;:V$=O&T6G T
M&*9*% FTU#]E <29J D%IS+5*1I>)1GS+%7MF*6]=+\9IG901-^;UCGJ8I:O
MSZ]BA-GL'<#;*[B8W.7OIOC3,R5,P(47P)8$<B;!*U7Z^KDD-*!%YAMM89L^
ML4GD[*+A26UQ[XRA+S -DXYLTV*2>CFK7)CME1%?++0DK766&\)\Z8Z@(1,K
M$Q#%LZ+.@O<2:MBE)RGJ>2IYI7VN&P4TL,O=I7^UWF(2T>GD"<M:H%R4(%[*
MB'*AWN)RR#Y6R9T_)J7GJ+X;'3]L5+B?P%N S.3R<C)>\'&P,J#&B<C!:J*R
M,$0ZC#RL")&8!!R,7%R(J *91Z3T/$%J3^6N&1F^AZ3;PLJ;%0<R&^<E-229
MLMD*$*5_#VJ71LYLD$K4FU5]GY2>9SU5P\HNDFX *^<P'<+LX,/-XQ>26;&2
M LU4T$PTQ2!"!F6)A\P)6.G1+>2>FRH!_#,T]3S,J5OT="7[OB.L#]-)'LYO
MNKO^-A[.9S?9+$#1<&9(]*7U:I::!-"%%:VBSL9OFA5\\A$]SU[J!A =2K%O
M+"PMXEWJJ=*@=1 8W2TV3TZ)DXM*T2"#<P:Y<!MAX-%7]SR[J$/=[R>U%K:1
M&[=]>>R+_'R>C,L-VX7K[F/43AM+<N8E49XP_$LH'.YX<EKFF&B5RNYGJ>K7
M<E2/D?=61 .H>L##S2J3*2JJ/+$0-3(A,1",%)>&"HYZ"MS3*K[L6FH:B9;W
MU_:D:]$W@)^E6;WK5@6?*:XN1Y);W*#6C/C,-'%1Z0R!,<ZKG'<_HJ2%XIR]
MM+LV$MI5U U@9:T7'KRS!A0E7/M )"WCJB)(8H-21KN0LZJ2E=LY]*D6.'>/
MF+T%WB-H$@P'[^&C'QV-Y\-578C+6C-'-;%H68F42I(@T/F+66<>-!.0U[2?
MG-V 90;QKQ\G7W[&KU[B!%\\A,>:Q_;K W?MQ>PKUYXAL:3Z6S 0E9&2$QI,
MN=II,6ICSA-32 ;.N7XX?'@G/-Q]9C^;RMY*FW0@P;[CWG<C^/IA47M]$\"A
ML:*6EU9"Q9))""08JX@(7%L0.CK_H._=$V'OPV_N3\F[*V?2E:0:<!1NQQN5
M$;_W3JBL!0VE"2DM4U:SEAC^4TY*5RG/G.;956GN]21%_4[-K1;B=J* %I!T
M2_Z)O\27C\LP)+I#)D D5*-3)*U,Y=#3X=HP L5D%$1>!5+?):WGP+<;##Q$
M5K<*:0!BIU]@>C :399])SX71FZLKN<6K:XEH *@U4VX^+PQ)*IL:/;!1%8E
MM'F2HIX!U;'J)S7TT "@[F:]WW]KI16ST58R2S 81"9X4B3D4&HSN'$1G4$F
MJMQ47TM-OV.Z:^UZ^PN^ ?2LOV>_>/?\\V@X/YR,<:',2J^1HC V\!PR^H&!
MT)(_DE098JWR1"9--8!AUM;9_[8DM)T*F!VQL5%#A(X4U0 0[Z0KSS$6@=GI
MU7PV]XLYRP.ELPR.9@*X((ET2A$?&. R!>]84"F$*BW+GR.JG;*9;@#6F0(:
M -."B^/9[ K2VZMR1_[#HDO0XI+]"?RY^,UL8%VBPA1!)8[>*4//P5KI2(PJ
MF!"=4Z[*T<-&U+535].A_>I4)8V4H*]E:[F";OGB1F:A+2<@.11/%8C-41"N
M4\K:).>AB@';C+QV2G:J8FT?I;0!MCLAT56)5? ?"YZ6O!Z/[X1( R=#DDQ;
MXA0M2PGY=)8I FC&5;1*:Z@R0FX;(MNI%^H(>+44U,*>>LO;A^DP JZI!6\#
MX""=0W.M&1/ETJTA0=I,O%*,VD"3YE6:P#U%4+\YUJJ@VEWP#0#HIL7JP3B=
M#3]^FM]U,"]@>CD %U7.C!$EO$9['#%B\1BQT-*A2#OF9)V<Q?<(ZS=]T3V@
M.E5$ \!:26C%UNETP=0W^_OM2O^A'XT@O;D^\O'3_<\.=-*X9@PE09E$I%*<
MV!B+9<Y:^>B3K],-:6_*-X*F?3W0?%E5MHK=HZ\PC<,9+,S];6_JU6]G;$!I
M9EJAY7<E.)("PZ2@LR76N! Y,LELG7S(+M1NA%'WRC':J<I:Q>73"_$AOP.7
MC#: _&F/895D4A/T:!E*6=ADC$NJSARW/>G>+&M,7SE8*^FQ =@^&_G?ILA/
M\_+U?!A&<"N%018TT>PI 5'N>( 4Q):.Q<A[]([:%%R5=B;[D;T9:%_;6<?+
M:+$!S'[PUXO1=RL1%K[].,+A9(;K#[@%",")-THM>W)87CSSJ''/X$8'5>7&
MYW-$;8:W5W3TT9D&&D#3LVMG^?Z[R?0<IE_049D-E ^1Y5RJ&PPG4OJ(RR0Z
MPE-2WENFF:_7T7YC,C=#W.L_#>E"2WW7W:[U."X0.[-R>HT6>X:6NG0[OICZ
MDG%XZZ_19&>P@3M/'$6!2AIQD6F491!E#(]$+MUFUY)W>?IFZ'H%YQ\O(_\&
MC-QS&:R!M<%:RA2BPY21L=R7M"@EW%DGF--,0JIATIXC:C.(O:*3CLXTT ":
M'O9#*_'0U;3(==EI/R[_,8!H! _>$^4 _4I=CFXD.@;X3Z65E]KK*L#:D+[-
M,/:*#CYJZ*4!N)W!YV_^YKT>MA#F X=V./@R1MN5*0U! /%>!1(T-T:*D*2K
M<FK['%&; >L5'8!TIH%7-2?CI@YVDO_NI\/%O)ZK&:#!?C/R\0_\+?[9[-=)
M@E&G@S2V?VR]21M[BJ#.* Z)CI93R9*L$<0(:01<U(E EI'%P)G(5<K07L]
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M%[LXGX<6,_-YQM0;U\'Z'A S&RY)X:1TFB [Q56*7&-"0@TB^Z0H6553S^=
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M:W,M,C R,# S,S$N>'-D4$L! A0#%     @ KX.O4#E"/DUY$P  *,   !4
M             ( !34H! &9L:W,M,C R,# S,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( *^#KU!38;B1<#$  (/_ 0 5              "  ?E= 0!F;&MS+3(P
M,C P,S,Q7V1E9BYX;6Q02P$"% ,4    " "O@Z]0*;,3K.B+  #&\P4 %0
M            @ &<CP$ 9FQK<RTR,#(P,#,S,5]L86(N>&UL4$L! A0#%
M  @ KX.O4,E4Q/.C4P  #<$# !4              ( !MQL" &9L:W,M,C R
M,# S,S%?<')E+GAM;%!+ 0(4 Q0    ( *^#KU"S;:L87@@  %DI   6
M          "  8UO @!S;')X,C R,# S,S%E>"TS,3$N:'1M4$L! A0#%
M  @ KX.O4!@4TL1J"   >2@  !8              ( !'W@" '-L<G@R,#(P
M,#,S,65X+3,Q,BYH=&U02P$"% ,4    " "O@Z]0\D__QE,%   !(@  %@
M            @ &]@ ( <VQR>#(P,C P,S,Q97@M,S(Q+FAT;5!+!08
.."0 ) %8"  !$A@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6611461680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_PrepaidClinicalTrialExpense', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">$ 140,964<span></span>
</td>
<td class="nump">$ 202,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">360,608<span></span>
</td>
<td class="nump">617,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other prepaid and current assets</a></td>
<td class="nump">144,788<span></span>
</td>
<td class="nump">136,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 646,360<span></span>
</td>
<td class="nump">$ 955,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_PrepaidClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_PrepaidClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6592158928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Variables used in Black-Scholes Model</a></td>
<td class="text"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Variables used in the Black-Scholes model are as follows:</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:75.146%;"><tr><td style="width:1.0%;"/><td style="width:42.163%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.161%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.459%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.356%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.461%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.37%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.69%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.81 years</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.06 years</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113.17%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103.07%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected dividend</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6847535040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVERSE ACQUISITION AND DISPOSAL - Summary of Purchase Consideration (Details) - Flex Pharma<br></strong></div></th>
<th class="th">
<div>Jul. 19, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Flex Pharma market capitalization at closing</a></td>
<td class="nump">$ 10,963,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants', window );">Fair value of rights to warrants</a></td>
<td class="nump">1,629,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions', window );">Fair value of Flex Pharma outstanding options on the merger date</a></td>
<td class="nump">132,227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
<td class="nump">$ 12,724,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Fair Value of Outstanding Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_BusinessCombinationConsiderationTransferredFairValueOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Fair Value of Rights to Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">flks_BusinessCombinationConsiderationTransferredFairValueOfRightsToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>flks_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=flks_FlexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=flks_FlexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
